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I. ABSTRACT 
 
The first synthesis of a naturally occurring 3-acyl tetramic acid glycoconjugate was 
investigated. An endofungal metabolite called epicoccamide D (see Figure I.1.) was 
synthesized for the first time. This was accomplished in 19 steps resulting in a 17% overall 
yield. The total synthesis was built on a modular base to possibly adapt the concept to other 
natural products. 
 
 
 
 
            1 
Figure I.1. Epicoccamide D with the assigned stereocenters being 5S and 7S configurated. 
The key steps of the synthesis were: a β-selective glycosylation followed by a C-2 
epimerisation reaction of the sugar moiety, a HWE olefination, an aminolysis reaction to 
install the L-alanine residue, followed by a Lacey-Dieckman cyclisation. The 7S stereocenter 
was established using a rhodium based homogeneous catalyst and applying a high-pressure 
hydrogenation to the tetramic acid. Stable BF2-chelate complexes are here utilized to disarm 
its metal chelating properties. This procedure allowed assignment of the hitherto unknown 
absolute configuration of the natural product by comparison of NMR data and optical 
rotation. 
Additional side chains of other naturally occurring 3-acyl tetramic acids were synthesized by 
applying similar retrosynthetic approaches used for epicoccamide D total synthesis. The 
dissacharide terminated alkyl chain of ancorinoside B bearing a galactose and a glucuronic 
acid (see Figure I.2. A) was successfully synthesized including two consecutive β-selective 
glycosylations and a C-6 oxidation protection procedure. 
Also a more substituted side chain for the total synthesis of virgeneone (see Figure I.2. B) was 
synthesized ready to couple it to a β-mannose as elaborated for epicoccamide D total 
synthesis. Assembly of this side chain included an ozonolysis reaction and involved a 
Grignard reaction. 
With both side chains in hand, the total synthesis of the two compounds ancorinoside B and 
virgineone can be performed by applying the protocol derived for epicoccamide D total 
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synthesis. All additional and new steps of these two side chains have been carried out within 
this thesis. 
Additionally, chemical N-glycosylation was investigated to allow access to aurantosides (see 
Figure I.2. C) by employing a Fukayama-Mitsunobu reaction. The behaviour of the tetramic 
acids, 3-acyl tetramic acids and their boron complexes towards Lewis-acidic glycosylation 
conditions was examined as well. 
 
A         B 
 
 
 
 
 
    2             3 
   C 
 
 
 
             4 
Figure I.2. Naturally occurring 3-acyl tetramic acid glycoconjugates: A) ancorinoside B; B) virgineone; 
C) aurantoside G/J. 
The last section of this thesis deals with the stereoinduction of the successfully applied 
BF2-complexes in terms of their behavior heterogeneous hydrogenations. This process is 
briefly investigated by building a diethyl boron complex of a tetramic acid. 
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II. INTRODUCTION 
 
Infectious diseases, their overall behaviour, and potential threat towards human health, have 
changed dramatically over the last two decades. Not only have emerging resistances
[1–4]
 of 
various human pathogens
[5]
 to medicines become a major issue, but also mortality from 
cancer is on the increase
[6]
. These problems give rise to the need for new drugs to counter the 
potentially huge impact on global human health. 
Techniques to find such drugs underwent a period of remarkable development in recent years. 
Different screening techniques like fragment-based drug discovery
[7,8]
 or combinatorial 
compound library screening
[9]
 combined with high-throughput analyzing methods have 
undergone much development and are highly efficient. Computational methods
[10]
 can 
determine potentially effective binding sites and drug like molecules to target these identified 
sites can be modelled in silico. Their limitation, however, is that only known targets can be 
challenged with different compounds in established screenings. Natural products and their 
derivatives have therefore returned into sharp focus over the last few years.
[11,12]
 Improved 
screening techniques allow the application of extracts from natural sources
[11]
, the mentioned 
compound libraries are extended by bio-inspired derivatives
[13]
 and natural products can lead 
to an important identification of new druggable targets
[12]
. After identifying a potential drug 
candidate, total synthesis is still required to eventually confirm the absolute configuration and 
to get higher amounts of the desired pure compound in hand. 
There are several natural product lead compound classes
[14]
 usable as inspiration for 
derivatives, target identification, or even directly as a drug. Most of the natural products, 
besides primary metabolites like peptides, nucleic acids and saccharides, are secondary 
metabolites bearing various additional functional groups
[14]
. The largest of these naturally 
occurring compound classes can be divided into alkaloids, polyketides, phenolic products, 
terpenes including steroids and poylenes. A reoccurring motif in most of these natural product 
classes is a so called tetramic acid
[15]
 also referred to as pyrroldine-2,4-dione system. 
 
II.1. Tetramic acid derivatives and their structural diversity 
 
Tetramic acids, in addition to their oxygen based analogues called tetronic acids
[16,17]
 are an 
important and persistent motif found in many natural product classes. The common structural 
feature of this compound class is the 5-membered ring system called pyrroldine-2,4-dione (6). 
INTRODUCTION - Tetramic acid derivatives 
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Most naturally occurring tetramic acids are acylated in the C-3 position and can have an 
additional moiety at the C-5 being derived from natural amino acids as shown in Figure 
II.1.D.
[15,18–20]
 A tetramic acid of natural origin can also be 4-O-alkylated in some cases. 
Tetronic acids are also an important part in many natural products. One of the most famous 
and very well studied representative is called ascorbic acid better referred to as vitamin C (see 
Figure II.1.A). 
    A    B        C            D 
 
 
 
      5           6      7            8 
Figure II.1. Examples of tetramic and tetronic acids. A) L-ascorbic acid
[17]
, the widely known tetronic 
acid derivative better referred to as vitamin C; B) core pyrrolidine-2,4-dione structure of tetramic acids; 
C) most frequent occurring 3-acylated tetramic acid derivative shown in their exo-enol form. The 
variable residue R can be a polyene, a fatty acid or incorporated in a ring system normally ending at 
the C-5 position of the tetramic acid heterocycle. D) tenuazonic acid
[21,22]
. 
The tetramic acid core pyrrolidine-2,4-dione system 6 was first synthesized 1911 by 
Benary
[23]
. It took almost fifty years until Thomas et al.
[21]
 found the first example of a natural 
occurring tetramic acid called tenuazonic acid (8) and one year later the structure was 
elucidated by Stickings et al.
[22]
. Since then nearly 200 other tetramic acid derivatives have 
been isolated, their structures determined, and total syntheses performed
[18]
. These 
descriptions and findings are published in more than 600 articles (SciFinder 05/2015). 
 
II.1.1. 3-Acyl tetramic acids 
 
The most important and biggest subfamily of tetramic acids are 3-acyl derivatives since most 
other classes can are derived directly from them. Simple representatives of this class are, 
beside the mentioned tenuazonic acid, melophlins and penicillenoles.
[18,20]
 Both of these 
groups bear an N-methylated pyrrolidine-2,4-dione system derived from either glycine or 
alanine (in the case of melophlins
[24–26]
), or from threonine including its possible elimination 
product (in the case of penicillenols
[27]
). Beside these minor differences their C-3 position is 
always acylated with a fatty acid chain comprising of various methylation patterns. It is 
possible to add glycosylated tetramic acids such as epicoccamide D
[28]
 to this compound class 
but these, and other sugar bearing tetramic acids, are discussed later in this thesis in more 
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detail. The most important structural features of these compounds are exemplarily shown in 
Figure II.2. 
A          B     C 
 
 
 
      9            10           1 
Figure II.2. Structure of three linear 3-acylated tetramic acids. A) melophlin B
[24]
; B) penicillenol C1
[27]
; 
C) epicoccamide D
[28]
. 
Melophlins
[24–26]
 (9) include the largest numbers of compounds in their family (19), whereas 
only six representatives of penicillenols
[27]
 (10) and four in case of the epicoccamides
[28,29]
 (1) 
are known to date. These three examples of 3-acylated tetramic acids, shown in Figure II.1., 
have numerous different biological activities reaching from antibacterial over antifungal to 
cytotoxic properties. 
The first synthesis of one of the shown compounds was carried out in 2005 by Schobert et 
al.
[30]
 using immobilized Ph3PCCO in a domino style acylation Wittig reaction to gain access 
to melophlins. They achieved the first synthesis of several melophlin derivatives. Five years 
later Yoda et al.
[31]
 found an approach to get penicillenols synthesized by a 4-O-acylation 
rearrangement procedure. Total synthesis of epicoccamide D was again achieved by Schobert 
et al.
[32]
 in 2013. This particular synthesis is the major part of this thesis utilizing a 
Lacey-Dieckman approach to get the desired 3-acyl tetramic acid moiety in place. 
 
II.1.2. 3-Polyenoyl tetramic acids 
 
Derived from these 3-acyl tetramic acids, the next compound class that will be investigated 
are the 3-di- or 3-polyenoyl tetramic acids. In contrast to the above mentioned compounds 
they bear two or more double bonds in conjugation with the 3-exo enol double bond making 
this tautomer even more favourable. Examples of open chained 3-polyenoyl tetramic acids are 
shown in Figure II.3. However, hybrids of the later discussed 3-decalinoyl or macrocyclic 
tetramic acids with a polyene side chain also occur. 
Ravenic acid (11) was first isolated by Michael et al.
[33]
 and eight years later synthesized by 
Schobert et al.
[34]
 using Ph3PCCO for building up the tetramic acid moiety itself and again the 
same reagent for a 3-acylation Wittig reaction procedure. Harzenic acid (12) has been known 
for over 25 years and was originally isolated by Casser et al.
[35]
, but it took until early 2015 to 
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develop a synthetic access to this tetramic acid. Healy et al.
[36]
 published a smart synthesis 
using a known
[37]
 lactone also occurring in 3-decanoylic tetramic acids
[37]
 with all the desired 
stereocenters already in place. The alkaline conditions of the Lacey-Dieckman cyclisation 
deprotonated the β-keto amide moiety, as usual, and then opened the lactone to establish the 
desired tetramic acid moiety, yielding the desired C-5 substitution pattern shown in Figure 
II.3.B. 
  A          B 
 
 
 
             11            12 
 C           D 
 
 
 
 
        13      4 
Figure II.3. Structure of 3-polyenoyl tetramic acids. A) ravenic acid
[33]
; B) harzianic acid
[35]
; C) 
streptolydigin
[38]
; D) aurantoside G
[39]
. 
Streptolydigin (13) has been known since 1963
[38]
 and extracts with high amounts of this 
tetramic acids were intensively studied for their biological properties such as a strong E. coli 
RNA polymerase inhibition first discussed by McClure
[40]
. Starting from the early 1980s 
many suggestions concerning the biosynthetic pathway
[41,42]
 of this compound have been 
published and recent results were able to almost show the complete path. From the first 
assessment of the structure of streptolydigin, it took nearly fifty years until Pronin et al.
[43]
 
facilitated the first total synthesis. Their outstanding synthetic approach utilized cross-
metathesis, Evans auxiliary techniques, selective and easy to perform N-glycosylation with 
rhodinose, HWE olefination and again a Lacey-Dieckman cyclisation step at the very end of 
their synthesis. This approach was also the first known synthesis of a naturally occurring 
glycotetramic acid and by the start of this project the only one as far as the non-standard 
bacterial hexose rhodinose can be described as a sugar derivative. 
Aurantosides (4) form another large compound class with currently eleven known 
members
[39,44–48]
. Their general structure has an N-glycosylation in common with 
streptolydigin being connected to D-xylose or a trisaccharide starting with xylose and all 
derivatives bear a polyene 3-acyl side chain. Another uncommon feature is their chlorination 
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on the polyene side chain. Total synthesis is currently in focus of intense research
[49]
 but has 
not yielded any publications to date. 
 
II.1.3. 3-Decanoyl tetramic acids 
 
Another large group belonging to the group of 3-acyl tetramic acids are showing a decalinic 
acid moiety attached by acylation at the C-3. Again numerous representatives of this large 
tetramic acid family are currently known and some examples will be shown herein. Most of 
them differ in their absolute configuration, and the length of their substituents mainly around 
the decalin system. Structural variety of the 3-decanoyl tetramic acid groups is shown in 
Figure II.4. including a highly functionalized hexacyclic 3-decanoyl tetramic acid called 
integramycin
[50]
 (Figure II.4.C), bearing various groups like a spiro acetal or an aromatic 
residue on the decalin system. 
 A    B              C 
 
 
 
 
 
 
  14      15           16 
Figure II.4. Structural diversity of 3-decanoyl tetramic acids. A) equisetin
[51]
; B) methiosetin
[52]
; C) 
integramycin
[50]
. 
The first synthesis of equisetin
[51]
 (14) was carried out by Turos together with Danishefsky et 
al.
[53]
 which was later improved by Yuki et al.
[54]
, Burke together with Ley et al.
[55,56]
 and Yin 
et al.
[57]
 all using a Diels-Alder approach and later again a Lacey-Dieckman cyclisation step. 
A similar approach might be useful for the recently found methiosetin
[52]
 (15) but no synthesis 
has been published yet. 
Integramycin
[50]
 (16) has also been a reoccurring subject of research, but so far total synthesis 
remains elusive. Only two groups have currently published their results on setting up the 
bicyclic spiro moiety
[58,59]
 of the molecule. Their contribution combined with the above 
mentioned methodology should make total synthesis reachable in the near future. 
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II.1.4. Macrocyclic tetramic acids 
 
The last group of tetramic acids to discuss in detail are the macrocylic tetramic acids. Their 
macrocycles can be built up featuring all above mentioned possible derivatives. The 
macrocycle of these tetramic acid representatives are, in many cases, built as a 3-acyl residue 
ending at the C-5 position. The tetramic acid moiety is normally derived from a natural 
occurring amino acid. In contrast to the above shown 3-decanoyl tetramic acids this 
compound class often bears a pentalene system incorporated into the macrocyclic ring. Most 
representatives show an amide bond in the ring system closing the ring over a tetramic acid 
moiety derived from L-ornithine which, in turn, is a common metabolite from the urea 
cycle
[60]
. Examples of some macrocyclic tetramic acids are summarized in Figure II.5. 
      A       B               C 
 
 
 
 
 
     17      18            19 
Figure II.5. Exemplary representatives of macrocyclic tetramic acids. A) macrocidin A
[61]
; B) 
cylindramid
[62]
; C) discodermid
[63]
. 
Macrocidin A
[61]
 (17), a 17-membered macrocyclic tetramic acid, displays strong herbicidal 
activity compared to most tetramic acids being active against bacteria or fungi. The first and 
only known total synthesis was achived by Yoshinari et al.
[64]
 Their approach combines a 
HWE olefination, an asymmetric homogeneous catalytic hydrogenation using a Crabtree’s 
catalyst, a macrolactamization using a protected β-enol carboxylic acid derived 
phosphonate
[65]
 and again a Lacey-Dieckman cyclisation. 
Also the remarkable total synthesis of the 20-membered ring tetramic acid macrocycle 
cylindramid
[62]
 (18) established by Cramer et al.
[66]
 in 2005 needs to be mentioned. He not 
only synthesized the pentalen system, he also published the above mentioned 
macrolactamization using a tetrazoylsulfone, utilized a Suzuki cross-coupling and finishing 
his synthesis off with the common Lacey-Dieckman cyclisation to build the desired 
5-membered tetramic acid ring. His synthesis was also stereoselective. 
Discodermide
[63]
 (19), again a 17-membered macrocycle, is yet another tetramic acid 
derivative that should be mentioned. The pentalen system is here connected to another 
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6-membered ring and the 3-acyl side chain connecting the tricyclus to the tetramic acid 
moiety is shorter compared to the moiety at the C-3 position in cylindramid. No total 
synthesis has appeared so far in the literature. 
 
II.1.5. Additional tetramic acids 
 
Besides those major classes of tetramic acids outlined above, there are several smaller classes 
of these compounds which, whilst they will not be discussed in detail here, deserve a brief 
mention. Tetramic acids can also be N-acylated
[67,68]
, bear a spirocyclic moiety at the carbon 
at 5-position
[69]
, can be derived from alkaloids
[70]
, polyketides like the huge lydiamycin
[71]
 
(20) and even peptides like the proline rich dolastatin
[72]
, the newly found janolusimide
[73]
, or 
cyclic peptides
[74]
 as summerazied in some review articles
[15,18,20]
. The spirotetramic acids are 
an example for a quickly growing tetramic acid class
[20]
. This set of diverse tetramic acids is 
completed by a recently discovered compound where even tetramic acid hetereoatoms are 
changed. Cladosins
[75]
 bear a 3-exo enamine unit where normally the 3-acyl enol functionality 
is placed. The structure shown below is the mentioned lydicamycin
[71]
 (20) which should 
display and sum up the huge structural variety of tetramic aicds. 
 
 
 
 
              20 
Figure II.6. Structural variety of tetramic acids: Lydicamycin. 
The speed of discovery of tetramic acids is increasing and it is certain that more and more 
derivatives of these important groups or their hybrids are to be found in the future. 
Their diversity in biological activities is as diverse as their shown structural omnifariousness. 
 
 
II.2. Biological function of tetramic acids 
 
One of the most important principles in nature is the fact that structure leads to function. 
Therefore the biological functions of tetramic acids found in diverse microorganisms of 
terrestrial and marine origin can turn out to be as diverse as their structure. However, most of 
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the above mentioned tetramic acids can be grouped by one of the following broad functions: 
They can be antibacterial, antifungal, antiherbal or cytotoxic.
[15,18,20]
 These activities are 
widely investigated using state-of-the-art screening techniques. Several targets are now 
identified and can be inhibited or activated by individual tetramic acids selectively. 
Reutericyclin
[76,77]
 interferes in the pH difference between the membranes of gram-positive 
bacteria
[78,79]
 and therefore interfers directly with the biosynthesis of ATP (more of which 
below – section II.2.1.). It is not only an effective antibacterial agent against S. aureus but 
also for disarming its major virulence factor toxin-1 which interacts strongly with the human 
interleukin-8 in a phosphate dependent manner.
[80,81]
 
Tetramic acids are also known to selectively inhibit chitin synthase making them in addition 
to their other biological activities a candidate for an anti-insectile agent.
[69]
 
Additional specific functions have also been discovered. The N-acyl tetramic acid eliamid was 
found to be active against diverse fungi and strongly cytotoxic. Its mode of action was 
revealed by Höfle et al. to be a NADH complex I inhibitor which disrupts the eukaryotic 
respiratory chain.
[68]
 
HIV integrase inhibitory activity was also found among the class of tetramic acids. 
Integramycin (Figure II.4.C) was discovered to inhibit this enzyme being critical for viral 
replication.
[50]
 
Streptolydigin (Figure II.3.C) was found to have similar effects on the RNA polymerase
[40]
 of 
E. coli. It seems to bind to the initiation complex of the polymerase and thereby prohibiting 
the substrate nucleotide, which can be referred to as the elongation triphosphate like UTP, 
from binding to the complex. Streptolydigin aborts the formation of the complexes necessary 
for the polymerase initiation phase right before an elongation step can start. 
 
II.2.1. Cell wall interaction of tetramic acids and quorum sensing 
 
It is worth noting that one general aspect of the antimicrobial functionality of tetramic acids is 
their interaction with cell walls of bacteria. Most natural occurring tetramic acids are highly 
active against gram-positive bacteria
[15,18,20]
. This fact is mainly due to a lack of penetration of 
some tetramic acids through the inner cellular membrane of bacteria having a negative gram 
staining. In these
[78,79]
 as well as other related studies
[82,83]
 the tetramic acid is altering the 
chemical potential of the cellular membrane being again involved in bacterial ATP synthesis 
and ATP dependent processes. This shift of membrane potential is not only involved in 
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shutting down the cellular energy supply but is also directly responsible for disrupting 
membrane cohesion and stability.
[79,82]
 
Another effect of this alteration of the bacterial cell wall is the inhibitory potency of tetramic 
acids on an inter-cell communication and interaction possessed by many human pathogens 
called quorum sensing
[84]
. This system describes the behaviour of bacteria changing their 
expression pattern completely when a critical cell density is passed. Triggered by small 
molecules (inducers) binding to receptors of a neighboured cell, the expression of certain 
genes are activated leading to effects like biofilm formation, production and release of 
virulence factors or expression of channels for active and controlled antibiotic agent efflux 
leading to resistances.
[84]
 This quorum sensing system is also affected by many tetramic acids. 
An example of further investigations concerning quorum sensing suppression can be seen 
from the 2014 study published by Murray et al.
[81]
 An autoinducer peptide (AIP) from 
S. aureus interacts with a transmembrane histidine kinase AgrC which phosphorylates AgrA. 
This phosphorylation is ultimately leading to reengineering of the transcriptional profile by 
AgrA induced expression of a promoter and RNAIII, an effector of downstream signalling 
events.
[85]
 The tetramic acids tested were found to be a competitive inhibitor of the AIP/AgrC 
complex.
[81]
 Assayed tetramic acids can be accounted for as a rearrangement product of a 
known inhibitor derived from a 3-oxo homoserine lactone. However Kaufmann et al.
[86]
 found 
out in 2005 that the pH dependent ring opening of this lactone is undergoing an 
intramolecular rearrangement in a Lacey-Dieckman styled condensation to form a vinylogous 
product, a tetramic acid.
[86]
 This formed tetramic acid was found to be the active inhibitor of 
the above mentioned interaction.
[86]
 Additionally, homoserine derived tetramic acids showed 
even stronger inhibition.
[81]
 Indeed, this inhibition was increased even further when the 3-acyl 
fatty acid chain was extended, which might have led on to higher intercalation of the tetramic 
acid into the membrane where AgrC is located.
[81]
 
It is shown that the above mentioned results can be transferred to other organisms. One 
example for a proof of principle showed similar homoserine derived tetramic acids are active 
against C. difficile quorum sensing
[87]
 besides their general antibacterial properties leading to 
cell lysis for example. 
 
II.2.2. Tetramic acids as nucleotide or pyrophosphate mimics 
 
The implications here are that of a tetramic acid moiety being a good mimic of nucleotides, 
and therefore potentially inhibit nucleotide dependent enzymes. Their mode of action is often 
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referred to competing with ATP, UTP
[40,50]
, UDP
[69]
 or even NADH
[68]
. Some studies
[88,89]
 
suggest that this fact can be explained by the overall electronical properties of tetramic acids 
being similar to nucleotides and especially regarding their phosphate residues. Peukert et 
al.
[89,90]
 really emphasized this statement. These effects are acknowledged by molecular 
modelling when a target structure was known. Most people refer to this effect when asked for 
the biological activities of tetramic acids and their mode of action. 
However four different studies supported by various 3-dimensional protein structures with 
3-acyl tetramic acids crystallized as inhibitors
[91–95]
 have been published which contest this 
position. In the case of streptolydigin RNA polymerase inhibition, an x-ray crystal structure is 
available where a nucleotide and the tetramic acid derived inhibitor are cocrystallized
[94]
. 
This, and other structures, showed the very narrow similar binding motif of a phosphate 
residue and the 3-acyl tetramic acid anion often binding to positive charged residues like 
arginine, glutamine and sometimes histidine, as well. And yet, in all the published cases, no 
colocalization of substrate and tetramic acid residue is confirmed. Streptolydigin, for instance, 
disrupts protein-protein interactions or protein-RNA interactions in case of the RNA 
polymerase, but is never colocalized with any nucleotidic substrate nor residue. 
 
 
II.3. Chemical and structural properties of tetramic acids 
 
The core pyrrolidine-2,4-dione system is normally present in the 2,4-diketo form. The pKa 
value of the core structure of tetramic acids is around 6.4 in aqueous solution. The core 
structure of the comparable furane-2,4-dione tetronic acid is far more acidic with a pKa of 
roughly 3.7 mostly showing the 4-enol form.
[15]
 
The 3-acylated derivatives are more acidic than the core structure itself in both cases with a 
pKa value in the range of 3.0 – 3.5.
[15]
 The NMR spectra and other techniques like HPLC 
purification of the acylated derivatives are rather complex since they usually appear as a 
mixture of four stable tautomers.
[15,18,20]
 Not This mixture is very heterogenous and their ratio 
can widely differ dependent on the electronic nature of the whole 3-acyl substituent as well as 
the substitution pattern at the C-5. Scheme II.1. is showing the four stable tautomers and their 
conversion into each other.
[15]
 
Each groups of the two exo-enol tautomers (21 together with 23) on the left hand side of 
Scheme II.1. and the two enol forms on the right handed side (22 and 24) can be referred to as 
internal tautomers.
[15]
 Single crystal structures of 3-acyl tetramic acid also confirmed the 
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predominant form in solution
[96]
 and crystalline state
[97]
 of the 3-acyl tetramic acid being the 
exo-enol tautomer 23.
[15,18]
 Metal chelate complexes utilizing boron trifluoride as strong 
Lewis-acid revealed chelate complexes of the same tautomer only.
[98]
 
 
 
 
 
          21        22 
 
 
 
          23        24 
Scheme II.1.  Tautomerism of 3-acyl tetramic acids. Tautomerism between exo-enol forms (21, 23) on 
the left side and either the 4-enol form 22 or the corresponding amide enol 24 on the right side 
happens faster than directly between the two exo-enol forms. 
The metal chelating propensity of 3-acyl tetramic acids is also worth noting. Some natual 
compounds could be isolated as their corresponding magnesium complexes exclusively
[99,100]
 
and their metal chelating power can overcome those of EDTA. Many studies suggest that the 
metal chelating properties of the 3-acyl tetramic acids are partly responsible for their 
biological activity.
[18,20]
 It is also suggested that this effect is part of the proposed phosphate 
mimicry theorem but again, no structure mentioned above revealed a bivalent ion near the 
tetramic acid moiety of the tested inhibitors
[91–95]
. However, the function of the metal chelates 
might also be involved in transportation.
[20,99,100]
 
The chemical reactivity of tetramic acids can be as versatile as their structural variations. 
Their overall structural and chemical features make many chemical substitutions on the 
pyrrolidine-2,4-dione system possible including olefination, arylation, amination, acylation, 
glycosylation and many places for potential alkylation attempts. This is outlined in Figure 
II.7. 
 
 
 
 
 
Figure II.7. Potential chemical substitution positions on tetramic acids. 
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Most of these possible modifications are represented within many natural products as 
explained in chapter II.1. To investigate the origin of these chemical modifications in nature, 
it will be necessary to take a closer look at the biosynthesic pathways of this extensive, natural 
product class. 
 
II.4. Biosynthesis of tetramic acids 
 
One rather seldom used biosynthetic pathway to 3-acyl tetramic acids is mentioned in chapter 
II.2.1. The quorum sensing molecules N-acylhomoserine lactones are converted into the 
corresponding 3-acyl tetramic acids under physiological conditions.
[86]
 The thus formed 
tetramic acid is hence a competitive inhibitor to the normally occurring activating peptide for 
AgrC, a transmembrane histidine kinase. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme II.2.  First biosynthetic steps to streptolydigin. The product is bound to an enzyme shown as 
grey cloud during most steps of the biosynthesis. 
The standard in vivo biosynthetic pathway for 3-acyl tetramic acids normally involves a 
multiple domain bearing gene cluster encoding for multiple protein complexes involved in the 
biosynthesis of tetramic acids. These proteins or protein complexes might have tasks such as 
eventual necessary manipulation of a natural occurring amino acid like, for example: 
methylation, inversion of the C-5 and acylation carried out by non-ribosomal peptide 
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synthases, N-acylation, side chain elongation accomplished by polyketide synthases, 
cyclisation or functionalization of the finalized natural product. The biosynthesis of 
streptolydigin has been extensively covered in literature
[41,42,101,102]
. The biosynthesis of 
streptolydigin is a process which requires from malonyl coenzyme A (Mal-CoA) for four 
steps, methylmalonyl coenzyme A (MeMal-CoA)
[41,42]
 also for four steps, besides 
N
2
-methyl-β-methyl asparagine and the desoxysaccharide rhodinose[91]. 
The first set of biosynthetic steps are common in polyketide biosynthesis. The substrate amino 
acid is attached to an enzyme by thioester bond formation. Elongation of the open chain is 
achieved by incorperation of all C3 (derived from MeMal-CoA) and three out of four C2 (Mal-
CoA) parts including several steps of reduction and dehydration carried out by additional 
enzymes. It is not known precisely when the actual methylation steps of the corresponding 
amino acid occur. However, it likely happens in later steps of the biosynthetic pathway. 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme II.3.  Second part of the biosynthesis of streptolydigin showing additional elongation steps. 
After the last attachement of a C2 unit the heterocycle is closed by spontaneous or enzymatic 
formation of a hemiacetal followed by formation of a full acetal. This step is not well studied 
and the sequence of acetal formation and the enzymes involved remain unclear. Nevertheless 
this step is followed by an oxidative epoxidation which forms the spirocenter on the 
heterocycle. 
Biosynthesis is completed by closing the tetramic acid moiety and cleaving the product 
molecule from the enzyme. This step can spontaneously occur within the cytosol but recent 
literature
[102]
 suggests that various Lacey-Dieckman cyclases may be catalysing this step. The 
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terminal step of the biosynthesis is thought to be the cytosolic glycosylation with the 
deoxysugar rhodinose. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme II.4.  Third set of biosynthetic steps to streptolydigin including formation of the heterocyclic 
acetal residue. It is not known which path for acetal formation is used in biosynthesis and whether it is 
a spontaneous or catalyzed step.
[42]
 Route A shows first the hemiacetal closure from the “inner” 
hydroxyl group to form a six-membered ring before the eight-membered ring is closed. Route B shows 
acetal formation in a reversed way. 
 
 
 
 
 
 
 
 
 
 
Scheme II.5.  Terminal biosynthetic steps to streptolydigin. Colors in the last structure indicating the 
origin of the carbon
[41]
 and some of the oxygen
[42]
 atoms. The orange part is derived from dimethylated 
asparagine, the blue part is the desoxysugar rhodinose attached by terminal glycosylation, the green 
parts are C2 units derived from Mal-CoA and the red parts are C3 units with MeMal-CoA origin. 
Another important class of enzymes involved in the biosynthesis of tetramic acids are 
Diels-Alderases
[101]
 occurring in the synthesis of terpene derived tetramic acids like equisetin. 
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Many published syntheses of these types of compounds are recorded as utilizing similar steps 
to the streptolydigin biosynthetic pathway. Very recent results published by Kakule et al.
[103]
 
confirm this position through their descriptions of the biosynthesis of an equisetin analogue 
bearing a 4-hydroxy-4-methyl glutamate residue. 
 
 
II.5. Chemical synthesis of tetramic acids 
 
Methods to synthesize tetramic acids can be divided into two categories: Those that form the 
core structure of the tetramic acids followed by later acylation steps and methods that 
synthesize the 3-acyl tetramic acid directly. Both methods are shown below summarizing 
various approaches. An approach to perform a later C-5 oxidation complements the other 
methods. 
 
II.5.1. Synthetic methods to form the core pyrrolidine-2,4-dione system 
 
Synthesis of pyrrolidine-2,4-diones via Meldrum’s acid 
Nisato et al.
[104]
 developed a method to directly convert N-Boc protected amino acids into 
their corresponding tetramic acid by the use of Meldrum’s acid (26)[105] under acylation, 
thermic elimination of CO2 as well as acetone and cyclisation. Additional methods were 
found to exchange the expensive and sensitive isopropenyl chloroformate with 
dicyclohexylcarbodiimide (DCC)
[106]
 and later with less toxic water-soluble 
1-ethyl-3-(dimethylaminopropyl)carbodiimide (EDCI)
[107]
. 
 
 
 
 
        25      26          27         28           29 
Scheme II.6.  Tetramic acid synthesis via Meldrum’s acid. R = various substitutions mainly derived 
from naturally occurring amino acids. 
The protected amino acid or derivative 25 is attached to the Meldrum’s acid 26 by an 
acylation supported by the above mentioned substances. The nucleophilic nitrogen of the 
amino acid then attacks one of the carbonyl carbons on the Meldrum’s acid via 28 and 
thermic elimination occurs to form the tetramic acid 29. 
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Synthesis of pyrrolidine-2,4-diones via domino-Wittig reaction 
Another broadly used method to form tetramic acids, or in this case 4-O-protected tetramates, 
is the usage of ketenylidentriphenylphosphorane (Ph3PCCO) often referred to as Bestmann’s 
ylide
[108]
. This method was later further improved by Schobert et al.
[109]
 through using the 
stable ketenylide (31) as acyl donor to form the desired tetramic acid. 
 
 
 
 
        30           31       32   33         34 
Scheme II.7.  Mechanism of tetramate synthesis with Bestmann’s ylide
[108]
. R = various substitutions 
mainly derived from naturally occurring amino acids; R’ = methyl, ethyl, tbutyl, benzyl. 
In the first step the amino acid ester 30 attacks the ylide 31 to form a N-acyl yilide 32. The 
subsequent intramolecular Wittig reaction between the ylide and the ester group via the 
formation of either a betain (not shown) or an oxaphosphetane structure (33) forms the 
desired tetramate 34 under thermodynamic conditions. The tetramate 34 is deprotected to 
yield the desired pyrrolidine-2,4-dione. 
To simplify purification of the desired tetramic acids and to separate the product from 
triphenylphosphine oxide, an immobilized derivative of Bestmann’s ylide was synthesized 
and tested successfully
[110]
 in synthesis. 
 
Synthesis of 3-methylated pyrrolidine-2,4-diones via SmI2 
A rather new method established by Bai et al.
[111]
 uses N-2-bromopropionated amino acid 
esters, cyclizes them by the use of samarium iodide and traps the product with diazomethane 
to yield a 3-methylated 4-O-methyl tetramate (36). The educt for the cyclisation is prepared 
by N-acylation of a protected amino acid with nBuLi and 2-bromopropionyl bromide. 
 
 
 
 
          35        36 
Scheme II.8.  Tetramate synthesis with SmI2 and CH2N2 via a 2-bromopropionated and protected 
amino acid derivative. R = various substitutions mainly derived from naturally occurring amino acids. 
Their synthetic approach seems to be limited in terms of the products possible but their 
method is quite new and it might be worth investigating other variants by attaching longer 
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N-acyl residues. It is worth noting that this synthetic possibility works better when 
unprotected proline is used
[111]
 to yield the corresponding bicyclic tetramic acid. 
 
Synthesis of 3-arylated pyrrolidine-2,4-diones via silver and CO2 incorporation 
Another recently published method for tetramic acid synthesis elaborated by Ishida et al.
[112]
 
uses catalytic amounts of silver(I) salts to incorporate CO2 into an existing amino alkine and 
then utilizing an intramolecular rearrangement. The base used to catalyze this type of reaction 
was DBU. 
 
 
 
 
            40             41          42    43 
 
 
 
 
      43           44            45            46 
Scheme II.9.  Tetramic acid synthesis via CO2 incorperation catalyzed by silver(I) salt and DBU. 
Proposed mechanism
[112]
 shown. R = any (branched) alkyl chain, cyclohexyl. 
Firstly the carbon dioxide is attacked by an amino alkine 40, to form an acylated alkine 41. 
Then the electron densitiy on the double bond is reduced by complexation of silver(I) to allow 
the attack of the negatively charged oxygen and subsequent formation of an oxazolidinone 42 
followed by reprotonation. This reprotonated oxazolidinone 43 is deprotonated again by DBU 
to form a charged isocyanate (44). This is attacked by the double bond again forming the 
desired tetramic acid 46 over an enamide (45). 
Their first published studies were limited to 3-aryl compounds with various electron rich or 
poor aromats. The C-5 was tested to yield an glycine derived tetramic acid or to have an 
cyclohexyl residue on the corresponding alkine to yield C-5 spiro tetramic acids which are a 
growing class of tetramic acids. 
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II.5.2. 3-Acylation of the tetramic acid core 
 
3-Acylation via 4-O-acylation and rearrangement 
A more frequently used method for 3-acylation of the above gained pyrroldine-2,4-dione 
system is to first perform a 4-O-acylation and in situ rearrangement sequence. Several groups, 
including, Yoda et al.
[31]
, Moloney et al.
[79]
 and Yoshii et al.
[113]
 studied this rearrangement 
tactic, leading to good yields of the desired tetramic acids. 
 
 
 
 
         47        48               49 
Scheme II.10.  3-Acylation by a 4-O-acylation rearrangement strategy using Ca
2+
 as published by 
Yoda et al.
[31]
 in their stereoselective total synthesis of penicillenol A1. 
The mildest, and eventually most usable, method to induce the rearrangement is published by 
Yoda et al.
[31]
 utilizing Ca
2+
 instead of high amounts of Et3N to induce acyl migration in situ 
right after 4-O-acylation. The tetramic acid 47 used in their synthesis was derived from 
threonine and utilizing the above shown Meldrum’s acid methodology. The remaining steps 
after isolation of the 3-acyl tetramic acid 49 are N-methylation and TBS deprotection. 
 
3-Acylation via acylation with Bestmann’s ylide and subsequent Wittig reaction 
Schobert et al.
[34]
 figured out that the Bestmann’s ylide can directly act as an acylation reagent 
to selectively attack the C-3 position on pyrrolidine-2,4-dione systems. 
 
 
 
 
            50    51            52 
Scheme II.11.  3-Acylation by Bestmann’s ylide acylation and Wittig olefination published by Schobert 
et al.
[34]
 for the total synthesis of ravenic acid. R = any alkyl chain. 
This shown synthesis (Scheme II.11.) is part of a published
[34]
 total synthesis of ravenic acid. 
An accordingly protected amino acid 50 is acylated by addition of the 
ketenylidentriphenylphosphorane to yield a 3-acyl ylide 51. This step normally proceeds 
quantitatively. The ylide can then undergo a Wittig reaction without further purification to 
INTRODUCTION - Chemical synthesis 
21 
 
yield the desired 3-acylated tetramic acid 52. The ylide needs to be activated by a base and 
only KOtBu proved to accomplish
[34]
 this activation. 
 
Direct 3-acylation with acyl chloride and BF3 etherate 
Schobert et al.
[30]
 used also carboxylic acid chlorides and converted tetramic acids diretctly 
into the corresponding 3-acyl tetramic acid complex derivatives by heating the educts in the 
microwave. The solvent was BF3•OEt2 and these aggressive reaction conditions are also 
directly the limitation of this type of acylation reaction. These conditions were successfully 
applied to the total synthesis of several melophlins
[30]
. 
 
3-Acylation by lithiated tetramic acids and subsequent oxidation 
Another worth noticing method to perform a 3-acylation was investigated by the group around 
Jones et al.
[114]
 but this method is less favoured because of the used strongly basic conditions. 
They were able to lithiate a tetramic acid selectively in the 3-position and isolating the 
corresponding 3-alkylated hydroxyl tetramic acid (55). 
 
 
 
 
       53       54        55    56 
Scheme II.12.  Published
[114]
 3-acylation by lithiation, aldehyde addition and oxidation. R = any alky 
chain; R’ = various substitutions mainly derived from naturally occurring amino acids. 
The mentioned hydroxyl tetramic acid 55 can be oxidized by MnO2 to yield the desired 
3-acylated tetramic acid 56. The limitation within this 3-acylation procedure is again the 
strongly basic reaction conditions resulting in lots of C-5 isomerized product. 
 
II.5.3. Aldol reaction for C-5 alkylation 
 
This short chapters shows the synthesis of 3-methylated pyrrolidine-2,4-diones via aldol 
reaction as a C-5 alkylation. David et al.
[115]
 figured out that similar products as above 
mentioned can be obtained by forming various pyrrols as a TMS enol ether and then 
performing a diastereoselective catalytic vinylogous aldol reaction using catalytic amounts of 
SnCl4 and an aldehyde to introduce various residues on the tetramic acid C-5. 
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The protected amino acid 37 is again protected as a TMS enol ether. This enol ether pyrrol 
derivative 38 then undergoes the desired aldol reaction when the necessary aldehyde is added 
alongside a catalytic amount of SnCl4. 
 
 
 
 
            37    38            39 
Scheme II.13.  Mechanism of tetramate synthesis with an aldol reaction via a PMP protected amino 
acid derivative. 
This reaction sequence formed also a limited set of simple 4-O-methylated tetramic acids (39) 
and further investigation is necessary to figure out the limitations of this reaction. However, 
David et al.
[115]
 reported an enantiomeric excess of 20:1. 
 
II.5.4. Direct synthesis of 3-acyl tetramic acids 
 
Lacey-Dieckman cyclisation 
Besides many reactions to form the core pyrrolidine-2,4-dione system and subsequent 
3-acylation in the shown manner, there’s currently one very important reaction to directly 
form 3-acyltetramic acids. The Lacey
[116,117]
 group improved the Dieckman condensation so 
as to have direct access to 3-acyltetramic and -tetronic acids derived from β-keto amides or 
the corresponding esters. Since nature is also using the nucleophilic properties of a β-keto 
carbonyl precursor in the biosynthetic path to close the heterocycle as shown in chapter II.4., 
this synthetic approach can be considered as biomimetic. 
 
 
 
 
             57             58 
Scheme II.14.  Mechanism of a Lacey-Dieckman cyclisation to directly yield 3-acyl tetramic acids. X is 
NH (tetramic acid) or O (tetronic acid), R is any side chain including aromatic derivatives, polyene 
chains and branched chains and R’ is another side chain normally derived from naturally occurring 
amino acids. 
This method is the most used synthetic tool to gain access to 3-acyl tetramic acids. The 
reaction tolerates most functional groups and is not limited to size or electronic properties of 
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the substituents. The scope of the Lacey-Dieckman cyclisation is limited, though. The use of 
strongly basic conditions to achieve the cyclisation step normally leads to a noteworthy 
isomerisation at the C-5 position. Lots of attempts have been carried out recently to prevent 
this unwanted side reaction by either changing the base to milder ones like 
tetra-nbutylammonium fluoride (TBAF)
[118]
 or using smaller amounts of sodium methoxide 
decreasing isomerisation to a minimum of less than 4%
[32]
. 
 
 
II.6. Glycosylated tetramic acids 
 
Since this work is focussed on glycosylated 3-acyltetramic acids, the known derivatives as 
well as their origin and biological function will be discussed. Members of this class can be 
divided into two subfamilies: Tetramic acids being 3-acylated with a saturated fatty acid chain 
which is terminally glycosylated or N-glycosylated tetramic acids having a polyene 3-acyl 
side chain. Members of both families are described as follows. 
 
II.6.1. Ancorinosides 
 
Ancorinosides were isolated by Ikegami et al
[119]
. in 1997, its magnesium salt four years later 
by the same workgroup
[100]
 and three additional representatives of this compound class by 
Fusetani et al.
[120]
 also in 2001. All four derivatives were isolated from marine sponges like 
Ancorina (A) or Penares sollasi (B-D). Their structural motif consists of three major parts: A 
disaccharide with a β(1-4) linkage either being galactose and glucose or vice versa having the 
sugar moiety on the reducing end oxidized at the C-6 to the corresponding uronic acid. The 
second part is a C22 or C24 fatty acid chain with no or single substitutions. The third section of 
all ancorinoside species is a tetramic acid moiety derived from D-aspartic acid. Their 
structural variations are summarized in Figure II.8. 
Ancorinoside A and its magnesium salt were tested for their inhibitory potency on embryonic 
development using fertilized starfish eggs. Both substances allow initial cellular divisions and 
formation of a morula, but development was inhibited and no further cell division was 
observed at a state of 256-512 cells where normally the formation of a blastula occurs.
[100,119]
 
Ancorinosides were tested for their potency to inhibit matrix metalloproteinases (MMP) 
revealing a moderate effect on MMP type 2 and a weak effect on transmembrane MMP type 1 
while maintaining very weak cytotoxic side effects.
[120]
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Figure II.8. Ancorinosides A-D derived from marine sponges. 
Since this tetramic acid is derived from N-methyl-D-aspartic acid (NMDA) it might be worth 
testing
[121]
 the behaviour of nerve cells towards ancorinosides since NMDA is a known 
agonist of the well studied NMDA receptor ion channels
[122]
 which are known to be involved 
in learning deficiencies and eventually Alzheimer’s disease. 
 
II.6.2. Epicoccamides 
 
Six years after the first isolation of ancorinosides by Ikegami et al. epicoccamide A was first 
isolated by the workgroup around G. König et al.
[29]
 in 2003. This glycosylated tetramic acid 
was found in extracts of cultures derived from the fungi Epicoccum purpurascens. This fungi 
is of marine origin and is normally associated with the common moon jellyfish (Aurelia 
aurita). 
Four years later Hertweck et al.
[28]
 found three additional representatives of epicoccamides 
(B-D). These compounds were isolated from a terrestrial Epicoccum species living associated 
with a tree fungus called Pholiota squarrosa. All four tetramic acids share the same motif of a 
natural product similar to ancorinosides consisting of three major parts: A β-branched 
mannose, a long (C18) and unsubstituted fatty acid chain and a tetramic acid derived from 
alanine. These structural features are summarized in Figure II.9. 
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              A:  n = 13, R
1
 = R
2
 = H 
              B:  n = 13, R
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 = H 
              C:  n = 13, R
1
 = H, R
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              D:  n = 15, R
1
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 = H 
Figure II.9. Epicoccamides A-D derived of marine and terrestrial origin. 
Hertweck et al. found identical structures compared to the epicoccamide derived from marine 
fungi with different acetylation patterns. Epicoccamide A was the major metabolite in their 
extracts as well but epicoccamide D proved the most active and showed notable cytotoxic and 
good antiproliferative effects. 
The absolute configuration concerning the two methyl substituted stereocenters within the 
aglycon part of the molecule remained unclear, because no total synthesis was available for 
this compound class when the work on this thesis started. 
The absolute configuration 5S and 7S suggested in this work was later acknowledged by a 
total synthesis performed by Yajima et al. 
[123]
 yielding epicoccamide A and D. They used 
Meldrum’s acid to build up the alanine derived tetramic acid, a tandem 4-O-acylation 
rearrangement setup to build the 3-acyl tetramic acid moiety with approximately half the 
length of the fatty acid side chain, a β-selective glycosylation and a final cross-metathesis. 
Since their synthetic approach is similar to the one published by the same group
[124]
 
concerning virgineone aglycon synthesis, which is outlined below (Scheme II.15.), their key 
steps of their synthesis are not shown here. 
 
 
II.6.3. Virgineone 
 
Singh et al.
[125]
 isolated another member of the glycosylated tetramic acid family in 2009 
called virgineone. This compound was isolated from the fungus Lachnum virgineum 
belonging to the class of natural decomposers. The overall structural motif is similar to the 
two already mentioned classes. A β-mannosylated fatty acid chain being oxidized to a ketone 
in almost the middle and connected via 3-acylation to a tetramic acid derived from tyrosine. 
The fatty acid chain is additionally methylated in the same position as epicoccamides and 
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bears a hydroxyl functionality neighboured to the glycosidic bond. These structural features 
are shown in Figure II.10. 
 
 
 
 
          3 
Figure II.10. Virgineone produced by the fungus Lachnum virgineum. 
Virgineone was tested more extensively than the two already mentioned families of 
glycosylated 3-acyl tetramic acids. Singh et al. investigated the biochemical activity of the 
isolated compound with a Candida albicans fitness test. They tested
[125]
 the effect of the 
compound on roughly 2900 deletion strains of the fungus C. albicans eventually elucidating 
the mode of action of virgineone. This showed the origin of the molecule’s antifungal activity 
was connected to the stress response system. They also tested for the activity of the aglycon in 
their assays revealing that the mannose residue is absolutely necessary to show any biological 
activity. 
It is worth noting that Yajima et al.
[124]
 published a synthesis of the virgineone aglycon 
similar to their published work on epicoccamides. The key intermediates of their synthesis are 
shown in Scheme II.15.  
 
 
 
 
      59   60         61 
 
 
 
 
         61         62          63 
Scheme II.15.  Published
[124]
 synthesis of the virgineone aglycon. A tyrosine derived tetramic acid 
prepared by the shown method utilizing Meldrum’s acid is acylated by a 4-O-acylation rearrangement 
strategy. The second part of the side chain including the ketone and the hydroxyl groups where the 
primary is β-mannosylated in the natural product is attached by Grubbs generation II catalyzed olefin 
cross metathesis. 
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Their preliminary synthetic steps revealed the configuration of the hydroxyl group next to the 
glycoside needs to be most likely R-configurated. They also propose that the stereocenter of 
the tyrosine moiety on the C-5 of the tetramic acid seems to bear the natural S-configuration. 
Concerning the C-7 methyl group their data suggest a racemic configuration. 
The central steps of the published aglycon synthesis are assembly of the tetramic acid moiety 
59 via the method utilizing Meldrum’s acid, a 4-O-acylation rearrangement reaction between 
the tetramic acid, an olefinic side chain 60 and a cross metathesis to attach the diol 62 for 
glycosylation to the other half of the side chain bearing the tetramic acid. 
 
II.6.4. Streptolydigin 
 
The first member of the general class of gylcosylated tetramic acids to be isolated, and one of 
the most extensively studied, is streptolydigin, which was originally described by Rinehart et 
al.
[38]
 in 1963. However, streptolydigin is not referred to as glycosylated tetramic acid in the 
literature. This is possibly due to the uncommon origin of the saccharide moiety. Because of 
having the nitrogen of the tetramic acid glycosylated with L-rhodinose streptoglydin can be 
accounted for to be a member of the N-glycosylated tetramic acid subfamily. The tetramic 
acid moiety of streptolydigin is derived from N
2
-methyl-β-methyl asparagine connected to a 
diene side chain via 3-acylation. The side chain terminates with a complex acetal heterocycle 
including a spiro epoxide. The overall structural features of streptolydigin was shown in 
Figure II.3. and Scheme II.5.  
Streptomyces lydicus strains were found to produce high amounts of streptolydigin beside 
several other antifungal and antibacterial agents released by these actinomycetes
[126]
 of marine 
or terrestrial origin. 
The most important biological activity of streptolydigin is the selective inhibition of bacterial 
RNA polymerases
[40,91]
 as mentioned above. This strongly antibacterial compound is thought 
to bind to the polymerase and prohibit association of the next nucleotide by destroying the 
initiative complex necessary to start RNA elongation, thereby not allowing the DNA template 
strain to move along the polymerase. This theory is supported by a published crystal structure 
of the complete polymerase with UTP (elongation triphosphate) and streptolydigin showing 
the compound prohibits the binding of UTP or another triphosphate to the RNA chain 
3’-terminus[91,92,94]. 
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A     B 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure II.11. Mode of bacterial RNA polymerase inhibition by streptoglydin. A) Within the protein 
(cyan) the DNA template binds to the polymerase. The unused strand (blue) is separated from the 
template strain (red). Without inhibitor (left side) another nucleotide triphosphate NTP (green) binds, 
aligns to its paired base from the template strain and is attached via phosphate linkage. The last step 
is the movement of the next base of the template DNA from the separation domain to the elongation 
domain. When streptolydigin (black) is bound, this movement is prevented. Used with kind permission 
from Elsevier
[92]
. B) Structure of E. coli RNA polymerase derived from published structural data
[94]
 
(PDB code: 2PPB). The structure shows the mechanism of inhibition shown in A) in more detail. The 
unused DNA strain is shown in blue, the template DNA strain in red, the formed new RNA strain in 
yellow, the nucleotide (here UTP) in green and the inhibitor streptolydigin in black. Protein (cyan) and 
the DNA/RNA strains are shown in cartoon presentation and the organic molecules in stick 
presentation. 
Pronin et al.
[43]
 achieved the first, and only, total synthesis in 2010, nearly 50 years after its 
structure was determined. Their key steps are a ring closure metathesis catalyzed by Grubbs 
catalyst, an acetalization over a Weinreb amide, a Wittig reaction, epoxidation, easy to 
facilitate N-glycosylation, aminolysis and HWE olefination. The key steps of their synthesis 
are shown in Scheme II.16. and Scheme II.17.  
The two shown precursors 64 and 65 were derived by Sharpless dihydroxylation (64) and 
stereoselective aldol reaction followed by Evans-Tishchenk reaction (65) respectively. Both 
educts were coupled by standard Steglich conditions for esterification. 
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 67       68         69    70 
Scheme II.16.  Published
[43]
 synthesis of streptolydigin showing the key steps.  
The lactone 67 was formed by ring closing metathesis catalyzed by a Grubbs 2
nd
 generation 
catalyst. This lactone was then transferred into its Weinreb amide, methylated and the acetal 
was closed to form the desired product 68. The side chain was elongated by a Wittig 
olefination and after protective group manipulation, an epoxidation was carried out and later 
formation of the desired aldehyde 70. 
 
 
 
 
 
    71       72                  13 
Scheme II.17.  2
nd
 part of the published
[43]
 synthesis of streptolydigin showing additional key steps.  
The amine 71 was derived from a chiral acid utilizing Evans auxiliary technique to prepare an 
azide which was converted into the corresponding amine and cyclized in an oxidative 
TEMPO catalyzed manner. The L-rhodinose was attached by simply stirring it with the cyclic 
amine 71. A known
[56]
 phosphonate was introduced to this N-glycoside by aminolysis using 
the corresponding β-keto thioester. This phosphonate 72 was attached to the heterocycle by 
HWE olefination. The last step of the synthesis before global deprotection was the Lacey-
Dieckman cyclisation. This cyclisation step yielded the desired tetramic acid 13 by lactam 
opening during Lacey-Dickman cyclisation instead of ester cleavage. 
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II.6.5. Aurantosides 
 
Another class of N-acylated tetramic acids are called aurantosides. Currently eleven 
members
[39,44–48]
 of this compound class are known and their first representative was isolated 
1991 by Matsunaga et al.
[44]
 Their origins are marine sponges like Theonella, Homophymia 
conferta, Siliquariaspongia japonica and the melophlins producing Melophlus family. These 
compounds are normally responsible for the slight orange to dark red color of the sponges. 
Besides the mentioned N-glycosylation with xylose or a trisaccharide starting from xylose, 
they all share a polyene side chain bearing at least one chlorine atom. The general structural 
features of aurantosides are summarized in Figure II.12. 
 
 
 
 
 
 
              4 
Figure II.12. Overview of possible aurantoside structures. R can be H, Me or Ac, R’ only H or Ac 
(orange). The length of the polyene chain can vary from the shortest (black) to the longest (red) C16 
derivative. The saccharide can either be xylose (black) or a trissaccharide starting with xylose (blue). 
The chlorination pattern (green) can be one or more in 1,3- or 1,5-distance. 
Aurantosides A, B and D-F revealed significant cytotoxicity towards leukemia cells and are 
shown to be antifungal on C. albicans and A. fumigates.
[46]
 Their activity was demonstrated to 
be 100 fold higher under the test conditions compared to other tetramic acid glycoconjugates. 
Interestingly aurantosides G, H and J did not show any significant biological activity
[39,47]
 
whatsoever, whereas aurantosides I and K exhibited significant antifungal effects
[47,48]
. 
Unfortunately the applied assays did not allow to determine any structure-activity relationship 
(SAR) between the compounds. The most efficient natural product had the shown 
trisaccharide unit together with a monochlorinated C12 polyene side chain in common. No 
total synthesis of aurantosides is known to date. 
 
II.6.6. Rubrosides 
 
The last subfamily of the N-glycosylated tetramic acid class is built up from compounds 
called rubrosides, found by Sata et al.
[127]
 in 1999. Currently eight members are known
[127]
, 
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and their overall structural motif is identical to the shown variation of aurantosides (Figure 
II.12.). The only difference between the two molecule classes is that all rubrosides have a 
terminal heterocycle at the end of the polyene 3-acyl chain. This hetereocycle is derived from 
tetrahydrofuran (THF), attached by its C-1 carbon to the side chain, R-methylated at C-4 and 
S-chlorinated at the C-2 position. This hereocycle is eventually attached to the above shown 
aurantosides as described in Figure II.13. 
 
 
 
          73 
Figure II.13. Heterocycle attached to aurantosides. The C-1 stereocenter for attachment to the 
polyene side chain derived from aurantosides can be R- or S-configurated.  
Chlorination and chain length can have additional variations compared to aurantosides. All 
rubrosides showed significant cytotoxicity against leukemia cells and comparable but higher 
antifungal activity compared to aurantosides.
[127]
 
Since no total synthesis for aurantosides is published so far, rubrosides bearing an almost 
identical substitution pattern also lack of synthetic access to natural or synthetic derivatives 
for studies of an eventually occuring structure-activity relationship. 
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III. PROJECT AIMS 
 
The aim of this work was to first establish an approach to the natural product compound class 
of glycosyl tetramic acids. The eventually established total synthesis should then be adopted 
to another class of glycoconjugated tetramic acids to verify its generality. Epicoccamide D 
(see Figure III.1.) was chosen to be the first candidate for total synthesis since it bears an 
uncommon β-mannosyl sugar residue together with two stereocenters of unknown 
configuration and a simple tetramic acid residue derived from alanine. It was necessary to find 
an approach which could potentially give rise to the four possible isomers concerning the 
tetramic acid C-5 and its acyl C-7 position, in order to gain insight into the absolute 
configuration of epicoccamides. As next natural products in the focus of this thesis 
ancorinoside B and virgineone were chosen. Their side chains should be synthesised with 
respect to differences in the substititution pattern, the sugar residue and the eventually found 
synthetic procedure for epicoccamide synthesis should be applied when possible. 
 
 
 
 
               1 
Figure III.1. Epicoccamide D and the two stereocenters of unknown configuration shown in red. 
This will be the first total synthesis of a member of this product class bearing the 3-acyl 
tetramic acid motif on one end of a fatty acid chain, and a β-branched mannose on the other. 
Additionally, a route to synthesize N-glycosylated tetramic acids as in the natural product 
group of aurantosides or rubrosides should be investigated. 
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IV. RESULTS 
 
IV.1. Total synthesis of epicoccamide D 
 
Epicoccamides can be fragmented into three major parts which is shown in Figure IV.1.
[28,29]
 
The sugar moiety is connected by a β-glycosidic linkage to a fatty acid chain. The fatty acid 
chain is terminated by a tetramic acid moiety derived from alanine via 3-acylation. 
Epicoccamide D was selected for total synthesis because it is said to have the highest 
cytotoxic and antiproliferative effects in initial cellular based tests.
[28]
 More material is also 
required to perform additional biochemical tests on possible drug-like properties and to 
potentially find a mode of action of this compound class. 
 
 
 
 
                1 
Figure IV.1. Epicoccamide D (1) consists of three major parts: A β-mannose (blue) connected to a 
fatty acid chain (green) by which an alanine derived tetramic acid (red/orange) is 3-acylated. 
The first attempt to synthesize epicoccamides started from a peracetylated 
trichloroacetimidate glucose donor in order to benefit from the β-directing effect of a 
2-O-acetyl participating group and after glycosylation changing the protective group pattern 
to a 2-O-unprotected sugar residue. This approach allows performing the necessary 
2-O-epimerisation. The protective group pattern was chosen to be 4,6-O-benzylidene
[128,129]
 
together with a selective 3-protection
[130–132]
 but failed on selective introduction of any 
protective group on 2- or 3-position after benzylidene protection due to proposed sterical 
hinderance by backflipping (backfolding)
[133]
 of the alkyl chain. Starting from a mannose 
lacks β-stereoselectivity in a synthetic approach for a total synthesis[124]. 
The first trials also included a 3-acylation method developed by Schobert et al.
[34,134]
 starting 
from a tetramic acid
[110]
. The 3-acylation would be followed by a new methylation procedure 
of the 3-acylylide. This methylation was also not successful. 
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IV.1.2. Retrosynthesis of epicoccamide D 
 
It was evident from these first trials of synthesis that the protective groups of the sugar residue 
must be in place right before glycosylation and the sugar must bear an orthogonal protection 
at the 2-position. The assembly of the tetramic acid moiety was planned to be done in a very 
late step of synthesis to avoid purification problems concerning the 3-acyl tetramic acid with 
its metal chelating properties
[20,99,100]
. Closure of the tetramic acid moiety should be carried 
out by a Lacey-Dieckmann cyclisation
[117]
 to avoid these problems. With that information in 
hand an approach to epicoccamide D seems possible. This retrosynthetic plan was developed 
with regards to the three major parts of the target molecule and is summarized in Scheme 
IV.1.  
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Scheme IV.1.  Retrosynthetic approach to epicoccamide D. 
The retrosynthesis started with a stereoselective hydrogenation of a double bond formed by 
HWE reaction (Horner-Wadsworth-Emmons). This step allows access to both diastereomers 
which can prove useful to get insight into the hitherto unknown absolute configuration. 
Retrosynthesis continued with a Lacey-Dieckmann cyclisation
[117]
 which is a common method 
for tetramic acid formation at a late step of synthesis.
[64,66]
 The educt for this cyclisation step 
was built by aminolysis of the HWE product 74
[56]
 using a thioester functionality and the 
corresponding amino acid methyl ester. The necessary aldehyde 75 for this olefination step 
was to be formed from a corresponding diol 78 by oxidation which was introduced via 
glycosylation of trichloracetimidate 77. The β-configuration of the glycosidic bond was 
formed by glycosylation utilising a donor derived from D-glucose bearing a 2-O-participating 
RESULTS - Epicoccamide D 
35 
 
protective group. Other donors like a diacetylated sugar
[135]
, a 1-hydroxy donor
[136]
, a 
α-bromide under Koenigs-Knorr conditions[137] or directly from an orthoester[138,139] failed. To 
gain access to the manno-configuration of the desired natural product an epimerisation 
reaction was carried out right after glycosylation. The donor 77 for glycosylation was built 
with a 2-O-protecting group which should be participating and orthogonal to the other 
protective groups for the sugar moiety. A standardized trichloroacetimidate donor should be 
used for glycosylation as a first test. 
 
IV.1.3. Total Synthesis 
 
The forward synthesis started from D-glucose which was first peracetylated with acetic acid 
anhydride in pyridine with a 96% yield.
[140]
 The peracetylated glucose 80 was transferred into 
a known ethoxy-orthoester 81
[141,142]
 by a newer I2/Et3SiH mediated reaction procedure
[143]
 in 
over 99% yield. This orthoester allowed manipulation of the protecting groups in 3-, 4- and 
6-position. 
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Scheme IV.2.  Synthesis of the glycosyl donor. Reagents and conditions: a) 3:2 pyridine:Ac2O, RT, 
overnight, 96%; b) I2 (1.4 equiv), Et3SiH (1.4 equiv), CH2Cl2, reflux, 1 h; c) 2,6-lutidine (4 equiv), EtOH 
(6 equiv), TBAI (0.25 equiv), reflux, 3 h, >99% over two steps; d) NaOMe (0.2 equiv), MeOH, RT, 
45 min; e) BnBr (4.5 equiv), NaH (4 equiv), DMF, RT, 1 h, 91% over 2 steps; f) p-TsOH (0.5 equiv), 
dimethoxyethane:H2O 10:1, RT, 2 h; g) Cl3CCN (8 equiv), DBU (0.2 equiv), CH2Cl2, RT, 90 min, 83% 
over 2 steps. 
The acetates where exchanged with benzyl ethers by a known
[144–146]
 ester interchange method 
and protecting procedure using first sodium methoxide in methanol and then benzyl bromide 
and sodium hydride to yield 91% of the benzylated product 82. To open the formed orthoester 
selectively, different methods were evaluated. While methods via aqueous acetic acid
[147]
 or 
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sulfuric acid
[145]
 failed and a method via a 1,2-O-diacetate
[148]
 included one more step, a 
procedure using p-TsOH in a mixture of dimethoxyethane and water (10:1) yielded the 
desired 2-O-acetyl hemiacetal which was directly transferred into the imidate 77 with DBU 
and trichloroacetonitrile under standard conditions.
[149]
 The yield for this reaction was 83% 
over two steps. All the steps to form the desired glycosyl donor are summarized in Scheme 
IV.2.  
The desired glycosyl acceptor 78 consisting of a monoprotected C16 alkyl chain diol was 
synthesized by starting from hexadecanolide 83. The free diol was prepared by nearly 
quantitative reduction of 83 using LiAlH4 in THF.
[150,151]
 The monoprotection was carried out 
under improved standard conditions
[88]
 with imidazole and TBSCl to get the desired 
monoprotected diol 78 in 63% yield. Other methods using sodium hydride as base to make the 
sodium alcoholate and take the advantage of a phase transfer as reported
[152,153]
 for shorter 
alkyl chains normally yielding high amounts of the desired monosilylated diol failed. The 
reason for this fact might be the alkyl chain being too long to distinguish between the two 
alcohol groups. The synthetic procedure to form the glycosyl acceptor 78 can be seen in 
Scheme IV.3.  
 
 
 
     83           84            78 
Scheme IV.3.  Synthesis of the monoprotected diol 78. Reagents and conditions: a) LiAlH4 (2.5 equiv), 
THF, reflux, 1 h, then RT, 12 h, 99%; b) TBS-Cl (1 equiv), imidazole (2 equiv), THF, RT, 12 h, 63%. 
The educt phosphonate 76 for the key step HWE reaction was prepared corresponding to a 
procedure published by Burke et al.
[56]
 with higher yields. The first step of this reaction 
sequence was to install the β-ketothioester moiety by mixing bromopropionyl bromide with 
Meldrum's acid and after acidic extraction adding 2-methylpropane-2-thiol. This reaction 
yielded the bromo β-ketothioester 86 in 81% yield over two steps. 
 
 
 
 85      26        86          76 
Scheme IV.4.  Synthesis of the phosphonate 76. Reagents and conditions: a) pyridine (2 equiv), 0 °C, 
1 h; b) 2-methylpropane-2-thiol (TBM, 3 equiv), toluene, reflux, 1 h, 81% over 2 steps; c) NaH 
(1.1 equiv), THF, -20 °C, 10 min then Na (1.3 equiv), diethylphosphite (1.2 equiv), THF, RT, 16 h, 
97%. 
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In the next step the actual phosphonate 86 was built by an Arbuzov reaction of 26 with 
diethylphosphite and sodium hydride
[56]
. The desired phosphonate 76 was assembled by this 
reaction in 97% yield without purification in sufficient quality and can be stored for up to four 
weeks. This procedure is shown in Scheme IV.4.  
Assembly of the starting material for the actual total synthesis continued by forming 
N-methylated alanine methylesters 89 for aminolysis and Lacey-Dieckmann cyclisation
[56,117]
 
(see Scheme IV.1.). Cheap tbutoxycarbonyl (BOC) protected alanine was first methylated 
using MeI and sodium hydride.
[56,154–156]
 The methylation yielded 98% of the corresponding 
pure S-enantiomer of the N-methyl amino acid 88 or its racemic mixture depending on the 
starting material. It is not understandable why examples in literature
[157,158]
 first deprotect the 
amine with aqueous HCl and in the next do an esterification in methanol by SO2Cl2. The 
liberation of HCl during esterification should be sufficient for BOC-deprotection in one single 
step. For this reason a one pot esterification and BOC-deprotection procedure was applied as 
stated in Scheme IV.5. The procedure was very close to the published ones
[157,158]
 used to 
form the actual methyl ester starting from the deprotected N-methyl amino acid. This reaction 
gave the desired ester 89 in 88% yield concerning the S-enantiomer or 72% for the racemate. 
 
 
 
        (S)-87  (S)-88            (S)-89 
      (R/S)-87           (R/S)-88           (R/S)-89 
Scheme IV.5.  Synthesis of amino acid derivatives. Reagents and conditions: a) NaH (3 equiv, 60% in 
mineral oil), MeI (8 equiv), THF, RT, 20 h, 98%; b) SOCl2 (4 equiv), MeOH, RT, 24 h, 72-88%. 
With all the necessary starting material for total synthesis in hand, the first key step of the 
actual synthesis of epicoccamide D was the glycosylation. First trials showed that the 
2-O-participating acetyl group works as anticipated
[159–161]
 during glycosylation of donor 77 
with 1.1 equiv. of the acceptor alkyl chain 78 yielding only the β-configurated product. No 
trace of the corresponding α-product in crude thin layer chromatography, 1H and 13C NMR 
could be found. The initial yields were slighty above 60% at -20 °C. The lack of a good yield 
was explained by isolating a side product which was identified to be acetylated alkyl chain 78. 
The product was formed by transferring the 2-O-acetyl group from the sugar to the alkyl chain 
under Lewis-acidic conditions. To get less of this side product it was possible to decrease 
glycosylation temperature to -78 °C due to the reactivity of linear alkyl chains in 
glycosylations. This increased the initial yield to above 70% but still the fully protected alkyl 
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chain was a major side product. Since the side chain can be generated in two steps with good 
yields (see Scheme IV.3.) the equivalence of the acceptor side chain 78 was increased step by 
step to 1.7 yielding 84% of the desired glycosylation product 90 (see Scheme IV.6.). Roughly 
0.5 equivalence of the side chain could be reisolated after glycosylation and again be used. 
The next challenge was the epimerisation reaction to form the desired manno-configurated 
glycoside 93. For that purpose a standard procedure for deacytelation
[144,146]
 was applied to 
form the 2-hydroxy product 91 in nearly quantitative yield. Since first trials with the 
Cornforth reagent pyridinium dichromate
[162]
 failed, Swern oxidation and variations were 
tested to oxidize the sugar which could in a next step be reduced stereoselectively. A standard 
Swern oxidation using DMSO and oxalyl chloride
[163,164]
 or trifluoroacetic anhydride
[163,165–
167]
 failed also like the variants established by Pfitzner-Moffat utilizing DMSO and 
dicyclocarbodiimide
[168]
, the mild Albright-Goldman procedure with DMSO and acetic 
anhydride
[169,170]
 often used for sugar oxidation
[168,171–173]
 and the Corey-Kim type reaction 
with dimethyl sulfide and N-chlorosuccinimide
[174–176]
. Where the other reactions showed no 
conversion, the Corey-Kim procedure also used for sterically hindered products
[177]
 and 
sugars
[178]
 yielded a 2-O-methylsulfonated product. At the end the oxidation was successful 
by switching to the Dess-Martin periodinane (DMP)
[179]
 which was applied in sugar oxidation 
as well
[180]
. Oxidation of the sugar moiety with DMP yielded in 96% yield the desired sugar 
ketone 92. Due to the mentioned backfolding of the alkyl chain (see chapter IV.1) 3 equiv. of 
DMP were necessary. The selective reduction could be carried out easily with NaBH4 
yielding the desired manno-configurated product 93 in 97% yield. The only side product of 
the reaction was 3% of the gluco-configurated product 91 which could be separated by 
chromatography. The glycosylation and epimerisation sequence is shown in Scheme IV.6.  
To prepare the desired aldehyde for HWE reaction, TBS deprotection was necessary first 
which was carried out using a TBAF solution in THF
[181]
. This step yielded 98% of the 
desired diol 94. 
For the following steps of synthesis the sterical blockage of the sugar moiety by the alkyl 
chain was helpful, because no 2-O-protecting group was necessary. The free axial 
2-O-hydroxy functionality did neither disturb the oxidation of the alkyl chain to an aldehyde 
nor was able to catch away base for the HWE reaction. However, it can be protected e.g. with 
sodium hydride and benzyl bromide in 68% yield but it was evident that the overall yield with 
this additional step might be less. 
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    77       90: R
1
 = Ac               92 
           91: R
1
 = H 
 
 
 
     92    93: R
2
 = TBS     75 
        94: R
2
 = H 
Scheme IV.6.  Synthesis of glycoside 90, epimerisation and oxidation. Reagents and conditions: a) 78 
(1.7 equiv), BF3•OEt2 (0.15 equiv), 4 Å mol. sieves, CH2Cl2, -78 °C, 2 h, 84%; b) NaOMe (2 equiv), 
MeOH, RT, 12 h, 99.2%; c) DMP (3 equiv), CH2Cl2, RT, 16 h, 96%; d) NaBH4 (10 equiv), 
MeOH:CH2Cl2 1:1, RT, 12 h, 97%; e) TBAF (1 M in THF, 2 equiv), THF, RT, 12 h, 98%; f) DMP 
(1.15 equiv), CH2Cl2, 0°C to RT, 3 h, 70%. 
The actual oxidation of the primary hydroxy group on the alkyl chain was carried out again 
with DMP
[179]
. To avoid the possible reoxidation of the sugar moiety the reaction was started 
at 0 °C and with no huge excess of oxidation reagent. This oxidation yielded in 70% the 
desired aldehyde for Horner-Wadsworth-Emmons olefination 75 and about 22% of recovered 
dialcohol 94. 
 
 
 
 
           75     76              74 
Scheme IV.7.  Subsequent HWE olefination. Reagents and conditions: a) 76 (1.4 equiv), nBuLi 
(2.8 equiv), THF, -78 °C to RT, 4 h, 80%. 
The following HWE reaction
[182,183]
 was carried out to install a β-ketothioester unit which in 
turn enabled access to an aminolysis reaction where the corresponding amino acid from the 
natural chiral pool was connected. This olefination step needed a good tuning in reaction 
parameters as well as screening for the most efficient base. The work of Ley et al.
[56]
 where 
the used phosphonate 76 is derived from, KHMDS is proposed to give good yields and 
satisfactorily E/Z rates. Other publications
[184–186]
 showed a wide set of different bases and the 
influence of lithium salts
[185]
 for higher Z-selectivity than the HWE normally provides
[183]
. 
e 
b 
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Trials with different bases are summarized in Table IV.1. For these initial trials, a test system 
with the same phosphonate 76 and hexanal was established which was also applied for tests of 
catalysts later on. 
Table IV.1. Overview of the tested bases screened in the HWE olefination step. 
Entry Base
[a]
 Additive
[b]
 Yield
[c]
   E:Z
[d]
 Notice 
1 KHMDS  -- 80% 4:3 Slow addition of base by syringe pump 
2 KHMDS  -- 79% 5:1 Fast addition of base 
3 KHMDS LiCl 65% 5:6 Slow addition of base by syringe pump 
4 NaHMDS  -- 60% 1:1 Slow addition of base by syringe pump 
5 LiHMDS  -- 25%
[e]
 10:11 Slow addition of base by syringe pump 
6 NaH  -- 72% 4:3  
7 LDA  -- < 5% 1:1 Nearly no conversion
[e]
 
8 DBU  -- < 5% 7:5 Decomposition 
9 DBU LiCl < 5% 10:11 Strong decomposition 
10 t-BuOK  -- 14% 7:5 Nearly no conversion 
11 t-BuOK LiCl 8% 11:10 Decomposition 
12 n-BuLi  -- 88% 6:5 Slow addition of base by syringe pump 
13 n-BuLi  -- 82% 12:5 Fast addition of base 
[a] always 2 equiv based on the phosphonate 76 used; [b] 1:1 ratio concearning the base used; 
[c] based on the aldehyde 75, [d] determined by NMR, [e] old reagent used. 
Table IV.1 shows that the usage of KHMDS yields the highest E-selectivity as supposed by 
the results of Ley et al.
[56]
 It was also evident that slow addition of the base via syringe pump 
worsened the E-selectivity of the used KHMDS possibly due to equilibration of different ylide 
species. The two highest yielding bases KHMDS and nbutyl lithium were then tested in the 
complete system with aldehyde 75 and phosphonate 76. In these experiments the silazane 
base failed to give good yields but nbutyl lithium gave stable yields around 80% with the 
mentioned bad E/Z-selectivity of 2.4:1. It was suprising that the E/Z-selectivity of nbutyl 
lithium did not play any role in the subsequent synthesis since the double bond seems to 
isomerize only to the E-derivative during Lacey-Dieckman cyclisation which will be 
described later on. The HWE olefination step was therefore carried out with nbutyl lithium, 
because it had always the highest and most reproducible yields. 
To attach the desired amino acid methyl ester 89, the aminolysis protocol from the equisetin 
total synthesis
[56]
 was adapted. The amount of base used was increased to account for the 
direct usage of the HCl salt gained from esterification with SOCl2 (see Scheme IV.5.). Since 
the methyl ester salt 89 dissolved slowly in CH2Cl2 and the sterical demanding thioester 74 
slowed the reaction speed down, reaction time was increased and the reaction was carried out 
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in complete darkness to avoid reduction of the silver salt
[187,188]
 F3CCOOAg. 
Triofluoroacetate was used as anion because it dissolves in organic solvents
[189]
. Since the 
configuration of the two additional stereocenters beside the sugar moiety was unclear
[28,29]
, it 
was likely that nature might have used the S-isomer concerning the tetramic acid C-5 for 
biosynthesis. Therefore aminolysis was carried out using the S-configurated ester (S)-89 and 
the racemic mixture (R/S)-89 for comparison to gain a β-ketoamide 95 necessary for 
Lacey-Dieckmann cyclisation. Both reactions yielded 89% of the desired ketoamide. 
 
 
 
 
        74                  (2S)-95 
                   (2R/S)-95 
Scheme IV.8.  Aminolysis. Reagents and conditions: a) 89 (2.5 equiv), NEt3 (3.5 equiv), F3CCOOAg 
(2 equiv), CH2Cl2, light exclusion, 0 °C, 5 h, 89%. 
The standard procedure of the Lacey-Dieckmann cyclisation
[117]
 step was slightly changed by 
reducing the used base sodium methoxide to a minimum (2 equiv instead of 5 equiv) to avoid 
racemisation of the formed tetramic acid moiety by C-5 epimerisation
[34]
 and also reducing 
stirring time (20 min instead of 45 min). 
 
 
 
 
        (2S)-95        (5S)-96 
      (2R/S)-95      (5R/S)-96 
Scheme IV.9.  Lacey-Dieckmann cyclisation. Reagents and conditions: a) NaOMe (2 equiv), MeOH, 
RT, 20 min, quant. 
With these changes epimerization could be decreased to less than 4% which was checked by 
again using the phosphonate 76 with (4S)-methylhexanal, going through the above illustrated 
reaction sequence and analyzing the Lacey-Dieckmann adduct by chiral HPLC. In respect of 
the educt aldehyde purity of 98% this value is acceptable. It was surprising that these reaction 
conditions isomerized the double bond which was only 70% E-configurated to 90% of the 
E-isomer. Later BF2-complexation steps isomerized the double bond further to only 
E-configurated isomer exclusively. This cyclisation step yielded the desired tetramic acid 
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quantitatively without purification which can be used directly in the following steps of 
synthesis. 
A          B         C 
 
 
 
 
 
 
D       E 
 
 
 
 
 
 
 
 
Figure IV.2. Base dependent E/Z-selectivity in HWE olefination step. A) HWE reaction of phosphonate 
76 with hexanal and NaHMDS as base; B) HWE reaction of phosphonate 76 with hexanal and n-BuLi 
as base added fast; C) chiral HPLC profile of the Lacey-Dieckmann cyclisation product derived from 
the phosphonate 76 and (4S)-methylhexanal; D) Lacey-Dieckmann cyclisation product of the auxiliary 
97 (see Scheme IV.10. ); E) product of BF2-complexation of 97. 
The final step of synthesis right before global deprotection needed to be an asymmetric 
hydrogenation to establish the second methyl substituted stereocenter in the side chain as 
selectively as possible. This step would also open access to both isomers. To test the different 
possible catalysts for asymmetric homogeneous hydrogenation the above mentioned test 
system also used for screening of bases concerning the HWE reaction was again applied. It 
was evident from first trials of the homogeneous hydrogenation with the corresponding 
3-octenoyl tetramic acid shown in Scheme IV.10. (97) that the metal chelating propensities of 
3-acyl tetramic acid traps the catalyst and therefore prohibits the actual reaction. 2-Octenic 
acid was also not reactive under similar conditions but its ethyl ester reacted well. This 
provided evidence that the metal chelating properties of the tetramic acid needed to be 
somewhat disarmed. For this reason the corresponding BF2-complex was formed which is a 
well known
[30,98,134]
, easy to handle and stable storage form of tetramic acids. The same 
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methodology as for the complete system shown in Scheme IV.7. and Scheme IV.8. was 
applied. 
 
 
 
           76        98               99 
 
 
 
 
           99            97            100 
 
 
 
 
         100               (5S,7S)-101 
Scheme IV.10.  Synthesis of a test system auxiliary. Reagents and conditions: a) Hexanal (1.0 equiv), 
76 (1.4 equiv), n-BuLi (2.8 equiv), THF, -78 °C to RT, 1.5 h, 87%; b) (S)-89 (2.5 equiv), NEt3 
(3.5 equiv), F3CCOOAg (2 equiv), CH2Cl2, light exclusion, 0 °C, 2 h, 83%; c) NaOMe (2 equiv), MeOH, 
RT, 20 min, quant.; d) BF3•OEt2 (5 equiv), CH2Cl2, RT, 12 h, 90%; e) [(R,R)-Rh-Et-DUPHOS]
+
 BF4
-
 
(4 mol%), 100 bar H2, CH2Cl2, 35 °C, 16 h, 97%. 
With this test system in hand different rhodium based catalysts were tested, analyzed via 
chiral HPLC and the reaction conditions (pressure and temperature) were optimized. The 
solvent was changed to CH2Cl2 since protic solvents dissolve the BF2-complex in a few hours. 
Rhodium catalysts with chiral mono- and bidendate phosphine ligands
[190–195]
 had been found 
to be active in other electron deficient systems
[196]
. Conditions were derived from the Nobel 
prize lecture 2001 (Prof. William S. Knowles)
[197]
 and others
[195,198]
. Beside different 
homogeneous catalysts also including a Crabtree like Ir-based catalyst
[199,200]
 the MacMillan 
organocatalyst S-Mac-H
[201]
 was used as well as Pd/C
[202,203]
 as reference. It is worth 
mentioning that the heterogeneous catalyst showed a certain stereoinduction which might be 
caused by the fact that tetramic acid BF2-complexes are generally not totally flat
[98]
 but have 
the boron atom elevated over the plain of the normally flat tetramic acid motif. This might 
give a heterogeneous hydrogenation using a catalyst like Pd/C a certain induction
[204]
 possibly 
also due to the slightly imposed methyl group attached to the C-5. These results are 
summarized in Table IV.2. 
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Table IV.2.  Catalysts and conditions for asymmetric hydrogenation. The individual catalysts tested 
are shown in Figure IV.3 below. 
Entry Catalyst Anion Conditions
[a]
 Yield de
[b]
 
1 Pd/C  -- 10 wt% catalyst, MeOH, 1 bar 99% 42% 
2 Pd/C  -- free tetramic acid
[c]
, 10 wt% catalyst, MeOH, 1 bar 99% 4% 
3 S-Mac-H  -- 10 mol% catalyst, RT 0%  -- 
4 Ir-ThrePHOX BARF 4 mol% catalyst, 180 bar 0%  -- 
5 Rh-BINAP
[d]
 BF4 4 mol% catalyst, 8mol% BINAP
[e]
 30% 18% 
6 Rh-MONOPHOS
[d]
 BF4 4 mol% catalyst, 8mol% MONOPHOS
[e]
 50% 19% 
7 Rh-iPr-FERPHOS BF4 4 mol% catalyst, 80 bar 85% 40% 
8 Rh-Me-DUPHOS BF4 4 mol% catalyst, 80 bar 48% 52% 
9 Rh-Et-DUPHOS OTf 4 mol% catalyst, 100 bar 10% 82% 
10 Rh-Et-DUPHOS BF4 4 mol% catalyst, 100 bar 97% 82% 
11 Rh-iPr-DUPHOS BF4 4 mol% catalyst, 120 bar 56% 69% 
[a] 35 °C, CH2Cl2, 16 h, 80 bar H2 pressure as indicated; [b] determined by chiral HPLC analysis and 
NMR spectra; [c] instead of the corresponding BF2-complex the free tetramic acid was used for 
comparison; [d] pre-catalyst [Rh(cod)2]
+
 BF4
-
 used; [e] BINAP and MONOPHOS ligands added to 
pre-catalyst. 
A         B      C 
 
 
 
 
 
D       E   F   G 
 
 
 
 
H        I         J 
 
 
 
 
Figure IV.3. Ligands tested for stereoselectivity in catalytic hydrogenation. A) Mac-Millan catalyst
[201]
 
with Hantzsch-Ester and 10 mol% of a imidazolidinone derivative; B) Crabtree like catalyst
[199,200]
; 
C) BARF anion
[199]
; D) [Rh(cod)2] BF4 pre-catalyst; E) BINAP
[190,195]
; F) MONOPHOS
[192–194]
; 
G) Rh-iPr-FERPHOS
[191]
; H) Rh-Me-DUPHOS
[191,194]
; I) Rh-Et-DUPHOS
[191]
; J) Rh-iPr-DUPHOS
[191]
. 
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To apply these results to the total synthesis, the method of BF2-complex formation needed to 
be changed. The amount of BF3•OEt2 used and temperature was decreased to a minimum 
since the strong Lewis-acidic BF3 degraded the glycosidic bond due to its strong sugar 
activating properties
[160]
 when the conditions for the auxiliary were adopted. The amount of 
BF3•OEt2 was minimized from 5 equiv to 1.2 equiv and the temperature was decreased to 
0 °C. Below that temperature complex formation was prevented nearly completely. 
With the appropriate BF2-complex in hand asymmetric hydrogenation was carried out under 
the same conditions as for the auxiliary and yielded exactly the same results as can be seen in 
Table IV.2. concerning yield and stereoselectivity and in Figure IV.4. below showing again 
stereoselectivity and purity. 
A        B 
 
 
 
 
 
 
 
 
C       D          E        F 
 
 
 
 
 
 
 
 
Figure IV.4. NMR and HPLC data showing purity and stereoselectivity of the hydrogenation products 
where Rh-Et-DUPHOS
[191]
 was used. A) Pd/C catalyzed hydrogenation and BF2-complexation 
thereafter to compare retention times and NMR spectra; B) (R,R)-configurated Rh-Et-DUPHOS 
catalyst used establishing a 7S stereocenter; C) (S,S)-configurated Rh-Et-DUPHOS catalyst used 
establishing a 7R stereocenter; D) HPLC profile of the BF2-complex educt used for hydrogenation; 
E) nearly racemic mixture of the Pd/C hydrogenated and afterwards complexed product; F) HPLC 
profile of the product hydrogenated using the (R,R)-configurated Rh-Et-DUPHOS catalyst. In D, E, and 
F the chromatogram shows the retention time (x-axis) plotted against the absorption in mAU (y-axis). 
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The final step of the total synthesis of epicoccamide D was a global deprotection step where 
the BF2-complex was also removed. Standard Pd/C hydrogenation was applied to remove the 
benzyl protecting groups. Methanol
[30]
 was employed as solvent in which BF2-chelate 
complexes are not stable
[134]
. The product (5R/S)-96 using the racemic amino acid methyl 
ester (R/S)-89 was directly hydrogenated to yield “racemic” epicoccamide with regard to the 
unknown absolute configuration of the C-5 and C-7 stereocenter. 
 
 
 
 
      (5S)-96      (5S)-102 
 
 
 
 
       (5S)-102     (5S,7S)-103 
         (5S,7R)-103 
 
 
 
 
 
 
 
 
 
        (5S,7S)-103, (5S,7R)-103        (5S,7S)-1, (5S,7R)-1 
    or (5R/S)-96           or (5R/S,7R/S)-1 
Scheme IV.11.  Final global deprotection step of the total synthesis of epicoccamide D. Reagents and 
conditions: a) BF3•OEt2 (1.2 equiv), CH2Cl2, 0 °C to RT, 12 h, 62%; b) (S,S)- or (R,R)-Rh-Et-DUPHOS 
(0.04 equiv), 80 bar H2, CH2Cl2, 35 °C, 16 h, 97%; c) Pd/C (5%, 100 wt%), 1 bar H2, MeOH, 35 °C, 
4 h, 97%; d) Pd/C (5%, 10 wt%), 1 bar H2, MeOH, RT, 4 h, 97%. 
With the different final products of total synthesis in hand assignment of the stereocenter 
established by the catalyst was necessary as a final working step to compare raised data with 
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published
[28]
 results and eventually figure out the absolute configuration of natural 
epicoccamide D. 
 
IV.1.4. Assignment and absolute configuration of synthetic products 
 
The model compound 100 shown in Scheme IV.10. was subjected to hydrogenation with both 
(S,S)- and (R,R)-Et-DUPHOS configurated catalysts and afterwards compared to the same 
model compound made by another route with a known stereocenter at C-7. NMR shifts as 
well as optical rotation were consulted to assign the stereoinduction of the used catalyst 
Rh Et-DUPHOS
[191]
 and with this information in hand the absolute configuration at the C-7 
methyl group on the side chain. The model compound was synthesized via 3-acylation of a 
free tetramic acid using the method described by Yoda et al.
[205]
 and afterwards BF2-complex 
formation was applied. The starting compounds required for this model compound were 
available in the work group made from octanoic acid α-methylated by the Evans auxiliary 
technique
[206,207]
 and tetramic acid formation of the corresponding N-Boc-protected amino 
acid benzyl ester using ketenylidentriphenylphosphorane
[34,110,134,208,209]
 and hydrogenolytic 
deprotection
[30]
. 
 
 
 
 
              (2S)-104    (5S)-105        (5S,7S)-101 
Scheme IV.12.  Alternative access to the model compound to assign the stereocenters. Reagents and 
conditions: a) tetramic acid 105 (1 equiv), EDCI (2 equiv), DMAP (2 equiv), CH2Cl2, 0 °C to RT, 4 h; b) 
CaCl2 (1.5 equiv), DMAP (0.3 equiv), NEt3 (1.2 equiv), CH2Cl2, RT, 90 min; c) BF3•OEt2 (5 equiv), 
CH2Cl2, RT, 16 h, 52% over three steps. 
The tetramic acid (5S,7S)-101 obtained from the 3-acylation with a known stereocenter was 
then compared to the one obtained from a HWE olefination, aminolysis, Lacey-Dieckmann 
cyclisation and asymmetric hydrogenation sequence in regard to their HPLC- and NMR-data 
shown in Figure IV.4. The mentioned tetramic acid (5S,7S)-101 had 
1
H and 
13
C NMR shifts 
and a retention time in agreement with the tetramic acid gained from the developed reaction 
set by usage of the (R,R)-Rh-Et-DUPHOS catalyst. These results lead to the assumption that 
the (R,R)-catalyst is building a S-configurated stereocenter and a (S,S)-catalyst gave rise to a 
R-configurated stereocenter. The shown data gave all the information necessary to assign the 
stereocenters in natural epicoccamide D. 
RESULTS - Epicoccamide D 
48 
 
IV.1.5. Comparison of synthetic products with natural epicoccamide D 
 
The specific rotation of the synthetic products were compared to the one from natural 
epicoccamide D
[28]
 besides their 
13
C chemical shift in respect of the carbon at position 5 and 7 
to assign the absolute configuration of natural epicoccamide. These results are summarized in 
Figure IV.5. and Table IV.3. 
 
 
 
 
 
 
 
 
Figure IV.5. 
13
C NMR shifts of two synthetic epicoccamide D isomers yielded from usage of the (R,R)- 
and (S,S)-Et-DUPHOS catalyst. 
An overview concerning these results is given in Table IV.3. 
Table IV.3. Comparison of the specific optical rotation
[a]
 and 
13
C NMR shifts
[b]
 of natural and synthetic 
epicoccamide D beside another epicoccamide isomer. 
Entry  Natural 1 (5S,7S)-1 (5S,7R)-1 
1 [α]D
25
 [°] -40 -39 -30 
2 
13
C-NMR: C-5 [ppm] 14.8 15.0 15.3 
3 
13
C-NMR: C-7 [ppm] 17.0 17.3 17.7 
[a] recorded in MeOH with c = 0.2 g cm
-3
; [b] 75 MHz in CDCl3. 
These results gave strong evidence that the absolute configuration of natural epicoccamide D 
is 5S and 7S respectively and that the right product was synthesized. This assumption was 
confirmed by Yajima et al.
[123]
 after publication
[32]
 of the shown data. 
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IV.2. Total synthesis of ancorinoside B diglycoside 
 
A similar fragmentation for ancorsinosides
[100,119,120]
 as for epicoccamides
[28,29]
 is possible. 
The major difference to epicoccamides is a disaccharide unit at one end of the fatty acid chain 
in contrast to a single mannose. In case the of ancorinosides the tetramic acid moiety is 
derived from D-aspartic acid and the side chain is longer and can be substituted with a methyl 
group near the middle (ancorinoside C)
[120]
 or a Z-configurated double bond 
(ancorinoside D)
[120]
. The disaccharide unit consists either of a Glc-β(1-4)GalU unit 
(ancorinoside A and D)
[100,119,120]
 or a vice versa configurated Gal-β(1-4)GlcU unit 
(ancorinoside B and C)
[120]
. Ancorinoside B was chosen for total synthesis since it shares a 
simple side chain with ancorinoside A and was tested in more detail revealing interesting 
properties like a quite selective inhibition of MMP2
[120]
, a matrix metalloprotease connected 
to disease by its angiogenic effect
[210,211]
 in tumor growth. The target structure of 
ancorinoside B is shown in Figure IV.6. displaying its three major parts: The disaccharide 
unit, the fatty acid chain and the tetramic acid moiety. 
 
 
 
 
            2 
 
Figure IV.6. Ancorinosid B (2) consists of three parts: The blue dissacharide with a light blue 
galactose and a dark blue glucuronic acid connected by a β(1-4) linkage again β-connected to a fatty 
acid chain (green). The fatty acid chain is attached via 3-acylation to an aspartic acid derived tetramic 
acid (red). 
 
IV.2.2. Retrosynthesis of ancorinoside B 
 
Retrosynthesis commenced with similar steps as for the synthesis of epicoccamides as stated 
above (Scheme IV.1.). No asymmetric hydrogenation was necessary to build up 
ancorinoside B since the side chain of the chosen target molecule has no substitution. 
Additional differences to epicoccamide are the two β-configurated glycosidic bonds and a 
glucose residue oxidised to the corresponding glucuronic acid. The disaccharide bearing a 
lactose pattern should be build up by either using a readily oxidised glucuronic acid acceptor 
with a galactose donor or by utilizing a accordingly protected glucose acceptor and oxidize 
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right after the first or second glycosylation step. With respect to these differences the 
following retrosynthetic plan was developed. 
 
 
 
 
        107 
 
 
 
 
    107          108 
 
 
 
 
      108           110           111 
 
 
 
 
 
   110      112              113 
Scheme IV.13.   Retrosynthetic approach to ancorinoside B. X = β-SPh or OAllyl (converted to 
α-trichloroacetimidate); Y = COOBn, COOMe or CH2OTBS. 
The retrosynthetic goal for the total synthesis of ancorinoside B was again to build up the 
tetramic acid moiety as late as possible, because of its metal chelating propensity. This part 
was therefore assembled by a Lacey-Dieckmann cyclisation
[117]
 of the product gained from an 
aminolysis reaction with a protected homoserine which was converted into the actual aspartic 
acid derivative by deprotection and oxidation right after the cyclisation step. This was carried 
out to avoid formation of a 6-membered ring side product which might turn out to be hardly 
removed once the polar tetramic acid is established. Expensive D-homoserine can be derived 
from cheap D-methionine.
[212]
 In front of the cyclisation step the necessary connection 
between the diketo moiety and the fatty acid glycoside was formed by a HWE olefination 
reaction
[32,56]
. The aldehyde 108 was to be build by glycosylation of an adequate disaccharide 
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donor 110 and the corresponding side chain acceptor 111 which was in turn assembled via 
reduction of eicosanedioic acid
[213]
 and monoprotection. The desired glycosyl donor 110 
should be assembled by glycosylation of a perbenzoylated donor 112 and either a readily 
oxidized and accordingly protected glucoronic acid ester acceptor 113 or, since the oxidized 
sugars are difficult to handle
[214]
 and often oxidized right after glycosylation
[215]
, an 
accordingly 6-O-protected acceptor 113 which can be deprotected and oxidized directly after 
one of the glycosylation steps. The actual functional group for gylcosylation was to be 
elaborated in preliminary experiments. Both Fischer
[216]
 and Schmidt
[217,218]
 donors 
(thioglycosides and trichloroacetimidates respectively) should be considered. Lactose bearing 
the same substitution pattern (Gal-β(1-4)Glc) could also be used and needed to be oxidized at 
the C-6 of the glucose unit. This approach is a highly specialized approach which wouldn’t 
complement a set building blocks for assembly of glucuronic acid bearing saccharides and it 
also needs a longer reaction sequence to manipulate the protecting groups accordingly
[219–223]
. 
 
IV.2.3. Disaccharide unit of ancorinoside B via glucuronic acid 
 
Glucuronic acids are well investigated concerning their properties as donors in glycosylation 
reactions
[214,215,220,224–226]
 but there’s a lack of knowledge using them first as acceptors[227], 
especially in the case of even more electron deficient acceptors. The following chapter 
describes the different used donor and acceptor combinations. 
     D1    D2           D3 
 
 
 
 
     D4     D5    D6 
 
 
 
 
 
Figure IV.7. Tested donors for glycosylation. D1) perbenzylated thioglycoside donor; D2) 
perbenzylated and 2-O-acylated thioglycoside donor to have an participating group effect; D3) 
perbenzylated and 2-O-acylated trichloroacetimidate donor; D4) perbenzoylated trichloroacetimidate 
donor; D5) peracetylated trichloroacetimidate donor; D6) perbenzylated and 2-O-benzoylated 
thioglycoside donor. 
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Actual synthesis of these glycosylation educts is not shown, because these synthetic steps 
mainly consisted of known chemistry and protective group manipulations. 
These donors were combined with different acceptors in different generations shown 
afterwards. The different combinations were tested to find some hints about the sterical and 
electronical behaviour of the tested acceptors. The actual procedure of this process and the 
evolving of these generations will be described after the actual overview over exemplary 
results shown in Table IV.4. 
  A1             A2             A3 
 
 
 
  A4              A5             A6 
 
 
 
Figure IV.8. Tested acceptors for glycosylation. A1) C-6 benzyl ester protected thioglycoside acceptor; 
A2) C-6 benzyl ester and 1-O-allyl protected acceptor; A3) C-6 methyl ester and 1-O-allyl protected 
acceptor; A4) C-6 methyl ester protected thioglycoside acceptor; A5) C-6 methyl ester, 
2,3-O-dibenzylated and 1-O-allyl protected acceptor; A6) C-6 methyl ester, 3-O-dibenzylated, 
2-O-benzoylated and 1-O-allyl protected acceptor to have subsequent participating group effects for 
the next glycosylation and maintaining a minimum of electron richness. 
The following Table IV.4. gives an overview over the tested donor-acceptor combinations 
shown in Figure IV.7. and Figure IV.8. as well as the tested reaction conditions and a short 
summary of their outcome. Not all tested conditions are shown since some only varied in the 
promoter (e.g. TMSOTf vs. BF3•OEt2) or in temperature and stirring time. Always the best 
result or at least a representative example is given in the following table. 
Two different 2,3-O-benzoylated acceptors were used in the first set of experiments which 
were either 1-O-allyl protected or the corresponding 1-S-phenyl thioglycoside was employed. 
Both acceptors A1 and A2 were oxidized selectively by the use of a catalytic amount of 
TEMPO and stoichiometric BAIB (Diacetoxyiodobenzene)
[224,225]
 while their 4,6-diol 
functionality was unprotected followed by a subsequent benzyl protection step under standard 
conditions. Another oxidation procedure with periodic acid and chromium(VI)oxide
[228]
 was 
also tested in some experiments but the TEMPO catalyzed oxidation remained superior in all 
experiments. This complete set of experiments with acceptor A1 and A2 and five different 
donors (entry 1-9) remained unsuccessful or gave the corresponding α-product only probably 
due to some sterical hindrance caused by the C-6 benzyl ester which might shield the 
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4-hydroxy group from attacking the donor. No reaction was observed in most trials until the 
reaction was warmed up to room temperature step by step and only decomposition or 
hydrolysis of the donor was then observed. This is the reason why the benzyl ester was 
exchanged with its methyl derivative in the next set of experiments. 
Table IV.4.  Overview of different donor-acceptor combinations tested to build the disaccharide for 
ancorinoside B total synthesis. 
Entry Donor Acceptor Conditions
[a]
 Outcome 
1 D1 A1 
1.1 equiv NIS, 0.11 equiv TfOH, 
-45 °C, 3 h 
54%, α-product 
2 D2 A1 
1.1 equiv NIS, 0.1 equiv TfOH, 
-40 °C, 3 h 
No reaction 
3 D2 A1 
1.1 equiv NIS, 0.1 equiv TfOH, 
0 °C to RT, 3 h 
No reaction 
4 D2 A1 
1.1 equiv NIS, 0.1 equiv TMSOTf, 
-40 °C to RT, 3 h 
First no reaction 
then decomposition 
5 D3 A1 0.1 equiv BF3•OEt2, -15 °C, 3 h No reaction 
6 D4 A1 0.15 equiv BF3•OEt2, -40 °C, 2 h No reaction 
7 D3 A2 0.15 equiv BF3•OEt2, -40 °C, 2 h No reaction 
8 D3 A2 0.1 equiv BF3•OEt2, -20 °C, 2 h No reaction 
9 D5 A2 0.1 equiv TMSOTf, -20 °C, 2 h No reaction 
10 D2 A3 
2 equiv NIS, 0.1 equiv TMSOTf, 
-78 °C to -20 °C, 3 h 
12%, α-product 
11 D3 A3 0.1 equiv BF3•OEt2, -40 °C, 2 h No reaction 
12 D4 A3 0.1 equiv BF3•OEt2, -78 °C, 3 h 33%, α-product 
13 D3 A4 0.1 equiv BF3•OEt2, -40 °C, 3 h No reaction 
14 D4 A4 0.1 equiv TMSOTf, -0 °C to RT, 2 h Decomposition 
15 D4 A4 0.1 equiv BF3•OEt2, -40 °C to 0 °C, 3 h 
40% β-product, 
next glycosylation failed 
16 D5 A4 0.1 equiv BF3•OEt2, -40 °C, 3 h No reaction 
17 D4 A5 0.12 equiv BF3•OEt2, -40 °C, 2 h 
70%, α:β = 45:55, 
next glycosylation α-product only 
18 D3 A6 0.12 equiv BF3•OEt2, -40 °C, 3 h No reaction 
19 D4 A6 0.1 equiv BF3•OEt2, -78 °C, 3 h No reaction 
20 D4 A6 0.1 equiv TMSOTf, -40 °C, 3 h Decomposition 
[a] Reactions were carried out with 1.1 equiv donor, in CH2Cl2 and with 4 Å molecular sieves. 
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Two analogous methyl esters A3 and A4 were used as acceptors in the next set of experiments 
(entry 10-16) revealing that the attack of the acceptor might not only be a steric but an 
electronic problem as well. This was obvious, because again most reactions showed either no 
reaction or mainly the α-product in bad yield. The only exception to that was the combination 
of the very electron deficient donor D4 in combination with the thioglycoside acceptor A4. 
This reaction yielded 40% of the desired β-product as major product in the first shot. The next 
glycosylation to the side chain failed due to the known very poor activity of thioglucuronic 
acids
[214]
. 
The mentioned knowledge of a steric and electronic problem was combined to form the next 
acceptor A5 which was designed to be much more electron rich to allow a faster reaction with 
the electrophilic and activated donors (entry 17). The reaction went quite well when only the 
yield (70%) is considered showing that the thoughts about the electronic and steric problems 
of the donor were correct. Looking more into detail revealed a bad α/β-selectivity with a near 
1:1 ratio and hard to separate isomeric mixtures. However, the reaction sequence was 
continued with allyl deprotection and imidate formation
[229]
. Glycosylation with BF3•OEt2 to 
get the desired diglycoside yielded the α-linked product only. The reason was apparently the 
missing participating 2-O-protecting group. 
An acceptor A6 was designed which should combine all the knowledge about the electronic 
system and the important participating group at the 2-hydroxy position mentioned above for 
the last set of experiments (entry 18-20). The 1-O-allyl glucose was protected at the 
4,6-position with benzylidene acetal
[230]
 and afterwards selectively 2-O-benzoylated
[231]
. After 
3-O-benzoylation under standard conditions with pyridine and benzoyl chloride, the sugar 
latter was oxidized as usual with TEMPO and BAIB
[224,225]
 to yield the desired acceptor A6. 
This acceptor was unfortunately again too electron poor to react under any temperature with 
the tested donors D3 and D4. 
 
IV.2.4. Total synthesis of ancorinoside B diglycoside 
 
The next synthetic approach changed the acceptor to a 6-O-TBS protected glucose to carry 
out the first glycosylation, performing the C-6 oxidation and after protection trying to get the 
second glycosylation done. For this approach an 1-O-allyl-2,3-O-benzoyl-6-O-TBS protected 
donor was synthesized via a 4,6-O-benzylidene acetal, benzoylation and selective TBS 
protection. All steps were high yielding including the first glycosylation as well as the 
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oxidation step (data not shown) but the second glycosylation failed again on 
β-stereoselectivity using the readily oxidized disaccharide. 
Since the synthetic trials to this point failed due to the problematic reactivity concerning the 
used glucuronic acid building blocks and their properties as donors and acceptors, the 
retrosynthetic plan in terms of the diglycoside was changed to account for these problems and 
avoid them eventually by establishing the desired diglycoside and performing the oxidation 
right after the 2
nd
 glycosylation. The plan regarding the diglycoside was now as follows: 
 
 
 
 
  120          121          111 
 
 
 
 
 
          121              112          122 
Scheme IV.14.  2
nd
 retrosynthetic approach to the diglycoside for ancorinoside B synthesis. 
The other difference in this approach beside the late oxidation step at the C-6 position of the 
glucose moiety was the use of a Fischer donor in the 2
nd
 glycosylation to avoid additional 
protecting group manipulation. 
The C20 fatty acid chain for ancorinoside B was synthesized in a comparable manner as for 
epicoccamide D. Buyable eicosanedioic acid 117 was reduced with LiAlH4 in THF
[213]
 
yielding 89% of the corresponding diol 118. The TBS monoprotection was difficult in that 
case, because diol 118 did not dissolve in acceptable quantities in any organic solvent 
applicable for TBS protection. The reaction was carried out by partly dissolving the diol in 
hot 1,4-dioxane and fast addition of first TBSCl and the imidazole. This procedure gave the 
monoprotected C-20 diol 111 in 52% yield. The yield for setting up the same reaction in hot 
THF, other solvents or their mixtures and just let the reaction slowly take place by dissolving 
the educt stepwise was always below 10%. The reaction was also carried out in a solvent free 
manner by melting all educts in a preheated flask using the almost identical melting points 
(roughly 110 °C) and letting the reaction take place for about 5 min before standard workup. 
This attempt yielded 28% of the desired monoprotected diol 111. 
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           117       118          111 
Scheme IV.15.  Synthesis of the monoprotected diol side chain of ancorinoside B. Reagents and 
conditions: a) LiAlH4 (3 equiv), THF, 0 °C 3 h then reflux 12 h, 89%, b) TBSCl (1 equiv), imidazole 
(2 equiv), 1,4-dioxane, reflux, 10 h, 52%. 
Glycosylation with a 1-O-allyl-2,3-O-dibenzoyl-6-O-TBS protected glucose had no special 
requirements concerning the donor. A perbenzoylated imidate donor D4 (see Figure IV.7.) 
was chosen for this purpose. Galactose was first perbenzoylated
[232]
 with BzCl and pyridine. 
 
 
 
 
 
         114          115       112 
Scheme IV.16.   Synthesis of the donor for disaccharide assembly. Reagents and conditions: a) BzCl 
(5.5 equiv), pyridine, 0 °C to RT, 12 h, quant.; b) HBr in ethyl acetate, 0 °C, 2 h; c) Ag2CO3 (0.5 equiv), 
acetone:H2O = 19:1, RT, 12 h; d) Cl3CCN (7 equiv), DBU (1.1 equiv), CH2Cl2, RT, 3 h, 57% over three 
steps. 
Tetra-O-benzoyl galactose trichloroacetimidate 112 was formed by perbenzoylation, anomeric 
deprotection via the corresponding α-halide followed by treatment with Ag2CO3
[233,234]
 and 
imidate formation
[233]
. The corresponding α-halide and the hemiacetal were used in 
consecutive steps without purification. This known
[235]
 and more expansive route compared to 
deprotection with MeNH2
[236]
 gave pure donor 112. Deprotection with hydrazine acetate
[237]
 
was not tested. 
 
 
 
 
      80    123            124 
Scheme IV.17.  Anisaldehyde acetal formation. Reagents and conditions: a) BF3•OEt2 (3.5 equiv), 
PhSH (1.8 equiv), CH2Cl2, reflux, 72 h, 52%; b) NaOMe (0.5 equiv), MeOH, RT, 45 min; c) p-TsOH 
(6.5 equiv), anisaldehyde dimethyl acetal (2 equiv), DMF, 50 °C, 8 h, 86% (two steps). 
The necessary thioglycoside donor 122 was assembled starting from peracetylated glucose
[32]
. 
Penta-O-acetyl glucose was transformed into the corresponding thiophenyl glycoside 123 by 
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the use of BF3•OEt2.
[238]
 To form the selective 6-O-PMB protected alcohol the thioglycoside 
was converted into a 4,6-O-anisol acetal 124 right after ester interchange. This was achieved 
by a known method
[230,239,240]
 with ansialdehyde dimethyl acetal and ptoluenesulfonic acid in 
DMF. 
Reaction sequence continued with benzoylation of the diol 124 under standard conditions
[241]
 
with BzCl and pyridine. The last step for donor synthesis was a reductive acetal opening to 
form the desired 6-O-PMB protected donor with a free alcohol function at the 4-O-position. 
This was accomplished by the use of NaBH3CN and TFA
[242]
. A slightly changed method 
published for similar glycosyl acceptors
[243]
 was used. 
 
 
 
 
   124         125     122 
Scheme IV.18.  Assembly of the monosaccharide acceptor. Reagents and conditions: a) BzCl 
(3 equiv), pyridine, 0 °C to RT, 12 h, 76%; b) NaBH3CN (5 equiv), TFA (10 equiv), 4 Å mol. sieves, 
DMF, 0 °C to RT, 12 h, 88%. 
With donor 112 and acceptor 122 in hand the first glycosylation was carried out using 
BF3•OEt2 at -40 °C. This procedure gave about 40% of the wrong configurated α-glycosidic 
linkage. Switching from BF3•OEt2 to TMSOTf as lewis acid to activate the Schmidt donor at 
again -40 °C yielded the desired β-branched disaccharide 121 in 62% yield. 
 
 
 
 
 
         112             122         121 
Scheme IV.19.  First glycosylation with PMB protected acceptor. Reagents and conditions: a) 112 
(1.2 equiv), TMSOTf (0.1 equiv), CH2Cl2, -40 °C, 3 h, 62%. 
The advantage of using a thioglycoside as acceptor came now into play, because no further 
protecting group manipulation was necessary before the 2
nd
 glycosylation was carried out. By 
the use of a Fischer type donor for this purpose, NIS and firstly TfOH was used under 
standard conditions
[244,245]
 for this kind of glycosylation. These reaction conditions and the 
Brønsted-Lowry acidic TfOH showed TBS deprotection as major product during reaction 
monitoring which in turn gave rise to several side products. The desired diglycoside 126 was 
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only isolated in about 40% yield. Since other Lewis acids like BF3•OEt2 or TMSOTf can also 
be used as activating agents both were tested and both gave unsatisfying yields around 20% of 
the β-product caused by the lower activation rate of these Lewis acids and the therefore higher 
reaction temperature which lead to more α-configurated product. The mixture of both Lewis 
acids in a 2:1 fashion of TMSOTf and BF3•OEt3 led to a very high Lewis acidity caused by a 
BF2OTF•OEt2 species as published
[246]
. This procedure gave 58% of the desired diglycoside 
126 which was formed at -40 °C, with only a small excess of the monoprotected acceptor side 
chain 111 and without any oberservation of the corresponding and unwanted α-side product. 
 
 
 
 
   121             126 
Scheme IV.20.  Second glycosylation with PMB protected acceptor to attach the fatty acid chain. 
Reagents and conditions: a) 111 (1.05 equiv), TMSOTf (0.1 equiv), BF3•OEt2 (0.05 equiv), NIS 
(1.8 equiv) CH2Cl2, –40 °C, 3.5 h, 58%. 
The next crucial step of the synthesis of the desired diglycoside for the ancorinsoside B total 
synthesis was the selective deprotection of the 6-hydroxy functionality by removal of the 
PMB ether. Standard oxidative conditions utilizing CAN
[247]
 or DDQ
[248,249]
 in various 
amounts
[250]
 and temperatures always led to TBS protection on the side chain first. This 
undesired deprotection always occurred even before PMB deprotection started to take place as 
strict reaction control by tlc indicated. This effect was known for CAN under certain 
conditions but not known in literature for DDQ. Another deprotection trial was carried out 
under mild Lewis acidic conditions utilizing MgBr2•OEt2 and Me2S which is a known 
method
[251]
 allowing PMB deprotection by specifically mentioned TBS retention. These 
conditions showed nearly no reaction (about 10% conversion), even after three days. Another 
more acidic deprotection condition was tested using a catalytic amount of SnCl2, an excess of 
TMSCl and anisole as scavenger.
[252]
 Tin chloride dihydrate was used and therefore 4 Å 
molecular sieves were added to this reaction to trap the water and prevent accidental TBS 
deprotection. This quite fast reaction yielded the desired alcohol 127 in 99.6% yield after 
90 min with no observed side reaction. 
The last two steps of the reaction sequence for setting up the diglycoside 120 were the 
oxidation to the corresponding glucuronic acid derivative and afterwards the installation of a 
reasonable protecting group like a benzyl ester which can eventually be cleaved by 
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hydrogenation to remove also the formed double bond from the HWE olefination in later 
steps of the synthesis. 
 
 
 
 
     126           127 
 
 
 
 
     127            120 
Scheme IV.21.  Oxidation of the full diglycoside. Reagents and conditions: a) SnCl2•2H2O (0.1 equiv), 
TMSCl (3 equiv), anisole (1.5 equiv), 4 Å mol. sieves, CH2Cl2, RT, 90 min, 99.6%; b) PDC (2 equiv), 
Ac2O (10 equiv), CH2Cl2, RT, 6 h; c) BnOH (20 equiv), CH2Cl2, RT, 3 h, 71% (over two steps). 
The first trial to achieve this goal was a TEMPO catalyzed oxidation with BAIB as 
reoxidation reagent in a phase transfer like reaction. Since this reaction conditions proved 
successful not only for the synthesis of the monosaccharide glucuronic acid building blocks 
(see Table IV.4.) it was obvious to test this oxidation protection cascade with the side chain 
already attached. Since this attempt proved unsuccessful with no reaction shown by tlc and 
crude NMR analysis under different conditions
[225,253,254]
, other TEMPO based methods (e.g. 
with NaClO, NaHCO3, (C4H9)4NBr and NaBr
[226]
 or NaClO, NaHCO3 and KBr
[255]
) were also 
tested with no success. Conditions utilizing TEMPO and periodic acid
[228]
 or Jones reagent
[256]
 
were not tested, because of their acidic nature and therefore likely occuring TBS deprotection. 
Another sometimes used method for carbohydrate oxidation
[257,258]
 is the use of the Cornforth 
reagent
[259]
 pyridinium dichromate (PDC) often referred to as Corey-Schmidt oxidation
[260]
. 
The free carboxylic acid is either directly isolated
[258]
 or transferred into its tbutyl ester by 
direct addition of tbutanol
[257]
 which cannot be oxidized by PDC. In both cases acetic 
anhydride (Ac2O) was added to speed up the reaction as published by Corey et al.
[261]
 for the 
use of carbohydrate oxidation utilizing Collins reagent without isolating the aldehyde 
intermediate. In the case of the ancorinoside B total synthesis the mentioned benzyl ester 120 
was in focus so only the oxidation part was first carried out as mentioned in literature
[257,258]
. 
After tlc and crude NMR analysis showed complete conversion to a lower running spot and 
the appearance of an additional quaternary carbon signal at 165.6 ppm together with a large 
shift of the C-5 proton, changing the signal form from a doublet triplet signal to a singulet 
RESULTS - Ancorinoside B 
60 
 
signal accompanied by disappearance of the protons at the C-6 position a complete and clean 
oxidation was assured. The oxidation was stopped by addition of large excess of benzyl 
alcohol to trap the remaining PDC. This addition produced reaction conditions where benzyl 
esterification took place over 3 h. The shown oxidation esterification yielded the desired 
glucuronic acid bearing diglycoside in 71% yield. 
With the knowledge how to synthesize the diglycoside moiety of ancorinoside B in hand, the 
remaining steps of the synthesis will be carried out and published soon. These necessary steps 
will be shown and discussed in the conclusion section. 
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IV.3. Contribution to virgineone total synthesis 
 
Another natural product total synthesis should be initialized with all the knowledge mentioned 
in the last two chapters. The next natural product named virgineone
[125]
 shares some structural 
features with epicoccamides. Virgineone is a tetramic acid which is 3-acylated with a long 
fatty acid chain (C22) attached to a mannose residue by β-linkage (see Figure IV.9.). This 
chain is also methylated at the same position as epicoccamides are. Additional features are a 
ketone within the side chain and a hydroxyl group next to the glycosidic linkage. Virgineone 
whose tetramic acid moiety is derived from tyrosine has only one representative member to 
date. Its biological mode of activity is not known but virginieone is more characterized in 
terms of a possible target being associated with the stress response pathway and the 
respiratory chain.
[125]
 The structure of the mannosylated tetramic acid is shown in Figure IV.9. 
It is worth noting that upon start of this project the configuration of the three stereocentres 
besides those from the sugar residue were unknown. 
 
 
 
 
 
            3 
Figure IV.9. Virgineone (3) consists of three parts: The blue β-linked mannose residue connected to a 
fatty acid chain showing three different substitutions (green). This side chain is connected to a tyrosine 
derived tetramic acid (red/orange) by 3-acylation. 
Only the retrosynthesis for the substituted side chain and the trials of forward synthesis are 
described in the following chapters since virgineone shares its major motifs with 
epicoccamides and therefore the retrosynthetic approach for assembly of the whole molecule 
is similar having the same key steps like glycosylation, epimerisation, HWE olefination and 
Lacey-Dieckmann cyclisation once the side chain is assembled. The difference in synthesis 
concerning the tyrosine derived tetramic acid is meant to be trivial and there should only be 
an additional deprotection oxidation step for the ketone in the side chain. 
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IV.3.2. Retrosynthesis of the virgineone side chain 
 
The following retrosynthetic approach was elaborated using a Grignard reaction beside a 
Sharpless dihydroxylation as key steps in the side chain synthesis which allowed breaking the 
synthesis down into two cheap starting materials. Scheme IV.22. shows the general approach 
for the synthesis of the virgineone side chain. The exact pattern of protecting groups is not 
stated in the retrosynthetic scheme, because the three groups needed to be orthogonal and it 
was attempted to tune their reactivity during the following synthetic trials when necessary. 
The first introduced protecting group was set as TBS to start with. 
 
 
 
 
         129       130    131            132 
 
 
 
            132          133      134    135 
Scheme IV.22.  Retrosynthetic approach to the virgineone side chain. X, Y, Z = orthogonal protecting 
groups. 
The retrosynthetic approach commenced from selectively protected diol 129 which was in 
turn made from the a similar molecule bearing a double bond via asymmetric Sharpless 
dihydroxylation
[262,263]
. This step might open access to both stereoisomers to potentially gain 
insight into the absolute configuration which was unclear
[125]
 when this project was. The 
ketone in almost the middle of the side chain came from a protected alcohol bearing aldehyde 
131. The right time in synthesis when to deprotect and oxidize needs to be evaluated during 
total synthesis. The aldehyde necessary for the HWE olefination step
[32]
 to connect the 
glycosylated side chain to the tetramic acid moiety is also derived from a protected alcohol 
132 which can be deprotected and oxidized when required. The molecule is then cut into two 
parts next to the middle alcohol. These two parts are connected via a Grignard reaction
[264]
 
since a certain stereoselectivity is not required at that position. Bromide 133 and aldehyde 134 
are needed starting materials for this Grignard reaction. The bromide is buyable and the 
aldehyde 134 can be made from cheap alcohol 135 by protection and direct ozonolysis.
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IV.3.3. Synthesis of the virgineone side chain 
 
The first starting material necessary for the planned synthesis of the virgineone side chain was 
aldehyde 134 (9-[(tbutyldimethylsilyl)oxy)]nonanal). This educt was formed by protecting 
buyable 9-decen-1-ol (135) with TBSCl and imidazole in THF in quantitative yield. 
 
 
       135   136            134 
Scheme IV.23.  Synthesis of the aldehyde 134 for Grignard reaction. Reagents and conditions: 
a) TBSCl (1.25 equiv), imidazole (2 equiv), THF, RT, 16 h, quant.; b) O3 (6% in O2), CH2Cl2, -78 °C, 
30 min; c) PPh3 (2.5 equiv), CH2Cl2, RT, 2 h, 81% (two steps). 
The protected alcohol 136 was converted into the desired aldehyde 134 by Crigee's 
ozonolysis
[265]
 under standard conditions. The hereby formed trioxolan was intercepted under 
reductive conditions. Using PPh3
[266]
 instead of dimethylsulfide
[267]
 increased the yield from 
60% to 81% forming less side products. 
The formed aldehyde 134 was reacted with buyable 11-bromoundec-1-ene 133 in a Grignard 
reaction under standard conditions
[268]
 with roughened magnesium to yield 82% of the desired 
racemic alcohol 137 as a transparent oil. 
Since the racemic alcohol formed by the Grignard reaction above should be deprotected and 
oxidized late in total synthesis, THP was chosen as protective group, because it is acid labile 
like TBS but the silyl protecting group can be removed orthogonally with F
-
 salts earlier in 
synthesis. Moreover a THP acetal can also be converted into the corresponding ketone under 
oxidative conditions
[269]
. This protection step was achieved by using dihydropyrane (DHP) 
and PPTS
[270]
 yielding 86% of the diprotected diol 138. MOM or MEM protection was tested 
as well but proved too unstable for later steps of synthesis. 
 
 
 
  133     137         138            139 
Scheme IV.24.  Grignard reaction and protection. Reagents and conditions: a) Mg (2 equiv), 133 
(1.5 equiv), THF, reflux, 1 h; b) 134 (1 equiv), THF, 50 °C, 2 h, 82%; c) DHP (5 equiv), PPTS 
(0.1 equiv), CH2Cl2, RT, 8 h, 86%; d) K2CO3 (3 equiv), K3Fe(CN)6 (3 equiv), (DHQD)2PHAL (1 mol%), 
K2OsO2(OH)4 (2 mol%), t-butanol:water = 1:1, 4 °C, 4 d, 92%. 
The next step of synthesis was the important asymmetric Sharpless dihydroxylation
[263]
 of the 
double bond to have access to both isomers concerning the C-2 alcohol since its absolute 
configuration remained unclear in the natural product
[125]
 so far but there was some 
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evidence
[124]
 that this alcohol is S-configurated. With a Sharpless dihydroxylation one might 
access both isomers to clarify this suggestion. The reaction was carried out under 
conditions
[262,263]
 which are known to form the corresponding R-isomer using the 
(DHQD)2PHAL ligand to compare the results to the published
[124]
 data. Later access to the 
S-configurated isomer should then be possible by using the (DHQ)2PHAL ligand
[263,271]
. The 
actually used conditions
[271]
 were utilizing K3Fe(CN)6 to reoxidize the catalyst, the above 
mentioned ligand (1 mol%) as well as K2OsO2(OH)4 (2 mol%) in a 1:1 mixture of 
tbutanol:water and allowing the two phase mixture to stirr at 4 °C for four days. This 
procedure yielded 92% of the desired R-configurated diol 139. The diastereomeric excess of 
this reaction was found to be above 90% by chiral HPLC analysis. 
The most challenging step was now the protection of the secondary alcohol selectively or 
trying to first protect the primary alcohol with another protecting group if selectivity turned 
out to be a problem. The goal was to protect the secondary alcohol as a benzyl ether, because 
once this particular ether is formed it need not to be changed until deprotection and the benzyl 
ether will thus be cleaved in the final global deprotection step together with the sugar 
protecting groups. 
One attempt was to first protect the primary alcohol selectively with a trityl group
[272]
, 
introducing the benzyl protecting group and directly afterwards cleave again the bulky trityl 
group. Cleavage of the bulky trityl group failed with PPTS which removed first the TBS and 
then the THP protecting group before cleavage of the trityl group was observed. Other 
attempts with ZnCl2, ZnBr2, CeCl3
[273]
 and BF3•OEt2
[274]
 gave either no conversion or even 
more complex product mixtures. 
An obvious trial to achieve this goal was the protection of the 1,2-diol as a benzylidene acetal 
to open it under reductive conditions directly after protection to the desired secondary benzyl 
ether as published in many cases
[275–277]
 for instance within the first trials of total synthesis of 
virgineone
[124]
. Selective deprotection failed in this case as well after several tests with 
reducing agents like DIBAL-H
[124,275,277]
 or BH3 together with Cu(OTf)2
[278]
. 
The last attempt was to selectively form a primary pivaloyl ester and then execute the benzyl 
ether protection on the secondary alcohol as stated above. This procedure should leave the 
other protecting groups untouched during cleavage since the ester deprotection is done under 
basic conditions. Pivaloyl ester protection of diol 139 was carried out with the corresponding 
ester chloride and pyridine
[279]
 and gave 32% of the corresponding ester 140. The benzyl 
protection with benzyl bromide and sodium hydride and pivaloyl deprotection can be carried 
out in one single step, because stopping the protecting reaction with water delivers enough 
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hydoxide to hydrolyze the ester. This was only achieved with unsatisfactory yield of 13%. 
The benzyl protection without ester hydrolysis gave the desired fully protected alkyl chain 
141 only in 10% yield. The following ester hydrolysis can be done with an unsatisfying yield 
of 8% of the desired glycosyl acceptor 142. The poor yields resulted maybe from the lack of 
educt for these protection trials and therefore the hard to handle small scale of these reactions. 
These synthetic attempts are shown in Scheme IV.25. Coupling the alkyl chain to the 
necessary glucose donor was not tested because of the limited time for the whole project and 
lack of starting material. 
 
 
 
        139       140      141              142 
 
 
Scheme IV.25.  Trials of selective secondary alcohol protection. Reagents and conditions: a) PivCl 
(1.05 equiv), pyridine (2.5 equiv), CH2Cl2, RT, 16 h, 32%; b) BnBr (1.5 equiv), NaH (2 equiv), TBAI 
(cat.), DMF, RT, 2 h, 10%; c) NaH (2 equiv), H2O (1 equiv), DMF, RT, 4 h, 8%; d) BnBr (1.5 equiv), 
NaH (3 equiv), TBAI (5 mol%), DMF, RT, 24 h; e) H2O (20 equiv), DMF, RT, 12 h 13% (two steps). 
This work on the virgineone side chain was carried out with two bachelor students
[280,281]
 and 
yielded the fully protected side chain of virgineone which can be glycosylated and conntected 
to a tetramic acid moiety followed by the necessary deprotection, oxidation and reduction 
steps. The missing steps for the total synthesis of virgineone are summarized in the conclusion 
section. 
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IV.4. Contribution to aurantoside G and J total synthesis 
 
Aurantosides are another big class of glycosylated tetramic acids with currently eleven known 
members (A-K)
[39,44–48]
. The first member was found in 1991 and the last one 2012 so far. 
Unique in their structure is that the sugar residue (either xylose or a xylose containing 
trisaccharide) is not linked via a side chain to the tetramic acid moiety but is rather directly 
linked to the acid by N-glycosylation. The tetramic acid moiety is derived from D-aspartic 
acid in the case of the aurantosides. The overall structural motif is similar to that of the 
rubrosides A-H
[127]
 whose polyenoyl side chain ends up with an additional heterocycle and 
whose tetramic acid is derived from asparagine. Again, this type of tetramic acids showed 
several biological activities reaching from a certain cytotoxicity towards cancer cells
[44]
 to 
antibacterial or antifungal properties. 
 
 
 
 
         4 
Figure IV.10. Aurantosides G and J (4) revealing again three typical parts for tetramic acid 
glycoconjugates: The blue N-glycosylated xylose residue, a tetramic acid derived from asparagine 
(orange/red) and a polyene 3-acyl side chain in green with an uncommon chlorine in purple at the end. 
The conjugated side chain can be longer than shown in Figure IV.10. and bear additional 
chlorine atoms. The focus of the first attempts of total synthesis should be carried out on 
model systems similar to aurantoside G and J since both natural products are very similar and 
only differ in the configuration of the N-glycosidic linkage
[39,47]
. Since stereoinduction on this 
type of chemical N-glycosylation is unknown, both isomers can eventually be synthesized and 
separated in subsequent steps of synthesis.  
 
IV.4.2. Retrosynthesis of aurantoside G and J 
 
The planned synthesis of aurantosides is shown below and focuses on the N-glycosylation. 
The shown retrosynthetic approach where the sugar moiety of the aurantosides is attached via 
N-glycosylation or Fukuyama-Mitsunobu reaction
[282,283]
 before the actual tetramic acid is 
formed, this project was mainly focussed on the behaviour of tetramic acids and their 3-acyl 
derivatives in terms of the capability being a N-glycosyl acceptor. 
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Scheme IV.26.  Retrosynthetic approach to aurantoside G and J; R = Ac, Bn, Bz, PMB. 
Retrosynthesis for this project started with the N-glycosylation as keystep of the synthesis. 
The donor for this step should be a trichloracetimidate since this type of donors are generally 
proved more active
[159]
 than e.g. the corresponding thioglycosides and they have been 
published for use in amide glycosylation
[284]
 with TMSOTf as promoter. The most useful 
protective groups on the xylose donor should be elaborated in a later step of this project to 
gain insight into possibly occurring 2-O-protective group participation or the electronic 
influence of the protective group pattern onto the actual glycosylation process. The necessary 
tetramic acid was again planned to be synthesized by a Lacey-Dieckmann cyclisation. Trityl 
protected asparagine can be purchased and esterified with methanol. The shown 
β-ketothioester 145 can be assembled by a HWE olefination as before. Phosphonate 148 (not 
shown) can be derived by the protocol from Ley et al.
[56]
 starting from bromoacetyl bromide. 
The polyene aldehyde 147 can be made by repetitive usage of a Wittig olefination with the 
buyable dioxolane 150
[285]
 for instance. The chlorine bearing aldehyde 149 can be derived 
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from cheap 2-butyn-1-ol by reductive radical chlorination after a known
[286]
 method and DMP 
mediated oxidation. 
The mentioned retrosynthesis via N-glycosylation before tetramic acid formation is shown 
below as an alternative if the direct glycosylation of an already established 3-acyl tetramic 
acid fails. 
 
 
 
 
 
      152          145 
 
 
 
 
 
 
            153    154           155 
Scheme IV.27.  Retrosynthetic approach to aurantosides via Mitsunobu reaction; R = Ac, Bn, Bz, 
PMB. For the upper aminolysis the lower sugar amino acid derivative 153 is used. 
This alternative retrosynthetic plan should be applied whenever direct N-glycosylation 
attempts of the 3-acyl tetramic acid fail. 
Starting again from a Lacey-Dieckmann cyclisation step, the necessary glycosylated 
β-ketoamide 152 was to be established by aminolysis of the readily glycosylated amino acid 
153 and the corresponding β-ketothioester 145 mentioned in the retrosynthetic plan before. 
The sugar moiety can therefore be introduced by a Mitsunobu reaction (Fukuyama type
[287]
) 
of an accordingly protected hemiacetal and a nosyl protected amino acid methyl ester. Nosyl 
protection was said to be necessary for this Mitsunobu reaction.
[43,283,288–290]
 The actual 
protective group pattern on the monosaccharide needs again to be evaluated depending on the 
requirements of the Mitsunobu reaction
[43]
. 
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IV.4.3. Direct N-glycosylation trials with tetramic acids 
 
The first attempt of chemical N-glycosylation of a tetramic acid was to attach the sugar 
moiety before the actual 3-acylation process was to be carried out. This was done by first 
synthesizing a rather unfunctionalized tetramic acid derived from isoleucine since it was 
available in our workgroup and synthesized by a known method
[291]
 by Yoda et al. using 
Meldrum’s acid, EDCI and DMAP. The Boc-protected tetramic acid was deprotected as 
mentioned in the same publication. The published
[32]
 imidate for epicoccamide D synthesis 77 
was again used in this test system, because it is said to be moderately armed
[160]
 and it bears a 
2-O-participating group. 
 
 
 
 
 
       156           77          157 
Scheme IV.28.  Glycosylation of a tetramic acid: O-glycosylation. Reagents and conditions: a) 77 (1.1 
equiv), TMSOTf (0.2 equiv), CH2Cl2, -45 °C, 1 h then -20 °C, 2 h, 42%. 
Reaction of the isoleucine derived tetramic acid 156 with the already applied imidate 77 
yielded only a 4-O-glycosylated product 157 in 42% yield. The anomeric center was built as a 
β-only product due to the possible side group effect of the 2-O-acetyl group. No 
N-glycosylation was observed and the only additional side product was the hydrolyzed donor. 
The 
13
C NMR spectra confirmed this assumption showing an anomeric carbon atom at 
98.5 ppm, a C-4 at 173.8 ppm and a C-3 at 99.3 ppm indicating an existing 4-O-enol 
derivative. An anomeric N-glycoside would have a C-1 shift of smaller than 90 ppm which 
will be shown afterwards. 
To avoid this possible side reaction, a corresponding 4-O-protected tetramate was synthesized 
with two different protecting groups to account for the different electronic requirements for 
this N-glycosylation. The two tested tetramates bearing a 4-O-benzyl or a 
4-O-(2-trimethylsilylethyl) group (TMSE) proved unsuccessful in the N-glycosylation and 
only hydrolyzed donor was isolated. 
The same tetramic acid 156 was transferred into its 3-oct-2-enoyl derivative by treatment with 
ketylidenetriphenylphosphorane
[109]
 (Ph3PCCO). The formed 3-acyl ylide 158 was 
transformed into the corresponding 3-acyl derivative by addition of hexanal and KOC(CH3)3 
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in a Wittig-like reaction developed by Schobert et al.
[34]
 Since this 3-acyl tetramic acid 159 
showed no reaction with the used imidate 77 under different temperatures and only hydrolysis 
and decomposition of the donor was observed, the 3-acyl tetramic acid was transferred into 
the corresponding BF2-complex 160 by standard methods
[32]
 to push the reaction to 
N-glycosylation and avoid other possible side products like a 3’-O-acyl glycosylation. 
 
 
 
 
 
     156         158       159       160 
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Scheme IV.29.  Glycosylation of a 3-acyl tetramic acid. Reagents and conditions: a) Ph3PCCO 
(1 equiv), THF, reflux, 2.5 h, quant; b) KOC(CH3)3 (1 equiv); THF, reflux, 20 min then hexanal 
(1 equiv), THF, reflux, 6 h, 15%; c) BF3•OEt2 (5 equiv), THF, RT, 24 h, 32%; d) 77 (1.1 equiv), 
BF3•OEt2 (0.15 equiv), CH2Cl2, -40 °C to RT, 2 h, 8%; e) 77 (1.1 equiv), TMSOTf (0.1 equiv), CH2Cl2, 
-40 °C, 1 h, 7%. 
On one hand the direct chemical N-glycosylation of a 3-acyl tetramic acid BF2-complex was 
successful. On the other hand the reproducible unsatisfying yield of this reaction showed its 
limitations already. For this reason, the 2
nd
 retrosynthetic approach (Scheme IV.27.) via a 
Mitsunobu type reaction was tested. 
 
IV.4.4. N-Glycosylated tetramic acids via Fukuyama-Mitsunobu reaction 
 
The Fukuyama-Mitsunobu reaction was always said to be a good choice for chemical 
N-glycosylation in literature.
[43,283,288–290]
 The known
[290,292]
 2-nosyl protected alanine methyl 
ester derived from alanine methyl ester hydrochloride
[32]
 was reacted with anomeric 
unprotected 2,3,4,6-tetraacetyl galactose which was available in the lab and prepared by a 
known
[288,293]
 standard method. This Mitsunobu variant yielded 94% of the desired 
N-glycoside 163. 
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  154          162            163 
Scheme IV.30.  Fukuyama-Mitsunobu reaction for N-glycosylation. Reagents and conditions: a) 162 
(2.1 equiv), PPh3 (2.1 equiv), DIAD (2.1 equiv), THF, -78 °C, 2 h, then RT 8 h, 94%. 
The anomeric linkage was roughly 1:3 α:β but with this N-glycosylated product 163 in hand, 
the synthesis can be continued as stated in Scheme IV.27. to get both natural products 
aurantoside G and J which only differ in the anomeric linkage. Similar conditions were used 
in a test with 2,3,4-triacetyl xylose
[294]
 164. These conditions yielded only 50% of the desired 
N-glycoside 165 due to the hard purification of the products. In this case the diastereomeric 
ratio was about 1:4 α:β. These problems could be avoided when nosyl deprotection was 
carried out direct after glycosylation without further purification steps in 69% yield over two 
steps as shown by M. Petermichl
[49]
. Similar conditions were applied with different protected 
sugars and the corresponding buyable N-trityl and protected L-asparagine which was methyl 
esterified and nosyl protected. All tested variants gave comparable good yields.
[49]
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Scheme IV.31.  Fukuyama-Mitsunobu reaction with xylose. Reagents and conditions: a) 164 
(2.1 equiv), PPh3 (2.1 equiv), DIAD (2.1 equiv), THF, -78 °C, 2 h, then RT 8 h, 50%. 
This part of the project was carried out by M. Petermichl who continued the total synthesis of 
the aurantosides successfully
[49]
 using the herein elaborated Fukayama-Mitsunobu reaction. 
The results of his total synthesis will be published soon. 
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IV.5. Stereoinduction by tetramic acid boron complexes 
 
It is worth to shortly note that tetramic acid 3-acyl BF2-complexes showed a significant 
stereoinduction in terms of the hydrogenation of a double bond which is in conjugation with 
the 3-acyl exo-enol double bond (see Scheme IV.10.) as shown for epicoccamide D total 
synthesis. This induction gave a diastereomeric excess of 42% when a non-chiral and 
heterogenous catalyst was used (see Table IV.2.). 
This behaviour is explainable by a closer look on the 3-dimensional structure of tetramic acid 
BF2-complexes. Jones et al.
[98]
 found a BF2-chelate complex in one certain orientation 
building a chelate with the oxygen of the 3’-enoyl function and the C-2 amide oxygen as 
shown in Figure IV.11. Residues on the tetramic acid C-5 are said to be the only moieties 
sticking out of the 3-acyl tetramic acid plane besides a potentially existing modification 
starting at the C-7 and the mentioned BF2-complex.
[98,295]
 
   A    B 
 
 
 
 
 
 
 
       166 
Figure IV.11. Jones et al.
[98]
 showed the 3-dimensional structure of a 3-acyl tetramic acid BF2-chelate 
complex derived from valine. A) Tetramic acid used for crystallization studies. B) 3-dimensional 
structure of 166 showing the whole 3-acyl tetramic acid in one plane except the C-5 isopropyl residue 
derived from valine and the BF2 itself. The boron atom is 0.37 Å below the other carbon and oxygen 
atoms forming the 6-membered BF2-chelate ring. The only found tautomer in their complexation trials 
was the shown 3-exo-enol form 166. Adopted from Jones et al.
[98]
 with permission from The Royal 
Society of Chemistry. 
In case of the stereoinduction concerning the used epicoccamide auxiliary BF2-chelate 
complex it looks like the heterogeneous and therefore very bulky catalyst is hindered in 
attacking from one side by the C-5 residue and the BF2 atoms. This effect might lead to the 
mentioned diastereomeric excess of 42%. 
To account for this assumption different 3-acyl tetramic acid boron chelates were in focus of 
synthesis. The tetramic acid derived auxiliary 97 used in the epicoccamide test system should 
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be converted into the corresponding boron complex by utilizing diethyl boron fluoride which 
was thankfully provided by the group of Wrackmeyer et al.
[296]
 
 
 
 
 
  97        167              168 
Scheme IV.32.  Alternative boron 3-acyl tetramic acid complex for trials of the stereoinduction of 
homogeneous catalysts in catalytic hydrogenation of 167. Reagents and conditions: 
a) BEt2F•pyridine
[296]
 (5 equiv), CH2Cl2, RT, 12 h, 65%; b) Pd/C (5%, 10 wt%), 1 bar H2, CH2Cl2, RT, 
4 h, 34%. 
This conversion was carried out in the same manner as for the auxiliary of the 
epicoccamide D total synthesis
[32]
. The free 3-acyl tetramic acid 97 was transferred into its 
BEt2-complex by the use of BEt2F•pyridine derived from B. Wrackmeyer’s group
[296]
. This 
procedure yielded the desired BEt2-complex 167 in 65% yield. 
The complex was subjected to identical conditions of hydrogenation (see Table IV.2.) as the 
BF2-complex. This boron-dialkyl complex of a 3-acyl tetramic acid was not stable under 
standard hydrogenation conditions using palladium on charcoal. Since the complex 
decomposed rapidly during reaction, the hydrogenation stopped after roughly 35% 
conversion. The resulting product mixture contained the educt 97 and the reduced 
diethylboron complex of the 3-acyl tetramic acid 168. This mixture was analyzed again by 
chiral HPLC which revealed a diastereomeric excess of about 60%. Exact numbers were not 
accessible since the educt eluted in the middle of the two possible diastereomers and without 
baseline separation. 
These preliminary results looked promising and additional work needs to be carried out at 
least with more stable boron complexes. 
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V. CONCLUSION 
 
V.1. Total synthesis of epicoccamide D 
 
The secondary metabolite epicoccamide D, derived from fungal sources, was synthesized for 
the first time. The overall yield was 17% over 19 steps in the longest linear sequence starting 
from D-glucose. These high yielding steps included a C-2 glucose epimerisation reaction, a 
HWE olefination and a Lacey-Dieckman cyclisation as key steps of the total synthesis. 
Another key step was the stereoselective hydrogenation of the corresponding 3-acyl tetramic 
acid BF2-complex, which not only enabled access to all four possible configurations in terms 
of the unknown configuration of the stereocenters on the tetramic acid moiety, but also 
allowed the assignment of the absolute configuration of the natural product. An auxiliary 
technique was applied comparing NMR spectra and optical rotation of a synthetic tetramic 
acid derivative prepared by two different protocols. The auxiliaries were chosen to have 
similar substitutions as the natural product. The auxiliary was, on one hand, derived from the 
same methodology applied for the epicoccamide D total synthesis, and on the other hand 
prepared by an acylation method having a known absolute configuration
[28,29]
. Subsequent 
experiments showed that the same catalyst employed for both the auxiliary and the natural 
product synthesis had identical stereoinduction. Applying the other enantiomer of the catalyst 
(R,R instead of S,S-DUPHOS derived catalyst) revealed full inversion of the formed 
stereocenter (no match-mismatch), and showed that the stereocontrol in this homogeneous 
hydrogenation was only accomplished by the chiral catalyst with no observed substrate 
control. This hydrogenation step, using a cheap rhodium based chiral catalyst revealed the 
absolute configuration of natural epicoccamide D to be (5S,7S). The suggested absolute 
configuration was later confirmed by the Yajima group.
[123]
 The hydrogenation step was 
achieved by employing a known
[30,98,134]
 BF2-chelate complex forming procedure. 
The described method establishing the C-7 stereocenter complements other routes with 
similar synthetic C-7-branched targets using the Evans auxiliary technique
[207]
. After this 
selective alkylation a 4-O to C-3 acylation rearrangement protocol
[123,205]
, developed by 
Yoshii et al.
[113]
, and improved by Yoda et al.
[31,205]
, was carried out. This method can also 
referred to be a direct C-3 acylation
[297]
. Additionally this total synthesis clears the way for the 
synthesis of members from the large glycotetramate family including ancorinosides and 
virgineone. 
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It is also worth noting that the access to N-methylated amino acid methyl esters was improved 
by direct usage of the Boc-protected amino acid and a two steps N-methylation esterification 
procedure. The second step liberated enough HCl to remove the Boc-group in situ without 
purification in between as it is usually described in literature
[157,158]
. 
The shown total synthesis of epicoccamide D was of a modular character and allows access to 
additional natural derivatives and synthetic ones inspired by nature. Synthesizing such 
compounds in future might deliver an insight into the importance of the β-configurated 
glycosidic linkage, in which improvements, in terms of biological activities of another sugar 
moiety, can be made. Potentially other biological functions can be revealed by changing the 
alanine derived tetramic acid moiety to other (natural) amino acids. All this information might 
show an overall structure-activity relationship. Preliminary work has been carried out together 
with D. Linder
[298]
 finding access to α-branched epicoccamide derivatives. Having an 
adequate amount of material, not only of natural occurring epiccoccamide D, but also of other 
non-natural derivatives, in hand will allow extensive biochemical assays to be performed in 
order to find the mode of action of epicoccamides, and eventually reveal their biological 
target to elucidate their antimicrobial and cytotoxic effects. 
To the best of our knowledge the published
[32]
 epicoccamide D total synthesis was the first 
total synthesis of a naturally occurring glycosylated tetramic acid beside a synthesis by Pronin 
et al.
[43]
. In their synthetic approach no common hexose or pentose was attached to the 3-acyl 
fatty acid residue of a tetramic acid rather than a hexose named L-rhodinose
[299,300]
 
(2,3,6-trideoxy-L-galactose) which only occurs in gram-negative bacteria
[301]
. 
 
 
V.2. Total synthesis of the ancorinoside B diglycoside 
 
The synthesis of the ancorinoside B diglycoside using either a readily C-6 oxidized acceptor 
for the first glycosylation or performing a convenient oxidation stept right before the second 
one failed. Many different donor-acceptor combinations were tested and temperature, 
promoter load and type of promoter (TMSOTf vs. BF3•OEt2) were changed with no positive 
result. 
The diglycoside Gal-β(1-4)GlcU (part of ancorinoside B and C) was synthesized with 7.6% 
overall yield over 10 steps, starting from D-glucose. The total amount of steps was 16 to gain 
the desired diglycoside. This synthesis utilized a new glycosylation acceptor (or donor in case 
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of the 2
nd
 glycosylation), two subsequent glycosylation steps and a high yielding late 
oxidation protection procedure. 
This synthesis needs to be continued using the methodology also used for epicoccamide D 
total synthesis. The goal to get access to ancorinoside B should be reachable with this 
methods and the diglycoside already in hand. The only difference compared to epicoccamides 
might be a problem arising from two occuring esters, one from aspartic acid side chain and 
one amino acid methyl ester, close to each other during Lacey-Dieckmann cyclisation. In 
respect to this fact the necessary remaining steps of the total synthesis are shown below 
starting from the fully protected diglycoside. The remaining steps start with regard to the later 
oxidation of the C-5 tetramic acid side chain to install the aspartic acid functionality from the 
synthesis of a fully protected N-methyl homoserine
[212,302]
 methyl ester derivative which can 
be derived from affordable D-methionine. 
Additionally another phosphonate needs to be synthesized since ancorinosides do not bear a 
methyl group on the side chain. This can be accomplished using the method from Ley et al.
[56]
 
but starting with bromoacetyl bromide rather than bromopropionly bromide. 
With all that material in hand, the total synthesis of ancorinoside B can be commenced in 
future with similar steps as for the epicoccamide D synthesis. The primary TBS group on the 
side chain will be deprotected, oxidized and transferred into the corresponding β-ketoamide 
via HWE olefination and aminolysis. The synthesis will be finalized by removal of the silyl 
protective group on the amino acid side chain from the above mentioned homoserine 
derivative after the mentioned cyclisation followed by oxidation. 
 
 
 
 
 
  107 R = CH2OTBS         169    R = CH2OTBS 
             170    R = CH2OH 
             171    R = COOH 
Scheme V.1.  Suggested cyclisation, deprotection and oxidation step of the aminolysis product 107 to 
finalize ancorinoside B total synthesis. X = perbenzoylated β-D-galactose. Suggested reagents and 
conditions: a) NaOMe (1 equiv), MeOH, 0 °C, 6 h; b) TBAF (4 equiv), THF, RT, 12 h; c) TEMPO 
(0.1 equiv), BAIB (2.5 equiv), CH2Cl2:H2O = 2:1, RT, 2 h. 
The last step will be a global deprotection step by hydrogenation since all functional groups 
are protected by benzylic esters and can therefore be cleaved, also reducing the double bond 
c 
b 
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derived from the HWE olefination step. Ancorinosides do not possess a methyl substitution at 
the C-7 and hence no stereoselective hydrogenation is necessary during synthesis. 
With this natural product in hand, biochemical evaluation can again be carried out, not only to 
find similarities or differences between ancorinoside B and epicoccamide D, but also 
eventually find additional information concerning the mode of action of the type-1 matrix 
metalloproteinase (MT1-MMP) inhibition which was found
[120]
 in the case of the 
ancorinoside B. It is assumed that tetramic acids derived from different amino acids strongly 
differ in their biological activity. 
Since ancorinosides have a tetramic acid moiety derived from N-methyl D-aspartic acid 
(NMDA), it might also be worth to test
[121]
 for occurring activating behaviour of nerve cells. 
NMDA is a known agonist for receptors bound in the postsynaptic membrane regulating ion 
in- and efflux normally in a voltage-dependent manner.
[122]
 The function of this receptor is 
directly connected to the process of learning and disfunction of the receptor leading to 
depression, including several other mood disorders
[303]
, or is involved in Alzheimer’s 
disease
[304]
. 
 
 
V.3. Contribution to virgineone total synthesis 
 
The protected side chain of virgineone was synthesized in nine steps with a poor overall yield 
of 2.2%. This yield issue was caused by the problematic selective protection of the 1,2-diol 
gained from Sharpless dihydroxylation. It might be worth performing the synthesis, to this 
point, anew, since at least the selective pivaloyl esterification should give yields better than 
32%. If this particular route still returns poor yields it might be useful to protect the starting 
material for this synthesis (dec-9-en-1-ol) with a more stable triisopropylsilyl (TIPS) group, 
which can possibly sustain trityl deprotection and still maintaining orthogonality to the THP 
protective group. 
If these changes to the synthesis of the virgineone side chain prove successful the remaining 
steps for total synthesis can be then derived from epicoccamide D total synthesis. The only 
three differences compared to these synthetic routes are the missing N-methylation, the usage 
of an accordingly protected L-tyrosine derivative, and the required THP deprotection and 
oxidation late in synthesis. The oxidation step needs to be carried out at any point after the 
HWE olefination step to avoid side reactions and possibly before the actual Lacey-Dieckman 
cyclisation step in order to circumvent purification problems which might occur once the 
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corresponding tetramic acid is in place. A suitably protected tyrosine derivative (172) for 
aminolysis is shown in Figure V.1. as well as the step where THP deprotection and oxidation 
seems most reasonable (173). 
 A    B 
 
 
 
 
 
  172        173 
Figure V.1. Suggested tyrosine derivative and educt for oxidation. A) O-acetyl protected tyrosine 
derivative usable for the aminolysis reaction during the virgineone total synthesis. B) Key step and 
educt for the oxidation process to get the desired ketone which also arises in the natural product. 
The acetyl protective group might be a clever choice since the conditions necessary to 
perform the Lacey-Dieckman cyclisation are conform to the normal standard conditions for 
removing an acetyl-group. It is also worth noting that the 2-hydroxyl group on the sugar 
moiety again needs to be protected right after the epimerisation has been performed. 
With all these tools in hand a virgineone total synthesis should be reachable. If all these 
methods fail there is still the possibility to combine the knowledge of establishing the 
β-glycosidic linkage between mannose and its side chain with the published virgineone 
aglycon synthesis by Yajima et al.
[124]
 It might be possible to use their methodology to install 
the long oxidized fatty acid by cutting it into two pieces with one bearing the ketone from a 
retrosynthetic view and later connect both parts by cross metathesis. The required glycoside 
174 is shown in Figure V.2. besides the second reaction partner 175 for cross metatesis. 
     A                B 
 
 
 
    174                 175 
Figure V.2. Possible educts for cross metathesis. A) Necessary glycoside synthesized by the 
epicoccamide methodology. B) 3-acyl tetramic acid bearing also a terminal double bond for cross 
metathesis. 
If a cross metathesis is performed to bring both the glycoside and the tetramic acid together, a 
C-2 protection of the sugar moiety might not be necessary. It is obvious that the cross 
metathesis is best performed right before the Lacey-Dieckman cyclisation step in order to 
have the product easily purified and avoid catching of the cross metathesis catalyst by the 
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tetramic acid. It might also be necessary to build up the tetramic acid moiety by a HWE-, 
Lacey-Dieckman- and aminolysis reaction sequence in order to have access to both 
stereoisomers at the C-7 methyl group. 
It is imaginable, and indeed beneficial to perform this total synthesis in collaboration with 
Prof. Arata Yajima (personal communication). That might combine different approaches in a 
helpful way and can be important for future projects. 
After successful total synthesis of virgineone biochemical tests and comparisons can be 
performed to eventually find a target where virgineone interacts with the calmodulin-
dependent stress response system
[125]
 and potentially explain its antifungal behaviour
[125]
. 
 
 
V.4. N-Glycosylation for aurantoside G and J synthesis 
 
The first trial of chemical N-glycosylation using a tetramic acid derivative which was not 
3-acylated and a trichloroacetimidate derived Schmidt donor yielded 42% of a selective 
4-O-glycosylation product. From the current point of view other donors might react in a 
similar way since no other products or side reactions were observed. This reaction was not 
useful in terms of the planned aurantoside total synthesis but can potentially be used to 
synthesize tetramic acid 4-O-glycosides and investigate their biological behaviour. The sugar 
moiety of this new compound class might either be cleaved once transported into a cell or 
retained and partly involved into the biological function. Both compounds are worth to test for 
potential antibacterial, antifungal or cytotoxic properties. 
The desired N-glycosylation was successful albeit with poor yields, using a readily available 
BF2-complex of a 3-acyl tetramic acid with a Schmidt donor. Both BF3•OEt2 and TMSOTf 
were tested as promoter for this type of reaction. Since both activating reagents gave 
comparable yields below 10% the actual route for direct N-glycosylation of a tetramic acid 
was discarded and an approach using the Fukayama-Mitsunobu reaction to gain access to the 
desired N-glycoside was explored. The direct glycosylation tested might still be a reasonable 
approach for this type of reaction. Literature suggests changing the solvent for a direct 
N-glycosylation utilizing a Schmidt type donor from CH2Cl2 to nitromethane as shown by 
Takahashi et al.
[284]
 In their studies this change increased the yield from 46% to 98%. To 
optimize this reaction might still be useful: It can be used to build up a small compound 
library of N-glycosylated tetramic acids fast and eventually get some insight into structure-
function relationships (SAR) of this compound class. 
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The tested approach using the mentioned Mitsunobu type reaction yielded a N-glycoside of an 
amino acid in excellent yields (94%) but was not very stereoselective (α:β 1:3 or 1:4 
respectively) since the participating group effect cannot play a role in this reaction as can be 
seen from the mechanism
[282]
. This reaction opened a possible approach for the aurantoside 
total synthesis and after altering electronic properties of the donor as well as some changes in 
the reaction sequence proved to be a successful advancement. The full synthetic record of this 
approach can be seen in the Master thesis of M. Petermichl.
[49]
 
 
 
V.5. Stereoinduction by tetramic acid boron complexes 
 
Substrate controlled asymmetric hydrogenation was not observed in terms of the applied 
homogeneous catalysis as shown by the results for epicoccamide synthesis using the rhodium 
based Et-DUPHOS catalyst. Utilizing palladium on charcoal on the same substrate (the 
BF2-complex) revealed a detectable stereoinduction (42%). 
In this hetereogeneous hydrogenation the stereoinduction is definitely substrate controlled. 
This is because not only the catalyst bears no stereogenic information, but also an increase of 
diastereomeric excess during some trials using different substrates was discovered. Whereas a 
non-complexed 3-acyl tetramic acid had a barely detectable stereoinduction of 4% possibly 
due to the elevated methyl group standing over the tetramic acid plane
[98]
, the corresponding 
BF2-chelate complex had already a stereoinduction of 42%. This induction was increased by 
changing the chelate from a difluoroboron to a diethylboron complex. This complex showed a 
diastereomeric excess of 60% during hetereogeneous catalytic hydrogenation, but was not 
stable during the reaction revealing only 35% conversion until the tetramic acid complex was 
hydrolyzed which additionally induced deactivation of the catalyst. The evidence of 
deactivated catalyst was supported by the fact that hydrolyzed tetramic acid was barely (and 
unselectively) hydrogenated and a high amount of educt was found during chiral HPLC 
analysis. A fast hydrolysis rate is explainable by the fact that the used diethylboron complex 
is by far not as Lewis-acidic as the BF2 derivative and therefore not strongly bound and 
complexed by the tetramic acid. 
To circumvent this fast hydrolysis rate during hydrogenation a more Lewis-acidic, therefore 
more stable and maybe even larger boron complex, can be supposed. A boron complex 
derived from a dialky boronic acid ester can be synthesized and used in the hetereogeneous 
hydrogenation step. Synthesis from literature of dialkyl or diaryl boronic acid ester fluorides 
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was performed by A. Meller et al.
[305]
 utilizing a corresponding alcoholate (e.g. 
2,2-dimethylpropanol or 2,6-di-tbutylphenol) lithium salt together with BF3•OEt2. A second 
approach in literature is the synthesis of various large alkyl boronic acid esters published by 
Medrano et al.
[306]
 as shown below. 
 
 
 
 
    176      177          178 
Scheme V.2.  Synthesis of a chiral dialkyl boronic acid ester fluoride taken from Medrano et al.
[306]
 
Reagents and conditions: a) RT, 30 min, 0.1 torr; b) TBAF (1 equiv), THF, RT, 14 h. 
The shown chiral diol 177 is cheap since it is used as educt for chiral catalyst synthesis and 
easily accessible by Sharpless dihydroxylation. 
Another thing that can be changed in terms of the hetereogeneous hydrogenation, is the solid 
support of the used palladium species. It is known that the used solid support for a given 
hydrogenation catalyst has a huge influence on kinetics of the hydrogenation
[307]
. Beside 
palladium on charcoal, which is meant to be a more “dirty” catalyst bearing a varying number 
of functional groups on its surface, silica, alumina or a polymeric support
[308,309]
 can be 
applied. The catalysing metal atom can be changed as well by employing e.g. platinum. 
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VI. EXPERIMENTAL SECTION 
 
VI.1. General remarks 
 
All chemicals and solvents were purchased from ABCR, Acros Organics, Alfa Aesar, 
Carbolution Chemicals, Fisher Scientific, Merck, Sigma-Aldrich and Strem Chemicals. The 
used solvents were dried under standard conditions for the corresponding solvent or directly 
used in p.a. quality as purchased. CH2Cl2 and DMF were dried over CaH2, THF over sodium 
and methanol over phosphorous pentoxide. Solvents for chromatography and extraction were 
purchased in technical grade and destilled prior to use or also directly used in p.a. quality. 
An inert atmosphere was applied using nitrogen (technical grade) with a standard pressure of 
1 bar when not stated otherwise. When argon was necessary, the gas was used in a purity of 
4.8 and dried prior to use with CaCl2 and blue silica gel. The gases were purchased from 
Riessner gas. 
Analytical tlc was performed on silica gel 60 F254 foil plates purchased from Merck. The 
retention factor was measured in relation to the complete way and the substances were made 
visible using either UV-light (254 nm or 366 nm) or stained using acidified ceric ammonium 
molybdate (1 g Ce(SO4)2, 2.5 g (MoO3)12•H3PO4, 6 ml H2SO4, 94 ml H2O). Silica gel based 
column chromatography was performed over a mesh of 63-200 nm and for flash 
chromatography a silica gel with a particle size of 25-40 nm was applied. 
IR-spectra were recorded on a PerkinElmer ONE FT-IR spectrometer equipped with an ATR 
sampling module. The absorption was noted as spectroscopic wavenumer in cm
-1
. The given 
peaks were labelled with s (strong), m (medium), w (weak), br (broad). 
Specific rotation was measured using a PerkinElmer Polarimeter 241 and applying a 1 ml 
cuvette with a beam path of 10 cm. All measurements were carried out at 589 nm and with a 
given concentration and temperature. 
Melting points were recorded on a Büchi M-565 melting point apparatus and noted 
uncorrectedly. 
High resolution mass spectrometry was performed on either a UPLC/Q-TOF MS from Bruker 
or a Thermo Scientific Q Exactive Obritrap connected to a Dionex UltiMate 300 UPLC unit. 
All spectra were recorded in ESI
+
 mode, the mass to charge ratio (m/z) of a given substance 
was detected and compared to the calculated value. 
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Analytical HPLC was performed on a Beckman system with solvent module 126 and a diode 
array detector module 168. For standard analytics a Phenomenex Gemini NX 5 µm C-18 
reversed phase column sized 250•4.6 mm or a Phenomenex Kinetex 5 µm C-18 reversed 
phase column with the same size. Chiral HPLC was performed using a Macharey-Nagel 
Nucleodex CD β-OH column sized 150•4.0 mm. 
NMR spectrometry was performed on either a Bruker Avance 300 or a Bruker Avance 
DRX-500 spectrometer. Chemical shifts (δ) are given in parts per million (ppm) downfield 
from a Me4Si signal as internal standard. Coupling constants are noted in Hertz (Hz). Spectra 
were standardized using the given signal of the deuterated solvents in which the substances 
were measured. These shifts
[310]
 were δ(1H)CDCl3 = 7.26 ppm, δ (
1
H)D2O = 4.79 ppm, 
δ(1H)CD3OD = 3.31 ppm, δ(
13
C)CDCl3 = 77.16 ppm and δ(
13
C)CD3OD = 49.00 ppm. Signals 
are indicated to be s (singlet), d (doublet), t (triplet), q (quartet), qui (quintet), m (multiplet) or 
combinations thereof. 
 
VI.2. Epicoccamide D 
 
VI.2.1. Glycosyl donor (imidate 77) 
 
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (80) 
 
 
 
              79               80 
Scheme VI.1.  Synthesis of peracetylated D-glucose 80. 
D-Glucose 79 (5.80 g, 32.36 mmol) was dissolved in 125 mL of a 3:2 mixture of pyridine and 
Ac2O and stirred at room temperature overnight. All volatiles were removed by repeated use 
of toluene as an azeotropic entraining agent. The remainder was dissolved in EtOAc and 
washed with sat. aqueous CuSO4, brine, sat. NaHCO3 and again brine. The organic layer was 
dried (Na2SO4) and concentrated. The crude product was purified by column chromatography 
(silica gel; 50% EtOAc in c-hexane) to yield 80 (12.01 g, 96%) as a white solid; mixture of 
isomers α:β = 6.5:1. 
Rf =0.70 (ethyl acetate/cyclohexane 1:1); 
m.p. 107 °C; 
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[α]D
22
 = 82.9 (c = 1.0 g cm
-3
, chloroform); 
HRMS (ESI) calcd for C16H22O11Na [M+Na]
+
 413.1026, found: 413.1012. 
 
 
3,4,6-Tri-O-acetyl-1,2-O-(1-ethoxyethylidene)-α-D-glucopyranose (81)[145] 
 
 
 
 
          80        81 
Scheme VI.2.  Synthesis of orthoester 81 from peracetylated D-glucose 80. 
A solution of 80 (5.07 g, 13.0 mmol) in CH2Cl2 (60 mL) was treated with I2 (4.6 g, 
18.2 mmol) and Et3SiH (2.9 mL, 18.2 mmol). The mixture was heated at reflux for 1 h, cooled 
to RT and treated with 2,6-lutidine (6.0 mL, 51.9 mmol), EtOH (4.6 mL, 77.9 mmol) and 
NEt4I (1.20 g, 3.3 mmol). The mixture was heated at reflux for 3 h, the volatiles were 
removed under reduced pressure and the residue was purified by flash chromatography (silica 
gel; 15% EtOAc in c-hexane) to give 81 as transparent hygroscopic crystals (5.10 g, 
quantitative). 
Rf=0.56 (EtOAc/c-hexane 1:1); 
m.p. 82-85 °C; 
[α]D
23
 = 44.6 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=5.69 (d, 
3
J(H,H)=5.2 Hz, 1H, 1-H), 5.17 (t, 
3
J(H,H)=2.8 Hz, 
1H, 3-H), 4.90 (ddd, 
3
J(H,H)=9.6 Hz, 2.8 Hz, 0.9 Hz, 1H, 4-H), 4.32 (ddd, 
3
J(H,H)=5.2 Hz, 
2.8 Hz, 0.9 Hz, 1H, 2-H), 4.20 (dd, 
3
J(H,H)=5.0 Hz, 2.8 Hz, 2H, 6-H), 3.95 (ddd, 
3
J(H,H)=9.2 Hz, 5.0 Hz, 2.8 Hz, 1H, 5-H), 3.54 (q, 
3
J(H,H)=7.1 Hz, 2H, OCH2), 2.11 (s, 3H, 
OAc), 2.10 (s, 3H, OAc), 2.09 (s, 3H, OAc), 1.72 (s, 3H, CH3), 1.18 (t, 
3
J(H,H)=7.1 Hz, 3H, 
OCH2CH3); 
13
C NMR (75 MHz, CDCl3): δ=170.8, 169.8, 169.3, 121.4, 97.0, 73.2, 70.3, 68.3, 67.0, 63.2, 
59.3, 20.9, 20.9, 15.4; 
IR (thin film) ṽ=2976 (w), 2944 (w), 1741 (s), 1732 (s), 1447 (w), 1367 (s), 1295 (w), 1223 
(s), 1205 (s), 1175 (s), 1157 (s), 1121 (m), 1105 (s), 1081 (m), 1034 (s), 983 (s), 952 (s), 906 
(s), 875 (s), 805 (m), 733 (m) cm
-1
; 
HRMS (ESI) Calcd for C16H24O10Na [M+Na]
+
 399.1267, found: 399.1213. 
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3,4,6-Tri-O-benzyl-1,2-O-(1-ethoxyethylidene)-α-D-glucopyranose (82)[145,149] 
 
 
 
 
   81         82 
Scheme VI.3.  Protective group manipulation for synthesis of benzylated orthoester 82. 
A solution of 81 (2.07 g, 5.5 mmol) in MeOH (21 mL) was treated with NaOMe (60 mg, 
1.10 mmol) in one portion and the resulting mixture was stirred at RT until consumption of 
the starting material (ca. 45 min). The volatiles were removed under reduced pressure and the 
residue was dissolved in dry DMF (21 mL). The mixture was cooled to 0 °C and NaH (1.0 g, 
22.0 mmol, 60% in mineral oil) was added in one portion. C6H5CH2Br (2.9 ml, 24.8 mmol) 
was added via syringe and the resulting mixture was stirred for 1 h at RT. The reaction was 
quenched with 50 g of ice and extracted twice with EtOAc. The combined organic phases 
were washed with brine, dried, concentrated and the residue was purified by flash 
chromatography (silica gel; 5% EtOAc in c-hexane) to afford 82 (2.6 g, 91%) as a clear oil. 
Rf=0.88 (EtOAc/c-hexane 1:1); 
[α]D
23
 = 16.3 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.38-7.19 (m, 15H, H
ar
), 5.79 (d, 
3
J(H,H)=5.3 Hz, 1H, 1-H), 
4.73 (d, 
2
J(H,H)=11.7 Hz, 1H, 3O-CH
a
), 4.62 (d, 
2
J(H,H)=11.7 Hz, 2H, 3O-CH
b
, 4O-CH
a
), 
4.61 (d, 
2
J(H,H)=12.2 Hz, 1H, 6O-CH
a
), 4.52 (d, 
2
J(H,H)=12.2 Hz, 1H, 6O-CH
a
), 4.45 (dd, 
3
J(H,H)=5.3 Hz, 3.9 Hz, 1H, 2-H), 4.41 (d, 
2
J(H,H)=11.7 Hz, 1H, 4O-CH
b
), 3.90 (t, 
3
J(H,H)=3.9 Hz, 1H, 3-H), 3.82 (dt, 
3
J(H,H)=9.4 Hz, 3.0 Hz, 1H, 5-H), 3.74 (dd, 
3
J(H,H)=9.4 Hz, 3.9 Hz, 1H, 4-H), 3.69 (m, 2H, 6-H), 3.57 (q 
3
J(H,H)=7.1 Hz, 2H, OCH2), 
1.69 (s, 3H, CH3), 1.22 (t, 
3
J(H,H)=7.1 Hz, 3H, OCCH3); 
13
C NMR (75 MHz, CDCl3): δ=138.2 (6O-CC
ipso
), 138.1 (4O-CC
ipso
), 137.9 (3O-CC
ipso
), 
128.6 (3xCH
ar
), 128.4 (2xCH
ar
), 128.2 (2xCH
ar
), 128.1 (2xCH
ar
), 128.05 (3xCH
ar
), 128.0 
(CH
ar
), 127.9 (CH
ar
), 127.7 (CH
ar
), 121.1 (C(OR)3), 97.9 (C-1), 78.9 (C-3), 75.9 (C-2), 75.0 
(C-4), 73.5 (6O-CH2), 73.1 (4O-CH2), 72.0 (3O-CH2), 70.6 (C-5), 69.3 (C-6), 58.8 (OCH2), 
22.0 (Me), 15.5 (OCCH3); 
IR (thin film) ṽ=3030 (w), 2978 (w), 2932 (w), 2868 (w), 1496 (w), 1454 (m), 1382 (m), 1364 
(m), 1308 (w), 1252 (m), 1207 (m), 1094 (s), 1045 (s), 1027 (s), 988 (s), 951 (s), 907 (s), 731 
(s), 695 (s) cm
-1
; 
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HRMS (ESI) Calcd for C31H36O7Na [M+Na]
+
 543.2359, found: 543.2294. 
3,4,6-Tri-O-benzyl-2-O-acetyl-α-D-glucosyl trichloroimidate (77)[149] 
 
 
 
 
          82                77 
Scheme VI.4.  Synthesis of benzylated imidate 82 for glycosylation. 
A solution of 82 (885 mg, 1.70 mmol) in 20 mL of a mixture of 10% H2O in DME was 
treated with pTosOH•H2O (162 mg, 0.85 mmol) and stirred for 2 h. The reaction was 
quenched with sat. aqueous NaHCO3, extracted three times with EtOAc, and the combined 
organic layers were washed with H2O and brine, dried over Na2SO4 and concentrated. The 
crude product was dissolved in dry CH2Cl2 (35 mL), treated with CCl3CN (1.6 mL, 
16.1 mmol) and DBU (60 µL, 0.40 mmol) and stirred at RT for 1.5 h. The solvent was 
stripped off and the brownish remainder was purified by column chromatography (silica gel; 
15% EtOAc in c-hexane) to remove the 1-O-acetyl-2-trichloroimidate by-product and to leave 
77 (940 mg, 87%) as a colourless oil. 
Rf=0.58 (EtOAc/c-hexane 1:2); 
[α]D
22
 = 67 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=8.56 (s, 1H, NH), 7.38-7.19 (m, 15H, H
ar
), 6.53 (d, 
3
J(H,H)=3.6 Hz, 1H, 1-H), 5.06 (dd, 
3
J(H,H)=10.0 Hz, 3.6 Hz, 1H, 2-H), 4.86 (d, 
2
J(H,H)=11.5 Hz, 1H, 3O-CH
a
), 4.83 (d, 
2
J(H,H)=10.6 Hz, 1H, 4O-CH
a
), 4.76 (d, 
2
J(H,H)=11.5 Hz, 1H, 3O-CH
b
), 4.63 (d, 
2
J(H,H)=12.0 Hz, 1H, 6O-CH
a
), 4.57 (d, 
2
J(H,H)=10.6 Hz, 1H, 4O-CH
b
), 4.50 (d, 
2
J(H,H)=12.0 Hz, 1H, 6O-CH
b
), 4.09 (t, 
3
J(H,H)=10.0 Hz, 1H, 4-H), 4.01 (ddd, 
3
J(H,H)=10.0 Hz, 2.8 Hz, 1.8 Hz, 1H, 5-H), 3.87 (t, 
3
J(H,H)=10.0 Hz, 1H, H-3), 3.81 (dd, 
2
J(H,H)=12.5, 
3
J(H,H)=2.8 Hz, 1H, 6-H
a
), 3.72 (dd, 
2
J(H,H)=12.5 Hz, 
3
J(H,H)=1.8 Hz, 1H, 6-H
b
), 1.92 (s, 3H, CH3); 
13
C NMR (75 MHz, CDCl3): δ=169.8 (COO), 160.8 (CNH) 138.1 (6O-CC
ipso
), 137.7 
(4O-CC
ipso
), 137.6 (3O-CC
ipso
), 128.3 (3xCH
ar
), 128.3 (2xCH
ar
), 128.2 (2xCH
ar
), 128.0 
(2xCH
ar
), 127.9 (2xCH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 127.6 (CH
ar
), 127.6 (CH
ar
), 93.9 (C-1), 
79.3 (C-3), 76.9 (C-4), 75.2 (3O-CH2), 75.2 (4O-CH2), 73.3 (C-5, 6O-CH2), 72.2 (C-2), 67.7 
(C-6), 20.4 (CH3); 
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IR (thin film) ṽ=3338 (w), 3031 (w), 2870 (w), 1737 (s), 1673 (m), 1497 (w), 1454 (m), 1368 
(m), 1291 (m), 1228 (s), 1045 (s), 1027 (s), 968 (s), 913 (m), 832 (m), 794 (s), 734 (s), 696 (s) 
cm
-1
; 
HRMS (ESI) Calcd for C31H32O7NCl3Na [M+Na]
+
 658.1142, found: 658.1263. 
All data in accordance with literature.
[149]
 
 
VI.2.2. Synthesis of the C16 alkyl chain 
 
1,16-Hexadecanediol (84)
[311]
 
 
 
 
     83         84 
Scheme VI.5.  Synthesis of diol 84. 
A solution of LiAlH4 (783 mg, 20.64 mmol) in THF (80 mL) was kept at 0 °C and treated 
dropwise over a period of 30 min with a solution of hexadecanolide 83 (2.10 g, 8.25 mmol) in 
THF (70 mL). The resulting solution was heated at reflux for 2 h, then stirred over night at RT 
and finally quenched by with sat. aqueous Na/K-tartrate. The mixture was extracted twice 
with Et2O, the combined organic layers were washed with brine, dried, and concentrated to 
leave pure 84 (2.13 g, 99.8%) as colourless crystals. 
Rf=0.36 (EtOAc/c-hexane 1:2); 
m.p. 92 °C; 
1
H NMR (300 MHz, CD3OD): δ=3.54 (t,
 3
J(H,H)=6.6 Hz, 4H, 1-H, 16-H), 1.51 (qui,
 
3
J(H,H)=6.6 Hz, 4H, 2-H, 15-H), 1.37-1.27 (m, 24H);
 
13
C NMR (75 MHz, CD3OD): δ=63.0 (C-1, C-16), 33.7 (C-2, C-15), 30.8 (7CH2), 30.7 
(2CH2), 30.6 (2CH2), 27.0 (2CH2); 
IR (thin film) ṽ=3411 (m), 3345 (m), 2919 (s), 2848 (s), 1480 (w), 1461 (m), 1356 (m), 1333 
(w), 1051 (s), 1017 (s), 996 (w), 971 (m), 727 (m) cm
-1
. 
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16-[(tButyldimethylsilyl)oxy]hexadecane-1-ol (78) 
 
 
 
              84           78 
Scheme VI.6.  Monoprotection of diol 84. 
A solution of diol 84 (440 mg 1.70 mmol) in THF (12 mL) was treated with imidazole 
(232 mg, 3.40 mmol) and TBSCl (256 mg, 1.70 mmol), stirred at RT for 12 h, quenched with 
sat. aqueous NaHCO3, and extracted three times with Et2O. The combined organic layers 
were dried, concentrated, and the residue was purified by column chromatography (silica gel; 
35% EtOAc in c-hexane) to afford 78 (312 mg, 0.85 mmol, 63%) as a colourless oil. 
Rf=0.57 (EtOAc/c-hexane 1:3); 
1
H NMR (300 MHz, CD3OD): δ=3.64 (t, 
3
J(H,H)=6.6 Hz, 2H, CH2OH), 3.61 (t, 
3
J(H,H)=6.6 Hz, 2H, CH2OTBS), 1.63-1.47 (m, 4H, 2-H, 15-H), 1.39-1.23 (m, 24H), 0.91 (s, 
9H, C(CH3)3), 0.06 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CD3OD): δ=63.6 (COTBS), 63.3 (COH), 33.1 (C-15), 33.0 (C-2), 29.9 
(C-7 to C-10), 29.9 (C-13), 29.8 (C-4), 29.7 (C-6, C-11), 27.1 (C-12, C-5), 26.2 (C(CH3)3), 
26.0 (C-14), 26.0 (C-3), 18.6 (SiC
q
), -5.0 (Si(CH3)2); 
IR (thin film) ṽ=3335 (br), 2924 (s), 2854 (s), 1470 (m), 1463 (m), 1388 (w), 1361 (w), 1254 
(m), 1099 (s), 1005 (m), 938 (w), 833 (s), 812 (m), 773 (s), 734 (m), 661 (m) cm
-1
; 
HRMS (ESI) Calcd for C22H49O2Si [M+H]
+
 373.3502, found: 373.3490. 
 
VI.2.3. Phosphonate (76)[56] 
S-tButyl-4-bromo-3-oxopentanethioate (76)
 
 
 
 
 85    26         86 
Scheme VI.7.  Synthesis of thioester 86 for Arbuzov reaction. 
A solution of Meldrum’s acid 26 (2.9 g, 20.2 mmol) in CH2Cl2 (30 mL) was treated with 
pyridine (3.3 mL, 40.45 mmol) while stirring, then cooled to 0 °C, treated slowly with 
bromopropionyl bromide 85 (2.3 mL, 22.3 mmol) via a syringe, and left to stirr at 0 °C for 
1 h. The mixture was separated between CH2Cl2 and 2 M aqueous HBr solution and extracted 
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two times with CH2Cl2. The combined organic phases were dried over Na2SO4, concentrated, 
and the residue was dissolved in toluene (30 mL). 2-Methylpropane-2-thiol (6.8 mL, 
60.7 mmol) was slowly added and the mixture was heated at reflux for 1 h. Removal of the 
volatiles and column chromatography (silica gel; 5% EtOAc in c-hexane) yielded 86 (4.35 g, 
81%) as a red oil which was a 3:2 mixture of keto and enol tautomers.  
Rf=0.77 (EtOAc/c-hexane 1:4); 
Major Tautomer (keto): 
1
H NMR (300 MHz, CDCl3): δ=4.59 (q, 
3
J(H,H)=6.7 Hz, 1H; CHBr), 
4.00 (d, 
2
J(H,H)=15.0 Hz, 1H; COCHH
a
CO), 3.73 (d, 
2
J(H,H)=15.0 Hz, 1H; COCHH
b
CO), 
1.74 (d, 
3
J(H,H)=6.7 Hz, 3H; HCCH3), 1.47 (s, 9H; C(CH3)3); 
13
C NMR (75 MHz, CDCl3): δ=196.0 (CO), 192.7 (COS), 54.2 (CH2), 49.5 (C(CH3)3), 47.5 
(CH), 29.8 (C(CH3)3), 19.6 (CH3); 
Minor tautomer (enol): 
1
H NMR (300 MHz, CDCl3): δ=12.80 (s, 1H; C(OH)CHCO), 5.53 (s, 
1H; C(OH)CHCO), 4.35 (q, 
3
J(H,H)=6.9 Hz, 1H; CHBr), 1.82 (d, 
3
J(H,H)=6.9 Hz, 3H; 
HCCH3), 1.51 (s, 9H; C(CH3)3); 
13
C NMR (75 MHz, CDCl3): δ=197.1 (COS), 171.3 (COH), 98.7 (C
enol
), 49.0 (C(CH3)3), 44.1 
(CH), 30.1 (C(CH3)3), 22.4 (CH3); 
IR (thin film) ṽ=2964 (m), 2925 (m), 1726 (m), 1672 (m), 1618 (s), 1476 (w), 1455 (m), 1401 
(w), 1364 (m), 1310 (m), 1193 (m), 1159 (s), 1086 (s), 1062 (s), 1048 (s), 973 (s), 816 (s), 
780 (m), 706 (m) cm
-1
. 
All data in accordance with literature.
[56]
 
 
S-tButyl-4-(diethoxyphosphoryl)-3-oxopentanethioate (76)
[56]
 
 
 
 
  86             76 
Scheme VI.8.  Arbuzov reaction to form the phosphonate 76. 
Na (336 mg, 14.6 mmol) layered with dry THF (20 mL) was slowly treated via a syringe with 
diethylphosphite (1.74 ml, 13.49 mmol). The resulting mixture was heated at reflux for 2 h. 
By that time the sodium had been completely consumed. In another flask a suspension of NaH 
(494 mg, 12.4 mmol, 60% in mineral oil) in dry THF (30 mL) was cooled to 0 °C and treated 
slowly with a solution of 86 (3.0 g, 11.1 mmol) in THF (20 mL). The phosphate containing 
solution was cooled to RT and slowly added to the solution of 86. The resulting mixture was 
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stirred at RT for 16 h, quenched with a sat. aqueous NH4Cl and extracted three times with 
Et2O. The organic layers were washed twice with water and brine, dried over Na2SO4 and 
concentrated to leave 76 (3.51 g, 97%) as a red oil of sufficient purity; 6:1 mixture of keto and 
enol tautomers, storable at –18 °C for ca. two weeks without decomposition. 
Rf=0.20 (EtOAc/c-hexane 2:3); 
Major tautomer (keto): 
1
H NMR (300 MHz, CDCl3): δ=4.08 (dq, 
3
J(H,H)=15.2 Hz, 7.0 Hz, 
4H, OCH2), 4.01 (d, 
2
J(H,H)=15.1 Hz, 1H, COCH
a
HCO), 3.70 (d, 
2
J(H,H)=15.1 Hz, 1H, 
COCHH
b
CO), 3.42 (dq, 
2
J(P,H)=26.1 Hz, 
3
J(H,H)=7.0 Hz, 1H, PCH), 1.42 (s, 9H, C(CH3)3), 
1.34 (d, 
3
J(H,H)=7.0 Hz, 3H, HCCH3), 1.32-1.25 (m, 3H; OCH3); 
13
C NMR (75 MHz, CDCl3): δ=197.9 (CO), 192.6 (COS), 100.8 (d, 
3
J(P,C)=7.5 Hz, CH2), 
62.7 (dd, 
2
J(P,C)=11.9 Hz, 6.7 Hz, 2xCH2), 58.1 (OCH2), 48.3 (C(CH3)3), 47.1 (d, 
1
J(P,C)=125.9 Hz, CH), 16.3 (d, 
3
J(P,C)=5.9 Hz, OCH2CH3), 10.6 (d, 
2
J(P,C)=6.3 Hz, CH3); 
31
P NMR (120 MHz, CDCl3): δ=22.15; 
Minor tautomer (enol): 
1
H NMR (300 MHz, CDCl3): δ=13.01 (s, 1H, C(OH)CHCO), 5.43 (d, 
2
J(H,H)=3.0 Hz, 1H, C(OH)CHCO), 4.08 (dq, 
3
J(H,H)=15.3 Hz, 7.3 Hz, 4H, OCH2), 2.65 
(dq, 
2
J(P,H)=23.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, PCH), 1.43 (s, 9H, C(CH3)3), 1.32-1.25 (m, 3H, 
OCCH3), 1.30 (d, 
3
J(H,H)=7.0 Hz, 3H, HCCH3); 
13
C NMR (75 MHz, CDCl3): δ=198.0 (COS), 171.5 (d, 
3
J(P,C)=6.9 Hz, C
enol
), 62.4 (dd, 
2
J(P,C)=11.9 Hz, 6.7 Hz, 2xCH2), 58.0 (OCH2), 48.3 (C(CH3)3), 38.7 (d, 
1
J(P,C)=135.9 Hz, 
CH), 30.0, 16.3 (d, 
3
J(P,C)=5.9 Hz, OCH2CH3), 12.5 (d, 
2
J(P,C)=5.9 Hz, CH3);
 
31
P NMR (120 MHz, CDCl3): δ=25.18; 
IR (thin film): ṽ=2963 (m), 2924 (m), 1722 (m), 1674 (m), 1614 (m), 1456 (m), 1393 (m), 
1365 (m), 1313 (m), 1251 (m), 1162 (m), 1017 (s), 960 (s), 836 (m), 789 (m), 688 (m) cm
-1
; 
All data in accordance with literature.
[56]
 
 
VI.2.4. Synthesis of alanine derivatives (89) 
 
N-tButoxycarbonyl-N-methyl-L-alanine ((S)-88) 
 
 
 
 
      (S)-87    (S)-88 
Scheme VI.9.  N-Methylation procedure of (S)-87. 
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A solution of N-tbutoxycarbonyl-L-alanine (1.43 g, 7.54 mmol) in THF (25 mL) was slowly 
treated at 0 °C with NaH (60% in mineral oil, 905 mg, 22.61 mmol). After the release of H2 
had ceased CH3I (3.9 mL, 60.3 mmol) was added, the reaction mixture was stirred at RT for 
24 h and then partitioned between H2O and Et2O. The organic layer was washed with a little 
sat. aqueous NaHCO3 and the combined aqueous layers were acidified to pH 3 with 5 M HCl 
and then extracted twice with EtOAc. The combined organic phases were washed twice with 
sat. aqueous Na2S2O3, dried over Na2SO4 and concentrated to leave (S)-88 (1.44 g, 98%) as a 
clear oil; unspecified 1:1 mixture of rotamers A and B. 
1
H NMR (300 MHz, CD3OD): δ=4.67 (q, 
3
J(H,H)=6.5 Hz, 1H, CH3CH
a
), 4.38 (q, 
3
J(H,H)=6.5 Hz, 1H, CH3CH
b
), 2.84 (s, 6H, NCH3), 1.44 (s, 18H, (CH3)3), 1.40 (d, 
3
J(H,H)=6.5 Hz, 6H, HCCH3); 
13
C NMR (75 MHz, CD3OD): δ=175.4 (CO2H), 157.6 (C
a
ON), 157.3 (C
b
ON), 81.7 (C
a
Me3), 
81.4 (C
b
Me3), 56.7 (CH3C
a
H), 54.9 (CH3C
b
H), 32.1 (NC
a
H3), 31.2 (NC
b
H3), 28.6 (C(CH3)3), 
15.5 (CHC
a
H3), 15.1 (CHC
b
H3); 
IR (thin film) ṽ=2978 (m), 2939 (m), 1731 (s), 1625 (s), 1488 (s), 1442 (m), 1410 (s), 1398 
(s), 1321 (s), 1256 (m), 1207 (s), 1156 (s), 1098 (s), 1052 (m), 995 (m), 867 (s), 853 (s), 821 
(m), 779 (s), 764 (s), 744 (m) cm
-1
; HRMS (ESI) Calcd for C9H17NO4Na [M+Na]
+
 226.1050, 
found: 226.1032. 
All data in accordance with a product prepared by a different protocol.
[156]
 
 
(±)-N-tButoxycarbonyl-N-methyl-alanine ((R/S)-88) 
 
 
 
    (R/S)-87            (R/S)-88 
Scheme VI.10.  N-Methylation procedure of 87. 
Analogously to (S)-88 racemic (R/S)-88 (1.80 g, 99.6%) was obtained as a colourless solid 
from (±)-N-tbutoxycarbonylalanine (1.68 g, 8.9 mmol), NaH (1.07 g, 26.7 mmol), and CH3I 
(4.6 mL, 71.1 mmol) as unspecified 1:1 mixture of rotamers A and B. 
1
H NMR (300 MHz, CD3OD): δ=4.68 (q, J=6.9 Hz, 1H, CH3CH
a
), 4.38 (q, J=6.8 Hz, 1H, 
CH3CH
b
), 2.85 (s, 6H, NCH3), 1.44 (s, 18H, (CH3)3), 1.40 (d, J=7.2 Hz, 6H, HCCH3); 
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13
C NMR (75 MHz, CD3OD): δ=175.4 (CO2H), 157.7 (C
a
ON), 157.3 (C
b
ON), 81.7 (C
a
Me3), 
81.4 (C
b
Me3), 56.7 (CH3C
a
H), 54.9 (CH3C
b
H), 32.1 (NC
a
H3), 31.2 (NC
b
H3), 28.6 (C(CH3)3), 
15.6 (CHC
a
H3), 15.1 (CHC
b
H3); 
IR (thin film) ṽ=2977 (m), 2940 (m), 1733 (s), 1626 (s), 1489 (s), 1451 (m), 1443 (m), 1407 
(s), 1398 (s), 1368 (s), 1321 (s), 1266 (s), 1256 (m), 1209 (s), 1156 (s), 1099 (s), 1050 (m), 
996 (m), 867 (s), 854 (s), 821 (m), 780 (s), 767 (s), 745 (m), 663 (s), 564 (s), 541 (m) cm
-1
; 
HRMS (ESI) Calcd for C9H17NO4Na [M+Na]
+
 226.1050, found: 226.1034. 
 
Methyl N-methyl-L-alaninate hydrochloride ((S)-89) 
 
 
 
      (S)-88     (S)-89 
Scheme VI.11.  Methyl esterification to form (S)-89. 
A solution of (S)-88 (2.29 g, 11.26 mmol) in CH3OH (50 mL) was treated dropwise with 
SOCl2 (3.3 mL, 45.1 mmol) and stirred at RT for 24 h. The volatiles were evaporated and 
residual traces of acid were removed by repeated azeotropic entrainment with toluene. The 
crude product was recrystallized from Et2O/EtOH to yield a white crystalline hydrochloride of 
(S)-89 (1.51 g, 88%). 
m.p. 92°C; 
[α]D
22
 = 4.0 (c = 2.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, D2O): δ=4.13 (q, 
3
J(H,H)=7.3 Hz, 1H, CH3CH), 3.85 (s, 3H, OCH3), 
2.77 (s, 3H, NCH3), 1.58 (d, 
3
J(H,H)=7.3 Hz, 1H; CHCH3); 
13
C NMR (75 MHz, D2O): δ=170.9 (C
q
), 57.4 (CH), 53.9 (OMe), 31.7 (NCH3), 14.6 (CH3); 
IR (thin film) ṽ=3398 (br) 2950 (m), 2676 (m), 2463 (m), 2434 (m), 2404 (m), 2048 (w), 
1744 (s), 1575 (w), 1567 (w), 1465 (m), 1434 (m), 1375 (w), 1350 (m), 1309 (m), 1230 (s), 
1203 (m), 1183 (m), 1157 (m), 1100 (s), 1071 (m), 1046 (m), 1011 (m), 966 (m), 906 (m), 
875 (m), 836 (w), 817 (m), 753 (m) cm
-1
; 
HRMS (ESI) Calcd for C5H12O2N [M+H]
+
 118.0863, found: 118.0867; 
All data in accordance with a product prepared by a different protocol.
[158]
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(±)-Methyl N-methyl-alaninate hydrochloride ((R/S)-89) 
 
 
 
     (R/S)-88   (R/S)-89 
Scheme VI.12.  Methyl esterification to form 89. 
Analogously to (S)-89 racemic (R/S)-89 (1.0 g, 74%) was obtained as a transparent oil from 
(R/S)-88 (1.8 g, 8.86 mmol) and SOCl2 (3 mL, 4.9 g, 41.13 mmol). 
1
H NMR (300 MHz, CD3OD): δ=9.21 (s, 1H, NH), 4.14 (q, J=7.2, 1H, CH3CH), 3.86 (s, 3H, 
OMe), 2.76 (s, 3H, NCH3), 1.59 (d, J=7.2 Hz, 1H, CHCH3); 
13
C NMR (75 MHz, CDCl3): δ=170.9 (C
q
), 57.4 (CH), 53.9 (OCH3), 31.7 (NCH3), 14.6 
(CH3); 
IR (thin film) ṽ=3392 (br) 2962 (m), 2699 (m), 2458 (m), 2432 (m), 1743 (s), 1572 (w), 1460 
(m), 1439 (m), 1385 (w), 1351 (m), 1308 (m), 1233 (s), 1204 (m), 1104 (s), 1074 (m), 1045 
(m), 1013 (m), 976 (m), 875 (m), 834 (w), 754 (m) cm
-1
; 
HRMS (ESI) Calcd for C5H12O2N [M+H]
+
 118.0863, found: 118.0859. 
 
VI.2.5. Synthesis of epicoccamide D ((5S,7S)-1) and derivatives 
 
1'-β-[16-(tButyldimethylsilyloxy)hexadecyl]-3',4',6'-tri-O-benzyl-2-O-acetyl-D-gluco-
pyranoside (90) 
 
 
 
 
 
        77      78           90 
Scheme VI.13.  Glycosylation procedure of 77 with 90. 
A mixture of 2 g powdered 4 Å molecular sieves, dried under vacuum at 600 °C for 20 min, 
alcohol 78 (2.19 g, 5.86 mmol), and CH2Cl2 (70 mL) was treated at RT with imidate 77 
(2.2 g, 3.45 mmol), then cooled to -78 °C and treated with BF3•OEt2 (64 µL, 0.52 mmol). 
Vigorous
[312]
 stirring was continued at -78 °C until completion (tlc control; approx. 2 h). The 
reaction mixture was filtered over celite, the celite pad was rinsed several times with CH2Cl2 
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and the combined organic phases were washed with sat. NaHCO3. The aqueous layer was 
reextracted with CH2Cl2, the organic phases were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product thus obtained was purified by flash 
chromatography (flash silica gel; 5% EtOAc in c-hexane) yielding 2.45 g of 90 (84%) as a 
clear oil. 
Rf=0.85 (EtOAc/c-hexane 1:3); 
[α]D
25
 = -1.1 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.39-7.19 (m, 15H, H
ar
), 5.05-4.96 (m, 1H, 2'-H), 4.80 (d, 
2
J(H,H)=10.9 Hz, 2H, 6'O-CH2), 4.68 (d, 
2
J(H,H)=11.7 Hz, 1H, 4'O-CH
a
), 4.64 (d, 
2
J(H,H)=12.1 Hz, 1H, 3'O-CH
a
), 4.57 (d, 
2
J(H,H)=11.7 Hz, 1H, 4'O-CH
b
), 4.56 (d, 
2
J(H,H)=12.1 Hz, 1H, 3'O-CH
b
), 4.37 (d, 
3
J(H,H)=8.0 Hz, 1H, 1'-H), 3.89 (dt, 
3
J(H,H)=6.3 Hz, 
2
J(H,H)=9.6 Hz, 1H, 1'O-CH
a
), 3.78 (dd, 
3
J(H,H)=2.3 Hz, 
2
J(H,H)=10.9 Hz, 
1H, 6'-H
a
), 3.75 (dd, 
3
J(H,H)=4.6 Hz, 1.4 Hz, 1H, 4'-H), 3.70 (dd, 
3
J(H,H)=10.9 Hz, 1.4 Hz, 
1H, 5'-H), 3.70 (dd, 
3
J(H,H)=4.6 Hz, 1.3 Hz, 1H, 3'-H), 3.63 (t, 
3
J(H,H)=6.6 Hz, 2H, 
CH2OSi), 3.51 (dd, 
3
J(H,H)=2.3 Hz, 
2
J(H,H)=10.9 Hz, 1H, 6'-H
b
), 3.46 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.6 Hz, 1H, 1'O-CH
b
), 1.99 (s, 3H, CH3CO), 1.60-1.49 (m, 4H, 2CH2), 1.35-1.26 
(m, 24H, 12CH2), 0.93 (s, 9H, C(CH3)3), 0.08 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=169.6 (CH3CO), 138.4 (4'O-CC
ipso
), 138.3 (3'O-CC
ipso
), 138.1 
(6'O-CC
ipso
), 128.6 (3CHar), 128.5 (2CHar), 128.2 (2CHar), 128.0 (2CHar), 127.9 
(4CHar), 127.8 (CHar), 127.7 (CHar), 101.2 (C-1'), 83.2 (C-3'), 78.2 (C-4'), 75.4 (C-5'), 75.2 
(3'O-CH2), 75.1 (4'O-CH2), 73.7 (6'O-CH2), 73.4 (C-2'), 69.8 (1'O-CH2), 69.0 (C-6'), 63.5 
(CH2OSi), 33.0 (2CH2), 29.8 (6CH2), 29.7 (CH2), 29.6 (CH2), 29.5 (CH2), 27.1 (CH2), 
26.15 (CH2), 26.1 (C(CH3)3), 26.0 (CH2), 21.0 (CH3CO), 18.5 (SiC), -5.1 (Si(CH3)2); 
IR (thin film): ṽ=2925 (m), 2853 (m), 1751 (m), 1497 (w), 1461 (m), 1454 (m), 1361 (m), 
1229 (s), 1147 (m), 1090 (s), 1058 (s), 1028 (m), 1005 (m), 938 (w), 906 (w), 834 (m), 814 
(m), 774 (m), 733 (m), 696 (s), 602 (w) cm
-1
; 
HRMS (ESI) Calcd for C51H78O8SiK [M+K]
+
 885.5103, found: 885.5081. 
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1'-β-[16-(tButyldimethylsilyloxy)hexadecyl]-3',4',6'-tri-O-benzyl-D-glucopyranoside (91) 
 
 
 
       90           91 
Scheme VI.14.  Acetyl deprotection by ester interchange. 
A solution of 90 (0.80 g, 0.94 mmol) in MeOH (10 mL) was treated with NaOMe (102 mg, 
1.88 mmol) in one portion, stirred until completion of reaction by tlc (approx. 12 h), then 
quenched with HOAc (81 µL, 1.39 mmol), and finally concentrated in vacuum. The residue 
was purified by column chromatography (flash silica gel; 5% EtOAc in c-hexane) to afford 
0.75 g 91 (99.2%) as a clear oil. 
Rf=0.76 (EtOAc/c-hexane 1:3); 
[α]D
25
 = -3.1 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.43-7.18 (m, 15H, H
ar
), 4.98 (d, 
2
J(H,H)=11.2 Hz, 1H, 
4'O-CH
a
), 4.87 (d, 
2
J(H,H)=10.1 Hz, 2H, 6'O-CH2), 4.65 (d, 
2
J(H,H)=12.2 Hz, 1H, 3'O-CH
a
), 
4.58 (d, 
2
J(H,H)=12.2 Hz, 1H, 3'O-CH
b
), 4.57 (d, 
2
J(H,H)=11.2 Hz, 1H, 4'O-CH
b
), 4.28 (d, 
3
J(H,H)=7.3 Hz, 1H, 1'-H), 3.95 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.5 Hz, 1H, 1'O-CH
a
), 3.78 
(dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.70 (dd, 
3
J(H,H)=7.3 Hz, 1.8 Hz, 1H, 
2'-H), 3.63 (t, 
3
J(H,H)= 6.6 Hz, 2H, CH2OSi), 3.62 (dd, 
3
J(H,H)=1.8 Hz, 
2
J(H,H)=10.8 Hz, 
1H, 6'-H
b
), 3.61 (dd, 
3
J(H,H)=7.3 Hz, 1.8 Hz, 1H, 3'-H), 3.55 (dt, 
3
J(H,H)=10.8 Hz, 1.8 Hz, 
1H, 4'-H), 3.53 (ddd, 
3
J(H,H)=10.8 Hz, 2.1 Hz, 1.8 Hz, 1H, 5'-H), 3.51 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.5 Hz, 1H, 1'O-CH
b
), 1.67 (m, 2H, CH2), 1.55 (m, 2H, CH2), 1.42-1.27 (m, 24H, 
CH2), 0.93 (s, 9H, C(CH3)3), 0.09 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=138.8 (4'O-CC
ipso
), 138.3 (3'O-CC
ipso
), 138.2 (6'O-CC
ipso
), 
128.6 (3xCH
ar
), 128.5 (2xCH
ar
), 128.4 (2xCH
ar
), 128.1 (2xCH
ar
), 128.0 (2xCH
ar
), 127.9 
(CH
ar
), 127.85 (CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 102.9 (C-1'), 84.7 (C-3'), 77.7 (C-4'), 75.3 
(C-5'), 75.2 (3'O-CH2), 75.1 (4'O-CH2), 74.9 (C-2'), 73.6 (6'O-CH2), 70.3 (C-6'), 69.0 
(1'O-CH2), 63.5 (CH2OSi), 33.0 (CH2), 29.8 (10CH2), 29.7 (CH2), 29.6 (CH2), 26.1 
(C(CH3)3), 25.9 (CH2), 18.5 (SiC
q
), -5.1 (Si(CH3)2); 
IR (thin film) ṽ=3481 (br), 2924 (m), 2853 (m), 1497 (w), 1463 (w), 1454 (m), 1360 (m), 
1254 (m), 1208 (w), 1098 (s), 1059 (s), 1027 (m), 910 (w), 834 (m), 774 (m), 732 (m), 695 
(s), 660 (m), 619 (w), 602 (w), 600 (w) cm
-1
; 
HRMS (ESI) Calcd for C49H76O7SiNa [M+Na]
+
 827.5258, found: 827.5235. 
EXPERIMENTAL - Epicoccamide D 
96 
 
16-O-(tButyldimethylsilyl)hexadecane-3',4',6'-tri-O-benzyl-β-D-arabinohexapyranosid-
2-ulose (92) 
 
 
 
   91       92 
Scheme VI.15.  First step of epimerisation reaction by sugar oxidation. 
A solution of 91 (0.75 g, 0.93 mmol) in CH2Cl2 (10 mL) was treated with Dess-Martin 
periodinane (1.19 g, 2.79 mmol) in one portion. The resulting suspension was stirred under 
argon for 16 h, then treated with 50% sat. aqueous NaHCO3 and extracted three times with 
CH2Cl2. The combined organic layers were dried, concentrated, and the remainder was 
purified by column chromatography (silica gel; 10% EtOAc in c-hexane) to afford 714 mg 
(96%) of 92 as a transparent oil. 
Rf=0.49-0.72 (due to formation of hydrates; EtOAc/c-hexane 1:3); 
[α]D
25
 = -18.4 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.44-7.17 (m, 15H, H
ar
), 5.00 (d, 
2
J(H,H)=11.4 Hz, 1H, 
3'O-CH
a
), 4.87 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.79 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.60 
(d, 
2
J(H,H)=9.4 Hz, 2H, 6'O-CH2), 4.60 (d, 
2
J(H,H)=11.4 Hz, 1H, 3'O-CH
b
), 4.56 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.24 (d, 
3
J(H,H)=7.9 Hz, 1H, 3'-H), 3.91 (dd, 
3
J(H,H)=1.7 Hz, 
2
J(H,H)=11.0 Hz, Hz, 1H, 6'-H
a
), 3.87 (dt, 
3
J(H,H)=3.6 Hz, 
2
J(H,H)=9.5 Hz, 
1H, 1'O-CH
a
), 3.77 (dd, 
3
J(H,H)=7.9 Hz, 5.0 Hz, 1H, 4'-H), 3.64 (ddd, 
3
J(H,H)=11.0 Hz, 
5.0 Hz, 1.7 Hz, 1H, 5'-H), 3.61 (t, 
3
J(H,H)=6.6 Hz, 2H, CH2OSi), 3.58 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.5 Hz, 1H, 1'O-CH
b
), 3.51 (dd, 
3
J(H,H)=1.7 Hz, 
2
J(H,H)=11.0 Hz, 1H, 6'-H
b
), 1.68 
(m, 2H, CH2), 1.52 (m, 2H, CH2), 1.39-1.24 (m, 24H, CH2), 0.91 (s, 9H, C(CH3)3), 0.06 (s, 
6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=197.4 (C-2'), 138.1 (4'O-CC
ipso
), 137.8 (3'O-CC
ipso
), 137.5 
(6'O-CC
ipso
), 128.6 (3xCH
ar
), 128.6 (2xCH
ar
), 128.5 (CH
ar
), 128.3 (CH
ar
), 128.2 (2xCH
ar
), 
128.1 (2xCH
ar
), 128.0 (CH
ar
), 127.9 (CH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 99.4 (C-1'), 85.7 
(C-3'), 80.2 (C-4'), 75.9 (C-5'), 75.0 (4'O-CH2), 73.7 (3'O-CH2), 73.6 (6'O-CH2), 70.0 (C-6'), 
69.2 (CH2), 63.5 (CH2OSi), 33.0 (CH2), 29.8 (9CH2), 29.7 (CH2), 29.6 (CH2), 26.1 
(C(CH3)3), 26.0 (CH2), 25.9 (CH2), 18.5 (SiC
q
), -5.1 (Si(CH3)2); 
IR (thin film) ṽ=2925 (m), 2854 (m), 1742 (m), 1497 (w), 1462 (m), 1454 (m), 1371 (m), 
1360 (m), 1247 (m), 1207 (w), 1145 (w), 1096 (s), 1047 (s), 1027 (s), 938 (w), 910 (w), 834 
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(s), 774 (m), 733 (m), 696 (s) cm
-1
; 
HRMS (ESI) Calcd for C49H74O7SiNa [M+Na]
+
 825.5102, found: 825.5125. 
 
1'-β-[16-(tButyldimethylsilyloxy)hexadecyl]3',4',6'-tri-O-benzyl-D-mannopyranoside 
(93) 
 
 
 
   92       93 
Scheme VI.16.  Second step of epimerisation reaction by stereoselective reduction. 
A solution of 92 (714 mg, 0.89 mmol) in 10 mL of a 1:1 mixture of CH2Cl2 and MeOH was 
treated with NaBH4 (336 mg, 8.88 mmol) and the resulting mixture was stirred for 12 h and 
then concentrated. The remainder was submitted to column chromatography (silica gel; 10% 
EtOAc in c-hexane) to separate 3% of the gluco-configured by-product and to afford 688 mg 
(97%) of pure 93. 
Rf=0.47 (EtOAc/c-hexane 1:3); 
[α]D
25
 = -9.4 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.19 (m, 15H, H
ar
), 4.89 (d, 
2
J(H,H)=10.9 Hz, 1H, 
4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 
4.63 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.10 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=6.7 Hz,
 2
J(H,H)=9.4 Hz, 1H, 1'O-CH
a
), 
3.86 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz,
 2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 
3.71 (dd, 
3
J(H,H)=5.3 Hz,
 2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.60 (t, 
3
J(H,H)=6.6 Hz, 2H, 
CH2OSi), 3.57 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.50 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.4 Hz, 1H, 1'O-CH
b
), 3.43 (ddd, 
3
J(H,H)=10.8 Hz, 5.3 Hz, 2.1 Hz, 1H, 5'-H), 
1.68-1.56 (m, 2H, CH2), 1.54-1.45 (m, 2H, CH2), 1.36-1.24 (m, 24H, 12CH2), 0.90 (s, 9H, 
C(CH3)3), 0.05 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=138.4 (4'O-CC
ipso
), 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 
128.6 (3xCH
ar
), 128.5 (2xCH
ar
), 128.4 (2xCH
ar
), 128.2 (2xCH
ar
), 128.0 (2xCH
ar
), 128.0 
(CH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 99.9 (C-1'), 81.8 (C-4'), 75.5 (C-5'), 75.3 
(4'O-CH2), 74.5 (C-3'), 73.6 (6'O-CH2), 71.5 (3'O-CH2), 70.0 (1'O-CH2), 69.5 (C-6'), 68.5 
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(C-2'), 63.5 (CH2OSi), 33.0 (CH2), 29.8 (6CH2), 29.8 (CH2), 29.8 (2CH2), 29.7 (CH2), 29.7 
(CH2), 29.6 (CH2), 26.2 (CH2), 26.1 (C(CH3)3), 25.9 (CH2), 18.5 (SiC
q
), -5.1 (Si(CH3)2); 
IR (thin film) ṽ=3440 (br), 2924 (m), 2853 (m), 1497 (w), 1462 (m), 1454 (m), 1385 (w), 
1361 (m), 1313 (w), 1253 (m), 1207 (w), 1097 (s), 1074 (s), 1027 (m), 1006 (m), 939 (w), 
909 (w), 834 (s), 812 (w), 774 (m), 732 (s), 695 (s) cm
-1
. 
HRMS (ESI) Calcd for C49H76O7SiK [M+K]
+
 843.4997, found: 843.5018. 
 
16-Hydroxyhexadecyl-3',4',6'-tri-O-benzyl-β-D-mannopyranoside (94) 
 
 
 
          93           94 
Scheme VI.17.  TBS deprotection. 
A solution of 93 (550 mg, 0.68 mmol) in dry THF (7 mL) was treated with a 1 M solution of 
TBAF in THF (1.4 mL, 1.4 mmol) and the resulting mixture was stirred at RT for 12 h, then 
quenched with sat. aqueous. NaHCO3 and extracted three times with CH2Cl2. The combined 
organic phases were washed with aqueous NaHCO3, dried over Na2SO4 and concentrated. 
The crude product was purified by column chromatography (silica gel; 20% EtOAc in 
c-hexane) to leave 94 (457 mg, 95%) as white crystals. 
m.p. 63 °C; 
Rf=0.42 (EtOAc/c-hexane 2:3); 
[α]D
25
 = -13.9 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ = 7.41-7.19 (m, 15H, H
ar
), 4.90 (d, 
2
J(H,H)=10.9 Hz, 1H, 
4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.66 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 
4.62 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.40 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H, 2'-H), 3.94 (dt, 
3
J(H,H)=6.6 Hz, 
2
J(H,H)=9.2 Hz, 1H, 1'O-CH
a
), 
3.87 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.78 (dd, 
3
J(H,H)=2.2 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 
3.71 (dd, 
3
J(H,H)=5.2, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.57 (t, 
3
J(H,H)=6.7 Hz, 2H, CH2OH), 
3.56 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.50 (dt, 
3
J(H,H)=6.6 Hz, 
2
J(H,H)=9.2 Hz, 1H, 
1'O-CH
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.2 Hz, 2.2 Hz, 1H, 5'-H), 1.69-1.58 (m, 2H, CH2), 
1.58-1.49 (m, 2H, CH2), 1.34-1.25 (m, 24H, 12CH2); 
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13
C NMR (75 MHz, CDCl3): δ=138.2 (4'O-CC
ipso
), 138.2 (3'O-CC
ipso
), 137.9 (6'O-CC
ipso
), 
128.4 (3xCH
ar
), 128.4 (2xCH
ar
), 128.3 (2xCH
ar
), 128.0 (2xCH
ar
), 127.8 (3xCH
ar
), 127.7 
(CH
ar
), 127.6 (CH
ar
), 127.5 (CH
ar
), 99.8 (C-1'), 81.6 (C-4'), 75.2 (C-5'), 75.1 (4'O-CH2), 74.3 
(C-3'), 73.4 (6'O-CH2), 71.2 (3'O-CH2), 69.8 (CH2), 69.2 (C-6'), 68.3 (C-2'), 62.7 (CH2OH), 
32.7 (CH2), 29.6 (CH2), 29.6 (13CH2), 29.5 (CH2), 29.45 (CH2), 29.4 (CH2), 26.0 (CH2), 
25.8 (CH2); 
IR (thin film) ṽ=3458 (br), 2924 (m), 2853 (m), 1496 (w), 1454 (m), 1368 (m), 1312 (w), 
1265 (m), 1242 (w), 1207 (w), 1177 (w), 1099 (s), 1057 (s), 1027 (m), 909 (m), 874 (w), 834 
(w), 789 (w), 731 (s), 696 (s) cm
-1
. 
HRMS (ESI) Calcd for C43H62O7K [M+K]
+
 729.4133, found: 729.4118. 
 
16-Oxohexadecyl-3',4',6'-tri-O-benzyl-β-D-mannopyranoside (75) 
 
 
 
       94       75 
Scheme VI.18.  Dess-Martin periodinane mediated selective oxidation to form aldehyde 75. * 92% 
based on recovered starting material. 
A mixture of alcohol 94 (321 mg, 0.47 mmol), Dess-Martin periodinane (227 mg, 0.54 mmol) 
and CH2Cl2 (10 mL) at 0 °C was allowed to warm up to RT over 3 h, treated with 50% sat. 
aqueous NaHCO3 (15 mL) and extracted three times with CH2Cl2. The combined organic 
layers were washed with water, dried over Na2SO4 and concentrated in vacuum. The residue 
was purified by flash chromatography (flash silica gel; 25% EtOAc in c-hexane) to yield 75 
(215 mg, 70%) as a transparent oil aside of 69 mg (0.10 mmol, 22%) of recovered alcohol 94. 
Rf=0.49 (EtOAc/c-hexane 1:2); 
[α]D
25
 = -16.8 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=9.76 (t, 
3
J(H,H)=1.9 Hz, 1H, HC=O), 7.42-7.20 (m, 15H, 
H
ar
), 4.92 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
a
), 4.80 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.68 
(d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.64 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.58 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.56 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.43 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.13 (dd, 
3
J(H,H)=3.1 Hz, 0.9 Hz, 1H, 2'-H), 3.96 (dt, 
3
J(H,H)=6.6 Hz, 
2
J(H,H)=9.7 Hz, 1H, 1'O-CH
a
), 3.89 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.80 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.9 Hz, 1H, 6'-H
a
), 3.73 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.9 Hz, 
1H, 6'-H
b
), 3.59 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.52 (dt, 
3
J(H,H)=6.6 Hz, 
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2
J(H,H)=9.7 Hz, 1H, 1'O-CH
b
), 3.45 (ddd, 
3
J(H,H)=9.4 Hz, 5.2 Hz, 2.1 Hz, 1H, 5'-H), 2.41 
(td, 
3
J(H,H)=7.3 Hz, 1.9 Hz, 2H, CH2C=O), 1.69-1.55 (m, 4H, 2CH), 1.39-1.24 (m, 22H, 
11CH2); 
13
C NMR (75 MHz, CDCl3): δ=202.9 (C=O), 138.3 (4'O-CC
ipso
), 138.3 (3'O-CC
ipso
), 137.9 
(6'O-CC
ipso
), 128.5 (3xCH
ar
), 128.4 (2xCH
ar
), 128.3 (2xCH
ar
), 128.1 (2xCH
ar
), 127.9 
(2xCH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 127.6 (CH
ar
), 99.8 (C-1'), 81.6 (C-4'), 
75.3 (C-5'), 75.2 (4'O-CH2), 74.3 (C-3'), 73.5 (6'O-CH2), 71.3 (3'O-CH2), 69.9 (1'O-CH2), 
69.3 (C-6'), 68.4 (C-2'), 43.9 (CC=O), 29.7 (2CH2), 29.6 (CH2), 29.6 (3CH2), 29.5 (CH2), 
29.4 (2CH2), 29.2 (CH2), 26.0 (CH2), 22.9 (CH2); 
IR (thin film): ṽ=3499 (br), 2923 (m), 2853 (m), 1723 (m), 1496 (w), 1464 (w), 1454 (m), 
1366 (m), 1312 (w), 1242 (w), 1207 (w), 1177 (w), 1099 (s), 1072 (s), 1027 (m), 910 (w), 874 
(w), 790 (w), 734 (s), 696 (s) cm
-1
; 
HRMS (ESI) Calcd for C43H60O7K [M+K]
+
 727.3976, found: 727.3991. 
 
[17-Methyl-18-oxo-19-(S-tbutylthiocarbonyl)-eicosa-16-enyl]-3',4',6'-tri-O-benzyl-β-D-
mannopyranoside (74) 
 
 
 
        75               74 
Scheme VI.19.  HWE reaction of aldehyde 75 and phosphonate 76. 
A solution of phosphonate 76 (76 mg, 0.234 mmol) in dry THF (3 mL) at -78°C was treated 
dropwise with a 1.6 M solution of nBuLi in hexanes (290 µL, 0.47 mmol) and stirred at 
-78 °C for 15 min. Aldehyde 75 (115 mg, 0.167 mmol) dissolved in 3 mL THF was added 
dropwise, the resulting mixture was stirred for 30 min, then warmed up to RT and stirring was 
continued for a further 3 h. The reaction was quenched with sat. aqueous NH4Cl, extracted 
three times with Et2O and the combined organic layers were dried over Na2SO4 and 
concentrated. The crude product was purified by column chromatography (silica gel; 10% 
EtOAc in c-hexane) affording 74 (114 mg, 80%) as a transparent oil; 3:1:1 mixture of a major 
keto-E-isomer, a minor enol-E-isomer (A) and a minor keto-Z-isomer (B). 
[α]D
25
 = -14.5 (c = 1.0 g cm
-3
, chloroform); 
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IR (thin film) ṽ=3482 (br), 2923 (s), 2853 (m), 1688 (w), 1660 (m), 1641(m), 1584 (m), 1497 
(w), 1454 (m), 1364 (m), 1301 (m), 1208 (m), 1159 (m), 1100 (s), 1064 (s), 1027 (m), 992 
(w), 907 (w), 875 (w), 788 (w), 735 (m), 697 (m) cm
-1
; 
HRMS (ESI) Calcd for C52H74O8SNa [M+Na]
+
 881.4997, found: 881.5006. 
Major E-keto-isomer: 
Rf=0.72 (EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=7.41-7.19 (m, 15H, H
ar
), 6.66 (td, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 16-H), 4.90 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.63 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.1 Hz, 0.9 Hz, 1H, 2'-H), 3.94 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.8 Hz, 1H, 1'O-CH
a
), 
3.85 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.84 (s, 2H, OCCH2CO), 3.79 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.71 (dd, 
3
J(H,H)=5.3 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.57 
(dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.50 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.6 Hz, 1H, 
1'O-CH
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.3 Hz, 2.1, 1H, 5'-H), 2.27 (qui, 
3
J(H,H)=6.8 Hz, 2H, 
15-H), 1.79 (d, 
4
J(H,H)=1.3 Hz, 3H, CH3C=C), 1.63 (q, 
3
J(H,H)=6.9 Hz, 2H, OCH2CH2), 
1.47 (s, 9H, E-tBu), 1.37-1.24 (m, 24H; 12CH2); 
13
C NMR (75 MHz, CDCl3): δ=193.8 (C2C=O), 193.4 (COS), 146.3, (H3CC=C), 138.4 
(4'O-CC
ipso
), 138.3 (3'O-CC
ipso
), 137.9 (6'O-CC
ipso
), 128.6 (3xCH
ar
), 128.5 (2xCH
ar
), 128.4 
(2xCH
ar
), 128.2 (2xCH
ar
), 128.0 (2xCH
ar
), 128.0 (CH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 127.6 
(CH
ar
), 99.8 (C-1'), 81.7 (C-4'), 75.4 (C-5'), 75.3 (4'O-CH2), 74.4 (C-3'), 73.6 (6'O-CH2), 71.4 
(3'O-CH2), 69.9 (1'O-CH2), 69.4 (C-6'), 68.5 (C-2'), 54.0 (OCCH2CO), 48.9 (CMe3), 
(C(CH3)3), 29.8 (CH2), 29.7 (CH2CH2C=C), 29.7, 29.6, 29.5 (8CH2), 29.5 (CH2), 29.4 
(CH2), 29.0 (CH2C=CCH3), 28.6 (CH2), 26.1 (CH2CH2C=C), 11.4 (CH3C=C). 
Minor E-enol-isomer A: 
Rf=0.65 (EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=13.00 (s, 1H, HC=COH (enol)), 7.41-7.19 (m, 15H, H
ar
), 6.66 
(td, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 16-H), 5.49 (s, 1H, HC=COH), 4.90 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.63 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.1 Hz, 0.9 Hz, 1H, 2'-H), 3.94 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.8 Hz, 1H, 1'O-CH
a
), 3.85 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.79 (dd, 
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3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.71 (dd, 
3
J(H,H)=5.3 Hz, 
2
J(H,H)=10.8 Hz, 
1H, 6'-H
b
), 3.57 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.50 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.6 Hz, 1H, 1'O-CH
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.3 Hz, 2.1 Hz, 1H, 5'-H), 2.20 
(qui, 
3
J(H,H)=7.2 Hz, 2H, H3CC=CHCH2), 1.73 (d, 
4
J(H,H)=1.3 Hz, 3H, CH3C=C), 1.63 (q, 
3
J(H,H)=6.9 Hz, 2H, OCH2CH2), 1.53 (s, 9H, Z-tBu), 1.37-1.24 (m, 24H, 12CH2); 
13
C NMR (75 MHz, CDCl3): δ=193.8 (C2C=O), 193.4 (COS), 146.3, (H3CC=C), 138.4 
(4'O-CC
ipso
), 138.3 (3'O-CC
ipso
), 137.9 (6'O-CC
ipso
), 137.1 (H3CC=C), 128.6 (3xCH
ar
), 128.5 
(2xCH
ar
), 128.4 (2xCH
ar
), 128.2 (2xCH
ar
), 128.0 (2xCH
ar
), 128.0 (CH
ar
), 127.9 (CH
ar
), 127.8 
(CH
ar
), 127.6 (CH
ar
), 99.8 (C-1'), 97.4 (HC=COH), 81.7 (C-4'), 75.4 (C-5'), 75.3 (4'O-CH2), 
74.4 (C-3'), 73.6 (6'O-CH2), 71.4 (3'O-CH2), 69.9 (1'O-CH2), 69.4 (C-6'), 68.5 (C-2'), 54.0 
(OCCH2CO), 48.3 (CMe3) 30.28 (C(CH3)3), 29.8 (CH2), 29.7 (CH2CH2C=C), 29.7, 29.6, 29.5 
(8CH2), 29.5 (CH2), 29.4 (CH2), 29.0 (CH2C=CCH3), 28.6 (CH2), 26.1 (CH2CH2C=C), 11.4 
(CH3C=C). 
Minor Z-keto-isomer B: 
Rf=0.65 (EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=7.41-7.19 (m, 15H, H
ar
), 6.66 (td, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 16-H), 4.90 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.63 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.1 Hz, 0.9 Hz, 1H, 2'-H), 3.94 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.8 Hz, 1H, 1'O-CH
a
), 
3.85 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.84 (s, 2H, OCCH2CO), 3.79 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.71 (dd, 
3
J(H,H)=5.3 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.57 
(dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.50 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.6 Hz, 1H, 
1'O-CH
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.3 Hz, 2.1 Hz, 1H, 5'-H), 2.27 (qui, 
3
J(H,H)=6.8 Hz, 
2H, 15-H), 1.73 (d, 
4
J(H,H)=1.3 Hz, 3H, CH3C=C), 1.63 (q, 
3
J(H,H)=6.9 Hz, 2H, OCH2CH2), 
1.47 (s, 9H, E-tBu), 1.37-1.24 (m, 24H, 12CH2); 
13
C NMR (75 MHz, CDCl3): δ=193.8 (C2C=O), 193.4 (COS), 138.4 (4'O-CC
ipso
), 138.3 
(3'O-CC
ipso
), 137.9 (6'O-CC
ipso
), 138.0 (H3CC=C), 137.1 (H3CC=C), 128.6 (3xCH
ar
), 128.5 
(2xCH
ar
), 128.4 (2xCH
ar
), 128.2 (2xCH
ar
), 128.0 (2xCH
ar
), 128.0 (CH
ar
), 127.9 (CH
ar
), 127.8 
(CH
ar
), 127.6 (CH
ar
), 99.8 (C-1'), 81.7 (C-4'), 75.4 (C-5'), 75.3 (4'O-CH2), 74.4 (C-3'), 73.6 
(6'O-CH2), 71.4 (3'O-CH2), 69.9 (1'O-CH2), 69.4 (C-6'), 68.5 (C-2'), 54.0 (OCCH2CO), 48.9 
(CMe3), 29.8 (C(CH3)3), 29.8 (CH2), 29.7 (CH2CH2C=C), 29.7, 29.6, 29.5 (8CH2), 29.5 
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(CH2), 29.4 (CH2), 29.0, 28.8 (CH2C=CCH3), 28.6 (CH2), 26.1 (CH2CH2C=C), 12.2 
(CH3C=C). 
 
(22S)-[21-Aza-17,21,22-trimethyl-18,20,23-trioxo-pentacosa-16-enyl]-3',4',6'-tri-O-
benzyl-β-D-mannopyranoside ((5S)-95) 
 
 
 
 
        74           (2S)-95 
Scheme VI.20.  Silver salt mediated aminolysis with (S)-89. 
Under exclusion of moisture and light a solution of 74 (99 mg, 0.115 mmol) in CH2Cl2 
(5.5 mL) at 0 °C was treated with amino ester (S)-89 (hydrochloride, 44 mg, 0.289 mmol) in 
one portion. NEt3 (56 µL, 0.403 mmol) was added dropwise, the reaction was initiated by 
addition of F3CCO2Ag (51 mg, 0.230 mmol), and the mixture was stirred at 0 °C for 5 h. The 
silver salt was filtered off, rinsed with CH2Cl2, and the combined filtrates were concentrated 
under reduced pressure. The crude product was purified by flash chromatography (flash silica 
gel; 15% EtOAc in c-hexane) to leave (5S)-95 (91 mg, 89%) as a clear oil and a 3:1:1 mixture 
of a major (keto-E) isomer, a minor (enol-E) isomer (A) and a minor (keto-Z) isomer (B). 
Rf=0.36 / 0.17 (keto and enol isomers; EtOAc/c-hexane 1:2); 
[α]D
25
 = -28.6 (c = 1.0 g cm
-3
, chloroform); 
IR (thin film) ṽ=3490 (br), 2923 (s), 2853 (m), 1781 (m), 1742 (w), 1670 (m), 1645 (m), 1594 
(m), 1454 (m), 1437 (w), 1391 (w), 1370 (m), 1315 (m), 1209 (m), 1177 (m), 1101 (s), 1078 
(s), 1027 (m), 987 (m), 909 (w), 782 (w), 736 (m), 697 (m) cm
-1
; 
HRMS (ESI) Calcd for C53H75NO7Na [M+Na]
+
 908.5283, found: 908.5288. 
Major E-keto-isomer: 
Rf=0.36(EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.18 (m, 15H, H
ar
), 6.72 (td, 
4
J(H,H)=1.1 Hz, 
3
J(H,H)=7.2 Hz, 1H; 8-H), 5.22 (q, 
3
J(H,H)=7.3 Hz, 1H; 5-H), 4.89 (d, 
2
J(H,H)=10.9 Hz, 1H; 
4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H; 3'O-CH
b
), 
4.62 (d, 
2
J(H,H)=12.2 Hz, 1H; 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H; 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.9 Hz, 1H; 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H; 1'-H), 4.10 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H; 2'-H), 3.93 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.4 Hz, 1H; 23-H
a
), 
3.85 (t, 
3
J(H,H)=9.3 Hz, 1H; 4'-H), 3.84 (s, 2H; 3-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz, 
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2
J(H,H)=10.8 Hz, 1H; 6'-H
a
), 3.73 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.8 Hz, 1H; 6'-H
b
), 3.71 (s, 
3H; OCH3), 3.56 (dd, 
3
J(H,H)=9.3 Hz, 3.1 Hz, 1H; 3'-H), 3.49 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=11.0 Hz, 1H; 23-H
b
), 3.42 (ddd, 
3
J(H,H)=9.3 Hz, 5.2 Hz, 2.1 Hz, 1H; 5'-H), 2.93 (s, 
3H; NCH3), 2.25 (q, 
3
J(H,H)=7.2 Hz, 2H; 9-H), 1.80 (d, 
4
J(H,H)=1.1 Hz, 3H; 7-CH3), 1.62 
(qui, 
3
J(H,H)=7.1 Hz, 2H; 22-H), 1.44 (m, 2H; 21-H), 1.41 (d, 
3
J(H,H)=7.3 Hz, 3H; 5-CH3), 
1.36-1.22 (m, 22H; 11CH2); 
13
C (75 MHz, CDCl3): δ=207.0 (C-6), 188.6 (C-4), 170.3 (C-2), 148.0 (C-7), 145.9 (C-8), 
138.4 (4'O-CC
ipso
), 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 129.5 (3xCH
ar
), 129.1 (2xCH
ar
), 
128.6 (2xCH
ar
), 128.6 (CH
ar
), 128.5 (CH
ar
), 128.2 (CH
ar
), 128.1 (CH
ar
), 128.0 (CH
ar
), 127.9 
(CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 99.9 (C-1'), 81.7 (C-4'), 75.5 (C-5'), 75.3 (4'O-CH2), 74.5 
(C-3'), 73.7 (6'O-CH2), 71.5 (3'O-CH2), 70.0 (C-5), 69.5 (C-6'), 68.5 (C-2'), 52.4 (OCH3), 
52.4 (C-5'), 44.8 (C-3), 32.4 (NCH3), 29.9, 29.85 29.8, 29.75, 29.7, 29.65 (10CH2), 29.6 
(C-21), 29.5 (C-9), 28.7 (C-22), 26.2 (C-10), 14.6 (7-CH3), 11.4 (5-CH3). 
Minor E-enol-isomer A: 
Rf=0.17 (EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=13.2 (s, 1H, HC=COH), 7.40-7.18 (m, 15H, H
ar
), 6.87 (td, 
4
J(H,H)=1.1 Hz, 
3
J(H,H)=7.2 Hz, 1H, 8-H), 5.22 (q, 
3
J(H,H)=7.3 Hz, 1H, 5-H), 4.89 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.62 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.10 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.4 Hz, 1H, 23-H
a
), 3.85 (t, 
3
J(H,H)=9.3 Hz, 1H, 4'-H), 3.84 (s, 2H, 
3-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.73 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.71 (s, 3H, OCH3), 3.56 (dd, 
3
J(H,H)=9.3 Hz, 3.1 Hz, 1H, 
3'-H), 3.49 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=11.0 Hz, 1H, 23-H
b
), 3.42 (ddd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=9.3 Hz, 2.1 Hz, 1H, 5'-H), 2.84 (s, 3H, NCH3), 2.25 (q, 
3
J(H,H)=7.2 Hz, 2H, 9-H), 
1.77 (d, 
4
J(H,H)=1.1 Hz, 3H, 7-CH3), 1.62 (qui, 
3
J(H,H)=7.1 Hz, 2H, 22-H), 1.44 (m, 2H, 
21-H), 1.41 (d, 
3
J(H,H)=7.3 Hz, 3H, 5-CH3), 1.36-1.22 (m, 22H, 11CH2); 
13
C (75 MHz, CDCl3): δ=207.0 (C-6), 188.6 (C-4), 170.3 (C-2), 148.0 (C-7), 145.9 (C-8), 
138.4 (4'O-CC
ipso
), 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 129.5 (3xCH
ar
), 129.1 (2xCH
ar
), 
128.6 (2xCH
ar
), 128.6 (CH
ar
), 128.5 (CH
ar
), 128.2 (CH
ar
), 128.1 (CH
ar
), 128.0 (CH
ar
), 127.9 
(CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 110.1 (HC=COH), 99.9 (C-1'), 81.7 (C-4'), 75.5 (C-5'), 
75.3 (4'O-CH2), 74.5 (C-3'), 73.7 (6'O-CH2), 71.5 (3'O-CH2), 70.0 (C-5), 69.5 (C-6'), 68.5 
EXPERIMENTAL - Epicoccamide D 
105 
 
(C-2'), 52.4 (OCH3), 52.4 (C-5'), 32.4 (NCH3), 29.9, 29.85 29.8, 29.75, 29.7, 29.65 (10CH2), 
29.6 (C-21), 29.5 (C-9), 28.7 (C-22), 26.2 (C-10), 14.6 (7-CH3), 11.4 (5-CH3).
 
Minor Z-keto-isomer B: 
Rf=0.36(EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.18 (m, 15H, H
ar
), 6.53 (td, 
4
J(H,H)=1.1 Hz, 
3
J(H,H)=7.2 Hz, 1H, 8-H), 5.22 (q, 
3
J(H,H)=7.3 Hz, 1H, 5-H), 4.89 (d, 
2
J(H,H)=10.9 Hz, 1H, 
4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 
4.62 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.10 (dd, 
3
J(H,H)=3.1, 
0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.4, 1H, 23-H
a
), 3.85 (t, 
3
J(H,H)=9.3 
Hz, 1H, 4'-H), 3.84 (s, 2H, 3-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8, 1H, 6'-H
a
), 3.73 
(dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.8, 1H, 6'-H
b
), 3.71 (s, 3H, OCH3), 3.56 (dd, 
3
J(H,H)=9.3, 
3.1 Hz, 1H, 3'-H), 3.49 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=11.0, 1H, 23-H
b
), 3.42 (ddd, 
3
J(H,H)=9.5, 5.2, 2.1 Hz, 1H, 5'-H), 2.93 (s, 3H, NCH3), 2.25 (q, 
3
J(H,H)=7.3 Hz, 2H, 9-H), 
1.77 (d, 
4
J(H,H)=1.1 Hz, 3H, 7-CH3), 1.62 (qui, 
3
J(H,H)=7.1 Hz, 2H, 22-H), 1.46 (d, 
3
J(H,H)=7.3 Hz, 3H, 5-CH3), 1.44 (m, 2H, 21-H), 1.36-1.22 (m, 22H, 11CH2); 
13
C (75 MHz, CDCl3): δ=207.0 (C-6), 188.6 (C-4), 170.3 (C-2), 148.0 (C-7), 147.0 (C-8), 
138.4 (4'O-CC
ipso
), 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 129.5 (3xCH
ar
), 129.1 (2xCH
ar
), 
128.6 (2xCH
ar
), 128.6 (CH
ar
), 128.5 (CH
ar
), 128.2 (CH
ar
), 128.1 (CH
ar
), 128.0 (CH
ar
), 127.9 
(CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 99.9 (C-1'), 81.7 (C-4'), 75.5 (C-5'), 75.3 (4'O-CH2), 74.5 
(C-3'), 73.7 (6'O-CH2), 71.5 (3'O-CH2), 70.0 (C-5), 69.5 (C-6'), 68.5 (C-2'), 52.4 (OCH3), 
52.4 (C-5'), 44.8 (C-3), 32.4 (NCH3), 29.9, 29.85 29.8, 29.75, 29.7, 29.7 (10CH2), 29.6 
(C-21), 27.6 (C-9), 28.7 (C-22), 26.2 (C-10), 15.5 (7-CH3), 11.4 (5-CH3). 
 
(5R/S)-95 
 
 
 
       74            (2R/S)-95 
Scheme VI.21.  Silver salt mediated aminolysis with (R/S)-89. 
(5R/S)-95 (53 mg, 89%) was obtained analogously to (5S)-95 from 74 (58 mg, 0.063 mmol), 
rac-89 (25 mg, 0.158 mmol), NEt3 (31 µL, 0.222 mmol), and F3CCO2Ag (28 mg, 0.13 mmol) 
as a transparent oil. 
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Rf = 0.47 / 0.26 (EtOAc/c-hexane 1:2), keto:enol 6:1; 
[α]D
25
 = -12.7 (c = 1.0 g cm
-3
, chloroform); 
Only major isomer described: 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.17 (m, 15H, H
ar
), 6.72 (td, 
4
J(H,H)=1.1 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 5.22 (q, 
3
J(H,H)=7.3 Hz, 1H, 5-H), 4.89 (d, 
2
J(H,H)=10.8 Hz, 1H, 
4'O-CH
a
), 4.77 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 
4.62 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.40 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.10 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=6.7 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
a
), 
3.85 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.84 (s, 2H, 3-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=9.4 Hz, 1H, 6'-H
a
), 3.71 (dd, 
3
J(H,H)=5.3 Hz, 
2
J(H,H)=9.4 Hz, 1H, 6'-H
b
), 3.71 (s, 
3H, OCH3), 3.56 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.49 (dt, 
3
J(H,H)=6.7 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
b
), 3.41 (ddd, 
3
J(H,H)=9.4 Hz, 5.3 Hz, 2.1 Hz, 1H, 5'-H), 2.93 (s, 
3H, NCH3), 2.25 (q, 
3
J(H,H)=7.3 Hz, 2H, 9-H), 1.79 (d, 
4
J(H,H)=1.1 Hz, 3H, 7-CH3), 1.60 
(qui, 
3
J(H,H)=6.7 Hz, 2H, 22-H), 1.44 (m, 2H, 21-H), 1.41 (d, 
3
J(H,H)=7.3 Hz, 3H, 5-CH3), 
1.36-1.22 (m, 22H; 11CH2); 
13
C (75 MHz, CDCl3): δ=195.6 (C-6), 172.3 (C-4), 168.9 (C-2), 147.0 (C-7), 145.9 (C-8), 
138.4 (4'O-CC
ipso
), 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 128.6 (3xCH
ar
), 128.6 (2xCH
ar
), 
128.5 (2xCH
ar
), 128.2 (2xCH
ar
), 128.1 (2xCH
ar
), 128.0 (CH
ar
), 129.0 (CH
ar
), 127.9 (CH
ar
), 
127.7 (CH
ar
), 99.9 (C-1'), 81.8 (C-4'), 75.4 (C-5'), 75.3 (4'O-CH2), 74.5 (C-3'), 73.7 
(6'O-CH2), 71.5 (3'O-CH2), 70.0 (1'O-CH2), 69.4 (C-6'), 68.5 (C-2'), 52.5 (OCH3), 52.4 (C-5), 
44.8 (C-3), 32.4 (NCH3), 29.8, 29.7, 29.6 (11CH2), 29.5 (C-9), 28.7 (C-22), 26.2 (C-10), 
14.6 (7-CH3), 11.4 (5-CH3); 
IR (thin film) ṽ=2924 (s), 2854 (m), 1743 (m), 1672 (m), 1643 (m), 1599 (w), 1591 (w), 1496 
(m), 1454 (w), 1393 (m), 1371 (m), 1319 (m), 1211 (m), 1177 (w), 1101 (s), 1076 (s), 1028 
(m), 949 (w), 790 (w), 737 (w), 697 (m) cm
-1
; 
HRMS (ESI) Calcd for C53H75NO7Na [M+Na]
+
 908.5283, found: 908.5283. 
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(5''S, 16E)-18-(2''-Hydroxy-1'',5''-dimethyl-4''-oxo-4'',5''-dihydro-1''H-pyrrol-3''-yl)-17-
methyl-18-oxooctadec-16-enyl 3',4',6'-tri-O-benzyl-β-D-mannopyranoside ((5S)-96) 
 
 
 
 
              (2S)-95             (5S)-96 
Scheme VI.22.  Lacey-Dieckman cyclisation of enantiopure (S)-95. This scheme also shows the 
common numbering of 3-acyltetramic acids. 
A mixture of (5S)-95 (91 mg, 0.103 mmol), NaOMe (11.1 mg, 0.206 mmol) and dry MeOH 
(10 mL) was stirred for 20 min at RT, then quenched with 0.5 M aq. HCl. The aqueous phase 
was extracted five times with CH2Cl2, the combined extracts were dried over Na2SO4 and the 
solvent was removed under reduced pressure to leave pure (5S)-96 (88 mg, quantitative) as a 
viscous oil. 
Rf=0.51 (EtOAc/c-hexane 1:1); 
[α]D
25
 = -37.7 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.18 (m, 15H, H
ar
), 7.08 (tq, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 4.89 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=12.0 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=12.0 Hz, 1H, 3'O-CH
b
), 4.63 (d, 
2
J(H,H)=13.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=13.2 Hz, 1H, 6'O-CH
b
), 4.54 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.0 Hz, 0.9 Hz, 1H, 2'-H), 3.92 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.4 Hz, 1H, 23-H
a
), 
3.85 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.78 (dd, 
3
J(H,H)=2.0 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 
3.71 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.71 (q, 
3
J(H,H)=7.0 Hz, 1H, 5-H), 
3.57 (dd, 
3
J(H,H)=9.4 Hz, 3.0 Hz, 1H, 3'-H), 3.49 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.4 Hz, 1H, 
23-H
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.2 Hz, 2.0 Hz, 1H, 5'-H), 2.99 (s, 3H, NMe), 2.27 (qui, 
3
J(H,H)=7.3 Hz, 2H, 9-H), 1.90 (d, 
4
J(H,H)=1.3 Hz, 3H, 7-CH3), 1.62 (qui, 
3
J(H,H)=6.9 Hz, 
2H, 22-H), 1.38-1.22 (m, 24H, 12CH2), 1.36 (d, 
3
J(H,H)=7.0 Hz, 3H, 5-CH3); 
13
C NMR (75 MHz, CDCl3): δ=195.1 (C-6), 192.8 (C-4), 184.4 (C-7), 175.0 (C-2), 146.1 
(C-8), 138.4 (4'O-CC
ipso
) 138.4 (3'O-CC
ipso
), 138.0 (6'O-CC
ipso
), 129.5 (3xCH
ar
), 129.1 
(2xCH
ar
), 128.6 (CH
ar
), 128.5 (CH
ar
), 128.4 (CH
ar
), 128.2 (2xCH
ar
), 128.1 (CH
ar
), 128.0 
(CH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 128.7 (CH
ar
), 99.9 (C-1'), 81.7 (C-4'), 75.4 (C-5'), 75.3 
(4'-OCH2), 74.5 (C-3'), 73.6 (6'-OCH2), 71.5 (3'-OCH2), 70.0 (C-23), 69.4 (C-6'), 68.5 (C-2'), 
62.3 (NMe), 29.8, 29.7, 29.6, (11CH2), 29.3 (C-21), 28.5 (C-22), 26.7 (C-5), 26.2 (C-9), 
15.2 (7-CH3), 12.5 (5-CH3); 
EXPERIMENTAL - Epicoccamide D 
108 
 
IR (thin film) ṽ=3454 (br), 2924 (s), 2853 (m), 1742 (w), 1692 (w), 1646 (m), 1573 (m), 1494 
(m), 1454 (m), 1403 (w), 1368 (m), 1313 (w), 1261 (m), 1209 (m), 1177 (w), 1100 (s), 1074 
(s), 1027 (m), 931 (w), 872 (w), 794 (m) 735 (m), 697 (s) cm
-1
; 
HRMS (ESI) Calcd for C52H71NO9Na [M+Na]
+
 876.5021, found: 876.5010. 
 
(5R/S)-96 
 
 
 
             (2S)-95             (5S)-96 
Scheme VI.23.  Lacey-Dieckman cyclisation of (R/S)-95. 
(5R/S)-96 was obtained analogously to (5S)-96 from (R/S)-95 (53 mg, 0.06 mmol) and 
NaOMe (6.5 mg, 0.12 mmol). It was however stopped by neutralizing with DOWEX 50WX8 
ion exchange resin. The resin was washed three times with 10 mL MeOH and the combined 
extracts were concentrated to leave pure (5R/S)-96 (51 mg, quantitative). 
Rf=0.31 (EtOAc/c-hexane 1:1); 
[α]D
25
 = -10.7 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.18 (m, 15H, H
ar
), 7.08 (tq, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.2 Hz, 1H, 8-H), 4.89 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
b
), 4.62 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.2 Hz, 1H, 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 4.10 (dd, 
3
J(H,H)=3.1 Hz, 0.9 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=7.1 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
a
), 
3.86 (t, 
3
J(H,H)=9.4 Hz, 1H, 4'-H), 3.78 (dd, 
3
J(H,H)=2.2 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 
3.71 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.66 (q, 
3
J(H,H)=7.1 Hz, 1H, 5-H), 
3.56 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.49 (dt, 
3
J(H,H)=7.1 Hz, 
2
J(H,H)=9.7 Hz, 1H, 
23-H
b
), 3.42 (ddd, 
3
J(H,H)=9.4 Hz, 5.2 Hz, 2.2 Hz, 1H, 5'-H), 2.99 (s, 3H, NCH3), 2.28 (qui, 
3
J(H,H)=7.2 Hz, 2H, 9-H), 1.90 (d, 
4
J(H,H)=1.3 Hz, 3H, 7-CH3), 1.62 (qui, 
3
J(H,H)=7.1 Hz, 
2H, 10-H), 1.51 (qui, 
3
J(H,H)=7.1 Hz, 2H, 22-H), 1.38-1.21 (m, 22H, 11CH2), 1.36 (d, 
3
J(H,H)=7.1 Hz, 3H, 5-CH3); 
13
C NMR (75 MHz, CDCl3): δ=196.0 (C-6), 192.7 (C-4), 184.2 (C-7), 174.9 (C-2), 146.0 
(C-8), 138.3 (4'O-CC
ipso
) 138.2 (3'O-CC
ipso
), 137.9 (6'O-CC
ipso
), 128.5 (3xCH
ar
), 128.4 
(CH
ar
), 128.3 (2xCH
ar
), 128.1 (2xCH
ar
), 127.9 (3xCH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 127.7 
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(CH
ar
), 127.5 (CH
ar
), 99.7 (C-1'), 81.6 (C-4'), 75.3 (C-5'), 75.2 (4'-OCH2), 74.3 (C-3'), 73.5 
(6'-OCH2), 71.3 (3'-OCH2), 69.9 (C-23), 69.3 (C-6'), 68.4 (C-2'), 62.1 (NMe), 29.8, 29.7, 
29.6, 29.5 (10CH2), 29.4 (C-21), 29.2 (C-10), 28.4 (C-22), 26.6 (C-5), 26.0 (C-9), 15.1 
(7-CH3), 11.9 (5-CH3); 
IR (thin film) ṽ=3031 (br), 2923 (s), 2853 (m), 1714 (m), 1702 (m), 1649 (m), 1569 (m), 1496 
(w), 1462 (m), 1454 (m), 1405 (w), 1368 (m), 1312 (w), 1260 (w), 1209 (m), 1177 (w), 1103 
(s), 1074 (s), 1027 (m), 930 (m), 792 (w) 735 (w), 697 (s) cm
-1
; 
HRMS (ESI) Calcd for C52H71NO9Na [M+Na]
+
 876.5021, found: 876.5061. 
 
Difluoroboryl complex ((5S)-102) 
 
 
 
 
    (5S)-96             (5S)-102 
Scheme VI.24.  BF2-complex formation to avoid metal chelating of the hydrogenation catalyst later on. 
A solution of (5S)-96 (50 mg, 0.059 mmol) in CH2Cl2 (6 mL) was treated dropwise at 0 °C 
with BF3OEt2 (9 µL, 0.073 mmol), allowed to warm up to RT, and stirred at this temperature 
for another 12 h. The solvent was then removed under reduced pressure and the remainder 
was purified by flash chromatography (flash silica gel; 40% EtOAc in c-hexane) yielding 
33 mg (62%) of pure (5S)-102. 
Rf=0.44 (EtOAc/c-hexane 1:1); 
[α]D
25
 = -10.7 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.56 (tq, 
4
J(H,H)=1.4 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 
7.37-7.14 (m, 15H, H
ar
), 4.87 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
a
), 4.76 (d, 
2
J(H,H)=12.0 Hz, 
1H, 3'O-CH
a
), 4.65 (d, 
2
J(H,H)=12.0 Hz, 1H, 3'O-CH
b
), 4.61 (d, 
2
J(H,H)=12.3 Hz, 1H, 
6'O-CH
a
), 4.54 (d, 
2
J(H,H)=12.3 Hz, 1H, 6'O-CH
b
), 4.51 (d, 
2
J(H,H)=10.9 Hz, 1H, 4'O-CH
b
), 
4.39 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.09 (dd, 
3
J(H,H)=3.0 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.4 Hz, 1H, 23-H
a
), 3.86 (dd, 
3
J(H,H)=9.1 Hz, 5.4 Hz, 1H, 4'-H), 
3.80 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
a
), 3.68 (dd, 
3
J(H,H)=5.4 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.64 (q, 
3
J(H,H)=7.1 Hz, 1H, 5-H), 3.55 (dd, 
3
J(H,H)=9.1 Hz, 
3.0 Hz, 1H, 3'-H), 3.47 (dt, 
3
J(H,H)=6.9 Hz, 
2
J(H,H)=9.4 Hz, 1H, 23-H
b
), 3.41 (ddd, 
3
J(H,H)=9.1 Hz, 5.4 Hz, 2.1 Hz, 1H, 5'-H), 3.14 (s, 3H, NCH3), 2.28 (q, 
3
J(H,H)=7.3 Hz, 2H, 
9-H), 1.91 (d, 
4
J(H,H)=1.4 Hz, 3H, 7-CH3), 1.59 (qui, 
3
J(H,H)=7.3 Hz, 2H, 10-H), 1.50 (qui, 
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3
J(H,H)=6.9 Hz, 2H, 22-H), 1.43 (d, 
3
J(H,H)=7.1 Hz, 3H, 5-CH3), 1.38-1.19 (m, 22H, 
11CH2); 
13
C NMR (75 MHz, CDCl3): δ=196.2 (C-6), 189.5 (C-4), 178.1 (C-7), 172.7 (C-2), 151.8 
(C-8), 138.6 (4'O-CC
ipso
) 138.4 (3'O-CC
ipso
), 138.1 (6'O-CC
ipso
), 128.7 (3xCH
ar
), 128.6 
(2xCH
ar
), 128.5 (2xCH
ar
), 128.1 (2xCH
ar
), 128.05 (3xCH
ar
), 128.0 (CH
ar
), 127.8 (CH
ar
), 127.7 
(CH
ar
), 99.3 (C-1'), 80.5 (C-4'), 75.3 (4'-OCH2), 74.5 (C-5'), 73.6 (6'-OCH2), 72.1 (C-3'), 71.1 
(3'-OCH2), 69.1 (C-6'), 68.6 (C-2'), 68.0 (C-23), 64.1 (NMe), 30.0 (C-10), 29.8, 29.7, 29.6, 
(10CH2), 29.2 (C-21), 28.9 (C-11), 28.4 (C-22), 28.4 (C-5), 26.3 (C-9); 14.7 (7-CH3), 12.4 
(5-CH3); 
11
B NMR (100 MHz, CH2Cl2 + BF3OEt2): δ=1.29; 
IR (thin film) ṽ=3471 (br), 3031 (w), 2924 (s), 2853 (m), 1748 (w), 1710 (m), 1647 (m), 1582 
(m), 1513 (s), 1454 (m), 1395 (w), 1372 (m), 1314 (w), 1262 (w), 1234 (w), 1207 (w), 1096 
(m), 1054 (s), 1035 (s), 985 (w), 937 (w), 907 (w), 883 (w), 798 (w), 739 (w), 737 (m), 698 
(s), 667 (s) cm
-1
; 
HRMS (ESI) Calcd for C52H70BF2NO9Na [M+Na]
+
 924.5009, found: 924.5019. 
 
Difluoroboryl complex ((5S,7S)-103) 
 
 
 
 
  (5S)-102         (5S,7S)-103 
Scheme VI.25.  Stereoselective hydrogenation with Rh based Et-DUPHOS catalyst to form the natural 
product configuration. 
A glass vial was charged with complex (5S)-102 (32 mg, 0.036 mmol), dry CH2Cl2 (3.6 mL), 
and (R,R)-Rh-Et-DUPHOS BF4 (1 mg, 4 mol%,), and then put into a Parr high pressure 
autoclave which was sealed, pressurised with 80 bar H2 gas, and heated at 35 °C for 16 h. 
After removal of all volatiles the crude product was purified by flash column chromatography 
on silica gel with 40% ethyl acetate in cyclohexane to leave (5S,7S)-103 (31 mg, 97%; 
>83% de) as a colourless viscous oil. 
Rf = 0.50 (ethyl acetate/cyclohexane 1/1); 
[α]D
24
 = 1.7 (c = 1.0 g cm
-3
, chloroform); 
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1
H NMR (300 MHz, CDCl3, 20°C, TMS): δ=7.40-7.15 (m, 15H, H
ar
), 4.90 (d, 
2
J(H,H)=10.8 
Hz, 1H, 4'O-CH
a
), 4.78 (d, 
2
J(H,H)=11.9 Hz, 1H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=11.9 Hz, 1H, 
3'O-CH
b
), 4.63 (d, 
2
J(H,H)=12.4 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.4, 1H, 6'O-CH
b
), 
4.53 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=2.8 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=9.2 Hz, 1H, 23-H
a
), 
3.86 (dd, 
3
J(H,H)=9.1 Hz, 2.0 Hz, 1H, 4'-H), 3.79 (dd, 
3
J(H,H)=2.2 Hz, 
2
J(H,H)=11.4 Hz, 1H, 
6'-H
a
), 3.67 (dd, 
3
J(H,H)=5.4 Hz, 
2
J(H,H)=11.4 Hz, 1H, 6'-H
b
), 3.66 (q, 
3
J(H,H)=7.2 Hz, 1H, 
5-H), 3.57 (dd, 
3
J(H,H)=9.1 Hz, 2.8 Hz, 1H, 3'-H), 3.54 (m, 1H, 7-H), 3.50 (dt, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=9.2 Hz, 1H, 23-H
b
), 3.43 (ddd, 
3
J(H,H)=9.1 Hz, 5.4 Hz, 2.0 Hz, 1H, 
5'-H), 3.14 (s, 3H, NMe), 1.66 (qui, 
3
J(H,H)=6.9 Hz, 2H, 22-H), 1.45 (d, 
3
J(H,H)=7.2 Hz, 3H, 
5-CH3), 1.44 (m, 2H, 8-H), 1.32-1.22 (m, 26H, 13CH2), 1.20 (d, 
3
J(H,H)=6.8 Hz, 3H, 
7-CH3); 
13
C NMR (75 MHz, CDCl3, 20°C, TMS): δ=193.8 (C-6), 190.7 (C-4), 170.7 (C-2), 138.55 
(4'OCC
ipso
), 138.5 (3'OCC
ipso
), 138.4 (6'OCC
ipso
), 128.7 (3xCH
ar
), 128.6 (2xCH
ar
), 128.5 
(2xCH
ar
), 128.2 (2xCH
ar
), 128.1 (3xCH
ar
), 128.0 (CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 110.1 (C-
3), 99.3 (C-1'), 80.5 (C-4'), 75.3 (4'OCH2), 74.5 (C-5'), 73.6 (6'OCH2), 72.1 (C-3'), 71.1 
(3'OCH2), 69.1 (C-6'), 68.6 (C-2'), 68.0 (C-23), 37.6 (C-7), 33.8 (NCH3), 29.9, 29.8, 29.7, 
29.65, 29.6, (13CH2), 28.1 (C-5), 27.3 (C-8), 26.3 (C-22); 17.0 (7-CH3), 14.3 (5-CH3); 
11
B NMR (100 MHz, CH2Cl2, 20°C, BF3OEt2): δ=0.45; 
IR (film) ṽ=3496 (br), 2925 (s), 2853 (m), 1742 (w), 1721 (m), 1649 (s), 1574 (m), 1534 (m), 
1456 (m), 1454 (m), 1209 (m), 1098 (s), 1054 (s), 1031 (s), 936 (m), 749 (m), 738 (m), 699 
(m) cm
-1
; 
HRMS (ESI) Calcd for C52H72BF2NO9Na [M+Na]
+
 926.5166, found: 926.5184. 
 
Difluoroboryl complex ((5S,7R)- 103) 
 
 
 
 
  (S)-102          (5S,7R)-103 
Scheme VI.26.  Stereoselective hydrogenation with Rh based Et-DUPHOS catalyst. 
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Analogously to its (5S,7S)-diastereomer, (5S,7R)-103 (25 mg, 97%) was obtained from 
hydrogenation of complex (5S)-102 (26 mg, 0.029 mmol) in the presence of 
(S,S)-Rh-Et-DUPHOS BF4 (1 mg, 4 mol%). 
Rf=0.46 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -12.9 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.40-7.18 (m, 15H, H
ar
), 4.89 (d, 
2
J(H,H)=10.8 Hz, 1H, 
4'O-CH
a
), 4.78 (d, 
2
J(H,H)=12.0 Hz, 2H, 3'O-CH
a
), 4.67 (d, 
2
J(H,H)=12.0 Hz, 1H, 3'O-CH
b
), 
4.63 (d, 
2
J(H,H)=12.3 Hz, 1H, 6'O-CH
a
), 4.56 (d, 
2
J(H,H)=12.3, 1H, 6'O-CH
b
), 4.53 (d, 
2
J(H,H)=10.8 Hz, 1H, 4'O-CH
b
), 4.41 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 4.11 (dd, 
3
J(H,H)=3.1 Hz, 0.8 Hz, 1H, 2'-H), 3.93 (dt, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=9.2 Hz, 1H, 23-H
a
), 
3.85 (dd, 
3
J(H,H)=9.4 Hz, 5.4 Hz, 1H, 4'-H), 3.78 (dd, 
3
J(H,H)=2.1 Hz, 
2
J(H,H)=10.8 Hz, 1H, 
6'-H
a
), 3.67 (dd, 
3
J(H,H)=5.4 Hz, 
2
J(H,H)=10.8 Hz, 1H, 6'-H
b
), 3.66 (q, 
3
J(H,H)=7.2 Hz, 1H, 
5-H), 3.57 (dd, 
3
J(H,H)=9.4 Hz, 3.1 Hz, 1H, 3'-H), 3.54 (m, 1H, 7-H), 3.50 (dt, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=9.2 Hz, 1H, 23-H
b
), 3.43 (ddd, 
3
J(H,H)=9.4 Hz, 5.4 Hz, 2.1 Hz, 1H, 
5'-H), 3.15 (s, 3H, NCH3), 1.62 (qui, 
3
J(H,H)=7.0 Hz, 2H, 22-H), 1.46 (d, 
3
J(H,H)=7.2 Hz, 
3H, 5-CH3), 1.44 (m, 2H, 8-H), 1.32-1.22 (m, 26H, 13CH2), 1.20 (d, 
3
J(H,H)=6.8 Hz, 3H, 
7-CH3); 
13
C NMR (75 MHz, CDCl3): δ=193.5 (C-6), 190.4 (C-4), 171.1 (C-2), 138.3 (4'O-CC
ipso
) 
138.2 (3'O-CC
ipso
), 137.8 (6'O-CC
ipso
), 128.4 (3xCH
ar
), 128.3 (2xCH
ar
), 128.2 (2xCH
ar
), 128.0 
(2xCH
ar
), 127.9 (2xCH
ar
), 127.8 (CH
ar
), 127.8 (CH
ar
), 127.7 (CH
ar
), 127.5 (15Car), 99.7 
(C-1'), 81.6 (C-4'), 75.3 (C-5'), 75.1 (4'-OCH2), 74.3 (C-3'), 73.5 (6'-OCH2), 71,3 (3'-OCH2), 
69.8 (C-6'), 69.3 (C-23), 68.3 (C-2') 64.8 (NMe), 37.4 (C-7), 34.5 (C-8), 29.6, 29.5, 29.4 
(13CH2), 28.0 (C-5), 27.1 (C-20), 26.0 (C-22), 16.8 (7-CH3), 14.1 (5-CH3); 
11
B NMR (100 MHz, CH2Cl2): δ=0.38; 
IR (thin film) ṽ=3522 (br), 2925 (s), 2854 (m), 1720 (m), 1648 (s), 1569 (m), 1533 (m), 1496 
(w), 1454 (m), 1393 (w), 1367 (m), 1232 (m), 1205 (m), 1185 (m), 1175 (m), 1100 (s), 1070 
(s), 1058 (s), 1032 (s), 936 (w), 737 (m), 698 (m) cm
-1
; 
HRMS (ESI) Calcd for C52H72BF2NO9Na [M+Na]
+
 926.5166, found: 926.5197. 
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(5S,7S)-1d [Epicoccamide D] 
 
 
 
 
 
       (5S,7S)-103              1d 
Scheme VI.27.  Global deprotection to form the natural product 1d. 
A mixture of (5S,7S)-103 (10 mg, 0.011 mmol), 5% Pd on charcoal (10 mg), and dry 
methanol (2 mL) was saturated and pressurised with 1 bar of hydrogen gas. Stirring was 
maintained for 4 h at 35 °C. The mixture was filtered, the residue was thoroughly rinsed with 
methanol and CH2Cl2, and the combined filtrates were concentrated in vacuum to leave 
(5S,7S)-1d (6.9 mg, 97%) as a yellowish oil of ≥95% purity; 
[α]D
24
 = -39.0 (c = 0.2 g cm
-3
, methanol); 
1
H NMR (300 MHz, CD3OD): δ=4.51 (d, 
3
J(H,H)=0.9 Hz, 1H, 1'-H), 3.90 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
a
), 3.87 (dd, 
3
J(H,H)=2.4 Hz, 
2
J(H,H)=12.0 Hz, 
1H, 6'-H
a
), 3.84 (dd, 
3
J(H,H)=3.2 Hz, 0.9 Hz, 1H, 2'-H), 3.76-3.73 (m, 3H, 5-H, 4'-H, 6'-H
b
), 
3.55-3.53 (m, 2H, 7-H, 23-H
b
), 3.45 (dd, 
3
J(H,H)=9.4 Hz, 3.2 Hz, 1H, 3'-H), 3.21 (m, 1H, 
5'-H), 2.86 (m, 3H, NCH3), 1.62 (m, 4H, 8-H, 22-H), 1.40-1.26 (m, 26H, 13CH2), 1.32 (m, 
3H, 5-CH3), 1.15 (d, 
3
J(H,H)=6.2 Hz, 3H, 7-CH3); 
13
C NMR (75 MHz, CD3OD): δ=193.3 (C-6), 190.6 (C-4), 174.1 (C-2), 101.7 (C-1'), 100.7 
(C-3), 78.3 (C-5'), 75.4 (C-3'), 72.6 (C-2'), 70.6 (C-23), 68.6 (C-4'), 68.6 (C-5), 62.9 (C-6'), 
37.9 (C-7), 34.7 (NCH3), 30.8, 30.7, 30.6, 30.5, 30.4 (12CH2), 28.3 (C-8), 27.2 (C-22), 23.7 
(C-10), 17.4 (7-CH3), 15.1 (5-CH3); 
IR (film) ṽ=3340 (br), 2921 (s), 2851 (s), 1740 (w), 1728 (m), 1710 (m), 1680 (m), 1647 (m), 
1619 (s), 1466 (s), 1377 (m), 1365 (m), 1258 (m), 1203 (m), 1187 (m), 1173 (m), 1072 (s), 
1032 (s), 925 (m), 798 (m), 722 (m) cm
–1
; 
HRMS (ESI) Calcd for C31H55NO9Na [M+Na]
+
 608.3769, found: 608.3777. 
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(5S,7R)-1e 
 
 
 
 
      (5S,7R)-103               1e 
Scheme VI.28.  Global deprotection to form epicoccamide D derivative 1e. 
Analogously to its (5S,7S)-diastereomer, (5S,7R)-1e (22 mg, 85%) was obtained as a red oil of 
≥ 97% purity as to HPLC. The product was formed from hydrogenation of (5S,7R)-103 
(39 mg, 0.043 mmol) in the presence of 40 mg of 5% Pd on charcoal catalyst in dry MeOH 
(5 mL); conditions, however, were: 1 bar H2, stirring for 4 h at 35 °C. 
[α]D
24
 = -29.9 (c = 0.2 g cm
-3
, methanol); 
1
H NMR (300 MHz, CD3OD): δ=4.49 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 3.91 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
a
), 3.88 (dd, 
3
J(H,H)=2.4 Hz, 
2
J(H,H)=12.0 Hz, 
1H, 6'-H
a
), 3.84 (dd, 
3
J(H,H)=3.2 Hz, 0.8 Hz, 1H, 2'-H), 3.71 (m, 3H, 5-H, 4'-H, 6'-H
b
), 3.54 
(m, 2H, 7-H, 23-H
b
), 3.44 (dd, 
3
J(H,H)=9.5 Hz, 3.2 Hz, 1H, 3'-H), 3.20 (ddd, 
3
J(H,H)=9.5 Hz, 
5.7 Hz, 2.4 Hz, 1H, 5'-H), 2.96 (s, 3H, NCH3), 1.61 (m, 4H, 8-H, 22-H), 1.35-1.26 (m, 26H, 
13CH2), 1.33 (d, 
3
J(H,H)=7.0 Hz, 3H, 5-CH3), 1.17 (d, 
3
J(H,H)=6.9 Hz, 1H, 7-CH3); 
13
C NMR (75 MHz, CD3OD): δ=193.3 (C-6), 190.6 (C-4), 174.4 (C-2), 101.7 (C-1'), 100.1 
(C-3), 78.3 (C-5'), 75.4 (C-3'), 72.6 (C-2'), 70.6 (C-23), 68.6 (C-4'), 62.9 (C-5), 62.8 (C-6') 
37.0 (C-7), 34.8 (NMe), 30.8, 30.7, 30.6 (12CH2), 28.3 (C-8), 27.2 (C-22), 26.5 (C-10), 17.5 
(7-CH3), 15.1 (5-CH3); 
IR (thin film) ṽ=3356 (br), 2922 (s), 2852 (m), 1740 (w), 1710 (m), 1690 (m), 1649 (m), 1615 
(s), 1486 (w), 1460 (m), 1453 (m), 1399 (m), 1371 (m), 1343 (m), 1312 (m), 1266 (m), 1237 
(m), 1173 (m), 1067 (s), 1027 (s), 926 (m), 879 (m), 797 (m), 733 (m), 723 (m) cm
-1
; 
HRMS (ESI) Calcd for C31H55NO9Na [M+Na]
+
 608.3769, found: 608.3768. 
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(5R/S,7R/S)-1f 
 
 
 
 
    (5R/S,7R/S)-103              1f 
Scheme VI.29.  Global deprotection to form racemic epicoccamide D derivative 1f. 
A mixture of (5R/S)-96 (51 mg, 0.06 mmol), 5% Pd on charcoal catalyst (60 mg) and dry 
MeOH (6 mL) was saturated and pressurised with ca. 1 bar H2, stirred for 4 h, then filtered, 
the residue was thoroughly rinsed with MeOH and CH2Cl2 and the combined filtrates were 
concentrated to leave a mixture of diastereomers of 1 (34 mg, 97%) as a viscous yellow oil of 
≥98% purity as to HPLC. 
[α]D
24
 = -10.7 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (500 MHz, CD3OD): δ=4.50 (d, 
3
J(H,H)=0.8 Hz, 1H, 1'-H), 3.91 (dt, 
3
J(H,H)=6.8 Hz, 
2
J(H,H)=9.7 Hz, 1H, 23-H
a
), 3.87 (dd, 
3
J(H,H)=2.4 Hz, 
2
J(H,H)=12.0 Hz, 
1H, 6'-H
a
), 3.84 (dd, 
3
J(H,H)=3.2 Hz, 0.8 Hz, 1H, 2'-H), 3.72 (m, 3H, 5-H, 4'-H, 6'-H
b
), 3.54 
(m, 2H, 7-H, 23-H
b
), 3.44 (dd, 
3
J(H,H)=9.5 Hz, 3.2 Hz, 1H, 3'-H), 3.20 (ddd, 
3
J(H,H)=9.5 Hz, 
5.5 Hz, 2.4 Hz, 1H, 5'-H), 3.03 (s, 3H, NCH3), 1.61 (m, 4H, 8-H, 22-H), 1.40-1.26 (m, 26H, 
13CH2), 1.32 (d, 
3
J(H,H)=6.5 Hz, 3H, 5-CH3), 1.14 (d, 
3
J(H,H)=6.2 Hz, 0.5H, 7-CH3 of 
diastereomer A) / 1.05 (d, 
3
J(H,H)=6.9 Hz, 0.5H, 7-CH3 of diastereomer B); 
13
C NMR (125 MHz, CD3OD): δ=193.5 (C-6), 190.7 (C-4), 174.2 (C-2), 106.0 (C-1'),101.7 
(C-3), 78.2 (C-5'), 75.3 (C-3'), 72.6 (C-2'), 70.7 (C-23), 68.6 (C-4'), 64.2 (C-5), 62.8 (C-6'), 
36.5 (C-7), 33.1 (NMe), 30.8, 30.6, (12CH2), 28.0 (C-8), 27.2 (C-22), 23.7 (C-10), 19.3 
(7-CH3), 14.4 (5-CH3); 
IR (thin film) ṽ=3418 (br), 2953 (m), 2924 (s), 2853 (m), 1774 (w), 1733 (m), 1649 (w), 1579 
(w), 1542 (w), 1522 (w), 1496 (w), 1464 (m), 1457 (m), 1411 (m), 1379 (m), 1353 (w), 1284 
(m), 1270 (m), 1121 (s), 1074 (s), 953 (w), 941 (w) cm
-1
; 
HRMS (ESI) Calcd for C31H55NO9Na [M+Na]
+
 608.3769, found: 608.3774. 
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VI.2.6. Synthesis of model compounds 
 
Route A: From 3-acylation
[205]
 of (S)-105 with (S)-104 
Difluoroboryl complex ((5S,7S)-100) 
 
 
 
 
   104       105             (5S,7S)-100 
Scheme VI.30.   Synthesis of model compound: Via 3-acylation (protocol by Yoda et al.)
[205]
. 
A solution of (2S)-methyloctanoic acid 104
[30]
 (62 mg, 0.39 mmol) and tetramic acid 
(5S)-105
[30]
 (50 mg, 0.39 mmol) in CH2Cl2 (6 mL) was treated with EDCI (91 mg, 
0.47 mmol) and DMAP (95 mg, 0.79 mmol) and stirred for 1 h at RT before further EDCI 
(60 mg, 0.31 mmol) was added and stirring was continued for another hour. After addition of 
sat. aqueous NH4Cl the crude 4-O-acyl tetramic acid was extracted three times with EtOAc. 
The combined organic extracts were washed twice with sat. aqueous NH4Cl and brine, dried 
over Na2SO4 and concentrated. 
The crude product thus obtained was dissolved in CH2Cl2 (4.5 mL) and treated with CaCl2 
(66 mg, 0.59 mmol), DMAP (14 mg, 0.12 mmol), and NEt3 (66 µL, 0.47 mmol). The 
resulting suspension was stirred for 90 min at RT, diluted with EtOAc, acidified with 1 M 
aqueous HCl (5 mL), and extracted three times with EtOAc. The combined extracts were 
washed with brine, dried over Na2SO4, and concentrated. 
The crude material obtained was dissolved in CH2Cl2 (4 mL), treated with BF3OEt2 (243 µL, 
1.97 mmol), stirred for 16 h at RT, and concentrated by removal of all volatiles. Purification 
by column chromatography (silica gel; 40% EtOAc in c-hexane) furnished the desired 
BF2-complex (5S,7S)-100 (64 mg, 52% over 3 steps). 
Rf=0.55 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -75.7 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=3.91 (q, 
3
J(H,H)=7.1 Hz, 1H, 7-H), 3.53 (q, 
3
J(H,H)=6.8 Hz, 
1H, 5-CH), 3.16 (s, 3H, NCH3), 1.81-1.65 (m, 1H, 8-H
a
), 1.54-1.44 (m, 1H, 8-H
b
), 1.46 (d, 
3
J(H,H)=7.1 Hz, 3H, 7-CH3), 1.25 (m, 8H, 4×CH2), 1.19 (d, 
3
J(H,H)=6.8 Hz, 3H, 5-CH3), 
0.89 (m, 3H, CH3); 
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13
C NMR (75 MHz, CDCl3): δ=193.7 (C-4), 190.6 (C-6), 171.3 (C-2), 98.2 (C-3), 65.0 (C-5), 
37.6 (NMe), 33.8 (C-8), 31.7 (C-11), 29.3 (C-9), 28.1 (C-7), 27.2 (C-10), 22.7 (C-12), 16.9 
(5-CH3), 14.3 (7-CH3), 14.2 (CH3); 
IR (thin film) ṽ=2956 (w), 2927 (m), 2857 (w), 1720 (m), 1644 (s), 1566 (m), 1530 (s), 1453 
(m), 1417 (w), 1394 (m), 1375 (m), 1355 (m), 1270 (m), 1232 (m), 1183 (m), 1119 (m), 1074 
(m), 1024 (s), 935 (m), 885 (m), 858 (m), 798 (m), 782 (m), 725 (s), 707 (m), 663 (m) cm
-1
; 
HRMS (ESI) Calcd for C15H24BF2NO3Na [M+Na]
+
 338.1710, found: 338.1712. 
 
Route B: From hydrogenation of (5S)-22 with (R,R)-Rh-Et-DUPHOS BF4 
S-tButyl 4-methyl-3-oxodec-4-enethioate (98) 
 
 
 
       106        76          98 
Scheme VI.31.  Synthesis of model compound via epicoccamide route: HWE olefination 
A solution of phosphonate 76 (480 mg, 1.51 mmol,) dry THF (15 mL) was cooled to -78 °C, 
treated slowly via a syringe with nBuLi (1.9 mL, 1.6 M in hexanes, 3.02 mmol), stirred at 
-78 °C for 15 min, and finally treated slowly with hexanal (130 µL, 1.08 mmol) dissolved in 
3 mL THF. This mixture was stirred for 30 min at -78 °C and 1 h at RT before being 
quenched with sat. aqueous NH4Cl and extracted three times with Et2O. The combined 
extracts were dried over Na2SO4, concentrated and purified by chromatography (silica gel; 5% 
EtOAc in c-hexane) yielding 98 (250 mg, 87%) as a red oil. 3:1:1 mixture of keto-E, enol-E, 
and keto-Z isomers. 
Data only for the major keto-E isomer: 
Rf=0.62-0.86 (EtOAc/c-hexane 1:19); 
1
H NMR (300 MHz, CDCl3): δ=6.64 (td, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=6.6 Hz, 1H, 5-H), 3.02 (s, 
2H, 2-H), 2.24 (q, 
3
J(H,H)=6.6, 2H, 6-H), 1.77 (d, 
4
J(H,H)=1.3, 3H, 4-CH3), 1.47 (m, 10H, 
CH2), 0.88 (m, 3H, CH3); 
13
C NMR (75 MHz, CDCl3): δ=193.7 (C-3), 193.4 (C-1), 146.2 (C-5), 137.2 (C-4), 54.0 
(C-2), 48.3 ((CH3)3), 31.7 (C-6), 30.3 (CMe3), 29.4 (C-8), 28.7 (C-9), 22.6 (C-7), 14.1 (CH3), 
11.4 (4-CH3); 
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IR (thin film) ṽ=2959 (w), 2926 (m), 2859 (w), 1690 (m), 1661 (s), 1640 (s), 1582 (m), 1455 
(m), 1389 (w), 1375 (w), 1364 (w), 1351 (w), 1324 (w), 1294 (w), 1248 (w), 1161 (m), 1099 
(m), 1061 (s), 988 (m), 906 (m), 887 (m), 833 (m), 770 (s) cm
-1
. 
 
Corresponding amide (99) 
 
 
 
   98           (S)-89           99 
Scheme VI.32.  Synthesis of model compound via epicoccamide route: Aminolysis 
Analogously to (5S)-95, amide (S)-99 (223 mg, 83%) was obtained from 98 (248 mg, 
0.92 mmol), (S)-89 (350 mg, 2.29 mmol), NEt3 (0.5 mL, 3.67 mmol), and F3CCO2Ag 
(405 mg, 1.83 mmol); 3:1:1 mixture of keto-E, enol-E, and keto-Z isomers. 
Data only for the major keto-E isomer: 
Rf=0.53 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -102.2 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3; numbering scheme as for 95 (in Scheme VI.20.): δ=6.70 (td, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 5.22 (q, 
3
J(H,H)=7.3 Hz, 1H, 5-H), 3.84 (s, 2H, 
3-H), 3.68 (s, 3H, OCH3), 2.91 (s, 3H, NCH3), 2.22 (q, 
3
J(H,H)=7.3 Hz, 2H, 9-H), 1.77 (d, 
4
J(H,H)=1.3 Hz, 3H, 7-CH3), 1.39 (d, 
3
J(H,H)=7.3 Hz, 3H, 5-CH3), 1.48-1.25 (m, 6H, 
3×CH2), 0.90 (m, 3H, CH3); 
13
C NMR (75 MHz, CDCl3): δ=195.1 (C-6), 172.2 (C-4), 168.3 (C-2), 145.8 (C-7), 136.9 
(C-5), 135.8 (C-6), 52.4 (C-5), 52.3 (OCH3), 44.8 (C-3), 32.4 (C-8), 31.7 (NCH3), 29.4 
(C-10), 28.8 (C-12), 28.6 (C-13), 28.3 (C-11), 22.5 (C-9), 14.5 (7-CH3), 11.4 (C-14); 
IR (thin film) ṽ=2956 (w), 2928 (m), 2859 (w), 1742 (m), 1672 (m), 1643 (s), 1592 (m), 1548 
(s), 1456 (m), 1443 (w), 1394 (w), 1373 (w), 1325 (w), 1211 (m), 1175 (m), 1083 (m), 1044 
(s), 982 (m), 949 (m), 851 (m), 881 (m), 725 (s) cm
-1
. 
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(5S)-3-((2′E)-1′-Hydroxy-2′-methylocten-1′-ylidene)-1,5-dimethylpyrrolidine-2,4- 
dione (97) 
 
 
 
 
           99               97 
Scheme VI.33.  Synthesis of model compound via epicoccamide route: Lacey-Dieckmann cyclisation 
Analogously to 96, tetramic acid (5S)-97 (196 mg, quantitative) was obtained from amide 99 
(220 mg, 0.74 mmol) and NaOMe (80 mg, 1.48 mmol) as a colourless oil which was 
submitted to complexation without further purification. 
Rf=0.22 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -73.0 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=7.07 (tq, 
4
J(H,H)=1.2 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 
3.72-3.61 (m, 1H, 5-H), 2.96 (s, 3H, NCH3), 2.26 (dq, 
4
J(H,H)=1.2 Hz, 
3
J(H,H)=7.3 Hz, 2H, 
9-H), 1.89 (d, 
4
J(H,H)=1.2 Hz, 3H, 7-CH3), 1.49 (m, 2H, CH2), 1.34 (d, 
3
J(H,H)=7.0, 3H, 
5-CH3), 1.34-1.29 (m, 6H, 3×CH2), 0.89 (m, 3H, CH3); 
13
C NMR (70 MHz, CDCl3): δ=192.9 (C-4), 184.4 (C-6), 175.0 (C-2), 146.1 (C-8), 129.0 
(C-7), 110.1 (C-3), 62.3 (C-5), 31.8 (NMe), 29.3 (C-11), 28.2 (C-9), 26.7 (C-10), 22.6 (C-12), 
15.3 (5-CH3); 14.2 (CH3), 12.5 (7-CH3); 
IR (thin film) ṽ=2956 (w), 2928 (m), 2859 (w), 1716 (m), 1651 (s), 1607 (m), 1571 (s), 1464 
(m), 1440 (w), 1384 (w), 1346 (w), 1311 (w), 1270 (w), 1259 (m), 1212 (m), 1161 (m), 1103 
(m), 1078 (m), 1068 (s), 990 (m), 963 (m), 924 (m), 879 (m), 791 (w), 729 (s), 709 (m), 673 
(m) cm
-1
. 
 
Difluoroboryl complex ((5S)-100) 
 
 
 
 
         97       100 
Scheme VI.34.  Synthesis of model compound via epicoccamide route: Formation of corresponding 
BF2 complex. 
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Analogously to (5S)-102, complex (5S)-100 (202 mg, 90%) was obtained from 97 (190 mg, 
0.72 mmol) and BF3OEt2 (508 µL, 3.58 mmol). 
Rf=0.58 (EtOAc/c-hexane 1:1); 
[α]D
24
 = –10.4 (c=1.0, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ=7.54 (tq, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.2 Hz, 1H, 8-H), 3.88 (q, 
3
J(H,H)=7.2 Hz, 1H, 5-H), 3.16 (s, 3H, NCH3), 2.33 (dq, 
3
J(H,H)=7.2 Hz, 1.3 Hz, 2H, 9-H), 
1.91 (d, 
4
J(H,H)=1.3 Hz, 3H, 7-CH3), 1.52 (m, 2H, CH2), 1.45 (d, 
3
J(H,H)=7.2, 3H, 5-CH3), 
1.33 (m, 4H, 2×CH2), 0.89 (m, 3H; CH3); 
13
C NMR (70 MHz, CDCl3): δ=197.4 (C-6), 189.5 (C-4), 172.4 (C-2), 151.7 (C-8), 130.1 
(C-7), 96.5 (C-3), 64.1 (C-5), 31.7 (NMe), 29.9 (C-11), 28.3 (C-10), 28.0 (C-9), 22.6, (C-12), 
14.6 (5-CH3), 14.1 (7-CH3), 12.3 (CH3); 
IR (thin film) ṽ=2956, 2931, 2859, 1709, 1645, 1583, 1504, 1472, 1452, 1416, 1373, 1262, 
1234, 11175, 1057, 1024, 937, 867, 874, 785, 730, 699, 655, 632 cm
-1
. 
 
Difluoroboryl complex ((5S,7S)-101) 
 
 
 
 
   100         (5S,7S)-101 
Scheme VI.35.  Synthesis of model compound via epicoccamide route: Stereoselective hydrogenation 
to form the natural product configuration. 
A mixture of freshly prepared (5S)-100 (85 mg, 0.27 mmol), dry CH2Cl2 (8 mL), and 
(R,R)-Rh-Et-DUPHOS BF4 (7 mg, 0.01 mmol) was placed in a Parr high pressure autoclave 
which was sealed, pressurised with 80 bar H2 and heated to 35 °C for 16 h. After filtration 
through a plug of silica and removal of the volatiles (5S)-101 (80 mg, 94%) was obtained as a 
colourless oil. 
Rf=0.55 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -68.9 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=3.90 (q, 
3
J(H,H)=7.1 Hz, 1H, 7-H), 3.52 (q, 
3
J(H,H)=6.8 Hz, 
1H, 5-H), 3.16 (s, 3H, NCH3), 1.75-1.64 (m, 1H, 8-H
a
), 1.52-1.43 (m, 1H, 8-H
b
) 1.46 (d, 
3
J(H,H)=7.1 Hz, 3H, 7-CH3), 1.25 (m, 8H, 4×CH2), 1.19 (d, 
3
J(H,H)=6.8 Hz, 3H, 5-CH3), 
0.85 (m, 3H, CH3); 
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13
C NMR (75 MHz, CDCl3): δ=193.6 (C-4), 190.6 (C-6), 171.3 (C-2), 98.2 (C-3), 65.1 (C-5), 
37.6 (NMe), 33.6 (C-8), 31.7 (C-11), 29.2 (C-9), 28.1 (C-7), 27.2 (C-10), 22.7 (C-12), 16.9 
(5-CH3), 14.3 (7-CH3), 14.2 (CH3); 
IR (thin film) ṽ=2955 (w), 2931 (m), 2857 (w), 1720 (m), 1646 (s), 1568 (m), 1533 (s), 1453 
(m), 1417 (w), 1395 (w), 1374 (w), 1357 (w), 1232 (m), 1214 (m), 1184 (m), 1058 (m), 1029 
(s), 936 (m), 889 (m), 862 (m), 798 (w), 784 (w), 753 (m), 730 (s) cm
-1
; 
HRMS (ESI) Calcd for C15H25BF2NO3Na [M+H]
+
 316.1890, found: 316.1917. 
 
Difluoroboryl complex ((5S,7R)-101) 
 
 
 
 
   100        (5S,7R)-101 
Scheme VI.36.  Synthesis of model compound via epicoccamide route: Stereoselective 
hydrogenation. 
Analogously to (5S,7S)-101, its diastereomer (5S,7R)-101 was obtained by catalytic 
hydrogenation with (S,S)-Rh-Et-DUPHOS BF4 with similar nearly quantitative yield (97%). 
Rf=0.54 (EtOAc/c-hexane 1:1); 
[α]D
24
 = -6.3 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=3.90 (q, 
3
J(H,H)=7.1 Hz, 1H, 7-H), 3.51 (q, 
3
J(H,H)=6.8 Hz, 
1H, 5-H), 3.15 (s, 3H, NCH3), 1.69 (m, 1H, 8-H
a
), 1.51-1.41 (m, 1H, 8-H
b
) 1.45 (d, 
3
J(H,H)=7.1 Hz, 3H, 7-CH3), 1.24 (m, 8H, 4×CH2), 1.18 (d, 
3
J(H,H)=6.8 Hz, 3H, 5-CH3), 
0.84 (m, 3H, CH3); 
13
C NMR (75 MHz, CDCl3): δ=193.5 (C-4), 190.6 (C-6), 171.2 (C-2), 98.2 (C-3), 65.0 (C-5), 
37.5 (NMe), 33.6 (C-8), 31.7 (C-11), 29.2 (C-9), 28.1 (C-7), 27.1 (C-10), 22.6 (C-12), 16.9 
(5-CH3), 14.2 (7-CH3), 14.1 (CH3); 
IR (thin film) ṽ=2955 (w), 2928 (m), 2857 (w), 1719 (m), 1644 (s), 1565 (m), 1531 (s), 1454 
(m), 1417 (w), 1394 (w), 1375 (w), 1356 (w), 1268 (w), 1232 (m), 1181 (m), 1059 (m), 1026 
(s), 935 (m), 910 (m), 861 (m), 798 (w), 784 (w), 730 (s), 707 (m) cm
-1
. 
HRMS (ESI) Calcd for C15H25BF2NO3Na [M+H]
+
 316.1890, found: 316.1908. 
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VI.3. Ancorinoside B 
 
VI.3.1. Glycosyl donor 
 
D-Galactopyranose pentabenzoate (115)
[233,234]
 
 
 
 
          114      115 
Scheme VI.37.  Synthesis of perbenzoylated galactose 115. 
D-Glucose (5.39 g, 29.9 mmol) was suspended in 30 ml pyridine. The reaction was cooled to 
0 °C. BzCl (164.5 mmol, 19.1 ml) was slowly added. The resulting mixture was heated to RT 
and stirred for 12 h. The volatiles were removed under reduced pressure and the crude product 
was purified by column chromatography (silica gel; 10% EtOAc in c-hexane) to yield 
perbenzoylated galactose (20.96 g, quantitative) as white crystals with α to β ratio of roughly 
1:2. 
All data in accordance with literature.
[233,234]
 
 
2,3,4,6-Tetra-O-benzoyl-α-D-galactosyl trichloroimidate (112)[233] 
 
 
 
 
    115        112 
Scheme VI.38.  Anomeric deprotection of perbenzoylated galactose. 
Perbenzoylated galactose 115 (23.0 g, 29.9 mmol) was dissolved in 90 ml dry CH2Cl2. The 
solution was cooled to 0 °C and 45 ml of HBr in EtOAc (33 wt%) was slowly added. The 
reaction was stirred for 6 h. After complete consumption of the starting material, the reaction 
mixture was thrown on ice and diluted with diethylether. The organic layer was washed with 
H2O, slowly with NaHCO3, again H2O and brine. The washed organic layer was dried over 
Na2SO4 and all volatiles were removed under reduced pressure. The crude material which was 
a colorless oil was directly subjected to the next step. 
EXPERIMENTAL - Ancorinoside B 
123 
 
The remainder of the step above was redissolved in 120 ml acetone and 5 ml water was 
added. Ag2CO3 (4.5 g, 16.4 mmol) was added in one portion and stirring was maintained for 
16 h. The remaining dark solution was filtered over celite and the celite was rinsed with three 
times 200 ml CH2Cl2. All organic fractions were combined, dried over Na2SO4 and the 
solvents were removed under reduced pressure. The slightly yellow foam was directly used in 
the next step without further purification. 
The crude hemiacetal (8.8 g, 14.75 mmol) was dissolved in 120 ml dry CH2Cl2. The resulting 
solution was cooled to 0 °C. DBU (16.63 mmol, 2.5 ml) and Cl3CCN (103.3 mmol, 10.3 ml) 
were added in one portion. The reaction mixture was allowed to heat up to RT and stirring 
was maintained for 3 h. After complete consumption of the starting material all volatiles were 
removed under reduced pressure. The crude product was purified by column chromatography 
(silica gel; 25% EtOAc in c-hexane) to yield imidate 112 (6.22 g, 57% over three steps) as a 
slightly yellow foam. 
Rf=0.44 (EtOAc/c-hexane 1:3); 
1
H NMR (500 MHz, CDCl3): δ=8.64 (s, 1H, NH), 8.13-7.25 (m, 20H, H
ar
), 6.91 (d, 
3
J(H,H)=3.7 Hz, 1H, 1-H), 6.15 (dd, 
3
J(H,H)=3.7 Hz, 3.3 Hz, 1H, 4-H), 6.08 (dd, 
3
J(H,H)=10.7 Hz, 3.3 Hz, 1H, 3-H), 5.96 (dd, 
3
J(H,H)=10.7 Hz, 3.7 Hz, 1H, 2-H), 4.87 (dd, 
3
J(H,H)=6.9 Hz, 6.1 Hz, 1H, 5-H), 4.62 (dd, 
3
J(H,H)=11.4 Hz, 6.9 Hz, 1H, 6-H
a
), 4.44 (dd, 
3
J(H,H)=11.4 Hz, 6.1 Hz, 1H, 6-H
b
); 
13
C NMR (100 MHz, CDCl3): δ=166.1 (COPh), 165.8 (COPh), 165.7 (COPh), 165.6 (COPh), 
160.7 (CNH), 133.9 (2xCH
ar
), 133.7 (CH
ar
), 133.5 (CH
ar
), 133.4 (CH
ar
), 130.3 (CH
ar
), 130.2 
(2xCH
ar
), 130.1 (2CHar), 130.0 (2CHar), 129.9 (4CHar), 129.8 (CHar), 129.4 (Cq
ar
), 129.0 
(Cq
ar
), 128.9 (Cq
ar
), 128.9 (2xCH
ar
), 128.8 (Cq
ar
), 128.6 (3xCH
ar
), 128.5 (4xCH
ar
), 93.8 (C-1), 
69.8 (C-5), 68.6 (C-3), 68.5 (C-4), 67.9 (C-2), 62.3 (C-6); 
All additional data in accordance with literature.
[233,234]
 
 
VI.3.2. Synthesis of the C20 alkyl chain (111) 
 
1,20-Eicosane diol (118)
[213]
 
 
 
 
            117               118 
Scheme VI.39.  Synthesis of C20 diol 118. 
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755 mg of 1,20-eicosandioic acid 117 (2.20 mmol) was dissolved in 45 ml dry THF. The 
suspension was cooled to 0 °C and LiAlH4 (251 mg, 6.61 mmol) was slowly added. The 
resulting suspension was heated up to reflux and stirred for 12 h. Tlc analysis showed 
complete consumption of the starting material (baseline) and one single spot by that time. The 
mixture was again cooled to 0 °C and the reaction was stopped by dropwise addition of 
Na/K-tartrate. The product was extracted three times with CH2Cl2. The combined organic 
layers were dried over Na2SO4 and the volatiles were removed under reduced pressure. This 
reaction gave 615 mg (1.96 mmol) of the desired product as a white solid in 89% yield. 
Rf=0.18 (EtOAc/c-hexane 2:1); 
m.p. 102 °C; 
1
H NMR (300 MHz, CDCl3): δ=3.54 (t, 
3
J(H,H)=6.7 Hz, 4H, 2xOCH2), 1.53 (pqui, 
3
J(H,H)=6.7 Hz, 4H, OCH2CH2), 1.39-1.26 (m, 32H, CH2); 
13
C NMR (75 MHz, CDCl3): δ=63.0 (C-1, C-20), 33.7 (C-2, C-19), 30.8 (10CH2), 30.7 
(2CH2), 30.6 (2CH2), 27.0 (2CH2); 
IR (thin film) ṽ=3410 (m), 3342 (m), 2918 (s), 2850 (s), 1493 (w), 1460 (m), 1357 (m), 1333 
(w), 1321 (w), 1050 (s), 1017 (s), 996 (w), 980 (w), 971 (m), 727 (m) cm
-1
. 
All data in accordance with literature.
[213]
 
 
16-[(tButyldimethylsilyl)oxy]octadecane-1-ol (111) 
 
 
 
    118               111 
Scheme VI.40.  Synthesis of the mono-TBS protected C20 diol 111. 
1.21 g of the diol 118 (3.85 mmol) was suspended in 40 ml of 1,4-dioxan. The resulting 
mixture was heated to about 75 °C in order to dissolve the educt. TBSCl (580 mg, 3.85 mmol) 
and imidazol (524 mg, 7.70 mmol) was added in one portion. The mixture was heated to 
reflux for 10 h. The reaction was cooled to room temperature and then stopped by addition of 
saturated NaHCO3 solution. The product mixture was extracted three times with ethyl acetate, 
the combined organic layers were washed two times with water and brine and dried over 
Na2SO4. The crude mixture was purified by silica chromatography (silica gel; 10% EtOAc in 
c-hexane) to yield 111 (845 mg, 52%) as a white waxy substance. 
Rf=0.47 (EtOAc/c-hexane 1:3); 
1
H NMR (500 MHz, CDCl3): δ=3.63 (t, 
3
J(H,H)=6.7, 2H, CH2OH); 3.59 (t, 
3
J(H,H)=6.7, 2H, 
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CH2OTBS); 1.56 (pqui, 
3
J(H,H)=6.7, 2H, CH2CH2OH); 1.50 (pqui, 
3
J(H,H)=6.7, 2H, 
CH2CH2OTBS), 1.36-1.21 (m, 32H), 0.89 (s, 9H; C(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (125 MHz, CDCl3): δ=63.4 (COTBS), 63.1 (COH), 32.9 (C-19), 32.8 (C-2), 29.7 
(C-6 to C-16), 29.7 (C-17), 29.7 (C-4), 29.6 (C-16), 29.5 (C-5), 26.0 (C(CH3)3), 25.8 (C-18), 
25.7 (C-3), 18.4 (SiC
q
), -5.2 (Si(CH3)2); 
IR (thin film) ṽ=3375 (br), 2923 (s), 2853 (s), 1464 (m), 1367 (w), 1361 (w), 1254 (m), 1099 
(s), 1058 (m), 1006 (w), 939 (w), 908 (w), 834 (s), 810 (m), 774 (s), 735 (m), 7020 (m), 662 
(w) cm
-1
; 
HRMS (ESI) Calcd for C26H56O2SiNa [M+Na]
+
 451.3942, found: 451.3762. 
 
VI.3.3. 6-O-PMB protected glycosyl acceptor (122) 
 
1-S-Phenyl-2,3,4,6-tetra-O-acetyl-β-thio-D-glucopyranoside (123)[238] 
 
 
 
 
    80            123 
Scheme VI.41.  Thioglycoside formation to yield 123. 
Peracetylated D-glycopyranose
[32,140]
 80 (2.55 g, 6.533 mmol) was dissolved in 65 ml CH2Cl2. 
BF3•OEt2 (2.82 ml, 22.86 mmol) and PhSH (12.0 ml, 11.76 mmol) were added via syringe. 
The reaction mixture was heated up to reflux for three days. After cooling the mixture to RT 
the reaction was stopped by addition of 100 ml 1 M NaOH. The aqueous phase was extracted 
three times using CH2Cl2. The combined organic layers were washed with NaHCO3, H2O and 
brine. The layers were dried over Na2SO4 and the solvent was removed under reduced 
pressure. The crude material was purified by flash chromatography (silica gel; 12.5% EtOAc 
in c-hexane) to yield 123 (1.49 g, 52%) as a transparent oil. 
Rf=0.42 (EtOAc/c-hexane 1:2); 
1
H NMR (500 MHz, CDCl3): δ=7.45-7.41 (m, 2H, H
ar
), 7.27-7.23 (m, 3H, H
ar
), 5.18 (pt, 
3
J(H,H)=9.8 Hz, 1H, 4-H), 4.98 (dd, 
3
J(H,H)=9.8 Hz, 9.4 Hz, 1H, 3-H), 4.91 (dd, 
3
J(H,H)=10.1 Hz, 9.8 Hz, 1H; 2-H), 4.69 (d, 
3
J(H,H)=10.1 Hz, 1H, 1-H), 4.17 (dd, 
3
J(H,H)=5.2 Hz, 
2
J(H,H)=12.3 Hz, 1H, 6-CH
a
), 4.12 (dd, 
3
J(H,H)=2.4 Hz, 
2
J(H,H)=12.3 Hz 
1H, 6-CH
b
), 3.70 (ddd, 
3
J(H,H)=9.8 Hz, 5.2 Hz, 2.4 Hz, 1H, 5-H), 2.01 (s, 3H, CH3), 1.96 (s, 
3H, CH3), 1.95 (s, 3H, CH3), 1.92 (s, 3H, CH3); 
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13
C NMR (100 MHz, CDCl3): δ=170.3 (COPh), 169.9 (COPh), 169.2 (COPh), 169.0 (COPh), 
132.9 (2xCH
ar
), 131.6 (C
ar
), 128.8 (2xCH
ar
), 128.2 (CH
ar
), 85.4 (C-1), 75.6 (C-3), 73.8 (C-4), 
69.8 (C-5), 68.1 (C-2), 60.1 (C-6), 20.5 (CH3), 20.5 (CH3), 20.4 (2xCH3); 
All additional data in accordance with literature.
[313]
 
 
1-S-Phenyl-4,6-O-(methoxyphenyl)methylene-β-thio-D-glucopyranose (124)[239] 
 
 
 
 
   123             124 
Scheme VI.42.   Synthesis of anisaldehyde acetal 124. 
The peracetylated Schmidt-donor 123 (1.75 g, 3.973 mmol) was dissolved in 40 ml MeOH. 
Sodium methoxide (107 mg, 1.987 mmol) was added in one portion. The resulting suspension 
was stirred for 45 min (until complete consumption of the starting material). The solvents 
were removed under reduced pressure and the remainder was redissolved in 40 ml DMF. 
Toluenesulfonic acid (491 mg, 2.583 mmol) and anisaldehyde dimethyl acetal (1.35 ml, 
7.946 mmol) were added. The resulting solution was heated up to 50 °C and stirring was 
maintained for 8 h. The solvent was removed in vacuo and the crude material was purified by 
column chromatography (silica gel; 12.5% EtOAc in c-hexane) to yield 124 (1.33 g, 86% over 
two steps) as a white solid. 
Rf=0.29 (EtOAc/c-hexane 1:3); 
1
H NMR (500 MHz, CDCl3): δ=7.56-7.52 (m, 2H, H
ar
), 7.41-7.38 (m, 2H, H
ar
), 7.35-7.32 (m, 
3H, H
ar
), 6.90-6.87 (m, 2H, H
ar
), 5.49 (s, 1H, PhCH), 4.64 (d, 
3
J(H,H)=9.7 Hz, 1H, 1-H), 4.36 
(dd, 
3
J(H,H)=10.6 Hz, 4.1 Hz, 1H, 6-CH
a
), 3.84 (dd, 
3
J(H,H)=9.4 Hz, 8.7 Hz, 1H, 4-H), 3.79 
(s, 3H, OCH3), 3.76 (dd, 
3
J(H,H)=9.9 Hz, 9.4 Hz, 2.4 Hz ,1H, 3-H), 3.55 – 3.49 (m, 2H, 5-H, 
6-CH
b
), 3.47 (dd, 
3
J(H,H)=9.9 Hz, 9.7 Hz, 1H, 2-H); 
13
C NMR (100 MHz, CDCl3): δ=160.4 (CH3OC
ar
), 133.2 (2xCH
ar
), 131.4 (C
ar
), 129.5 (C
ar
), 
129.3 (2xCH
ar
), 128.6 (CH
ar
), (2xCH
ar
), 113.9 (2xCH
ar
), 102.0 (PhCH), 88.8 (C-1), 80.3 
(C-4), 74.6 (C-3), 72.2 (C-2), 70.7 (C-5), 68.7 (C-6), 55.5 (OCH3); 
All additional data in accordance with literature.
[239]
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1-S-Phenyl-2,3-O-benzoyl-4,6-O-(methoxyphenyl)methylene-β-thio-D-glucopyranose 
(125)
[241]
 
 
 
 
 
             124              125 
Scheme VI.43.  Benzoyl protection of the acetal donor. 
Diol 124 (1.33 g, 3.406 mmol) was dissolved in 40 ml pyridine. This solution was cooled to 
0 °C. BzCl (1.2 ml, 10.22 mmol) was slowly added via syringe. The reaction mixture was 
allowed to heat up to RT and stirring was continued for 12 h. Tlc analysis showed complete 
consumption of the starting material by that time and the volatiles were removed under 
reduced pressure. The crude material was purified by column chromatography (silica gel; 
10% EtOAc in c-hexane) to yield 125 (1.54 g, 76%) as a white foam. 
Rf=0.69 (EtOAc/c-hexane 1:3); 
1
H NMR (500 MHz, CDCl3): δ=8.01-7.93 (m, 4H, H
ar
), 7.55-7.45 (m, 4H, H
ar
), 7.42-7.31 (m, 
9H, H
ar
), 6.86-6.82 (m, 2H, H
ar
), 5.83 (dd, 
3
J(H,H)=9.6 Hz, 9.4 Hz, 1H, 3-H), 5.52 (s, 1H, 
PhCH), 5.51 (dd, 
3
J(H,H)=9.9 Hz, 9.4 Hz, 1H, 2-H), 5.07 (d, 
3
J(H,H)=9.9 Hz, 1H, 1-H), 4.46 
(dd, 
3
J(H,H)=10.5 Hz, 4.9 Hz, 1H, 6-CH
a
), 3.92 (dd, 
3
J(H,H)=9.6 Hz, 8.7 Hz, 1H, 4-H), 3.88 
(dd, 
3
J(H,H)=10.5 Hz, 5.2 Hz, 1H, 6-CH
b
), 3.77 (m, 5-H), 3.75 (s, 3H, OCH3); 
13
C NMR (100 MHz, CDCl3): δ=165.7 (COPh C-2), 165.3 (COPh C-3), 160.2 (CH3OC
ar
), 
133.4 (CH
ar
), 133.2 (CH
ar
), 133.1 (2xCH
ar
), 132.0 (C
ar
), 130.0 (2xCH
ar
), 129.9 (2xCH
ar
), 
129.4 (C
ar
), 129.3 (C
ar
), 129.2 (C
ar
), 129.1 (2xCH
ar
), 128.5 (2xCH
ar
), 128.4 (CH
ar
), 128.3 
(2xCH
ar
), 113.6 (2xCH
ar
), 101.5 (PhCH), 87.1 (C-1), 78.6 (C-4), 73.4 (C-3), 71.1 (C-2), 71.0 
(C-5), 68.5 (C-6), 55.3 (OCH3); 
All additional data in accordance with literature.
[241]
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1-S-Phenyl-2,3-O-benzoyl-6-O-pmethoxybenzyl-β-thio-D-glucopyranose (122)[242,243] 
 
 
 
 
 
           125                122 
Scheme VI.44.  Reductive acetal opening to yield the 6-O-PMB protected acceptor 122. 
The fully protected sugar 125 (3.4 g, 6.221 mmol) was dissolved in 50 ml DMF. The solution 
was cooled to 0 °C. Sodium cyanoborohydride (1.95 g, 31.103 mmol) was added in one 
portion. Trifluoroacetic acid (TFA, 4.8 ml, 62.21 mmol) was mixed with 35 ml DMF. This 
acidic solution was added dropwise to the reaction mixture while cooling was maintained. 
After completion of the TFA addition, the mixture was heated up to RT and stirring was 
continued for 12 h. Tlc analysis showed complete consumption of the starting material. The 
reaction mixture was filtrated over celite and neutralized using 100 ml sat. NaHCO3 solution. 
The crude product was extracted three times with CH2Cl2 and the combined organic layers 
were washed again with sat. NaHCO3 solution. The washed extracts were dried over Na2SO4 
and the volatiles were removed under reduced pressure. The crude material was purified by 
column chromatography (silica gel; 10% EtOAc in c-hexane) to yield 122 (2.99 g, 88%) as a 
transparent oil. 
Rf=0.58 (EtOAc/c-hexane 1:2); 
[α]D
22
 = 44.9 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (500 MHz, CDCl3): δ=7.99-7.93 (m, 4H, H
ar
), 7.54-7.48 (m, 4H, H
ar
), 7.41-7.34 (m, 
4H, H
ar
), 7.31-7.24 (m, 5H, H
ar
), 6.92-6.88 (m, 2H, H
ar
), 5.49 (dd, 
3
J(H,H)=9.5 Hz, 9.3 Hz, 
1H, 3-H), 5.43 (pt, 
3
J(H,H)=9.8 Hz, 1H, 2-H), 4.95 (d, 
3
J(H,H)=9.9 Hz, 1H, 1-H), 4.58 (d, 
2
J(H,H)=11.5 Hz, 1H, MPCH
a
), 4.54 (d, 
2
J(H,H)=11.5 Hz, 1H, MPCH
b
), 3.95 (pt, 
3
J(H,H)=9.3 Hz, 1H, 4-H), 3.86 (dd, 
3
J(H,H)=4.3 Hz, 
2
J(H,H)=5.4 Hz, 1H, 6-CH2), 3.82 (s, 
3H, OCH3), 3.74 (dt, 
3
J(H,H)=9.3 Hz, 4.3 Hz, 1H, 5-H), 3.30 (s, 1H, OH); 
13
C NMR (100 MHz, CDCl3): δ=167.2 (COPh C-3), 165.4 (COPh C-2), 159.5 (CH3OC
ar
), 
133.5 (CH
ar
), 133.4 (CH
ar
), 132.8 (2xCH
ar
), 132.5 (C
ar
), 130.1 (2xCH
ar
), 123.0 (2xCH
ar
), 
129.9 (C
ar
), 129.5 (2xCH
ar
), 129.4 (C
ar
), 129.1 (C
ar
) 129.0 (3xCH
ar
), 128.5 (3xCH
ar
), 128.2 
(CH
ar
), 114.0 (2xCH
ar
), 86.3 (C-1), 78.9 (C-5), 77.8 (C-3), 73.5 (MPCH2), 70.9 (C-4), 70.3 
(C-2), 69.9 (C-6), 55.4 (OCH3); 
IR (thin film) ṽ=3463 (br), 2923 (w), 1725 (s), 1602 (w), 1588 (w), 1568 (w), 1513 (m), 1451 
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(m), 1440 (w), 1315 (m), 1275 (s), 1248 (s), 1177 (m), 1128 (m), 1104 (m), 1085 (s), 1067 
(s), 1026 (m), 988 (w), 822 (w), 750 (m), 708 (s), 681 (m) cm
-1
; 
HRMS (ESI) Calcd for C34H32O8SNa [M+Na]
+
 623.1710, found: 623.1700. 
 
 
VI.3.4. Total synthesis of ancorinoside B diglycoside (120) 
 
Phenyl S-(2,3,4,5-tetra-O-benzoyl-β-D-galactopyranosyl)-(1-4)-2,3-di-O-benzoyl-6-O-
pmethoxybenzyl-β-thio-D glucopyrandoside (121) 
 
 
 
 
 
          112        122            121 
Scheme VI.45.  1
st
 glycosylation with PMB-protected acceptor 122 and Schmidt-Donor 112. 
Alcohol 122 (852 mg, 1.418 mmol) and donor 112 (1.26 g, 1.702 mmol) were dissolved in 
50 ml dry CH2Cl2 containing 1.3 g 4 Å molecular sieves. The suspension was cooled to 
-40 °C. TMSOTf (31 µl, 0.170 mmol) was added via syringe. The reaction mixture was 
stirred for 3 h at -40 °C until tlc analysis showed complete consumption of the donor. The 
reaction was stopped by addition of sat. NaHCO3 solution. The crude glycosylation product 
was extracted three times using CH2Cl2. The combined organic layers were dried over 
Na2SO4 and the solvent was removed under reduced pressure. The crude product was purified 
by flash chromatography (silica gel; 5% EtOAc in c-hexane) to yield 121 (1.03 g, 88%) as a 
transparent oil. 
Rf=0.29 (EtOAc/c-hexane 1:3); 
[α]D
22
 = 23.1 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (500 MHz, CDCl3): δ=8.03-8.00 (m, 2H, H
ar
), 7.97-7.94 (m, 4H, H
ar
), 7.87-7.84 (m, 
3H, H
ar
), 7.73-7.70 (m, 1H, H
ar
), 7.63-7.57 (m, 2H, H
ar
), 7.54-7.49 (m, 2H, H
ar
), 7.48-7.43 (m, 
6H, H
ar
), 7.41-7.35 (m, 6H, H
ar
), 7.32-7.27 (m, 4H, H
ar
), 7.25-7.19 (m, 4H, H
ar
), 7.16-7.11 (m, 
2H, H
ar
), 6.97-6.94 (m, 2H, H
ar
), 6.91-6.88 (m, 1H, H
ar
), 5.75 (pt, 
3
J(H,H)=9.7 Hz, 1H, 3’-H), 
5.71 (dd, 
3
J(H,H)=9.1 Hz, 3.4 Hz, 1H, 4-H), 5.60 (dd, 
3
J(H,H)=10.4 Hz, 8.0 Hz, 1H; 2-H), 
5.44 (dd, 
3
J(H,H)=9.9 Hz, 9.7 Hz, 1H, 2’-H), 5.36 (dd, 3J(H,H)=10.4 HZ, 3.4 Hz, 1H, 3-H), 
4.85 (d, 
3
J(H,H)=9.9 Hz, 1H, 1‘-H), 4.83 (d, 3J(H,H)=8.0 Hz, 1H, 1-H), 4.64 (dd, 
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3
J(H,H)=3.2 Hz, 
2
J(H,H)=11.7 Hz, 1H, 6’-Ha), 4.37 (dd, 3J(H,H)=0.7 Hz, 2J(H,H)=11.7 Hz, 
1H, 6’-Hb), 4.27 (pt, 3J(H,H)=9.7 Hz, 1H, 4‘-H), 3.86 (ddd, 3J(H,H)=9.1 Hz, 4.8 Hz, 3.4 Hz, 
1H, 5-H), 3.78 (s, 3H, OCH3), 3.77 (dd, 
3
J(H,H)=4.8 Hz, 
2
J(H,H)=11.5 Hz, 1H, 6-H
a
), 3.77 
(dd, 
3
J(H,H)=3.4 Hz, 
2
J(H,H)=11.5 Hz, 1H, 6-H
b
), 3.64-3.59 (m, 2H, MPCH2) 3.56 (ddd, 
3
J(H,H)=9.7 Hz, 3.2 Hz, 0.7 Hz, 1H, 5‘-H); 
13
C NMR (100 MHz, CDCl3): δ=165.8 (COPh C-6), 165.6 (2xCOPh C-2’, C-3), 165.4 (COPh 
C-3’), 165.3 (COPh C-4), 164.7 (COPh C-2), 159.7 (CH3OC
ar
), 133.6 (CH
ar
), 133.5 (2xCH
ar
), 
133.4 (CH
ar
), 133.3 (CH
ar
), 133.1 (CH
ar
), 132.9 (3xCH
ar
), 132.6 (C
ar
), 130.1 (2CHar), 130.0 
(2CHar), 129.9 (CHar), 129.9 (3xCHar), 129.8 (2CHar), 129.7 (2CHar), 129.6 (Car), 129.5 
(C
ar
), 129.3 (C
ar
), 129.0 (C
ar
), 129.0 (2xCH
ar
), 128.9 (C
ar
), 128.8 (CH
ar
), 128.7 (2CHar), 
128.7 (2CHar), 128.6 (2CHar), 128.5 (2xCHar), 128.4 (2xCHar), 128.3 (2xCHar), 128.2 
(CH
ar
), 114.0 (2xCH
ar
), 100.6 (C-1), 86.5 (C-1’), 79.0 (C-5’), 74.9 (C-4’), 74.5 (C-3’), 73.4 
(C-6’), 71.9 (C-3), 71.2 (C-5), 70.7 (C-2’), 70.1 (C-2), 67.8 (C-4), 67.3 (MPCH2), 61.1 (C-6), 
55.5 (OCH3); 
IR (thin film) ṽ=1723 (s), 1602 (m), 1584 (w), 1513 (m), 1451 (m), 1315 (m), 1247 (s), 1177 
(m), 1091 (s), 1068 (s), 1026 (s), 1001 (m), 847 (w), 820 (m), 804 (w), 752 (m), 706 (s), 687 
(m) cm
-1
; 
HRMS (ESI) Calcd for C68H58O17SNa [M+Na]
+
 1201.3287, found: 1201.3274. 
 
[(tButyldimethylsilyloxy)-eicosyl] O-(2,3,4,5-tetra-O-benzoyl-β-D-galactopyranosyl)-
(1-4)-2,3-di-O-benzoyl-6-O-pmethoxybenzyl -1-O-β-D-glucopyrandoside (126) 
 
 
 
 
        121                   126 
Scheme VI.46.  2
nd
 glycosylation with PMB-protected disaccharide 121 and the TBS monoprotected 
side chain 111 to yield 126. 
Disaccharide donor 121 (1.02 g, 0.865 mmol) and monoprotected acceptor 111 (290 mg, 
0.908 mmol) were dissolved in 15 ml dry CH2Cl2 containing 1 g 4 Å molecular sieves. The 
suspension was cooled to -40 °C. TMSOTf (15.7 µl, 0.086 mmol) and BF3•OEt2 (5.3 µl, 
0.043 mmol) were added via syringe to get the in situ produced active donor species of 
BF2OTF•OEt2
[246]
. N-Ioduccinimide (350 mg, 1.557 mmol) was added in one portion. The 
reaction mixture was stirred for 3.5 h at -40 °C until tlc analysis showed complete 
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consumption of the donor. The reaction was stopped by addition of sat. NaHCO3 solution. 
The crude glycosylation product was extracted three times using CH2Cl2. The combined 
organic layers were washed with 10 wt% Na2S2O3 solution, dried over Na2SO4 and the 
solvent was removed under reduced pressure. The crude product was purified by flash 
chromatography (silica gel; 5% EtOAc in c-hexane) to yield 126 (751 mg, 58%) as a 
transparent oil. 
Rf=0.43 (EtOAc/c-hexane 1:3); 
[α]D
22
 = 2.1 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=8.08-7.93 (m, 6H, H
ar
), 7.89-7.84 (m, 4H, H
ar
), 7.76-7.71 (m, 
2H, H
ar
), 7.65-7.56 (m, 2H, H
ar
), 7.54-7.43 (m, 6H, H
ar
), 7.42-7.29 (m, 8H, H
ar
), 7.25-7.11 (m, 
4H, Haromat.), 7.00-6.96 (m, 2H, Haromat.), 5.71 (dd, 
3
J(H,H)=7.1 Hz, 3.4 Hz 1H, 4-H), 5.70 (dd, 
3
J(H,H)=9.9 Hz, 9.6 Hz, 1H, 3’-H), 5.61 (dd, 3J(H,H)=10.4 Hz, 8.0 Hz, 1H, 2-H), 5.43 (dd, 
3
J(H,H)=9.9 Hz, 8.0 Hz, 1H, 2’-H), 5.35 (dd, 3J(H,H)=10.4 Hz, 3.4 Hz, 1H, 3-H), 4.79 (d, 
3
J(H,H)=8.0 Hz, 1H, 1-H), 4.73 (dd, 
3
J(H,H)=3.2 Hz, 
2
J(H,H)=11.9 Hz, 1H, 6’-Ha), 4.59 (d, 
3
J(H,H)=8.0 Hz, 1H, 1‘-H), 4.35 (dd, 3J(H,H)=0.7 Hz, 2J(H,H)=11.9 Hz, 1H, 6’-Hb), 4.30 (pt, 
3
J(H,H)=9.7 Hz, 1H, 4‘-H), 3.89-3.80 (m, 1H, 5-H), 3.85 (dt, 3J(H,H)=6.7 Hz, 
2
J(H,H)=9.6 Hz, 1H, sugar-OCH
a
), 3.78 (s, 3H, OCH3), 3.75-3.66 (m, 3H, 6-CH2, MPCH
a
), 
3.60 (t, 
3
J(H,H)=6.7 Hz, 2H, SiOCH2), 3.59 (d, 
2
J(H,H)=10.6 Hz, 1H, MPCH
b
), 3.51 (ddd, 
3
J(H,H)=9.7 Hz, 3.2 Hz, 0.7 Hz, 1H, 5‘-H), 3.42 (dt, 3J(H,H)=6.7 Hz, 2J(H,H)=9.6 Hz, 1H, 
sugar-OCH
b
), 1.57-1.45 (m, 4H, 2CH2), 1.35-0.97 (m, 32H, 16CH2), 0.90 (s, 9H, C(CH3)3), 
0.05 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=165.8 (COPh C-6), 165.6 (COPh C-3’), 165.5 (COPh C-3), 
165.4 (COPh C-4), 165.3 (COPh C-2’), 164.7 (COPh C-2), 159.7 (CH3OC
ar
), 133.6 (CH
ar
), 
133.5 (CH
ar
), 133.4 (CH
ar
), 133.3 (CH
ar
), 133.1 (3xCH
ar
), 130.1 (C
ar
), 130.1 (2CHar), 129.8 
(7CHar), 129.8 (2xCHar), 129.7 (3xCHar), 129.6 (Car), 129.3 (2xCar), 129.1 (Car), 128.9 (Car), 
128.7 (2xCH
ar
), 128.7 (2xCH
ar
), 128.6 (2CHar), 128.4 (4CHar), 128.2 (2xCHar), 114.2 
(2xCH
ar
), 101.4 (C-1’), 100.4 (C-1), 75.1 (C-4’), 74.8 (C-5’), 73.4 (C-6’), 73.3 (C-3’), 72.0 
(C-2’), 71.9 (C-3), 71.2 (C-5), 70.2 (sugar-OCH2), 70.2 (C-2), 67.9 (C-4), 67.1 (MPCH2), 
63.5 (SiOCH2), 61.3 (C-6), 55.5 (OCH3) 33.0 (CH2), 29.9 (4CH2), 29.8 (3xCH2), 29.8 
(3CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 (CH2), 29.4 (CH2), 26.1 (C(CH3)3), 25.9 
(2xCH2), 18.5 (SiC
q
), –5.1 (Si(CH3)2); 
IR (thin film) ṽ=2925 (m), 2854 (m), 1729 (s), 1602 (m), 1583 (w), 1514 (m), 1491 (w), 1462 
(m), 1452 (m), 1363 (m), 1315 (m), 1262 (s), 1253 (s), 1177 (m), 1094 (s), 1069 (s), 1028 (s), 
1001 (m), 835 (m), 776 (m), 704 (s), 686 (m) cm
-1
; 
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HRMS (ESI) Calcd for C88H108O19SiNa [M+Na]
+
 1519.7146, found: 1519.7151. 
 
[(tButyldimethylsilyloxy)-eicosyl] O-(2,3,4,5-tetra-O-benzoyl-β-D-galactopyranosyl)-
(1-4)-2,3-di-O-benzoyl-1-O-β-D-glucopyrandoside (127)[252] 
 
 
 
 
       126                 127 
Scheme VI.47.  Lewis acidic PMB-deprotection of 126 using SnCl2, TMSCl and anisole to yield 127. 
Diglycoside 126 (166 mg, 0.111 mmol) was dissolved in 4 ml dry CH2Cl2 containing 150 mg 
4 Å molecular sieves. SnCl2 dihydrate (2.5 mg, 0.011 mmol) was added. To the resulting 
mixture TMSCl (42 µl, 0.332 mmol) and anisole (18 µl, 0.166 mmol) were added under 
argon. The reaction mixture was stirred at RT for 90 min until tlc analysis showed complete 
conversion of the starting material to a lower running spot. The reaction was stopped by 
addition of sat. NaHCO3 solution. The crude product was extracted three times by the use of 
CH2Cl2. The combined organic layers were dried over Na2SO4 and all volatiles were removed 
under reduced pressure. The crude alcohol was purified by column chromatography (silica 
gel; 10% EtOAc in c-hexane) to yield 127 (152 mg, 99.6%) as a white solid. 
Rf=0.39 (EtOAc/c-hexane 1:2); 
[α]D
22
 = 8.4 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (500 MHz, CDCl3): δ=8.04-7.99 (m, 4H, H
ar
), 7.97-7.92 (m, 4H, H
ar
), 7.89-7.86 (m, 
2H, H
ar
), 7.76-7.72 (m, 2H, H
ar
), 7.63-7.55 (m, 2H, H
ar
), 7.54-7.44 (m, 6H, H
ar
), 7.43-7.30 (m, 
6H, H
ar
), 7.24-7.20 (m, 2H, H
ar
), 7.17-7.13 (m, 2H, H
ar
), 5.76 (pd, 
3
J(H,H)=3.4 Hz, 1H, 4-H), 
5.70 (dd, 
3
J(H,H)=9.9 Hz, 9.6 Hz, 1H, 3’-H), 5.67 (dd, 3J(H,H)=10.2 Hz, 7.9 Hz, 1H, 2-H), 
5.47 (dd, 
3
J(H,H)=10.2 Hz, 3.4 Hz, 1H, 3-H), 5.35 (dd, 
3
J(H,H)=9.9 Hz, 8.0 Hz, 1H, 2’-H), 
5.02 (d, 
3
J(H,H)=7.9 Hz, 1H, 1-H), 4.58 (d, 
3
J(H,H)=8.0 Hz, 1H, 1‘-H), 4.22 (pt, 
3
J(H,H)=9.7 Hz, 1H, 4‘-H), 3.91 (pdt, 3J(H,H)=6.7 Hz, 3.4 Hz, 1H, 5-H), 3.84-3.72 (m, 5H, 
6-CH2, 6’-CH2, sugar-OCH
a
), 3.59 (t, 
3
J(H,H)=6.7 Hz, 2H, SiOCH2), 3.43 (m, 2H, 5’-H, 
sugar-OCH
b
), 1.54-1.44 (m, 4H, 2CH2), 1.34-0.99 (m, 32H, 16CH2), 0.89 (s, 9H, C(CH3)3), 
0.04 (s, 6H, Si(CH3)2); 
13
C NMR (100 MHz, CDCl3): δ=165.8 (COPh C-6), 165.7 (2xCOPh C-2’, C-3’), 165.4 
(COPh C-2), 165.3 (COPh C-4), 164.8 (COPh C-3), 133.6 (CH
ar
), 133.5 (CH
ar
), 133.4 (CH
ar
), 
133.4 (CH
ar
), 133.1 (2xCH
ar
), 130.1 (2CHar), 130.1 (Car), 129.9 (2CHar), 129.9 (2xCHar), 
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129.8 (5xCH
ar
), 129.8 (C
ar
), 129.6 (C
ar
), 129.4 (C
ar
), 129.1 (C
ar
), 128.9 (C
ar
), 128.7 (3xCH
ar
), 
128.7 (2xCH
ar
), 128.6 (2CHar), 128.4 (4CHar), 128.3 (2xCHar), 101.1 (C-1), 100.7 (C-1’), 
75.3 (C-5’), 74.9 (C-4’), 73.3 (C-3’), 72.1 (C-3), 72.1 (C-2’), 71.3 (C-5), 70.2 (C-2), 69.9 
(sugar-OCH2), 67.9 (C-4), 63.5 (SiOCH2), 61.4 (C-6), 60.7 (C-6’), 33.0 (CH2), 29.9 (4CH2), 
29.8 (3CH2), 29.8 (3xCH2), 29.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 
29.4 (CH2), 27.1 (CH2), 26.1 (C(CH3)3), 26.0 (CH2), 25.9 (CH2), 18.5 (SiC
q
), –5.1 (Si(CH3)2); 
IR (thin film) ṽ=2925 (m), 2854 (m), 1727 (s), 1602 (m), 1586 (w), 1466 (m), 1451 (m), 1315 
(m), 1260 (s), 1177 (m), 1158 (m), 1093 (s), 1069 (s), 1027 (s), 1001 (m), 836 (m), 776 (m), 
707 (s), 686 (m) cm
-1
; 
HRMS (ESI) Calcd for C80H100O18SiNa [M+Na]
+
 1399.6571, found: 1399.6547. 
 
Benzyl [O-(2,3,4,5-tetra-O-benzoyl-β-D-galactopyranosyl)-(1-4)-2,3-di-O-benzoyl-1-O-
{(tbutyldimethylsilyloxy)-eicosyl}-β-D-glucopyrandoside] uronate (120)[257,258] 
 
 
 
 
  127                 120 
Scheme VI.48.  C-6 oxidation and protection procedure to yield the desired glucuronic acid 
diglycoside 120. X = perbonzoylated β-D-galactose. 
Alcohol 127 (37 mg, 0.027 mmol) was dissolved in 1 ml dry CH2Cl2. Pyridinium dichromate 
(PDC, 22 mg, 0.058 mmol) was added. Acetic anhydride (28 µl, 0.290 mmol) was added via 
syringe. The resulting suspension was stirred at RT for 6 h until tlc analysis showed complete 
conversion of the starting material to a lower running blurry spot. Benzyl alcohol (60 µl, 
0.581 mmol) was added dropwise. The benzyl protection was allowed to take place over 3 h. 
The reaction mixture was filtered over a small plug of silica gel. All volatiles were removed 
under reduced pressure. The crude desired diglycoside was purified by column 
chromatography (silica gel; 7.5% EtOAc in c-hexane) to yield 120 (28 mg, 71% over two 
steps) as a transparent oil. 
Rf=0.63 (EtOAc/c-hexane 1:3); 
[α]D
22
 = 8.0 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (500 MHz, CDCl3): δ=8.01-7.89 (m, 8H, H
ar
), 7.76-7.71 (m, 2H, H
ar
), 7.65-7.55 (m, 
2H, H
ar
), 7.50-7.28 (m, 19H, H
ar
), 7.25-7.20 (m, 2H, H
ar
), 7.18-7.13 (m, 2H, H
ar
), 5.74 (pd, 
3
J(H,H)=9.6 Hz, 1H, 3’-H), 5.71 (pd, 3J(H,H)=3.5 Hz, 1H, 4-H), 5.67 (dd, 3J(H,H)=10.3 Hz, 
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8.0 Hz, 1H, 2-H), 5.38 (dd, 
3
J(H,H)=9.6 Hz, 7.9 Hz, 1H, 2’-H), 5.36 (dd, 3J(H,H)=10.3 Hz, 
3.5 Hz, 1H, 3-H), 5.21 (d, 
2
J(H,H)=12.0 Hz, 1H, 6‘-OCHa), 5.13 (d, 2J(H,H)=12.0 Hz, 1H, 
6‘-OCHb), 4.73 (d, 3J(H,H)=8.0 Hz, 1H, 1-H), 4.60 (d, 3J(H,H)=7.9 Hz, 1H, 1‘-H), 4.13 (d, 
3
J(H,H)=10.6 Hz, 1H, 5’-H), 3.80 (dt, 3J(H,H)=6.4 Hz, 2J(H,H)=10.1 Hz, 1H, sugar-OCHa), 
3.76-3.69 (m, 2H, 5-H, 6-CH
a
), 3.66 (dd, 
3
J(H,H)=10.6 Hz, 9.2 Hz, 1H, 4’-H), 3.59 (t, 
3
J(H,H)=6.7 Hz, 2H, SiOCH2), 3.55 (dd, 
3
J(H,H)=6.7 Hz, 
2
J(H,H)=10.6 Hz, 1H, 6-CH
b
), 3.39 
(dt, 
3
J(H,H)=6.4 Hz, 
2
J(H,H)=10.1 Hz, 1H, sugar-OCH
b
), 1.52-1.41 (m, 4H, 2CH2), 
1.32-0.98 (m, 32H, 16CH2), 0.89 (s, 9H, C(CH3)3), 0.05 (s, 6H, Si(CH3)2); 
13
C NMR (100 MHz, CDCl3): δ=165.7 (COPh C-6), 165.6 (COPh C-2’), 165.5 (COPh C-3’), 
165.5 (COPh C-2), 165.4 (COPh C-4), 164.9 (COPh C-3), 154.8 (C-6’), 135.2 (Car), 133.7 
(CH
ar
), 133.6 (CH
ar
), 133.5 (CH
ar
), 133.4 (CH
ar
), 133.3 (CH
ar
), 133.2 (CH
ar
), 130.2 (2CHar), 
130.1 (C
ar
), 130.0 (2CHar), 129.9 (3xCHar), 129.9 (2CHar), 129.9 (3CHar), 129.8 (2xCHar), 
129.6 (C
ar
), 129.5 (C
ar
), 129.1 (C
ar
), 129.1 (C
ar
), 129.0 (CH
ar
), 128.9 (C
ar
), 128.9 (2xCH
ar
), 
128.9 (2xCH
ar
), 128.7 (3CHar), 128.7 (3CHar), 128.7 (CHar), 128.4 (CHar), 128.4 (2xCHar), 
101.2 (C-1), 101.1 (C-1’), 76.0 (C-5’), 73.0 (C-3’), 72.9 (C-4’), 71.9 (C-2’), 71.8 (C-3), 71.3 
(C-5), 70.4 (sugar-OCH2), 70.1 (BnCH2), 70.1 (C-2), 67.6 (C-4), 63.5 (SiOCH2), 61.0 (C-6), 
33.1 (CH2), 29.9 (2CH2), 29.9 (CH2), 29.9 (CH2), 29.8 (CH2), 29.8 (2xCH2), 29.8 (CH2), 
29.7 (CH2), 29.6 (2xCH2), 29.5 (CH2), 29.4 (CH2), 26.2 (C(CH3)3), 26.0 (CH2), 25.9 (CH2), 
18.6 (SiC
q
), –5.1 (Si(CH3)2); 
IR (thin film) ṽ=2925 (m), 2853 (m), 1730 (s), 1602 (m), 1586 (w), 1452 (m), 1315 (m), 1259 
(s), 1177 (m), 1092 (s), 1069 (s), 1026 (s), 807 (m), 755 (m), 707 (s) cm
-1
; 
HRMS (ESI) Calcd for C87H104O19SiNa [M+Na]
+
 1503.6833, found: 1503.6782. 
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VI.4. Virgineone 
 
VI.4.1. Synthesis of the C20-alkene (138) for Sharpless dihydroxylation 
 
10-(tButyldimethylsilyloxy)-1-decene (136) 
 
 
 
             135          136 
Scheme VI.49.  TBS protection of C10 building block. 
9-Decen-1-ol 135 (2.00 g, 12.80 mmol) was dissolved in 40 ml dry THF. TBSCl (2.18 mg, 
16.00 mmol) and imidazole (3.86 g, 25.60 mmol) were added in one portion. The resulting 
solution was stirred at RT for 16 h until all starting material was consumed. The reaction was 
stopped by addition of sat. NaHCO3 solution. The crude material was extracted three times 
using CH2Cl2. The combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by column chromatography 
(silica gel; 20% EtOAc in c-hexane) to yield 136 (3.5 g, quant.) as a transparent oil. 
Rf=0.89 (EtOAc/c-hexane 1:4); 
1
H NMR (300 MHz, CDCl3): δ=5.81 (ddt, 
3
J(H,H)=17.1 Hz, 10.2 Hz, 6.7 Hz, 1H, CH), 4,99 
(ddt, 
4
J(H,H)=2.2 Hz, 
3
J(H,H)=17.1 Hz, 
2
J(H,H)=1.4 Hz, 1H, 1-CH
a
), 4,93 (ddt, 
4
J(H,H)=2.3 Hz, 
3
J(H,H)=10.2 Hz, 
2
J(H,H)=1.4 Hz, 1H, 1-CH
b
), 3.60 (t, 
3
J(H,H)=6.6 Hz, 2H, 
SiOCH2), 2.08-2.00 (m, 2H, 3-CH2), 1.51 (pqui, 
3
J(H,H)=6.7 Hz, 2H, 9-CH2), 1.42-1.25 (m, 
10H, 5xCH2), 0.90 (s, 9H, C(CH3)3), 0.05 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=139.5 (CH), 114.4 (C-1), 63.6 (SiOCH2), 34.2 (C-3), 33.3 
(C-9), 29.9 (CH2), 29.8 (CH2), 29.5 (CH2), 29.3 (CH2), 26.3 (C(CH3)3), 26.2 (CH2), 18.7 
(SiC
q
), -4.9 (Si(CH3)2); 
IR (thin film) ṽ=2927 (w), 2856 (w), 1641 (m), 1472 (w), 1463 (m), 1388 (w), 1361 (m), 
1254 (s), 1097 (s), 1005 (m), 990 (m), 938 (w), 908 (w), 833 (m), 812 (m), 773 (m), 710 (m), 
661 (m) cm
-1
. 
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9-(tButyldimethylsilyloxy)-nonanal (134)
[266]
 
 
 
 
        136      134 
Scheme VI.50.  Ozonolysis of the TBS protected C10 building block 136. 
Alkene 136 (2.76 g, 11.65 mmol) was dissolved in 130 ml dry CH2Cl2. The solution was 
cooled to -78 °C. Ozon (6% v/v) was bubbled through the solution for 20 min until the 
solution turned dark blue. The solution and the gaseous phase above were washed with 
oxygen. PPh3 (7.64 g, 29.13 mmol) was added in one portion to stop the actual ozonolysis 
reductively and the mixture was allowed to heat up to RT. The resulting solution was stirred 
at RT for 2 h. 100 ml of water was added and the crude product was extracted three times 
using Et2O. The combined organic layers were dried over Na2SO4 and the solvent was 
removed under reduced pressure. The crude product was purified by flash chromatography 
(silica gel; 2.5% EtOAc in c-hexane) to yield 134 (2.56 g, 81% over two steps) as a 
transparent oil. 
Rf=0.49 (EtOAc/c-hexane 1:9); 
1
H NMR (300 MHz, CDCl3): δ=9.75 (t, 
3
J(H,H)=1.9 Hz, 1H, CHO), 3.59 (t, 
3
J(H,H)=6.4 Hz, 
2H, SiOCH2), 1.51 (dt, 
3
J(H,H)=7.4 Hz 1,9 Hz, 2H, 2-CH2), 1.62 (pqui, 
3
J(H,H)=7.4 Hz, 2H, 
3-CH2), 1.50 (pqui, 
3
J(H,H)=6.4 Hz, 2H, 8-CH2), 1.35-1.26 (m, 8H, 4xCH2), 0.89 (s, 9H, 
C(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=202.9 (CHO), 63.5 (SiOCH2), 44.1 (C-2), 33.1 (C-8), 29.6 
(CH2), 29.5 (CH2), 29.4 (CH2), 26.2 (C(CH3)3), 26.0 (CH2), 18.6 (SiC
q
), -5.0 (Si(CH3)2); 
IR (thin film) ṽ=2928 (w), 2855 (w), 1727 (s), 1462 (m), 1388 (w), 1360 (m), 1254 (s), 1094 
(s), 1005 (m), 990 (w), 938 (m), 832 (m), 812 (m), 774 (m), 661 (m) cm
-1
. 
 
20-(tButyldimethylsilyloxy)-12-hydroxy-1-icosene (137) 
 
 
 
    133      134         137 
Scheme VI.51.  Grignard reaction of the aldehyde 134 with 11-bromoundec-1-ene 133. 
Freshly roughened magnesium (271 mg, 11.17 mmol) and 11-bromoundec-1-ene 133 
(1.90 ml, 8.82 mmol) were transferred into a flask containing 25 ml dry THF. The resulting 
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mixture was heated to reflux for 1 h until the suspension turned dark grey and the magnesium 
was mostly dissolved. The Grignard reagent containing solution was cooled to RT and 
aldehyde 134 (1.60 g, 5.88 mmol) was added as a solution in 12 ml dry THF. The reaction 
mixture was heated up to 50 °C and stirred for additional 2 h. The reaction was stopped by 
addition of ice. The pH was adjusted to below 6 by the use of 1 M hydrochloric acid. The 
crude product of this Grignard reaction was extracted three times with ethyl acetate. The 
combined organic layers were washed with a sat. NaHCO3 solution, dried over Na2SO4 and 
all volatiles were removed under reduced pressure. The crude product was purified by flash 
chromatography (silica gel; 10% EtOAc in c-hexane) to yield 137 (2.05 g, 82% over two 
steps) as a transparent oil. 
Rf=0.24 (EtOAc/c-hexane 1:9); 
1
H NMR (300 MHz, CDCl3): δ=5.81 (ddt, 
3
J(H,H)=17.1 Hz, 10.2 Hz, 6.7 Hz, 1H, 2-CH), 
4,99 (ddt, 
4
J(H,H)=2.2 Hz, 
3
J(H,H)=17.1 Hz, 
2
J(H,H)=1.6 Hz, 1H, 1-CH
a
), 4,93 (ddt, 
4
J(H,H)=2.3 Hz, 
3
J(H,H)=10.2 Hz, 
2
J(H,H)=1.3 Hz, 1H, 1-CH
b
), 3.60 (t, 
3
J(H,H)=6.6 Hz, 2H, 
SiOCH2), 3.59 (m, 1H, HOCH), 2.08-1.99 (m, 2H, 3-CH2), 1.55-1.22 (m, 30H, 15xCH2), 0.89 
(s, 9H, C(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=139.5 (C-2), 114.4 (C-1), 72.3 (C-12), 63.6 (SiOCH2), 37.8 
(2xCH2), 34.1 (CH2), 33.2 (CH2), 30.0 (2xCH2), 29.9 (2xCH2), 29.8 (CH2), 29.7 (2xCH2), 
29.5 (CH2), 29.3 (CH2), 27.2 (CH2), 26.3 (C(CH3)3), 26.0 (2xCH2), 18.7 (SiC
q
), -4.9 
(Si(CH3)2); 
IR (thin film) ṽ=3362 (br), 2925 (m), 2854 (m), 1640 (m), 1463 (w), 1387 (w), 1360 (m), 
1254 (s), 1097 (s), 1004 (m), 993 (m), 908 (m), 834 (m), 812 (m), 774 (m), 741 (w), 661 (m) 
cm
-1
. 
 
20-(tButyldimethylsilyloxy)-12-(tetrahydropyran-2’-yloxy)-1-icosene (138) 
 
 
 
         137               138 
Scheme VI.52.  THP-protection of the C20 building block 137. 
Secondary alcohol 137 (2.05 g, 4.79 mmol) was dissolved in 100 ml CH2Cl2. Dihydropyrane 
(DHP, 2.02 ml, 23.97 mmol) and pyridinium ptoluenesulfonate (PPTS, 120 mg, 0.48 mmol) 
were added to the above solution. The resulting mixture was stirred at RT for 8 h. The 
reaction was stopped using sat. NaHCO3 solution and the crude product was extracted three 
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times with Et2O. The combined organic layers were dried over Na2SO4 and all volatiles were 
removed under reduced pressure. The crude product was purified by flash chromatography 
(silica gel; 2.5% EtOAc in c-hexane) to yield 138 (2.05 g, 82%) as a transparent oil. 
Rf=0.77 (EtOAc/c-hexane 1:19); 
1
H NMR (300 MHz, CDCl3): δ=5.81 (ddt, 
3
J(H,H)=17.1 Hz, 10.2 Hz, 6.8 Hz, 1H, 2-CH), 
4,99 (ddt, 
4
J(H,H)=1.8 Hz, 
3
J(H,H)=17.1 Hz, 
2
J(H,H)=1.5 Hz, 1H, 1-CH
a
), 4,92 (ddt, 
4
J(H,H)=2.3 Hz, 
3
J(H,H)=10.2 Hz, 
2
J(H,H)=1.5 Hz, 1H, 1-CH
b
), 4.64 (t, 
3
J(H,H)=3.6 Hz, 1H, 
THP-CH), 3.91 (dt, 
3
J(H,H)=4.9 Hz, 
2
J(H,H)=10.5 Hz, 1H, THP-6-CH
a
), 3.59 (t, 
3
J(H,H)=6.6 Hz, 2H, SiOCH2), 3.58 (m, 1H, THPOCH), 3.47 (dt, 
3
J(H,H)=6.3 Hz, 
2
J(H,H)=10.5 Hz, 1H, THP-6-CH
b
), 2.03 (pq, 
3
J(H,H)=6.8 Hz, 2H, 3-CH2), 1.89-1.66 (m, 2H, 
THP-2-CH2), 1.58-1.45 (m, 10H, THP-3-CH2, THP-4-CH2, 3xCH2), 1.39-1.22 (m, 24H, 
12xCH2), 0.89 (s, 9H, C(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=139.2 (C-2), 114.2 (C-1), 97.6 (THP-C-2), 76.9 (C-12), 63.5 
(SiOCH2), 62.8 (THP-C-6), 35.2 (CH2), 34.0 (CH2), 33.6 (CH2), 33.1 (CH2), 31.4 (THP-C-3), 
30.0 (CH2), 29.8 (2xCH2), 29.8 (CH2), 29.7 (CH2), 29.6 (CH2), 29.6 (CH2), 29.6 (CH2), 29.5 
(CH2), 29.3 (CH2), 29.1 (CH2), 26.1 (C(CH3)3), 26.0 (CH2), 25.8 (THP-C-5), 25.2 (CH2), 20.1 
(THP-C-4). 18.5 (SiC
q
), -5.1 (Si(CH3)2); 
IR (thin film) ṽ=2926 (m), 2854 (m), 1641 (m), 1463 (w), 1385 (w), 1360 (m), 1254 (s), 1200 
(s), 1097 (s), 1077 (s), 1004 (m), 907 (m), 868 (m), 835 (m), 813 (m), 773 (m), 721 (w), 661 
(m) cm
-1
. 
 
 
VI.4.2. Dihydroxylation and selective protection 
 
(2R)-20-(tButyldimethylsilyloxy)-12-(tetrahydropyran-2’-yloxy)icosane-1,2-diol (139)[271] 
 
 
 
        138                139 
Scheme VI.53.  Asymmetric Sharpless dihydroxylation of the C20 building block 138. 
The fully protected alkene 138 (770 mg, 1.51 mmol) was dissolved in 15 ml of a 1:1 mixture 
of tbutanol and water. The chiral ligand (DHQD)2PHAL (12 mg, 0.015 mmol), potassium 
ferricyanide(III) (1.49 g, 4.54 mmol), potassium carbonate (627 mg, 4.54 mmol) and 
potassium osmate dihydrate (0.030 mmol, 11 mg) were all added in one portion. The resulting 
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two phase system was stirred at 4 °C for four days. The reaction was stopped by addition of a 
1:1 mixture of sat. Na2SO3 and Na2S2O3 aqueous solution. Stirring was maintained for another 
hour before the crude material was extracted five times with ethyl acetate. The combined 
organic layers were washed with sat. NaCl solution, dried over Na2SO4 and all volatiles were 
removed under reduced pressure. The crude product was purified by flash chromatography 
(silica gel; 20% EtOAc in c-hexane) to yield 139 (760 mg, 92%) as a transparent oil. 
Rf=0.41 (EtOAc/c-hexane 1:1); 
[α]D
25
 = 1.2 (c = 1.0 g cm
-3
, chloroform); 
1
H NMR (300 MHz, CDCl3): δ=4.63 (t, 
3
J(H,H)=3.6 Hz, 1H, THP-CH), 3.89 (dt, 
3
J(H,H)=4.9 Hz, 
2
J(H,H)=10.5 Hz, 1H, THP-6-CH
a
), 3.73-3.63 (m, 2H, 1-CH
a
, 2-CH), 3.60 
(m, 1H, THPOCH), 3.58 (t, 
3
J(H,H)=6.6 Hz, 2H, SiOCH2), 3.48 (dt, 
3
J(H,H)=6.3 Hz, 
2
J(H,H)=10.5 Hz, 1H, THP-6-CH
b
), 3.40 (dd, 
3
J(H,H)=4.2 Hz, 
2
J(H,H)=9.9 Hz, 1H, 1-CH
b
), 
2.43 (s, 2H, 2xOH), 1.87-1.62 (m, 2H, THP-2-CH2), 1.59-1.36 (m, 14H, THP-3-CH2, 
THP-4-CH2, 5xCH2), 1.33-1.22 (m, 22H, 11xCH2), 0.89 (s, 9H, C(CH3)3), 0.03 (s, 6H, 
Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=97.6 (THP-C-2), 76.9 (C-12), 72.4 (C-2), 66.9 (C-1), 63.5 
(SiOCH2), 62.8 (THP-C-6), 35.2 (CH2), 33.6 (CH2), 33.3 (CH2), 33.0 (CH2), 31.3 (THP-C-3), 
30.0 (CH2), 29.8 (2xCH2), 29.7 (2xCH2), 29.6 (2xCH2), 29.6 (CH2), 29.5 (CH2), 26.1 
(C(CH3)3), 25.9 (CH2), 25.8 (THP-C-5), 25.7 (CH2), 25.1 (CH2), 20.1 (THP-C-4). 18.5 (SiC
q
), 
-5.1 (Si(CH3)2); 
IR (thin film) ṽ=3362 (br), 2926 (m), 2854 (m), 1463 (w), 1440 (m), 1385 (w), 1360 (m), 
1320 (w), 1254 (s), 1200 (s), 1183 (m), 1098 (s), 1076 (s), 1022 (m), 1004 (m), 937 (s), 907 
(m), 866 (m), 834 (m), 812 (m), 774 (m), 731 (w), 665 (m) cm
-1
. 
 
(2R)-20-(tbutyldimethylsilyloxy)-2-hydroxy-12-(tetrahydropyran-2’-yloxy)icoyl pivalate 
(140) 
 
 
 
             139           140 
Scheme VI.54.  Pivalate protection of the primary alcohol of diol 139. 
Diol 139 (760 mg, 1.395 mmol) was dissolved in 20 ml dry CH2Cl2. Pivaloyl chloride 
(180 µl, 1.464 mmol) and pyridine (282 µl, 3.487 mmol) were added. Stirring was maintained 
for 16 h. The starting material was completely consumed by that time. The reaction was 
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stopped by addition of sat. NH4Cl solution. The crude product was extracted three times using 
Et2O. The combined organic layers were washed with sat. CuSO4 solution, water and brine. 
The washed layers were dried over Na2SO4 and all violatiles were removed in vacuo. The 
crude product was purified by flash chromatography (silica gel; 20% EtOAc in c-hexane) to 
yield 140 (279 mg, 32%) as a transparent oil. 
Rf=0.85 (EtOAc/c-hexane 1:1); 
1
H NMR (300 MHz, CDCl3): δ=4.64 (t, 
3
J(H,H)=3.5 Hz, 1H, THP-CH), 4.12 (dd, 
3
J(H,H)=4.7 Hz, 
2
J(H,H)=11.4 Hz, 1H, 1-CH
a
), 3.97 (dd, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=11.4 Hz, 
1H, 1-CH
b
), 3.94-3.86 (m, 1H, 2-CH), 3.86-3.79 (m, 1H, THPOCH), 3.67 (dd, 
3
J(H,H)=6.7 Hz, 
2
J(H,H)=7.4 Hz, 1H, THP-6-CH
a
), 3.62-3.55 (m, 1H, 12-CH), 3.59 (t, 
3
J(H,H)=6.6 Hz, 2H, SiOCH2), 3.46 (dt, 
3
J(H,H)=4.5 Hz, 
2
J(H,H)=11.0 Hz, 1H, THP-6-CH
b
), 
1.87-1.62 (m, 4H, THP-3-CH2, THP-4-CH2), 1.59-1.28 (m, 10H, THP-5-CH2, 4xCH2), 
1.35-1.24 (m, 24H, 12xCH2), 1.22 (s, 9H, C(CH3)3), 0.89 (s, 9H, SiC(CH3)3), 0.04 (s, 6H, 
Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=177.9 (CO), 97.8 (THP-C-2), 76.9 (C-12), 73.3 (C-1), 72.3 
(C-2), 63.5 (SiOCH2), 62.8 (THP-C-6), 38.6 (tBuC
q
), 35.0 (CH2), 33.4 (CH2), 33.3 (CH2), 
33.0 (CH2), 31.4 (THP-C-3), 30.1 (CH2), 29.9 (2xCH2), 29.7 (2xCH2), 29.6 (2xCH2), 29.6 
(CH2), 29.5 (CH2), 27.1 (C(CH3)3) 26.1 (SiC(CH3)3), 25.9 (CH2), 25.8 (THP-C-5), 25.7 
(CH2), 25.1 (CH2), 20.1 (THP-C-4). 18.6 (SiC
q
), -5.1 (Si(CH3)2). 
 
(2R)-2-(benzyloxy)-20-(tbutyldimethylsilyloxy)-12-(tetrahydropyran-2’-yloxy)icoyl 
pivalate (141) 
 
 
 
       140                141 
Scheme VI.55.  Benzyl protection of the pivaloate protected alcohol 140. 
Pivalate ester 140 (96 mg, 0.153 mmol) was dissolved in 3 ml dry DMF. Benzyl bromide 
(27 µl, 0.229 mmol), sodium hydride (12 mg, 0.305 mmol, 60% in mineral oil) and a catalytic 
amount of tetra-nbutyl ammonium iodide (TBAI) were added. The resulting suspension was 
stirred for 2 h until tlc showed complete consumption of the starting material. The reaction 
was stopped with sat. NH4Cl solution. The crude product was extracted three times using 
ethyl acetate. The combined organic layers were washed with water and brine. The washed 
layers were dried over Na2SO4 and all violatiles were removed in vacuo. The crude product 
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was purified by flash chromatography (silica gel; 5% EtOAc in c-hexane) to yield 140 
(10 mg, 10%) as a transparent oil. 
Rf=0.79 (EtOAc/c-hexane 1:3); 
1
H NMR (300 MHz, CDCl3): δ=7.38-7.27 (m, 5H, Haromat.), 4.64 (t, 
3
J(H,H)=3.5 Hz, 1H, 
THP-CH), 4.56 (s, 2H, PhCH2), 4.13 (dt, 
3
J(H,H)=3.2 Hz, 
2
J(H,H)=11.4 Hz, 1H, 1-CH
a
), 3.97 
(dt, 
3
J(H,H)=7.0 Hz, 
2
J(H,H)=11.4 Hz, 1H, 1-CH
b
), 3.94-3.86 (m, 1H, 2-CH), 3.86-3.77 (m, 
1H, THP-6-CH
a
), 3.61-3.55 (m, 1H, 12-CH), 3.59 (t, 
3
J(H,H)=6.6 Hz, 2H, SiOCH2), 3.47 (dt, 
3
J(H,H)=4.5 Hz, 
2
J(H,H)=11.3 Hz, 1H, THP-6-CH
b
), 1.89-1.61 (m, 6H, THP-3-CH2, 
THP-4-CH2, CH2), 1.59-1.38 (m, 12H, THP-5-CH2, 5xCH2), 1.32-1.24 (m, 22H, 11xCH2), 
1.22 (s, 9H, C(CH3)3), 0.89 (s, 9H, SiC(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=177.9 (CO), 139.3 (C
ar
), 128.5 (CH
ar
), 128.4 (CH
ar
), 128.0 
(CH
ar
), 127.7 (CH
ar
), 127.5 (CH
ar
), 97.8 (THP-C-2), 76.9 (C-12), 76.1 (C-2), 75.6 (BnCH2), 
70.3 (C-1), 63.5 (SiOCH2), 62.8 (THP-C-6), 38.2 (tBuC
q
), 35.0 (CH2), 33.4 (CH2), 33.3 
(CH2), 33.0 (CH2), 31.4 (THP-C-3), 30.0 (CH2), 29.9 (2xCH2), 29.7 (2xCH2), 29.6 (2xCH2), 
29.5 (CH2), 29.4 (CH2), 27.0 (C(CH3)3) 26.1 (SiC(CH3)3), 25.8 (CH2), 25.8 (THP-C-5), 25.7 
(CH2), 25.1 (CH2), 20.1 (THP-C-4). 18.6 (SiC
q
), -5.1 (Si(CH3)2); 
IR (thin film) ṽ=2928 (m), 2854 (m), 1463 (w), 1385 (w), 1361 (m), 1284 (m), 1254 (s), 1201 
(s), 1161 (w), 1100 (s), 1078 (s), 1023 (m), 1004 (m), 836 (m), 775 (m), 699 (m), 665 
(w) cm
-1
. 
 
(2R)-2-(benzyloxy)-20-(tbutyldimethylsilyloxy)-12-(tetrahydropyran-2’-yloxy)icosan-1-ol 
(142) 
 
 
 
        140                142 
Scheme VI.56.  Benzyl protection of the alcohol 140 and direct hydrolysis of the pivaloate ester 141. 
Pivalate ester 140 (92 mg, 0.146 mmol) was dissolved in 3 ml dry DMF. Benzyl bromide 
(26 µl, 0.219 mmol), sodium hydride (18 mg, 0.439 mmol, 60% in mineral oil) and a catalytic 
amount of tetra-nbutyl ammonium iodide (TBAI) were added. The resulting suspension was 
stirred for 24 h until tlc showed complete consumption of the starting material. Hydrolysis of 
the fully protected intermediate 141 was started by addition of water (53µl, 2.925 mmol). This 
suspension was stirred for additional 12 h. The reaction was stopped with sat. NH4Cl solution. 
The crude product was extracted three times using ethyl acetate. The combined organic layers 
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were washed with water and brine. The washed layers were dried over Na2SO4 and all 
violatiles were removed in vacuo. The crude product was purified by flash chromatography 
(silica gel; 5% EtOAc in c-hexane) to yield 142 (12 mg, 13%) as a transparent oil. 
Rf=0.76 (EtOAc/c-hexane 1:1); 
1
H NMR (300 MHz, CDCl3): δ=7.39-7.27 (m, 5H, H
ar
), 4.64 (t, 
3
J(H,H)=3.5 Hz, 1H, 
THP-CH), 4.56 (s, 2H, PhCH2), 3.95-3.87 (m, 1H, 2-CH), 3.85-3.77 (m, 1H, THP-6-CH
a
), 
3.64-3.54 (m, 1H, 12-CH), 3.59 (t, 
3
J(H,H)=6.6 Hz, 2H, SiOCH2), 3.51 (dd, 
3
J(H,H)=3.0 Hz, 
2
J(H,H)=9.4 Hz, 1H, 1-CH
a
), 3.47 (dt, 
3
J(H,H)=4.5 Hz, 
2
J(H,H)=11.3 Hz, 1H, THP-6-CH
b
), 
3.32 (dd, 
3
J(H,H)=8.0 Hz, 
2
J(H,H)=9.4 Hz, 1H, 1-CH
b
), 1.88-1.65 (m, 4H, THP-3-CH2, 
THP-4-CH2), 1.59-1.38 (m, 12H, THP-5-CH2, 5xCH2), 1.35-1.19 (m, 24H, 21xCH2), 0.89 (s, 
9H, SiC(CH3)3), 0.04 (s, 6H, Si(CH3)2); 
13
C NMR (75 MHz, CDCl3): δ=138.2 (C
ar
), 128.6 (2xCH
ar
), 127.9 (CH
ar
), 127.9 (2xCH
ar
), 
97.6 (THP-C-2), 76.9 (C-12), 74.8 (PhCH2), 73.5 (C-1), 72.2 (C-2), 63.5 (SiOCH2), 62.8 
(THP-C-6), 37.7 (CH2), 35.2 (CH2), 33.3 (CH2), 33.0 (CH2), 31.4 (THP-C-3), 30.1 (CH2), 
29.8 (CH2), 29.8 (2xCH2), 29.7 (2xCH2), 29.6 (CH2), 29.5 (CH2), 26.2 (SiC(CH3)3), 26.0 
(CH2), 25.8 (CH2), 25.7 (THP-C-5), 25.7 (CH2), 25.2 (CH2), 20.1 (THP-C-4), 18.5 (SiC
q
), 
-5.1 (Si(CH3)2); 
IR (thin film) ṽ=3453 (br), 2925 (m), 2853 (m), 1463 (w), 1454 (m), 1385 (w), 1361 (m), 
1254 (s), 1200 (s), 1098 (s), 1077 (s), 1022 (m), 835 (m), 812 (w), 775 (m), 734 (w), 697 
(m) cm
-1
.
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VI.5. Aurantoside G and J 
 
VI.5.1. O-Glycosylation 
 
(5S,6S)-4-(3',4',6'-tri-O-benzyl-2-O-acetyl)-5-secbutyl-1,5-dihydro-2H-pyrrol-2-one-β-D-
glucopyranoside (157) 
 
 
 
 
 
       156        77          157 
Scheme VI.57.  Chemical 4-O-glycosylation of tetramic acid 156 derived from isoleucine with the 
Schmidt donor 77. 
Tetramic acid 156 (50 mg, 0.318 mmol) was dissolved in 6 ml dry DMF together with donor 
77 (223 mg, 0.349 mmol) and 250 mg 4 Å molecular sieves. The suspension was cooled to 
-45 °C. TMSOTf (5.7 µl, 0.032 mmol) was added via syringe. The resulting suspension was 
stirred for 1 h at -45 °C and the warmed up to -20 °C. Stirring was maintained for additional 
2 h until tlc analysis showed complete consumption of the donor. The reaction was stopped by 
the addition of NEt3 (22 µl, 0.159 mmol). The crude product was filtrated over celite and the 
filter was washed thouroughly with CH2Cl2. All volatiles of the combined organic fractions 
were removed under reduced pressure and the crude product was purified by flash 
chromatography (silica gel; 20% EtOAc in c-hexane) to yield 157 (84 mg, 42%) as a 
transparent oil. 
Rf=0.38 (EtOAc/c-hexane 1:1); 
1
H NMR (300 MHz, CDCl3): δ=7.36-7.23 (m, 13H, H
ar
), 7.22-7.17 (m, 2H, H
ar
), 6.51 (d, 
4
J(H,H)=4.9 Hz, 1H, NH), 5.20 (dd, 
3
J(H,H)=8.1 Hz, 3.2 Hz, 1H, H’-2), 5.19 (dd, 
4
J(H,H)=4.9 Hz, 3.3 Hz, 1H, 3-H), 4.89 (d, 
3
J(H,H)=8.1 Hz, 1H, 1’-H), 4.81 (d, 
2
J(H,H)=11.6 Hz, 1H, 4’O-CHa), 4.79 (d, 2J(H,H)=10.9 Hz, 1H, 6’O-CHa), 4.68 (d, 
2
J(H,H)=11.6 Hz, 1H, 4’O-CHb), 4.60 (d, 2J(H,H)=10.9 Hz, 1H, 6’O-CHb), 4.59 (d, 
2
J(H,H)=12.2 Hz, 1H, 3’O-CHa), 4.51 (d, 2J(H,H)=12.2 Hz, 1H, 3’O-CHb), 4.01 (dd, 
4
J(H,H)=3.3 Hz, 1H, 5-H), 3.83 (dd, 
3
J(H,H)=9.6 Hz, 5.4 Hz, 1H, 4’-H), 3.72 (m, 1H, 6’-H), 
3.71 (dd, 
3
J(H,H)=5.4 Hz, 3.2 Hz, 1H, H’-3), 3.56 (ddd, 3J(H,H)=9.6 Hz, 4.7 Hz, 3.0 Hz, 1H, 
H’-5), 1.95 (s, 3H, CH3CO), 1.88-1.73 (m, 1H, H-6), 1.41 (ddq, 
3
J(H,H)=7.4 Hz, 5.2 Hz, 
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4
J(H,H)=13.1 Hz, 1H, H-7
a
), 1.20 (ddq, 
3
J(H,H)=7.4 Hz, 5.9 Hz, 
4
J(H,H)=13.1 Hz, 1H, H-7
b
), 
0.95 (d, 
3
J(H,H)=6.9 Hz, 3H, H-9), 0.86 (t, 
3
J(H,H)=7.4 Hz, 3H, H-8); 
13
C NMR (75 MHz, CDCl3): δ=174.2 (C-2), 173.8 (C-4), 169.3 (CH3CO), 128.6 (3xCH
ar
), 
128.5 (2xCH
ar
), 128.1 (2xCH
ar
), 128.0 (CH
ar
), 127.9 (CH
ar
), 127.9 (2xCH
ar
), 127.8 (2xCH
ar
), 
127.8 (2xCH
ar
), 99.3 (C-3), 98.5 (C-1’), 82.5 (C-3’), 77.4 (C-4’), 76.0 (C-5’), 75.1 (6’-OCH2), 
75.0 (4’O-CH2), 73.4 (3’-OCH2), 72.2 (C-2’), 68.00 (C-6’), 62.3 (C-5), 36.4 (C-6), 23.2 (C-7), 
20.9 (CH3CO), 15.3 (C-9), 11.9 (C-8). 
 
VI.5.2. N-Glycosylation 
 
BF2-complex of (5S,6S)-N-(3',4',6'-tri-O-benzyl-2-O-acetyl)-5-secbutyl-3-(2’’E-
octenyl)pyrrolidine-2,4-dione-β-D-glucopyranoside (161) 
 
 
 
 
 
       160           161 
Scheme VI.58.  N-Glycosylation of 3-acyl tetramic acid BF2-complex 160. 
The known
[32,34,109]
 difluoroboryl complex 160 (55 mg, 0.169 mmol) and imidate 77 (118 mg, 
0.185 mmol) were dissolved in 3.5 ml dry CH2Cl2 containing 150 mg 4 Å molecular sieves. 
The resulting mixture was cooled to -40 °C. BF3•OEt2 (3 µl, 0.025 mmol) was added via 
syringe. The reaction was stirred for 2 h maintaining -40 °C. Tlc analysis showed complete 
consumption of the donor by that time. All volatiles were removed under reduced pressure 
and the crude product was purified by flash chromatography (silica gel; 20% EtOAc in 
c-hexane) to yield 161 (11 mg, 8%) as a slightly yellow oil. 
Rf=0.23 (EtOAc/c-hexane 1:4); 
1
H NMR (300 MHz, CDCl3): δ=7.54 (dt, 
4
J(H,H)=15.5 Hz, 
3
J(H,H)=7.1 Hz, 1H, 11-H), 
7.37-7.25 (m, 13H, H
ar
), 7.19-7.13 (m, 2H, H
ar
), 7.05 (dt, 
3
J(H,H)=7.1 Hz, 6.7 Hz, 1H, 12-H), 
6.35 (d, 
3
J(H,H)=3.6 Hz, 1H, 1’-H), 4.99 (dd, 3J(H,H)=9.5 Hz, 1.6 Hz, 1H, 3’-H), 4.85-4.48 
(m, 6H, 3xOCH2Ph), 4.02 (d, 
3
J(H,H)=3.1 Hz, 1H, 5-H), 3.81 (dd, 
3
J(H,H)=9.6 Hz, 3.6, 1H, 
2’-H), 3.77-3.72 (m, 1H, 5’-H), 3.65-3.59 (m, 1H, 4’-H), 3.42 (dd, 3J(H,H)=3.7 Hz, 1.9 Hz, 
2
J(H,H)=9.7 Hz, 1H, 6’-CHa), 3.39 (dd, 3J(H,H)=3.6 Hz, 1.9 Hz, 2J(H,H)=9.7 Hz, 1H, 
6’-CHb), 2.36 (ddt, 4J(H,H)=15.5 Hz, 3J(H,H)=7.2 Hz, 6.7 Hz, 1H, 13-H), 2.03 (s, 3H, 
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CH3CO), 2.01 (m, 1H, 6-H), 1.51 (pt, 
3
J(H,H)=7.2 Hz, 1H, 14-H), 1.36-1.27 (m, 4H, 15-H, 
16-H), 1.03 (d, 
3
J(H,H)=7.0 Hz, 2H, 7-H), 0.90-0.85 (m, 6H, 8-H, 17-H), 0.82 (d, 
3
J(H,H)=6.8 Hz, 3H, 9-H); 
13
C NMR (75 MHz, CDCl3): δ=190.7 (C-4), 174.2 (C-10), 171.2 (CO), 169.0 (C-2), 156.8 
(C-11), 137.8 (3xC
ar
), 128.6 (CH
ar
), 128.6 (4xCH2), 128.1 (2xCH
ar
), 128.1 (2xCH
ar
), 128.0 
(CH
ar
), 128.0 (2xCH
ar
), 127.9 (CH
ar
), 127.8 (CH
ar
), 127.8 (CH
ar
), 121.1 (C-12), 110.2 (C-3), 
91.2 (C-1’), 82.7 (C-4’), 78.8 (C-2’), 74.9 (C-5’, OCH2), 73.4 (OCH2), 73.0 (CH2), 72.8 
(C-3’), 72.2 (C-6’), 67.8 (C-5), 35.4 (C-6), 33.5 (C-13), 31.5 (CH2), 27.5 (C-14), 22.2 (CH2), 
20.7 (CH3CO), 15.4 (C-7), 14.0 (C-17), 12.8 (C-9), 11.8 (C-8); 
11
B NMR (75 MHz, CDCl3): δ=-2.47. 
 
N-Nosyl-N-(2’,3',4',6'-tetra-O-acetyl)-L-alanine methyl ester D-glucopyranoside (163) 
 
 
 
 
  154          162        163 
Scheme VI.59.  N-Glycosylation via Fukayama-Mitsunobu reaction of acetylated galactose
[288,293]
 162 
and N-nosyl protected L-alanine
[290,292]
 154. 
Peracetylated anomeric free galactose
[288,293]
 162 (90 mg, 0.336 mmol), nosyl protected 
alanine methyl ester
[290,292]
 154 (59 mg, 0.158 mmol) and PPh3 (88 mg, 0.336 mmol) were 
dissolved in 3.5 ml dry THF. The resulting mixture was cooled to -78 °C. Diisopropyl 
azodicarboxylate (66 µl, 0.336 mmol) was added via syringe. The reaction was stirred for 1 h 
maintaining -78 °C and then allowed to react over 8 h at RT. All volatiles were removed 
under reduced pressure and the crude product was purified by flash chromatography (silica 
gel; 30% EtOAc in c-hexane) to yield 163 (92 mg, 94%) as a white solid. 
Rf=0.04 (EtOAc/c-hexane 1:2); 
1
H NMR (300 MHz, CDCl3): δ=8.21-8.13 (m, 2H, H
ar
), 7.76-7.59 (m, 6H, H
ar
), 5.39 (d, 
3
J(H,H)=3.3 Hz, 1H, 1’-Hα), 5.36 (d, 3J(H,H)=8.0 Hz, 1H, 1’-Hβ), 5.29 (dd, 3J(H,H)=9.4 Hz, 
4.9 Hz, 2H, 3’-H), 5.16 (m, 2H, 5’-H), 5.05 (ddd, 3J(H,H)=9.4 Hz, 8.0 Hz 3.2 Hz, 2H, 2’-H), 
4.52 (q, 
3
J(H,H)=7.4 Hz, 1H, 1-H
α
), 4.29 (q, 
3
J(H,H)=7.4 Hz, 1H, 1-H
β
), 4.04 (m, 6H, 4’-H, 
6’-H), 3.59 (s, 3H, OCH3
α
), 3.48 (s, 3H, OCH3
β
), 2.00 (s, 6H, CH3CO), 1.97 (s, 6H, CH3CO), 
1.94 (s, 6H, CH3CO), 1.92 (s, 6H, CH3CO), 1.59 (d, 
3
J(H,H)=7.4 Hz, 3H, 4-H
α
), 1.59 (d, 
3
J(H,H)=7.4 Hz, 3H, 4-H
β
). 
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N-Nosyl-N-(2’,3',4'-tri-O-acetyl)-L-alanine methyl ester β-D-xylopyranose (165) 
 
 
 
 
      154            164            165 
Scheme VI.60.  N-Glycosylation via Fukayama-Mitsunobu reaction of acetylated xylose
[294]
 164 and 
N-nosyl protected L-alanine
[290,292]
 154. 
Peracetylated anomeric free xylose
[294]
 164 (488 mg, 1.767 mmol), nosyl protected alanine 
methyl ester
[290,292]
 154 (239 mg, 0.829 mmol) and PPh3 (463 mg, 1.767 mmol) were 
dissolved in 20 ml dry THF. The resulting mixture was cooled to -78 °C. Diisopropyl 
azodicarboxylate (350 µl, 1.767 mmol) was added via syringe. The reaction was stirred for 
1 h maintaining -78 °C and then allowed to react over 8 h at RT. All volatiles were removed 
under reduced pressure and the crude product was purified by flash chromatography (silica 
gel; 25% EtOAc in c-hexane) to yield 165 (223 mg, 50%) as a white solid. 
Rf=0.26 (EtOAc/c-hexane 1:1); 
Only the major β-anomer is described below: 
1
H NMR (300 MHz, CDCl3): δ=8.06-8.00 (m, 1H, H
ar
), 7.66-7.49 (m, 3H, H
ar
), 5.16 (dd, 
3
J(H,H)=9.3 Hz, 9.2 Hz, 1H, 2’-H), 5.09 (pt, 3J(H,H)=9.2 Hz, 1H, 3’-H), 4.96 (d, 
3
J(H,H)=9.3 Hz, 1H, 1’-H), 4.87 (ddd, 3J(H,H)=10.4 Hz, 5.8 Hz, 1.3 Hz, 1H, 4’-H), 4.41 (q, 
3
J(H,H)=7.4 Hz, 1H, 1-H), 3.98 (dd, 
3
J(H,H)=11.1 Hz, 5.8 Hz, 1H, 5’-CHa), 3.38 (s, 3H, 
OCH3), 3.27 (dd, 
3
J(H,H)=11.1 Hz, 1.3 Hz, 1H, 5’-CHb), 1.89 (s, 3H, CH3CO), 1.87 (s, 3H, 
CH3CO), 1.76 (s, 3H, CH3CO), 1.45 (d, 
3
J(H,H)=7.4 Hz, 3H, 4-H); 
13
C NMR (75 MHz, CDCl3): δ=170.6 (CO), 169.6 (CO), 169.1 (CO), 148.4 (C
ar
NO2), 134.0 
(CH), 133.1 (C
ar
), 131.5 (CH
ar
), 131.1 (CH
ar
), 123.8 (CH
ar
), 85.5 (C-1’), 73.4 (C-3’), 69.1 
(C-2’), 68.2 (C-4’), 64.8 (C-5’), 54.4 (C-1), 52.2 (OCH3), 20.3 (2xCH3CO), 20.3 (CH3CO), 
17.8 (C-4); 
IR (thin film) ṽ=1740 (s), 1546 (s), 1439 (w), 1365 (s), 1246 (s), 1215 (s), 1169 (s), 1085 (s), 
1036 (s), 989 (m), 940 (m), 909 (w), 853 (m), 770 (m), 742 (m), 729 (m), 689 (w), 655 (m) 
cm
-1
.
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VI.6. Tetramic acid boron complexes 
 
Diethylboron complex of (5S)-3-((2′E)-1′-hydroxy-2′-methylocten-1′-ylidene)-1,5-
dimethylpyrrolidine-2,4-dione (167) 
 
 
 
 
 
            97                167 
Scheme VI.61.  Diethylboron complex formation of 97 by a known
[32]
 method using BEt2F•pyridine
[296]
 
to get 167. 
The 3-acyl tetramic acid used for auxiliary synthesis 97 (37 mg, 0.139 mmol) was dissolved 
in 2.8 ml dry CH2Cl2. Analogously to the normal
[32]
 BF2 complex formation, BEt2F•pyridine 
from Wrackmeyer et al.
[296]
 (117 mg, 0.697 mmol) was added at RT. The resulting mixture 
was stirred for at least 12 h. All volatiles were removed under reduced pressure. The crude 
material was purified utilizing column chromatography (silica gel; 15% EtOAc in c-hexane) 
to yield 167 (30 mg, 65%) as a slightly red oil. 
Rf=0.63 (EtOAc/c-hexane 1:2); 
[α]D
24
 = 25.5 (c=1.0, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ=7.30 (tq, 
4
J(H,H)=1.3 Hz, 
3
J(H,H)=7.3 Hz, 1H, 8-H), 3.74 (q, 
3
J(H,H)=7.0 Hz, 1H, 5-H), 3.06 (s, 3H, NCH3), 2.29 (dq, 
3
J(H,H)=7.3 Hz, 1.3 Hz, 2H, 9-H), 
1.85 (d, 
4
J(H,H)=1.3 Hz, 3H, 7-CH3), 1.52 (m, 2H, CH2), 1.40 (d, 
3
J(H,H)=7.0, 3H, 5-CH3), 
1.33 (m, 4H, 2×CH2), 0.89 (m, 3H, CH3), 0.74 (t, 
3
J(H,H)=7.8 Hz, 6H, BCH2CH3), 0.40 (q, 
3
J(H,H)=7.8 Hz, 4H, BCH2); 
IR (thin film) ṽ=2954 (w), 2930 (m), 2860 (w), 1710 (m), 1651 (s), 1611 (s), 1488 (m), 1451 
(m), 1396 (w), 1381 (w), 1342 (w), 1312 (w), 1264 (w), 1228 (m), 1092 (m), 927 (s), 798 
(w) cm
-1
. 
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Diethylboron complex of (5S)-3-(-1′-hydroxymethyloctan-1′-ylidene)-1,5-
dimethylpyrrolidine-2,4-dione (168) 
 
 
 
 
     167           168 
Scheme VI.62.  Hydrogenation of the diethylboron complex 168. 
The diethylboron complex of 97 (30 mg, 0.090 mmol) was dissolved in 1 ml dry CH2Cl2. A 
catalytic amount of palladium on charcoal was added. Hydrogenation was carried at RT using 
H2 gas at standard pressure of 1 bar for 4 h. The catalyst was filtered off and the filter was 
washed thouroughly with CH2Cl2. The solvent was removed under reduced pressure. The 
crude material was purified utilizing column chromatography (silica gel; 15% EtOAc in 
c-hexane) to yield 167 (10 mg, 34%) as a slightly red oil. 
Rf=0.64 (EtOAc/c-hexane 1:2); 
[α]D
24
 = 37.2 (c=1.0, CHCl3); 
1
H NMR (300 MHz, CDCl3): δ=3.74 (q, 
3
J(H,H)=7.1 Hz, 1H; 7-H), 3.50 (q, 
3
J(H,H)=7.2 Hz, 
1H; 5-H), 3.04 (s, 3H; NCH3), 1.67 (m, 2H, CH2), 1.40 (d, 
3
J(H,H)=7.1 Hz, 3H; 7-CH3), 
1.31-1.20 (m, 8H; 4×CH2), 1.13 (d, 
3
J(H,H)=7.2 Hz, 3H; 5-CH3), 0.86 (m, 3H; CH3), 0.73 (t, 
3
J(H,H)=7.8 Hz, 6H, BCH2CH3), 0.39 (q, 
3
J(H,H)=7.8 Hz, 4H, BCH2); 
13
C NMR (75 MHz, CDCl3): δ=192.1 (C-4), 189.9 (C-6), 170.6 (C-2), 98.0 (C-3), 65.0 (C-5), 
37.5 (NMe), 33.6 (C-8), 31.7 (C-11), 29.2 (C-9), 28.1 (C-7), 27.2 (C-10), 22.7 (C-12), 16.8 
(5-CH3), 14.2 (7-CH3), 14.4 (2xBCH2), 14.2 (CH3), 7.6 (2xBCH2CH3); 
IR (thin film) ṽ=2947 (w), 2930 (m), 2869 (w), 1706 (m), 1629 (s), 1533 (s), 1459 (m), 1410 
(w), 1372 (w), 1356 (w), 1298 (w), 1273 (w), 1239 (w), 1094 (w), 1060 (m), 938 (m), 866 
(m), 795 (w) cm
-1
. 
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VII. ABBREVIATIONS 
 
Ac2O      acetic anhydride 
AIP      autoinducer peptide 
approx.     approximately 
ar      aromatic 
ATP      adenosine triphosphate 
BAIB      (diacetoxyiodo)benzene 
Bn      benzyl 
BnBr      benzyl bromide 
BnOH      benzyl 
BOC      tbutoxycarbonyl 
br      IR: broad 
Bz      benzoyl 
BzCl      benzoyl chloride 
CAN      cer ammonium molybdate 
cat.      catalytic 
CCO      ketenylidentriphenylphosphorane 
d      days 
d      NMR: doublet 
DBU      1,8-diazabicyclo[5.4.0]undec-7-en 
DCC      N,N’-dicyclohexylcarbodiimide 
DDQ      2,3-dichloro-5,6-dicyano-1,4-benzoquinone 
DHP      dihydropyran 
DIAD      diisopropyl azodicarboxylate 
DIBAL     diisopropylaluminium hydride, DIBAL-H 
DMAP     4-dimethylaminopyridin 
DMF      dimethyl formamide 
DMP      Dess-Martin periodinane 
DMSO     dimethyl sulfoxide 
EDCI      1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA      ethylenediaminetetraacetic acid 
e.g.      example given 
epox.      epoxidation 
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equiv      equivalence 
ESA      european space agency 
et al.      et alii/et aliae, and others 
g      grams 
glcos.      glycosylation 
h      hours 
HMDS     hexamethyldisilazane 
HPLC      high pressure liquid chromatography 
HWE      Horner-Wadsworth-Emmons (reaction) 
LDA      lithium diisopropyl amide 
M      molar 
m      IR: medium 
m      NMR: multiplet 
Mal-CoA     malonyl coenzyme A 
MeMal-CoA     methylmalonyl coenzyme A 
Min      minutes 
MS      mass spectrometer 
MMP      matrix metalloproteinases 
NADH     nicotinamide adenine dinucleotide 
NMDA     N-methyl-D-aspartic acid 
NTP      nucleotide triphosphate 
p      NMR: pseudo 
PDC      pyridinium dichromate 
PMB      p-methoxybenzyl 
PPTS      pyridinium ptoluenesulfonate 
pyr      pyridine 
q      NMR: quartet 
Q-TOF     quadrupole time of flight 
quant.      quantitative 
qui      NMR: quintet 
RT      room temperature 
s      IR: strong 
s      NMR: singulet 
SAR      structure-activity relationship 
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t      time 
t      NMR: triplet 
TBAI      tetra-nbutylammonium iodide 
TBSCl      tbutyldimethylsilyl chloride 
TEMPO     (2,2,6,6-teramethylpiperidin-1-yl)oxyl 
TFA      trifluoroacetic acid 
TfOH      trifluoromethanesulfonic acid 
THF      tetrahydrofuran 
THP      tetrahydropyran 
TIPSCl     tri-isopropylsilyl chloride 
TMSCl     trimethylsilyl chloride 
TMSE      trimethylsilylethane 
TrtCl      triphenylmethyl chloride, trityl chloride 
TLC      thin layer chromatography 
p-TsOH     ptoluenesulfonic acid 
UDP      uridine diphosphate 
UPLC      ultra high pressure liquid chromatography 
UTP      uridine triphosphate 
v/v      volume by volume 
vs.      versus 
w      IR: weak 
w/v      weight per volume 
wt%      weight percent 
LITERATURE 
152 
 
VIII. LITERATURE 
[1] K. E. Jones, N. G. Patel, M. A. Levy, A. Storeygard, D. Balk, J. L. Gittleman, P. Daszak, 
Nature 2008, 451, 990–993. 
[2] H. Nikaido, Annu. Rev. Biochem. 2009, 78, 119–146. 
[3] C. A. Arias, B. E. Murray, Nat. Rev. Microbiol. 2012, 10, 266–278. 
[4] M. Ahmed, in Antibiot. Resist. Bact. - Contin. Chall. New Millenn. (Ed.: M. Pana), 
InTech, 2012. 
[5] A. J. Hamilton, R. M. May, E. K. Waters, Nature 2015, 520, 42–43. 
[6] World Health Organization, D. L. Heymann, T. Prentice, L. T. Reinders, The World 
Health Report 2007 a Safer Future: Global Public Health Security in the 21st Century, 
World Health Organization, Geneva, 2007. 
[7] C. W. Murray, D. C. Rees, Nat. Chem. 2009, 1, 187–192. 
[8] D. E. Scott, A. G. Coyne, S. A. Hudson, C. Abell, Biochemistry (Mosc.) 2012, 51, 4990–
5003. 
[9] H. M. Geysen, F. Schoenen, D. Wagner, R. Wagner, Nat. Rev. Drug Discov. 2003, 2, 
222–230. 
[10] H. Li, V. Kasam, C. S. Tautermann, D. Seeliger, N. Vaidehi, J. Chem. Inf. Model. 2014, 
54, 1391–1400. 
[11] F. E. Koehn, G. T. Carter, Nat. Rev. Drug Discov. 2005, 4, 206–220. 
[12] A. L. Harvey, R. Edrada-Ebel, R. J. Quinn, Nat. Rev. Drug Discov. 2015, 14, 111–129. 
[13] J. Krysiak, R. Breinbauer, in Act.-Based Protein Profiling (Ed.: S.A. Sieber), Springer 
Berlin Heidelberg, Berlin, Heidelberg, 2011, pp. 43–84. 
[14] J. R. Hanson, in Nat. Prod., Royal Society Of Chemistry, Cambridge, 2003, pp. 1–34. 
[15] B. J. L. Royles, Chem. Rev. 1995, 95, 1981–2001. 
[16] J. L. Svirbely, A. Szent-Györgyi, Biochem. J. 1932, 26, 865–870. 
[17] A. Szent-Györgyi, W. N. Haworth, Nature 1933, 131, 24–24. 
[18] R. Schobert, A. Schlenk, Bioorg. Med. Chem. 2008, 16, 4203–4221. 
[19] G. Athanasellis, O. Igglessi-Markopoulou, J. Markopoulos, Bioinorg. Chem. Appl. 2010, 
2010, 1–11. 
[20] X. Mo, Q. Li, J. Ju, RSC Adv 2014, 4, 50566–50593. 
[21] T. Rosett, R. H. Sankhala, C. E. Stickings, M. E. U. Taylor, R. Thomas, Biochem. J. 
1957, 67, 390–400. 
[22] C. E. Stickings, Biochem. J. 1958, 72, 332–340. 
[23] E. Benary, Berichte Dtsch. Chem. Ges. 1911, 44, 1759–1765. 
[24] S. Aoki, K. Higuchi, Y. Ye, R. Satari, M. Kobayashi, Tetrahedron 2000, 56, 1833–1836. 
[25] C.-Y. Wang, B.-G. Wang, S. Wiryowidagdo, V. Wray, R. van Soest, K. G. Steube, H.-S. 
Guan, P. Proksch, R. Ebel, J. Nat. Prod. 2003, 66, 51–56. 
[26] B. Biersack, R. Diestel, C. Jagusch, G. Rapp, F. Sasse, R. Schobert, Chem. Biodivers. 
2008, 5, 2423–2430. 
[27] Z.-J. Lin, Z.-Y. Lu, T.-J. Zhu, Y.-C. Fang, Q.-Q. Gu, W.-M. Zhu, Chem. Pharm. Bull. 
(Tokyo) 2008, 56, 217–221. 
[28] H. V. K. Wangun, H.-M. Dahse, C. Hertweck, J. Nat. Prod. 2007, 70, 1800–1803. 
[29] A. D. Wright, C. Osterhage, G. M. König, Org. Biomol. Chem. 2003, 1, 507–510. 
[30] R. Schobert, C. Jagusch, Tetrahedron 2005, 61, 2301–2307. 
[31] T. Sengoku, J. Wierzejska, M. Takahashi, H. Yoda, Synlett 2010, 2010, 2944–2946. 
[32] S. Loscher, R. Schobert, Chem. - Eur. J. 2013, 19, 10619–10624. 
[33] A. P. Michael, E. J. Grace, M. Kotiw, R. A. Barrow, J. Nat. Prod. 2002, 65, 1360–1362. 
[34] A. Schlenk, R. Diestel, F. Sasse, R. Schobert, Chem. - Eur. J. 2010, 16, 2599–2604. 
[35] I. Casser, B. Steffan, W. Steglich, Angew. Chem. Int. Ed. Engl. 1987, 26, 586–587. 
[36] A. R. Healy, F. Vinale, M. Lorito, N. J. Westwood, Org. Lett. 2015, 17, 692–695. 
LITERATURE 
153 
 
[37] A. R. Healy, M. Izumikawa, A. M. Z. Slawin, K. Shin-ya, N. J. Westwood, Angew. 
Chem. Int. Ed. 2015, 54, 4046–4050. 
[38] K. L. Rinehart, J. R. Beck, D. B. Borders, W. W. Epstein, T. H. Kinstle, L. D. Spicer, D. 
Krauss, A. C. Button, Antimicrob. Agents Chemother. 1963, 161, 346–348. 
[39] A. S. Ratnayake, R. A. Davis, M. K. Harper, C. A. Veltri, C. D. Andjelic, L. R. Barrows, 
C. M. Ireland, J. Nat. Prod. 2005, 68, 104–107. 
[40] W. R. McClure, J. Biol. Chem. 1980, 255, 1610–1616. 
[41] H. Chen, P. H. M. Harrison, Org. Lett. 2004, 6, 4033–4036. 
[42] H. Chen, S. G. Olesen, Harrison, Org. Lett. 2006, 8, 5329–5332. 
[43] S. V. Pronin, S. A. Kozmin, J. Am. Chem. Soc. 2010, 132, 14394–14396. 
[44] S. Matsunaga, N. Fusetani, Y. Kato, H. Hirota, J. Am. Chem. Soc. 1991, 113, 9690–
9692. 
[45] D. Wolf, F. J. Schmitz, F. Qiu, M. Kelly-Borges, J. Nat. Prod. 1999, 62, 170–172. 
[46] N. U. Sata, S. Matsunaga, N. Fusetani, R. W. M. van Soest, J. Nat. Prod. 1999, 62, 969–
971. 
[47] R. F. Angawi, G. Bavestrello, B. Calcinai, H. A. Dien, G. Donnarumma, M. A. Tufano, 
I. Paoletti, E. Grimaldi, G. Chianese, E. Fattorusso, et al., Mar. Drugs 2011, 9, 2809–
2817. 
[48] R. Kumar, R. Subramani, K.-D. Feussner, W. Aalbersberg, Mar. Drugs 2012, 10, 200–
208. 
[49] M. Petermichl, Neue Wege zu N-glykosylierten 3-Acyltetramsäuren, MSc - Thesis, 
University of Bayreuth, 2015. 
[50] S. B. Singh, D. L. Zink, B. Heimbach, O. Genilloud, A. Teran, K. C. Silverman, R. B. 
Lingham, P. Felock, D. J. Hazuda, Org. Lett. 2002, 4, 1123–1126. 
[51] M. H. Wheeler, R. D. Stipanovic, L. S. Puckhaber, Mycol. Res. 1999, 103, 967–973. 
[52] K. Herath, H. Jayasuriya, D. L. Zink, J. Sigmund, F. Vicente, M. de la Cruz, A. Basilio, 
G. F. Bills, J. D. Polishook, R. Donald, et al., J. Nat. Prod. 2012, 75, 420–424. 
[53] E. Turos, J. E. Audia, S. J. Danishefsky, J. Am. Chem. Soc. 1989, 111, 8231–8236. 
[54] K. Yuki, M. Shindo, K. Shishido, Tetrahedron Lett. 2001, 42, 2517–2519. 
[55] L. T. Burke, D. J. Dixon, S. V. Ley, F. Rodríguez, Org. Lett. 2000, 2, 3611–3613. 
[56] L. T. Burke, D. J. Dixon, S. V. Ley, F. Rodríguez, Org. Biomol. Chem. 2005, 3, 274–
280. 
[57] J. Yin, L. Kong, C. Wang, Y. Shi, S. Cai, S. Gao, Chem. - Eur. J. 2013, 19, 13040–
13046. 
[58] L. Wang, P. E. Floreancig, Org. Lett. 2004, 6, 569–572. 
[59] H. Sun, J. R. Abbott, W. R. Roush, Org. Lett. 2011, 13, 2734–2737. 
[60] H. Sikorska, J. Cianciara, A. Wiercińska-Drapało, Pol. Merkur. Lek. Organ Pol. Tow. 
Lek. 2010, 28, 490–495. 
[61] P. R. Graupner, A. Carr, E. Clancy, J. Gilbert, K. L. Bailey, J.-A. Derby, B. C. Gerwick, 
J. Nat. Prod. 2003, 66, 1558–1561. 
[62] S. Kanazawa, N. Fusetani, S. Matsunaga, Int. J. Rapid Publ. Prelim. 1993, 34, 1065–
1068. 
[63] S. P. Gunasekera, M. Gunasekera, P. McCarthy, J. Org. Chem. 1991, 56, 4830–4833. 
[64] T. Yoshinari, K. Ohmori, M. G. Schrems, A. Pfaltz, K. Suzuki, Angew. Chem. Int. Ed. 
2010, 49, 881–885. 
[65] R. K. Boeckman Jr., T. M. Kamenecka, S. G. Nelson, J. R. Pruitt, T. E. Barta, 
Tetrahedron Lett. 1991, 32, 2581–2584. 
[66] N. Cramer, S. Laschat, A. Baro, H. Schwalbe, C. Richter, Angew. Chem. 2005, 117, 
831–833. 
[67] J. H. Cardellina, F. J. Marner, R. E. Moore, J. Am. Chem. Soc. 1979, 101, 240–242. 
LITERATURE 
154 
 
[68] G. Höfle, K. Gerth, H. Reichenbach, B. Kunze, F. Sasse, E. Forche, E. V. Prusov, Chem. 
- Eur. J. 2012, 18, 11362–11370. 
[69] J. Wenke, H. Anke, O. Sterner, Biosci. Biotechnol. Biochem. 1993, 57, 961–964. 
[70] C. W. Holzapfel, Tetrahedron 1968, 24, 2101–2119. 
[71] Y. Hayakawa, N. Kanamaru, N. Morisaki, H. Seto, K. Furihata, Tetrahedron Lett. 1991, 
32, 213–216. 
[72] G. R. Pettit, Y. Kamano, C. Dufresne, R. L. Cerny, C. L. Herald, J. M. Schmidt, J. Org. 
Chem. 1989, 54, 6005–6006. 
[73] J. Wang, M. R. Prinsep, D. P. Gordon, M. J. Page, B. R. Copp, J. Nat. Prod. 2015, 78, 
530–533. 
[74] H. Luesch, W. Y. Yoshida, R. E. Moore, V. J. Paul, J. Nat. Prod. 1999, 62, 1702–1706. 
[75] G. Wu, X. Sun, G. Yu, W. Wang, T. Zhu, Q. Gu, D. Li, J. Nat. Prod. 2014, 77, 270–275. 
[76] A. Höltzel, M. G. Gänzle, G. J. Nicholson, W. P. Hammes, G. Jung, Angew. Chem. Int. 
Ed. 2000, 39, 2766–2768. 
[77] R. Böhme, G. Jung, E. Breitmaier, Helv. Chim. Acta 2005, 88, 2837–2841. 
[78] P. T. Cherian, X. Wu, M. M. Maddox, A. P. Singh, R. E. Lee, J. G. Hurdle, Sci. Rep. 
2014, 4, DOI 10.1038/srep04721. 
[79] Y.-C. Jeong, Z. Bikadi, E. Hazai, M. G. Moloney, ChemMedChem 2014, 1826–1837. 
[80] A. J. Brosnahan, J. A. Merriman, W. Salgado-Pabón, B. Ford, P. M. Schlievert, PLoS 
ONE 2013, 8, e61255. 
[81] E. J. Murray, R. C. Crowley, A. Truman, S. R. Clarke, J. A. Cottam, G. P. Jadhav, V. R. 
Steele, P. O’Shea, C. Lindholm, A. Cockayne, et al., J. Med. Chem. 2014, 57, 2813–
2819. 
[82] C. A. Lowery, J. Park, C. Gloeckner, M. M. Meijler, R. S. Mueller, H. I. Boshoff, R. L. 
Ulrich, C. E. Barry, D. H. Bartlett, V. V. Kravchenko, et al., J. Am. Chem. Soc. 2009, 
131, 14473–14479. 
[83] A. Kotšubei, M. Gorgel, J. P. Morth, P. Nissen, J. L. Andersen, FEBS J. 2013, 280, 
5441–5449. 
[84] M. B. Miller, B. L. Bassler, Annu. Rev. Microbiol. 2001, 55, 165–199. 
[85] S. K. Srivastava, K. Rajasree, A. Fasim, G. Arakere, B. Gopal, J. Bacteriol. 2014, 196, 
2876–2888. 
[86] G. F. Kaufmann, R. Sartorio, S.-H. Lee, C. J. Rogers, M. M. Meijler, J. A. Moss, B. 
Clapham, A. P. Brogan, T. J. Dickerson, K. D. Janda, Proc. Natl. Acad. Sci. 2005, 102, 
309–314. 
[87] C. Ueda, K. Tateda, M. Horikawa, S. Kimura, Y. Ishii, K. Nomura, K. Yamada, T. 
Suematsu, Y. Inoue, M. Ishiguro, et al., Antimicrob. Agents Chemother. 2010, 54, 683–
688. 
[88] M. Sodeoka, R. Sampe, S. Kojima, Y. Baba, T. Usui, K. Ueda, H. Osada, J. Med. Chem. 
2001, 44, 3216–3222. 
[89] S. Peukert, Y. Sun, R. Zhang, B. Hurley, M. Sabio, X. Shen, C. Gray, J. Dzink-Fox, J. 
Tao, R. Cebula, et al., Bioorg. Med. Chem. Lett. 2008, 18, 1840–1844. 
[90] L. V. Lee, B. Granda, K. Dean, J. Tao, E. Liu, R. Zhang, S. Peukert, S. Wattanasin, X. 
Xie, N. S. Ryder, et al., Biochemistry (Mosc.) 2010, 49, 5366–5376. 
[91] S. Tuske, S. G. Sarafianos, X. Wang, B. Hudson, E. Sineva, J. Mukhopadhyay, J. J. 
Birktoft, O. Leroy, S. Ismail, A. D. Clark Jr., et al., Cell 2005, 122, 541–552. 
[92] D. Temiakov, N. Zenkin, M. N. Vassylyeva, A. Perederina, T. H. Tahirov, E. Kashkina, 
M. Savkina, S. Zorov, V. Nikiforov, N. Igarashi, et al., Mol. Cell 2005, 19, 655–666. 
[93] K. Moncoq, C. A. Trieber, H. S. Young, J. Biol. Chem. 2007, 282, 9748–9757. 
[94] D. G. Vassylyev, M. N. Vassylyeva, J. Zhang, M. Palangat, I. Artsimovitch, R. Landick, 
Nature 2007, 448, 163–168. 
LITERATURE 
155 
 
[95] J. Lu, S. Patel, N. Sharma, S. M. Soisson, R. Kishii, M. Takei, Y. Fukuda, K. J. Lumb, S. 
B. Singh, ACS Chem. Biol. 2014, 9, 2023–2031. 
[96] P. S. Steyn, P. L. Wessels, Tetrahedron Lett. 1978, 19, 4707–4710. 
[97] M. J. Nolte, P. S. Steyn, P. L. Wessels, J. Chem. Soc. [Perkin 1] 1980, 1057. 
[98] R. C. F. Jones, M. J. Begley, G. E. Peterson, S. Sumaria, J. Chem. Soc. [Perkin 1] 1990, 
1959. 
[99] N. Imamura, K. Adachi, H. Sano, J. Antibiot. (Tokyo) 1994, 47, 257–261. 
[100] E. Ohta, S. Ohta, S. Ikegami, Tetrahedron 2001, 57, 4699–4703. 
[101] J. W. Sims, J. P. Fillmore, D. D. Warner, E. W. Schmidt, Chem. Commun. 2005, 186. 
[102] C. Gui, Q. Li, X. Mo, X. Qin, J. Ma, J. Ju, Org. Lett. 2015, 17, 628–631. 
[103] T. B. Kakule, S. Zhang, J. Zhan, E. W. Schmidt, Org. Lett. 2015, 150417105358000. 
[104] P. Jouin, B. Castro, D. Nisato, J. Chem. Soc. [Perkin 1] 1987, 1177. 
[105] Y. Oikawa, K. Sugano, O. Yonemitsu, J. Org. Chem. 1978, 43, 2087–2088. 
[106] J. Jiang, W.-R. Li, R. M. Przeslawski, M. M. Joullié, Tetrahedron Lett. 1993, 34, 
6705–6708. 
[107] M. Hosseini, H. Kringelum, A. Murray, J. E. Tønder, Org. Lett. 2006, 8, 2103–2106. 
[108] H. J. Bestmann, Angew. Chem. Int. Ed. Engl. 1977, 16, 349–364. 
[109] J. Löffler, R. Schobert, J. Chem. Soc. [Perkin 1] 1996, 2799. 
[110] R. Schobert, C. Jagusch, C. Melanophy, G. Mullen, Org. Biomol. Chem. 2004, 2, 
3524. 
[111] W.-J. Bai, S. K. Jackson, T. R. R. Pettus, Org. Lett. 2012, 14, 3862–3865. 
[112] T. Ishida, R. Kobayashi, T. Yamada, Org. Lett. 2014, 16, 2430–2433. 
[113] K. Hori, M. Arai, K. Nomura, E. Yoshii, Chem. Pharm. Bull. (Tokyo) 1987, 35, 4368–
4371. 
[114] R. C. F. Jones, G. E. Peterson, Tetrahedron Lett. 1983, 24, 4751–4754. 
[115] J. G. David, W.-J. Bai, M. G. Weaver, T. R. R. Pettus, Org. Lett. 2014, 16, 4384–
4387. 
[116] R. N. Lacey, J. Chem. Soc. Resumed 1954, 832. 
[117] R. N. Lacey, J. Chem. Soc. Resumed 1954, 850. 
[118] S. V. Ley, S. C. Smith, P. R. Woodward, Tetrahedron 1992, 48, 1145–1174. 
[119] S. Ohta, E. Ohta, S. Ikegami, J. Org. Chem. 1997, 62, 6452–6453. 
[120] M. Fujita, Y. Nakao, S. Matsunaga, M. Seiki, Y. Itoh, R. W. van Soest, N. Fusetani, 
Tetrahedron 2001, 57, 1229–1234. 
[121] V. Yarotskyy, Mol. Pharmacol. 2005, 67, 1648–1654. 
[122] H. Furukawa, S. K. Singh, R. Mancusso, E. Gouaux, Nature 2005, 438, 185–192. 
[123] A. Yajima, A. Kawajiri, A. Mori, R. Katsuta, T. Nukada, Tetrahedron Lett. 2014, 55, 
4350–4354. 
[124] A. Yajima, C. Ida, K. Taniguchi, S. Murata, R. Katsuta, T. Nukada, Tetrahedron Lett. 
2013, 54, 2497–2501. 
[125] J. Ondeyka, G. Harris, D.  ink, A. Basilio, F.  icente, G. Bills, G. Platas, J. Collado, 
A. Gonz lez, M. de la Cruz, et al., J. Nat. Prod. 2009, 72, 136–141. 
[126] W. M. Yuan, D. L. Crawford, Appl. Environ. Microbiol. 1995, 61, 3119–3128. 
[127] N. U. Sata, S. Wada, S. Matsunaga, S. Watabe, R. W. M. van Soest, N. Fusetani, J. 
Org. Chem. 1999, 64, 2331–2339. 
[128] L. J. Brown, D. R. Bouvet, S. Champion, A. M. Gibson, Y. Hu, A. Jackson, I. Khan, 
N. Ma, N. Millot, H. Wadsworth, et al., Angew. Chem. Int. Ed. 2007, 46, 941–944. 
[129] L. J. Brown, N. Ma, D. R. Bouvet, S. Champion, A. M. Gibson, Y. Hu, A. Jackson, I. 
Khan, N. Millot, A. C. Topley, et al., Org. Biomol. Chem. 2009, 7, 564. 
[130] C.-C. Wang, J.-C. Lee, S.-Y. Luo, H.-F. Fan, C.-L. Pai, W.-C. Yang, L.-D. Lu, S.-C. 
Hung, Angew. Chem. Int. Ed. 2002, 41, 2360–2362. 
LITERATURE 
156 
 
[131] M. Poláková, M. U. Roslund, F. S. Ekholm, T. Saloranta, R. Leino, Eur. J. Org. 
Chem. 2009, 2009, 870–888. 
[132] H. Wang, J. She, L.-H. Zhang, X.-S. Ye, J. Org. Chem. 2004, 69, 5774–5777. 
[133] L. Yang, C. Adam, G. S. Nichol, S. L. Cockroft, Nat. Chem. 2013, 5, 1006–1010. 
[134] R. Schobert, M. Dietrich, G. Mullen, J.-M. Urbina-Gonzalez, Synthesis 2006, 2006, 
3902–3914. 
[135] P. Curcio, C. Zandanel, A. Wagner, C. Mioskowski, R. Baati, Macromol. Biosci. 
2009, 9, 596–604. 
[136] F. Compostella, D. Colombo, P. Ferraboschi, A. Scala, L. Toma, F. Ronchetti, Eur. J. 
Org. Chem. 2002, 2002, 1429–1435. 
[137] G. L. Simpson, A. H. Gordon, D. M. Lindsay, N. Promsawan, M. P. Crump, K. 
Mulholland, B. R. Hayter, T. Gallagher, J. Am. Chem. Soc. 2006, 128, 10638–10639. 
[138] N. K. Kochetkov, A. J. Khorlin, A. F. Bochkov, Tetrahedron 1967, 23, 693–707. 
[139] W. Wang, F. Kong, J. Carbohydr. Chem. 1999, 18, 451–460. 
[140] G. J. L. Bernardes, E. J. Grayson, S. Thompson, J. M. Chalker, J. C. Errey, F. El 
Oualid, T. D. W. Claridge, B. G. Davis, Angew. Chem. Int. Ed. 2008, 47, 2244–2247. 
[141] R. U. Lemieux, A. R. Morgan, Can. J. Chem. 1965, 43, 2198–2204. 
[142] A. Charette, N. Turcotte, B. Côté, J. Carbohydr. Chem. 1994, 13, 421–432. 
[143] M. Adinolfi, A. Iadonisi, A. Ravidà, M. Schiattarella, Tetrahedron Lett. 2003, 44, 
7863–7866. 
[144] K. Katano, P. I. Chang, A. Millar, V. Pozsgay, D. K. Minster, T. Ohgi, S. M. Hecht, J. 
Org. Chem. 1985, 50, 5807–5815. 
[145] C. Zhu, W. Peng, Y. Li, X. Han, B. Yu, Carbohydr. Res. 2006, 341, 1047–1051. 
[146] Y. A. Lin, J. M. Chalker, N. Floyd, G. J. L. Bernardes, B. G. Davis, J. Am. Chem. Soc. 
2008, 130, 9642–9643. 
[147] F. Yamazaki, S. Sato, T. Nukada, Y. Ito, T. Ogawa, Carbohydr. Res. 1990, 201, 31–
50. 
[148] F. John, T. L. Hendrickson, Org. Lett. 2010, 12, 2080–2083. 
[149] X. Liu, B. L. Stocker, P. H. Seeberger, J. Am. Chem. Soc. 2006, 128, 3638–3648. 
[150] H. Yue, D. H. Waldeck, K. Schrock, D. Kirby, K. Knorr, S. Switzer, J. Rosmus, R. A. 
Clark, J. Phys. Chem. C 2008, 112, 2514–2521. 
[151] K. Mori, Tetrahedron 2008, 64, 4060–4071. 
[152] M. Achmatowicz, L. S. Hegedus, J. Org. Chem. 2004, 69, 2229–2234. 
[153] P. G. McDougal, J. G. Rico, Y. I. Oh, B. D. Condon, J. Org. Chem. 1986, 51, 3388–
3390. 
[154] J. R. McDermott, N. L. Benoiton, Can. J. Chem. 1973, 51, 1915–1919. 
[155] S. T. Cheung, N. L. Benoiton, Can. J. Chem. 1977, 55, 906–910. 
[156] A.  . Malkov, S. Stončius, K. N. MacDougall, A. Mariani, G. D. McGeoch, P. 
Kočovský, Tetrahedron 2006, 62, 264–284. 
[157] J. B. Fang, R. Sanghi, J. Kohn, A. S. Goldman, Inorganica Chim. Acta 2004, 357, 
2415–2426. 
[158] L. Eberhardt, D. Armspach, D. Matt, L. Toupet, B. Oswald, Eur. J. Inorg. Chem. 
2007, 2007, 4153–4161. 
[159] K. Toshima, K. Tatsuta, Chem. Rev. 1993, 93, 1503–1531. 
[160] L. K. Mydock, A. V. Demchenko, Org. Biomol. Chem. 2010, 8, 497. 
[161] R. A. Salkar, H. Minamikawa, M. Hato, Chem. Phys. Lipids 2004, 127, 65–75. 
[162] G. Tojo, Oxidation of Alcohols to Aldehydes and Ketones: A Guide to Current 
Common Practice, Springer, New York, NY, 2006. 
[163] A. J. Mancuso, D. Swern, Synthesis 1981, 1981, 165–185. 
[164] K. Omura, D. Swern, Tetrahedron 1978, 34, 1651–1660. 
[165] S. L. Huang, K. Omura, D. Swern, Synthesis 1978, 1978, 297–299. 
LITERATURE 
157 
 
[166] K. Omura, A. K. Sharma, D. Swern, J. Org. Chem. 1976, 41, 957–962. 
[167] S. L. Huang, K. Omura, D. Swern, J. Org. Chem. 1976, 41, 3329–3331. 
[168] R. L. Whistler, J. N. BeMiller, Methods in Carbohydrate Chemistry Volume 6, Volume 
6, Academic, New York, 1972. 
[169] J. D. Albright, L. Goldman, J. Am. Chem. Soc. 1965, 87, 4214–4216. 
[170] J. D. Albright, L. Goldman, J. Am. Chem. Soc. 1967, 89, 2416–2423. 
[171] N. Katagiri, H. Akatsuka, T. Haneda, C. Kaneko, A. Sera, J. Org. Chem. 1988, 53, 
5464–5470. 
[172] C. M. Nycholat, D. R. Bundle, Carbohydr. Res. 2009, 344, 555–569. 
[173] P.  . Murphy, J. L. O’Brien, L. J. Gorey-Feret, A. B. Smith, Tetrahedron 2003, 59, 
2259–2271. 
[174] E. J. Corey, C. U. Kim, J. Am. Chem. Soc. 1972, 94, 7586–7587. 
[175] E. J. Corey, C. U. Kim, J. Org. Chem. 1973, 38, 1233–1234. 
[176] E. J. Corey, C. U. Kim, Tetrahedron Lett. 1974, 15, 287–290. 
[177] R. J. Ross, L. A. Paquette, J. Org. Chem. 1987, 52, 5497–5498. 
[178] J. P. Leeds, H. A. Kirst, Synth. Commun. 1988, 18, 777–782. 
[179] D. B. Dess, J. C. Martin, J. Am. Chem. Soc. 1991, 113, 7277–7287. 
[180] R. Cordonnier, A. N. Van Nhien, E. Soriano, J. Marco-Contelles, D. Postel, 
Tetrahedron 2010, 66, 736–742. 
[181] L.-Z. Liu, J.-C. Han, G.-Z. Yue, C.-C. Li, Z. Yang, J. Am. Chem. Soc. 2010, 132, 
13608–13609. 
[182] L. Horner, H. Hoffmann, H. G. Wippel, G. Klahre, Chem. Ber. 1959, 92, 2499–2505. 
[183] W. S. Wadsworth, W. D. Emmons, J. Am. Chem. Soc. 1961, 83, 1733–1738. 
[184] Y. Kobayashi, M. Matsuumi, J. Org. Chem. 2000, 65, 7221–7224. 
[185] S. K. Thompson, C. H. Heathcock, J. Org. Chem. 1990, 55, 3386–3388. 
[186] K. Ando, J. Org. Chem. 1998, 63, 8411–8416. 
[187] V. Logvinenko, O. Polunina, Y. Mikhailov, K. Mikhailov, B. Bokhonov, J. Therm. 
Anal. Calorim. 2007, 90, 813–816. 
[188] L. P. Olson, D. R. Whitcomb, M. Rajeswaran, T. N. Blanton, B. J. Stwertka, Chem. 
Mater. 2006, 18, 1667–1674. 
[189] Y. Shi, B. Sun, Z. Zhou, Y. Wu, M. Zhu, Prog. Nat. Sci. Mater. Int. 2011, 21, 447–
454. 
[190] A. Miyashita, A. Yasuda, H. Takaya, K. Toriumi, T. Ito, T. Souchi, R. Noyori, J. Am. 
Chem. Soc. 1980, 102, 7932–7934. 
[191] M. J. Burk, J. Am. Chem. Soc. 1991, 113, 8518–8519. 
[192] M. van den Berg, A. J. Minnaard, E. P. Schudde, J. van Esch, A. H. M. de Vries, J. G. 
de Vries, B. L. Feringa, J. Am. Chem. Soc. 2000, 122, 11539–11540. 
[193] D. Peña, A. J. Minnaard, J. G. de Vries, B. L. Feringa, J. Am. Chem. Soc. 2002, 124, 
14552–14553. 
[194] D. Peña, A. J. Minnaard, A. H. M. de Vries, J. G. de Vries, B. L. Feringa, Org. Lett. 
2003, 5, 475–478. 
[195] A. Preetz, H.-J. Drexler, S. Schulz, D. Heller, Tetrahedron Asymmetry 2010, 21, 
1226–1231. 
[196] M. J. Burk, F. Bienewald, M. Harris, A. Zanotti-Gerosa, Angew. Chem. Int. Ed. 1998, 
37, 1931–1933. 
[197] W. S. Knowles, Adv. Synth. Catal. 2003, 345, 3–13. 
[198] A. Crosman, W. F. Hoelderich, J. Catal. 2009, 265, 229–237. 
[199] R. Crabtree, Acc. Chem. Res. 1979, 12, 331–337. 
[200] S. P. Smidt, F. Menges, A. Pfaltz, Org. Lett. 2004, 6, 2023–2026. 
[201] S. G. Ouellet, J. B. Tuttle, D. W. C. MacMillan, J. Am. Chem. Soc. 2005, 127, 32–33. 
LITERATURE 
158 
 
[202] H. J. Bestmann, A. B. Attygalle, J. Glasbrenner, R. Riemer, O. Vostrowsky, Angew. 
Chem. 1987, 99, 784–785. 
[203] H. J. Bestmann, A. B. Attygalle, J. Glasbrenner, R. Riemer, O. Vostrowsky, M. G. 
Constantino, G. Melikian, E. D. Morgan, Liebigs Ann. Chem. 1988, 1988, 55–60. 
[204] M. Heitbaum, F. Glorius, I. Escher, Angew. Chem. 2006, 118, 4850–4881. 
[205] Y. Ujihara, K. Nakayama, T. Sengoku, M. Takahashi, H. Yoda, Org. Lett. 2012, 14, 
5142–5145. 
[206] D. A. Evans, M. D. Ennis, D. J. Mathre, J. Am. Chem. Soc. 1982, 104, 1737–1739. 
[207] A. Kumagai, Y. Nagaoka, T. Obayashi, Y. Terashima, H. Tokuda, Y. Hara, T. 
Mukainaka, H. Nishino, H. Kuwajima, S. Uesato, Bioorg. Med. Chem. 2003, 11, 5143–
5148. 
[208] H. Jürgen Bestmann, C. Geismann, Tetrahedron Lett. 1980, 21, 257–260. 
[209] K. Kempf, A. Raja, F. Sasse, R. Schobert, J. Org. Chem. 2013, 78, 2455–2461. 
[210] D. Rodríguez, C. J. Morrison, C. M. Overall, Biochim. Biophys. Acta BBA - Mol. Cell 
Res. 2010, 1803, 39–54. 
[211] C. Spoerlein, K. Mahal, H. Schmidt, R. Schobert, J. Inorg. Biochem. 2013, 127, 107–
115. 
[212] V. P. Prasad, S. Wagner, P. Keul, S. Hermann, B. Levkau, M. Schäfers, G. Haufe, 
Bioorg. Med. Chem. 2014, 22, 5168–5181. 
[213] Y. Gao, J. Z. Vlahakis, W. A. Szarek, I. Brockhausen, Bioorg. Med. Chem. 2013, 21, 
1305–1311. 
[214] A. V. Stachulski, G. V. Jenkins, Nat. Prod. Rep. 1998, 15, 173. 
[215] L. J. van den Bos, J. D. C. Codée, R. E. J. N. Litjens, J. Dinkelaar, H. S. Overkleeft, G. 
A. van der Marel, Eur. J. Org. Chem. 2007, 2007, 3963–3976. 
[216] E. Fischer, K. Delbrück, Berichte Dtsch. Chem. Ges. 1909, 42, 1476–1482. 
[217] R. R. Schmidt, J. Michel, Angew. Chem. 1980, 92, 763–764. 
[218] R. R. Schmidt, J. Michel, Angew. Chem. Int. Ed. Engl. 1980, 19, 731–732. 
[219] G. Zheng, A. Graham, M. Shibata, J. R. Missert, A. R. Oseroff, T. J. Dougherty, R. K. 
Pandey, J. Org. Chem. 2001, 66, 8709–8716. 
[220] G. Despras, C. Bernard, A. Perrot, L. Cattiaux, A. Prochiantz, H. Lortat-Jacob, J.-M. 
Mallet, Chem. - Eur. J. 2013, 19, 531–540. 
[221] P. L. Barili, G. Catelani, F. D’Andrea, F. De Rensis, P. Falcini, Carbohydr. Res. 1997, 
298, 75–84. 
[222] G. Catelani, F. D’Andrea, L. Puccioni, Carbohydr. Res. 2000, 324, 204–209. 
[223] E. Attolino, G. Catelani, F. D’Andrea, L. Puccioni, Carbohydr. Res. 2002, 337, 991–
996. 
[224] L. J. van den Bos, J. D. C. Codée, J. C. van der Toorn, T. J. Boltje, J. H. van Boom, H. 
S. Overkleeft, G. A. van der Marel, Org. Lett. 2004, 6, 2165–2168. 
[225] J. D. C. Codée, A. R. de Jong, J. Dinkelaar, H. S. Overkleeft, G. A. van der Marel, 
Tetrahedron 2009, 65, 3780–3788. 
[226] N. Takeda, R. Ikeda-Matsumi, K. Ebara-Nagahara, M. Otaki-Nanjo, K. Taniguchi-
Morita, M. Nanjo, J. Tamura, Carbohydr. Res. 2012, 353, 13–21. 
[227] C. Krog-Jensen, S. Oscarson, Carbohydr. Res. 1998, 308, 287–296. 
[228] E. R. Palmacci, P. H. Seeberger, Tetrahedron 2004, 60, 7755–7766. 
[229] A. V. Kornilov, E. V. Sukhova, N. E. Nifantiev, Carbohydr. Res. 2001, 336, 309–313. 
[230] H. Tanaka, K. Kawai, K. Fujiwara, A. Murai, Tetrahedron 2002, 58, 10017–10031. 
[231] K. A. Ness, M. E. Migaud, Beilstein J. Org. Chem. 2007, 3, 26. 
[232] R. S. Lankalapalli, A. Baksa, K. Liliom, R. Bittman, ChemMedChem 2010, 5, 682–
686. 
[233] W. Pilgrim, P. V. Murphy, J. Org. Chem. 2010, 75, 6747–6755. 
LITERATURE 
159 
 
[234] R. S. Loka, C. M. Sadek, N. A. Romaniuk, C. W. Cairo, Bioconjug. Chem. 2010, 21, 
1842–1849. 
[235] B. N. A. Mbadugha, F. M. Menger, Org. Lett. 2003, 5, 4041–4044. 
[236] F. S. Ekholm, P. Eklund, R. Leino, Carbohydr. Res. 2010, 345, 1963–1967. 
[237] D. Lafont, M.-N. Bouchu, A. Girard-Egrot, P. Boullanger, Carbohydr. Res. 2001, 336, 
181–194. 
[238] R. J. Ferrier, R. H. Furneaux, Carbohydr. Res. 1976, 52, 63–68. 
[239] B. K. S. Yeung, D. C. Hill, M. Janicka, P. A. Petillo, Org. Lett. 2000, 2, 1279–1282. 
[240] F. Sugawara, H. Nakayama, G. A. Strobel, T. Ogawa, Agric. Biol. Chem. 1986, 50, 
2251–2259. 
[241] S. Bera, R. J. Linhardt, J. Org. Chem. 2011, 76, 3181–3193. 
[242] N. L. Pohl, L. L. Kiessling, Tetrahedron Lett. 1997, 38, 6985–6988. 
[243] V. G. S. Box, V. Box, R. Hollingsworth, E. Roberts, Heterocycles 1980, 14, 1713. 
[244] F. Burkhart, Z. Zhang, S. Wacowich-Sgarbi, C.-H. Wong, Angew. Chem. Int. Ed. 
2001, 40, 1274–1277. 
[245] J.-C. Lee, W. A. Greenberg, C.-H. Wong, Nat. Protoc. 2007, 1, 3143–3152. 
[246] E. L. Myers, C. P. Butts, V. K. Aggarwal, Chem. Commun. 2006, 4434–4436. 
[247] B. Classon, P. J. Garegg, B. Samuelsson, S.-O. Lawesson, T. Norin, Acta Chem. 
Scand. 1984, 38b, 419–422. 
[248] Y. Oikawa, T. Yoshioka, O. Yonemitsu, Tetrahedron Lett. 1982, 23, 885–888. 
[249] K. Horita, T. Yoshioka, T. Tanaka, Y. Oikawa, O. Yonemitsu, Tetrahedron 1986, 42, 
3021–3028. 
[250] S. Chandrasekhar, G. Sumithra, J. S. Yadav, Tetrahedron Lett. 1996, 37, 1645–1646. 
[251] T. Onoda, R. Shirai, S. Iwasaki, Tetrahedron Lett. 1997, 38, 1443–1446. 
[252] T. Akiyama, H. Shima, S. Ozaki, Synlett 1992, 1992, 415–416. 
[253] R. Schwörer, O. V. Zubkova, J. E. Turnbull, P. C. Tyler, Chem. - Eur. J. 2013, 19, 
6817–6823. 
[254] M. Farrell, J. Zhou, P. V. Murphy, Chem. - Eur. J. 2013, 19, 14836–14851. 
[255] R. S. McGavin, R. A. Gagne, M. C. Chervenak, D. R. Bundle, Org. Biomol. Chem. 
2005, 3, 2723. 
[256] K. Bowden, I. M. Heilbron, E. R. H. Jones, B. C. L. Weedon, J. Chem. Soc. Resumed 
1946, 39–45. 
[257] J. Tatai, P. Fügedi, Tetrahedron 2008, 64, 9865–9873. 
[258] G. Gu, P. J. P. Adabala, M. G. Szczepina, S. Borrelli, B. M. Pinto, J. Org. Chem. 
2013, 78, 8004–8019. 
[259] R. H. Cornforth, J. W. Cornforth, G. Popják, Tetrahedron 1962, 18, 1351–1354. 
[260] E. J. Corey, G. Schmidt, Tetrahedron Lett. 1979, 20, 399–402. 
[261] E. J. Corey, B. Samuelsson, J. Org. Chem. 1984, 49, 4735–4735. 
[262] K. B. Sharpless, W. Amberg, Y. L. Bennani, G. A. Crispino, J. Hartung, K. S. Jeong, 
H. L. Kwong, K. Morikawa, Z. M. Wang, J. Org. Chem. 1992, 57, 2768–2771. 
[263] H. C. Kolb, M. S. VanNieuwenhze, K. B. Sharpless, Chem. Rev. 1994, 94, 2483–2547. 
[264] N. F. Sauty, H. Li, L. C. da Silva, K. B. Wagener, Synth. Commun. 2014, 44, 2409–
2415. 
[265] R. Criegee, Angew. Chem. Int. Ed. Engl. 1975, 14, 745–752. 
[266] H. Lu, C. Li, Org. Lett. 2006, 8, 5365–5367. 
[267] M. A. Brimble, C. L. Flowers, J. K. Hutchinson, J. E. Robinson, M. Sidford, 
Tetrahedron 2005, 61, 10036–10047. 
[268] K. Mori, Tetrahedron Asymmetry 2011, 22, 1006–1010. 
[269] M. M. Heravi, H. A. Oskooie, M. Ghassemzadeh, F. F. Zameni, Monatshefte Für 
Chem. Chem. Mon. 1999, 130, 1253–1256. 
[270] M. Miyashita, A. Yoshikoshi, P. A. Grieco, J. Org. Chem. 1977, 42, 3772–3774. 
LITERATURE 
160 
 
[271] H. Lin, S. S. Pochapsky, I. J. Krauss, Org. Lett. 2011, 13, 1222–1225. 
[272] S. K. Chaudhary, O. Hernandez, Tetrahedron Lett. 1979, 20, 95–98. 
[273] J. Yadav, B. Subba Reddy, Synlett 2000, 2000, 1275–1276. 
[274] D. Cabaret, M. Wakselman, Can. J. Chem. 1990, 68, 2253–2257. 
[275] S. Takano, M. Akiyama, S. Sato, K. Ogasawara, Chem. Lett. 1983, 1593–1596. 
[276] S. L. Schreiber, Z. Wang, G. Schulte, Tetrahedron Lett. 1988, 29, 4085–4088. 
[277] D. R. Gauthier, R. H. Szumigala, J. D. Armstrong, R. . Volante, Tetrahedron Lett. 
2001, 42, 7011–7014. 
[278] C.-R. Shie, Z.-H. Tzeng, S. S. Kulkarni, B.-J. Uang, C.-Y. Hsu, S.-C. Hung, Angew. 
Chem. Int. Ed. 2005, 44, 1665–1668. 
[279] D. Boschelli, T. Takemasa, Y. Nishitani, S. Masamune, Tetrahedron Lett. 1985, 26, 
5239–5242. 
[280] J. Borggraefe, Darstellung der Seitenkette von Virgineon, BSc - Thesis, University of 
Bayreuth, 2012. 
[281] T. Gmelch, Synthese einer Glycosyl-Akzeptor Seitenkette auf dem Weg zu Virgineon, 
BSc - Thesis, University of Bayreuth, 2013. 
[282] O. Mitsunobu, Synthesis 1981, 1981, 1–28. 
[283] W. Kurosawa, T. Kan, T. Fukuyama, Org. Synth. 2002, 79, 186. 
[284] H. Tanaka, Y. Iwata, D. Takahashi, M. Adachi, T. Takahashi, J. Am. Chem. Soc. 2005, 
127, 1630–1631. 
[285] L. Kuerschner, C. S. Ejsing, K. Ekroos, A. Shevchenko, K. I. Anderson, C. Thiele, 
Nat. Methods 2005, 2, 39–45. 
[286] N. A. Heaps, C. D. Poulter, J. Org. Chem. 2011, 76, 1838–1843. 
[287] T. Fukuyama, C.-K. Jow, M. Cheung, Tetrahedron Lett. 1995, 36, 6373–6374. 
[288] J. J. Turner, N. Wilschut, H. S. Overkleeft, W. Klaffke, G. A. van der Marel, J. H. van 
Boom, Tetrahedron Lett. 1999, 40, 7039–7042. 
[289] J. J. Turner, D. V. Filippov, M. Overhand, G. A. van der Marel, J. H. van Boom, 
Tetrahedron Lett. 2001, 42, 5763–5767. 
[290] C. Huo, C. Wang, M. Zhao, S. Peng, Chem. Res. Toxicol. 2004, 17, 1112–1120. 
[291] T. Sengoku, Y. Nagae, Y. Ujihara, M. Takahashi, H. Yoda, J. Org. Chem. 2012, 77, 
4391–4401. 
[292] E. Biron, H. Kessler, J. Org. Chem. 2005, 70, 5183–5189. 
[293] J. A. Himanen, P. M. Pihko, Eur. J. Org. Chem. 2012, 2012, 3765–3780. 
[294] J.-M. Lacombe, N. Rakotomanomana, A. A. Pavia, J. Carbohydr. Chem. 1990, 9, 85–
92. 
[295] M. Harras, T. Bauer, R. Kempe, R. Schobert, Tetrahedron 2013, 69, 3677–3682. 
[296] H. Nöth, B. Wrackmeyer, Chem. Ber. 1974, 107, 3089–3103. 
[297] Y.-C. Jeong, M. G. Moloney, J. Org. Chem. 2011, 76, 1342–1354. 
[298] D. Linder, Beiträge zur Synthese von α-verzweigten Epicoccamid, BSc- Thesis, 
University of Bayreuth, 2011. 
[299] H. Brockmann, T. Waehneldt, Naturwissenschaften 1963, 50, 43–43. 
[300] P. Herczegh, I. Kovács, A. László, Z. Dinya, F. J. Sztaricskai, Liebigs Ann. Chem. 
1991, 1991, 599–600. 
[301] O. Calin, R. Pragani, P. H. Seeberger, J. Org. Chem. 2012, 77, 870–877. 
[302] M.-C. Wang, Q.-J. Zhang, W.-X. Zhao, X.-D. Wang, X. Ding, T.-T. Jing, M.-P. Song, 
J. Org. Chem. 2008, 73, 168–176. 
[303] R. Wijesinghe, Ment. Health Clin. 2014, 4, 226–230. 
[304] C. Mount, C. Downton, Nat. Med. 2006, 12, 780–784. 
[305] E. v. Steuber, G. Elter, M. Noltemeyer, H.-G. Schmidt, A. Meller, Organometallics 
2000, 19, 5083–5091. 
LITERATURE 
161 
 
[306] P. Bayón, P. de March, M. Figueredo, J. Font, J. Medrano, Tetrahedron Asymmetry 
2000, 11, 4269–4278. 
[307] U. K. Singh, M. A. Vannice, Appl. Catal. Gen. 2001, 213, 1–24. 
[308] P. S. S. Prasad, N. Lingaiah, P. K. Rao, F. J. Berry, L. E. Smart, Catal. Lett. 1995, 35, 
345–351. 
[309] R. Akiyama, S. Kobayashi, Angew. Chem. Int. Ed. 2001, 40, 3469–3471. 
[310] H. E. Gottlieb, V. Kotlyar, A. Nudelman, J. Org. Chem. 1997, 62, 7512–7515. 
[311] A. K. L. Yuen, F. Heinroth, A. J. Ward, A. F. Masters, T. Maschmeyer, Microporous 
Mesoporous Mater. 2012, 148, 62–72. 
[312] M. O. Colfrey, F. E. Shonessy, J. Sustain. Agiation 2010, 1, 1–3. 
[313] A. P. Dieskau, B. Plietker, Org. Lett. 2011, 13, 5544–5547. 
 
ACKNOWLEDGEMENTS 
162 
 
IX. ACKNOWLEDGEMENTS 
 
The first person to thank is my supervisor Prof. Dr. Rainer Schobert who allowed me to 
perform the experimental work in his labs necessary to prepare this thesis. I also want to thank 
the people from the analytics centre of the University of Bayreuth for providing me all the 
required data. In general thanks to all the people from the Schobert lab, it has been a pleasure 
to work and discuss with all of you. I especially want to thank Matthias Göhl for many 
tempered chemical discussions, Katharina Mahal and Anders Kroschky for their help making 
my every day’s life bearable. I also want to thank not only the students mentioned in this 
thesis but also be grateful to all the other students I had in my lab contributing to my projects 
mostly in a helpful way. 
The next person to thank made an important contribution to this work: Thank you Matthew 
Fuszard for proof-reading this thesis. It is a pity that we get to know to each other only a short 
time before I’ll leave Bayreuth. 
I also want to thank again all the people who I met during my career. Every single one of you 
helped me and teached me a lot of important things. Special thanks to Prof. Dr. D. Gudat, 
Prof. Dr. D. Wolf, Prof. Dr. P. H. Seeberger, Prof. Dr. A. Adibekian, Prof. Dr. R. Dwek and 
most important to Dr. T. D. Butters and Dr. M. J. Lee. 
I want to thank my whole family. There have been hard times and I felt always greatly 
supported by all of you. Thank you so much for everything you did. I cannot go into more 
detail on how much you all contributed to get this work done, because that’ll be another 
thesis. 
The most important person to thank is my girlfriend Silke. You gave me shelter each day 
making all the above written things possible and supported me every second of your life never 
giving up and making me smile even after some bad days. I cannot put into words what this 
means to me and I would not have survived this PhD without you. Thank you so much. 
 
ABSTRACT (GERMAN VERSION) 
163 
 
X. ABSTRACT (GERMAN VERSION) 
 
Die Untersuchung eines synthetischen Zugangs zu natürlich vorkommenden Glycoconjugaten 
von 3-acylierten Tetramsäuren stand im Mittelpunkt dieser Arbeit. Der aus einem Pilz 
stammende Sekundärmetabolit Epicoccamid D (siehe Figure X.1.) wurde erstmals mit einer 
Gesamtausbeute von 17% über 19 Stufen synthetisiert. Die gezeigte Synthese hat einen 
modularen Charakter der es erlaubt, Teile der Totalsynthese auf andere ähnliche Naturstoffe 
zu übertragen und damit zugänglich zu machen. 
 
 
 
 
Figure X.1. Epicoccamid D. Die Abbildung zeigt die im Rahmen dieser Arbeit ermittelte absolute 
Konfiguration 5S,7S von Epicoccamid D. 
Die Schlüsselschritte der Synthese beinhalteten eine β-selektive Glycosylierung gefolgt von 
einer Epimerisierung am C-2 des Zuckers, eine HWE-Olefinierung, eine Aminolyse um die 
Aminosäure L-Alanin einzuführen und eine Lacey-Dieckman Zyklisierung. Das 7S 
Stereozentrum wurde durch die Verwendung eines Rhodium basierten homogenen 
Katalysators sowie einer Hochduck-Hydrierung aufgebaut. Um eine Chelatisierung von 
Metallionen, wie beispielsweise des verwendeten Katalysators, zu unterbinden wurde die 
Tetramsäure als stabiler BF2-Komplex verwendet. Da dieser synthetische Ansatz den Zugriff 
auf alle vier möglichen Isomere erlaubt war es möglich, die absolute Konfiguration des 
Naturstoffs durch Vergleich der NMR-Daten und des optischen Drehwertes zu bestimmen. 
Der retrosynthetische Ansatz der Epicoccamid Totalsynthese wurde erneut angewendet um 
die Synthese weiterer Seitenketten von natürlich vorkommenden, glykosylierten und 
3-acylierten Tetramsäuren zu ermöglichen. Ein Bespiel hierfür ist die erfolgreiche Synthese 
der Seitenketten von Ancorinosid B (siehe Figure X.2. A). Die Seitenkette dieses Naturstoffs 
ist aus einer C20 Alkylkette und einem Disaccharid bestehend aus Galactose und 
Glucuronsäure aufgebaut. Diese Seitenkette wurde erfolgreich mit Hilfe zweier 
aufeinanderfolgender sowie β-selektiver Glycosylierungen und einer Oxidation sowie 
gleichzeitiger Schützung des C-6 der Glucose synthetisiert. 
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Figure X.2. Natürlich vorkommende 3-acylierte Glycoconjugate von Tetramsäuren: A) Ancorinosid B; 
B) Virgineon; C) die beiden aurantoside G und J. 
Weiterhin wurde eine mehrfach substituierte Seitenkette für die Synthese von Virgineon 
(siehe Figure X.2. B) hergestellt. Diese Seitenkette muss ähnlich der Epicoccamid D 
Totalsynthese noch an einen Mannoserest gekoppelt und die β-konfigurierte glycosidische 
Bindung realisiert werden. Die Synthese dieser Seitenkette beinhaltete neben einer Ozonolyse 
auch eine Grignard-Reaktion. 
Mit den dargestellten Seitenketten sollte die Synthese der beiden Naturstoffe Ancorinosid B 
und Virgineon mit Hilfe des für Epicoccamid D entwickelten Protokolls möglich sein, da alle 
zusätzlichen und neuen Schritte in Bezug auf die Totalsynthese dieser Verbindungen in dieser 
Arbeit untersucht wurden. 
Zusätzlich wurde eine Vorschrift zur chemischen N-Glykosylierung etabliert um einen 
Zugang zur Stoffklasse der Aurantoside (siehe Figure X.2. C) zu erhalten. Diese 
N-Glykosylierung wurde mit Hilfe einer Fukayama-Mitsunobu-Reaktion erfolgreich 
bewerkstelligt. Hierbei wurde ebenfalls das Verhalten von Tetramsäuren, 3-acylierten 
Tetramsäuren und ihren Borkomplexen bei Lewis-sauren Bedingungen zur Glykosylierung 
untersucht. 
Als Letzter Abschnitt dieser Arbeit wurde die Stereoinduktion der oben erwähnten, 
synthetisch wertvollen BF2-chelat Komplexe analysiert und ihr Verhalten in einer 
heterogenen Hydrierung genauer untersucht. Für diesen Zweck wurde ein Diethylborkomplex 
einer Tetramsäure synthetisiert. 
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